

HOSPITAL PHARMACY SECTION - POSTER SESSION

HPS-P-005

EVALUATION OF TPN UTILIZATION FOR PATIENTS WITH RENAL INSUFFICIENCY

L.J. Lin¹, M.S. Gau Mau-Shiung¹, Y.H. Chen², M.T. Lin³, H.S. Lai³, F.Y. Lin², W.J. Chen³, J.M. Lien⁴

¹National Taiwan University Hospital, ²Postgrad School of Clin Pharm, ³Dept. of Surgery, ⁴Taipei Pharmacist Association, China Taiwan

Aims: To evaluate the outcome of TPN for renal insufficiency and to enhance patient safety. **Methods:** 1. To select ESRD under hemodialysis, chronic renal insufficiency, and acute renal failure as the key words. 2. During the period of Oct. 2003 and Dec. 2004, under the key words of diagnosis, to screen and monitor concurrently all adults on TPN. 3. Data collected from intraset e-hospital and medical records. 4. To evaluate and analyze the data via an Excel worksheet. **Results:** 22 patients (18M, 4F) aged 42-89.6 y/o (mean 69.1) with mild (3) to severe renal insufficiency (moderate 7, advanced 6 ESRD/failure 6) and under HD(16), CVVH (1), CAVH (1). 91% of NPO cases (22) was malnutrition. TPN indicated for UGI bleeding (41%), postoperation, chemotherapy, small bowel resection and so on. CPN-R2 G2 Nertifox Aminocrix and A2 formula were used to provide RDA TEE in 22.7% cases and RDA dextrose in 100% cases to keep 95.5% cases with normal level (NL) blood sugar. RDA amino acid provided in 85.4% cases. BUN and CrSr elevated in all cases. RDA fat provided in 72.7% cases to keep NL TG. Hyponatremia (18.2%), hypernatremia (4.6%), and hypokalemia (9.1%) occurred sporadically in 22 cases with RDA Na⁺ and K⁺. Hypochloremia occurred in 5% RDA Cl⁻ cases (20) and in 100% cases without Cl⁻. Hypocalcemia (5.3%) occurred in 19 cases with RDA Ca⁺⁺. Hyperphosphatemia occurred in 41% cases. Hypomagnesemia occurred in TPN without Mg⁺⁺. Complication rate was 13.6%. Liver enzyme, bilirubin, BUN and CrSr elevated obviously. 68.2% patients expired and 32% survived. **Conclusions:** Mortality rate is high in renal insufficiency, outcome evaluation will improve nutritional status and enhance patient safety.

HPS-P-007

ROLE OF THE CLINICAL PHARMACIST IN THE MANAGEMENT OF PATIENTS WITH HEART FAILURE

I.V. Korzh, I.F. Fedotova, V.D. Nemtsova,
National University of Pharmacy,
Ukraine

Introduction: Chronic heart failure is a common clinical condition with high morbidity and mortality. The aim of this study was to explore clinical pharmacists' accesses of their management of patients with heart failure and identify the perceived obstacles to diagnosis and management.

Methods: We conducted this qualitative study using semi-structured interviews in 31 clinical pharmacists. The interviews were based on a schedule of open questions based on the literature on diagnosis and management of patients with heart failure. Transcriptions of the audiotaped interviews were independently analyzed by two researchers and analysis was based on open coding using a constant comparative approach.

Results: Clinical pharmacists suspect heart failure when patients present with breathlessness or ankle edema. Obstacles to diagnosis were mentioned by most clinical pharmacists and included lack of facilities for appropriate investigations and lack of time and expertise. Obstacles to management included lack of time, high cost of drugs, difficulty with diagnosis, selection bias towards younger patients and not having the confidence to initiate angiotensin-converting enzyme inhibitors.

Conclusions: Although symptoms of heart failure are not sufficiently specific for diagnosing patients with heart failure, many clinical pharmacists recommend treating people with suspected heart failure on the basis of symptoms and signs alone. This study has identified many obstacles to the diagnosis and management of heart failure that may explain why patients are inadequately managed. Specific implementation strategies need to be tailored to overcome these obstacles.

HPS-P-006

CHANGES OF CALCIUM HOMEOSTASIS IN BRAIN UNDER THE INFLUENCE OF HYPOKINESIA AND GABA

V.P. Hskobyan, K.V. Melkonyan,
Yerevan State Medical University,
Armenia

Hypokinesia (HK) as a risk factor promotes development of cerebrovascular disturbances. Ca²⁺ is the most common signal transduction agent that controls many aspects of cellular function. Abnormal calcium homeostasis is usually thought to lead to neuronal death through rather complex degenerating processes.

The effects of HK and γ -aminobutyric acid (GABA) on free Ca²⁺ ions influx rate into the cells and its distribution between the subcellular fractions have been investigated in rat brain neurocytes. Male mature white rats were used. HK was modeled in individual small cages. Contemporary radioisotope method for ⁴⁵Ca²⁺ labeled ions influx rate measurement was used. Our results evidence that the Ca²⁺ ions influx rate increases. It is very important to note that the entered Ca²⁺ ions are mainly accumulated within the mitochondrial fraction of neurocytes thus promoting irreversible damage of the cells. Our morphological investigations revealed worsening of the state in brain tissue, especially blood-brain barrier permeability increases with formation of perivascular edema, neurophytosis, glial nodules, loss of capillary net in brain tissue. Our experiments show that administration of GABA prevents movement of Ca²⁺ ions into the neurocytes. On the other hand GABA inhibits worsening of the morphological picture of the brain tissue in conditions of HK and manifests expressed cerebroprotective effect.

HPS-P-008

EFFECTS OF THE CONCENTRATION OF PARENTERAL NUTRITION WITH AND WITHOUT GROWTH HORMONE ON BODY COMPOSITION IN GASTROINTESTINAL (GI) SURGERY PATIENTS

A. Aslani¹, A. Sevette¹, R.C. Smith¹, A.J. Kee¹, R.D. Hansen¹, S.McG. Barnitt¹, R.C. Baxter²

¹Royal North Shore Hospital, ²Kolling Institute Med Research, Australia

BACKGROUND: Protein loss is an inevitable consequence of major surgery which is associated with post-operative (PO) impaired immunity and increased morbidity and mortality. Growth hormone (GH) has powerful anabolic effects which are hypothesized to potentiate the effects of parenteral nutrition (PN) in maintaining the PO body composition (BC). **AIMS:** A randomised, controlled, double-blind study was carried out to determine the effects of 1/2 PN+GH, 1/2 PN-GH, Full PN+GH, or Full PN-GH on patients' BC following major GI surgery and whether lower nitrogen and calorie PN input is satisfactory in maintaining BC. **METHODS:** 43 major upper GI surgery patients were randomised into one of the 4 groups continuously from PO day 1 to 14. The 1/2 PN provided 0.3g N/kg/day & 65% of the non-protein calories as lipid whereas the Full PN provided 0.13g N/kg/day & 52% of the non-protein calories as lipid. GH/placebo (16 IU/day) was administered subcutaneously. Changes in BC were measured as changes in TBN, body fat (BF), total body water, and potassium. **RESULTS:** 35 of the 43 patients completed the study. The 1/2 PN-GH group (n=11) lost TBN (p=0.001) and MM (p=0.005) but not BF. The Full PN-GH group (n=9) maintained TBN, MM (p=0.055), and BF. The 1/2 PN+GH group (n=8) maintained TBN and BF but lost MM (p=0.038). The Full PN+GH group (n=7) maintained TBN and MM but lost BF (p=0.018). Statistical analyses indicated that concentration of PN input (p=0.031) and not GH had a significant effect on TBN/MM. **CONCLUSION:** In the PO setting, GH has a more significant effect on BC if administered with a higher strength PN input. In addition, higher strength PN input is more important than GH in preserving TBN/MM.

HPS-P-009

THE EFFECT OF CIGARETTE-SMOKING TO CLINICAL DATA OBTAINED FROM CITIZEN EXAMINATION

A. Kume¹, M. Sakaguchi², T. Kume¹, F. Shōbayu¹,
¹Kume Clinic, ²Tokyo Police Hospital,
 Japan

Object

At the annual meeting of the Pharmaceutical Society of Japan in March 29, 2004, we presented that there are the correlation between Smoking Index and clinical laboratory data of WBC or Hemoglobin. The aim of this study was to assess the effect of cigarette-smoking to clinical laboratory data.

Method

We asked about Cigarette-Smoking usage to the 497 people of who take citizens examination at Kume clinic, and lived in Fuchu-city, Tokyo, Japan. Smoking Index was calculated in each people. All data were obtained in individual people. The correlation of smoking index and clinical laboratory data was assessed.

Result

The study comprised 769 data of people (272 male and 497 female) who visited Kume clinic. Never-smoker were 537 person (125 male and 412 female), active-smokers were 136 person (77 male and 59 female), former-smoker were 96 person (70 male and 26 female). It was shown a relationship between WBC, Hemoglobin, or hematocrit and smoking index.

Conclusion

We showed that the cardiovascular risk is going to get higher with Smoking Index.

HPS-P-010

UNAFFORDABLE DRUG PRICES: THE MAJOR CAUSE OF NON-COMPLIANCE WITH HYPERTENSION MEDICATION IN GHANA

K.O. Busang¹, L.K. Matowe², J. Pflange-Rhale³,
¹KNUST, Ghana ²Management Sciences for Health, United States of
 America ³Department of Medicine, KATH, Ghana

INTRODUCTION: The HIV/AIDS epidemic in Sub-Saharan Africa appears to divert attention, care and resources from all other diseases. In Ghana, the prevalence of hypertension has been reported as increasing. A major concern is that many patients may not have access to standard hypertension medications. In this study we evaluate access to hypertension medications in Ghana and search for the reasons for non-compliance with hypertension medication. **METHODS:** Patient interviews were conducted on all new patients attending the hypertension clinic at Komfo Anokye teaching hospital between December 2001 and April 2002. Data were collected from 128 hypertension patients. **RESULTS:** 119 of the 128 interviewed patients (93%) did not comply with their medications. 114 (96%) of the non-compliant patients cited unaffordable drug prices as the main reason for non-compliance. **CONCLUSIONS:** Non-compliance with hypertension medication is a major problem in Ghana. Unaffordable drug prices appear the major cause. Effort should be made both locally and internationally to improve access to medications for chronic diseases in developing countries.

HPS-P-011

DEVELOPMENT AND ASSESSMENT OF A COMPUTERIZED PRESCRIPTION ALERT SYSTEM

S.H. Tai¹, C.Y. Lin¹, H.J. Chang¹, C.T. Yu¹, Y.H. Kao Yang², J.C. Tsai¹,
¹National Cheng Kung University Hospital, ²National Cheng Kung
 University,
 China Taiwan

Medication errors may result in adverse drug events, increase the workload of health professionals, and deplete medical resources. Many studies have demonstrated that CPOE with medication alerts may reduce medication errors.

This study developed a real time medication alert system in original computerized order entry system at the outpatient department. The impacts of medication alert system on physician's prescribing practices were evaluated. A prospective before-after comparison was carried out to assess the effects of the alert system in reducing the rate of prescribing and transcribing errors. After two months of intervening medication alert system in practice, we conducted questionnaire survey to evaluate the user's satisfaction. During the study, 0.74% of prescriptions triggered the alert. Fifty nine percent were avoided among the alerted prescriptions. The major reasons to override the drug alert was 'condition of patient's condition'. In comparison with pre-intervention period, the prescribing and transcribing error rate dropped from 0.20 per 1000 prescriptions to 0.12 per 1000 prescriptions (P<0.001) after intervention. The results of questionnaire survey revealed that over 60% of physicians, pharmacists and clerks agreed with the criteria of quality of the medication alert system. More than 90% of users had confidence on the alert system to reduce medication errors.

In conclusion, computerized order entry with medication alert is an effective tool for improving physician prescribing practices and substantially decreases the rate of prescribing and transcribing errors. Overall, users are satisfied with the medication alert

HPS-P-012

THE MANAGEMENT OF INTRAVASCULAR CATHETER-RELATED INFECTION

T. Takeda¹, T. Horikawa², S. Inagaki³,
¹Nippon Pharma Corporation, ²Saiseikai Matsusaka Hospital, ³Fujita Health
 University Hospital,
 Japan

Currently, many kinds of fluid catheter such as central venous catheter, CVC and intravenous catheter, IVH are used for the therapy of critically ill patients. Unfortunately, these devices are associated with a number of complications among which infection predominates, CVC.

Catheter-related infection, CRI is a major cause of patient morbidity and mortality.

I'll present the practice in the Saiseikai Matsusaka Hospital about the vein catheter of nutrition support therapy related infection CRI and the role of the pharmacist in the infection control team and the nutrition support team.

HOSPITAL PHARMACY SECTION - POSTER SESSION

HPS-P-013

MULTI-DRUG RESISTANCE GENE MUTATION (MDR-1) : ROLE IN DETERMINING INTERPATIENT VARIABILITY IN SERUM DIGOXIN LEVEL

G.S.F. Elfeky¹, S.S.A. Sanna Abdelshafie², A.I.E. Abdel Hamid Ibrahim³,
M.S.M. Mohamed Sherif Mokhta³,
¹,²Cairo university hospitals, ³Helwan university,
Egypt

Aim: outlining different MDR-1 genotypes (gtp) present in a group of Egyptian patients (pts), assessing the role of different MDR-1 gtp in affecting digoxin serum levels (DSL), studying the effects of different gtp on DSL and on pts' clinical outcome. **Methods:** 37 Egyptian pts suffering from congestive heart failure (CHF) were chosen. Pts were selected to have non-significant variability in their demographics and pretreatment clinical data. 2 venous blood samples were drawn from each pt after reaching steady state conditions: 1st one for DNA genotyping, 2nd one for serum digoxin assay. **Results:** 20 pts showed DSL within the therapeutic range, 12 pts showed DSL below minimum effective concentration, 5 pts showed DSL over maximum safety concentration, with a significant difference between the 3 groups. MDR-1 genotyping revealed 10 pts carrying the homozygous mutant TT gtp, 27 pts carrying the heterozygous mutant CT gtp, with no pts showing the wild CC gtp. A significant lower level in mean DSL was found in pts carrying the TT gtp than in those carrying the CT gtp. A significant relation was found between different MDR-1 gtp and outcome of CHF pts, where in the 15 pts who showed significant improvement, 14 carried the CT gtp (i.e. had DSL within the therapeutic range), while 1 pt carried the TT gtp. In pts with limited improvement the 2 gtp were equally prevalent. In those who showed no improvement, 4 pts showed the TT gtp, whereas 1 pt showed the CT gtp. **Conclusion:** Characterization of variations in the MDR-1 gene is an important tool for individualizing doses of drugs that are of its substrates. Identification of MDR-1 gtp was found useful in predicting therapy outcome.

HPS-P-015

UTILIZATION OF THE ANTIMICROBIAL DRUGS IN THE CLINICAL HOSPITAL

B. Virovkic-Zusec, A.A.A. Anzlojovic-Amidzic, S. Stiblik-Supestovic,
Clinical Hospital Osijek,
Croatia

Excessive drug use in Croatia requires continuous professional following of the utilization of the most prescribed and expensive drugs. The aim of the study was to analyse antimicrobial drugs utilization at our hospital according to the ATC. Drug consumption data help us determine the most prescribed groups in order to propose cost saving options.

This was a retrospective study conducted at our 1160 bed tertiary care hospital in the year 2004. A group of antimicrobial drugs was analysed (ATC-J), which makes 20% of the overall drug consumption. In this class, J01 medicines for the treatment of systemic bacterial infections make 86.33%. Beta-lactamic antimicrobials-penicillins, ATC-J01C, make 24% of this consumption (amoxicillin/clavulanate is the most prescribed medicine at our hospital and makes 69.57% of this group). The other beta-lactamic antimicrobials-J01D make 44.1%, followed by J01X group with 11.5%, quinolones J01M with 8.5%, aminoglycosides J01G with 6.3% and macrolides/lincosamides J01F with 5.1%. In group J01D, cephalosporins-J01DA make even 73.5% (cefuroxime is the third most prescribed medicine, which makes 30.2% of that subgroup), and group J01DH-carbapenems with 26.5% (meropenem makes 85.2% of the group).

Based on this analysis, we can conclude that significant cost saving effects and prevention of bacterial resistance is possible by defining measures for the rational use of J01C group of medicines, especially amoxicillin/clavulanate. The same applies for the J01DA, with the use of cefuroxime. Carbapenems are reserve antimicrobials and their use depends on the results of antimicrobial tests performed for each patient.

HPS-P-014

SAFETY EVALUATION FOR LONG-TERM ORAL AMIODARONE ADMINISTRATION AT A TEACHING HOSPITAL IN TAIWAN

Y.Y. Lin¹, S.C. Chien²,

¹Taipei Medical University Hospital, ²Taipei Medical University,
China Taiwan

Aim: To evaluate the monitoring rate and the frequency of LFTs and TFTs for amiodarone-treated patients, and to interpret results if such monitoring was done. **Aim:** to evaluate the drug interaction between amiodarone and digoxin or warfarin.

Method: A patient database of the 435-bed hospital was used to identify outpatients who take oral amiodarone for at least 6 months. A retrospective analysis of medication profile and lab data was performed to identify drug interactions and abnormal lab values. Patients' charts were reviewed to confirm findings. All data were analyzed by the descriptive statistics.

Results: Of 60 patients with age of 68±10.82 (mean±SD), 31 patients are male and 29 patients are female. They took amiodarone for 24±17.34 months at the daily dose of 169±80.83 mg. The rate of LFT is 65% at the baseline and 65% after 8.5±5.81 months of therapy. The rate of TFT is 5% at the baseline and 22% after 13.7±11.53 months of therapy. All patients' baseline LFTs were normal, but 25% of LFTs were above UNL after therapy. All patients' baseline TFTs were normal, but two patients developed hypothyroidism afterward. Seven patients took digoxin at the same time, but only one patient's dosage was adjusted based on the digoxin level. One patient developed digoxin-related toxicity with nausea and vomiting. Two patients took warfarin with amiodarone, and the dosage was adjusted based on INR.

Conclusion: Elevated LFTs and hypothyroidism exist after long-term amiodarone therapy. Clinical evaluation and periodic monitoring is the key to prevent these toxicities. Digoxin-related toxicity is noticed; therefore, the health care professionals need to be cautious about this combination.

HPS-P-016

CLASSIFICATION OF THE IDENTIFIED MEDICATION RELATED PROBLEMS (MRPs) IN RECENTLY DISCHARGED ELDERLY PATIENTS USING THE PCNE SYSTEM

N.A.S. Mohammed Safwat¹, L. Goodyer²,

¹Faculty of Pharmacy, Egypt ²DeMontfort University, United Kingdom

Introduction: Although there's no universal classification of MRPs, classification of it is important when assessing the effectiveness of pharmaceutical care services. There are a variety of ways in which MRPs can be classified. One of the recently developed systems is the PCNE system which was developed by the Pharmaceutical Care Network Europe.

Aim & Method: 61 Patients recently discharged from the hospital received structured pharmaceutical care & a second 61 patient group received normal discharge procedure provided by the hospital. Both groups were monitoring for MRPs patients suffered post hospital discharge. The identified problems in both groups were classified according to PCNE system. The basic classification has 6 primary domains for problems, 6 for causes & 5 for interventions.

Results: A total of 240 problems were reported during the 1st home visit, 56% were assigned for the control group. The percent of the identified MRPs in this group increased to 63% during the 2nd visit. Intervention group had 106 problems (44%) during the 1st visit and this number decreased to 37% during the 2nd visit. Side effects were the main problem (19%) during the 1st visit followed by insufficient awareness of the health & disease (18%). The opposite was true for the control group. The total number of identified problems was significantly lower for the intervention group during the 2nd visit.

Conclusion: The PCNE system was chosen because of its ability to classify both cases and interventions related to the identified problems. Also, it's more detailed in pinpointing a broad range of problems due to large numbers of sub-categories included in it.

HOSPITAL PHARMACY SECTION - POSTER SESSION

HPS-P-017

A HOSPITAL BASED DISCHARGE MEDICATION REVIEW SCHEME: HOMER TRIAL

N.A.S Mohammed Safwat¹, I. Goodyer²,

¹Faculty of Pharmacy, Egypt ²DeMontfort University, United Kingdom

Introduction: The HOMER trial recently identified an increased readmission rate & number of GP visits with a reduced quality of life in elderly patients who had received a community pharmacist domiciliary medication review.

Method: 122 elderly patients to be discharged from the Hospital were randomised into a control or active group. A hospital-based liaison pharmacist counselled patients in the intervention group concerning their medication prior to discharge. Detailed summaries of discharge medication were sent to the GP & community pharmacist. All patients were visited at home by the same pharmacist at 2 & 6 weeks post discharge. Compliance, quality of life (QoL) & medication knowledge were assessed. For the intervention group medication related problems (MRPs) were identified & resolved by liaison with the GP & hospital.

Results: Compliance was higher in the intervention group in both visits. Knowledge was also better. A wide range of MRPs were identified & the total number tended to be lower in the intervention group for 1st visit. The identified ADRs tended to be greater in the intervention group. QoL tended to be higher or no different in the 6 parameters of the MRP. There was no significant difference in readmission at 6 months.

Conclusion: The high compliance rates in both groups couldn't be an explanation for the readmission rates. However, the tendency for increased ADR reported may support the fact that patients had better understanding of their illness, prompting increased help seeking behaviour. Liaison pharmacist familiar with the medical history of the patient may reduce the complexity of care so that decreases admission and increases Quality of Life.

HPS-P-018

DECISION-MAKERS VIEWS OF ACCESS TO HIGH COST MEDICINES (HCMs) IN PUBLIC HOSPITALS IN AUSTRALIA.

G. Gallego¹, S. Taylor¹, J.E. Brien²,

¹The University of Sydney, ²St. Vincent's Hospital, Australia

OBJECTIVE: To investigate the perceptions, concerns and attitudes of decision-makers regarding access to HCMs in public hospitals.

METHODS: In-depth, semi-structured interviews were conducted with public hospital senior managers, directors of pharmacy and senior medical doctors in a Sydney Area Health Service. Interviews were audiotaped and transcribed verbatim.

RESULTS: Twenty-four in depth semi structured interviews were conducted. Data analysis identified several categories, which were collated into, inter-related themes (access, rationing, and equity). The central theme was tension between funding models, equity of access and budget constraints. Decision-makers perceived the current health care system funding model as obstacle to equity of access to HCMs. They were concerned that there were inequalities in decisions for individual patients depending on public or private sector hospital status. The majority of respondents identified problems in access to HCMs, and the ethical dilemmas they faced when decided if an HCM should be available, however they had difficulty in identifying solutions. Respondents described that, besides safety, effectiveness, efficacy and cost, ethical principles should be borne in mind when deciding whether a HCM should be available in a public hospital. Most wanted a transparent, accountable, evidence-based decision-making process.

CONCLUSION: The results of this study suggest that decision-makers were concerned about the equity of access to HCMs in public hospitals. They were concerned regarding the process for decision-making and the outcomes of these decisions.

HPS-P-019

CONSUMPTION OF CYTOSTATIC DRUGS ATC L IN CLINICAL HOSPITAL OSIJEK

B.V-Z. Virovkić-Zunec¹, S.S-S. Stiblik-Stipešević¹, A.A-A. Antolović-Amidžić¹, I.Z. Zunec²,

¹Clinical Hospital Osijek, ²Fidifarm, Croatia

Cytostatic drugs and immunomodulators ATC-L participate in overall drug consumption with 21,1% in our hospital. The purpose of the study was to analyse consumption according to ATC classification for the group of drugs L and to point out which subgroups, drugs and wards participate the most and to suggest cost saving options.

Clinical Hospital Osijek has 23 clinics/wards and fourteen of them use this group of drugs. Oncology participate with 60%, internal clinic with 20% and neurology with 11%.

Antineoplastic L01 make 70%, hormone-related drugs L02 1%, immunostimulators L03 28,5% and immunosuppressives L04 0,5%. Analysis of the group L01 shows that alkylating agents participate with 4,4%, antimetabolites with 7,7%, plant alkaloids with 34,9%(93,7% of that subgroup make paclitaxel and docetaxel), antitumor antibiotics with 20,8%(epirubicin makes 74,3%) and miscellaneous antineoplastic drugs with 32,2%(trastuzumab 22,9%,irinotecan 20,9%, imatinib 13,8%). Analysis of the group L03 shows that 95% of the costs make 5 drugs (interferon beta-1b with 29,2%, peginterferon alfa-2a with 25,3%, interferon alfa-2a with 21,4%, interferon beta-1a with 10,7% and interferon alfa-2b with 8,4%). Treating of malignant disease requires integral care for the patient, including doctors, pharmacists, nurses, social workers and other professions. Patient should be an active participant, not just the object of the therapy. Therapy guidelines, defined protocols and continuous education of all participants are essential for the rationalization and effective outcome of medical treatment.

HPS-P-020

CONTINUOUS CONTROL OF DRUG USE – A CONCEPT OF RATIONALIZATION OF DRUGS CONSUMPTION

B.V-Z. Virovkić-Zunec¹, A.A-A. Antolović-Amidžić¹, S.S-S. Stiblik-Stipešević¹, I.Z. Zunec²,

¹Clinical Hospital Osijek, ²Fidifarm, Croatia

Clinical Hospital Osijek has 23 clinics/wards, 19 with beds and all support services. In 2004 we had 392 828 inhabitants/day and, according to financial report for 2004, costs for medicines and other supply material made 20,1% of overall hospital costs. Medicines participated with 9,5% and supply material with 10,6%.

In this work drug consumption was analysed according to ATC classification. By pointing out groups of medicines with significant part in overall consumption and wards that use them, it is possible to recognize mistakes and remove them. In our hospital, ATC group B makes the most significant participation (32,7%), followed by ATC I with 21,1% and group J with 20%. In group B subgroup B05 makes 43,7% and 73,5% of that makes B05B-intravenous solutions (B05BB-electrolytic infusions make 73%, B05BA-glucose and aminoacid solutions 24%). In group L three clinics/wards make significant part (oncology 60%, hematology 26% and neurology 11%). In group J subgroups J01C and J01D make the most of financial costs. This group of drugs is continuously analysed for the reasons of possible irrational use and developing bacterial resistance.

Optimizing drug use and adequate education, recognizing irregularities and correcting them is essential for each health care programme. By preventing overuse of drugs and polypharmacy, serious adverse drugs reactions and decreasing duration of hospitalization made by drugs side effects it is possible to reduce costs of healthcare without limiting patient rights.

HOSPITAL PHARMACY SECTION - POSTER SESSION

HPS-P-021

EFFICIENCY OF GENE DELIVERY ON HEPATOMA CELLS WITH POLYPLEX AND TERNARY COMPLEX

H. Sasaki¹, Y. Nakamura¹, T. Nakamura¹, M. Nakashima¹, N. Ichikawa¹, K. Nishida², J. Nakamura²,
¹Nagasaki University Hospital, ²Nagasaki University,
Japan

Aims: The aims of this study is to investigate the efficiency of plasmid DNA (pDNA)/polyethylenimine (PEI) complex (polyplex) and pDNA/PEI/polyanion complex (ternary complex) as gene delivery vectors in a human hepatoma cell line HepG2.

Methods: pDNA encoding luciferase gene was complexed with PEI at various charge ratios. It was also complexed with both PEI and polyanions, such as carboxymethyl cellulose sodium salt (CMC), sodium alginate (SA) and poly-L-aspartic acid sodium salt (PAA). The cultured HepG2 cells were incubated at 37 °C for various transfection times in the presence or in the absence of fetal bovine serum (FBS) and albumin. Thereafter the cells were lysed for luciferase activity quantum by a luminometer.

Results: When HepG2 was incubated with naked pDNA, luciferase activity was not detected. Polyplex, however, showed high transfection activity. The polyplex prepared at a nitrogen/phosphate ratio (N/P ratio) of +8 showed the highest luciferase activity. The luciferase activity was clearly depending on the transfection time and the incubation time. Various ratios of the polyanions added to the polyplex prepared ternary complex at a N/P ratio of +8. pDNA/PEI/PAA complex showed high transfection activity although a decreased activity was observed with pDNA/PEI/CMC and pDNA/PEI/SA complexes. **Conclusions:** Efficient gene transfection in HepG2 cells was achieved by polyplex and ternary complex on the optimal conditions.

HPS-P-022

REVIEW AND ANALYSIS OF MEDICATION ERROR-INDUCED ADVERSE DRUG REACTIONS

M.H. Chuang, L.J. Lin, Ch. Lee,
Buddhist Tzuchi Dalin General Hospital,
China Taiwan

Objective: Preventable adverse drug events (ADEs) are commonly associated with medication errors. Besides, lots of hospitalized patients suffer from renal insufficiency, which is ignored frequently in clinical settings. Therefore, patients are under the potential risk for adverse drug reaction (ADRs) occurrence or even death. An automatic reporting system for ADRs and medication errors provides institutions an opportunity for self-inspection this dilemma. The purpose of this study is to evaluate the cause-effect relationship between adverse drug reactions and medication errors. **Methods:** From January 2003 to December 2004, all ADRs were extracted from a teaching hospital in southern of Taiwan. **Results:** Total 122 ADRs were reviewed. Thirty cases (30/122, 25%) were defined as medication error-related ADRs. Reasons for causing these errors were as follows: non-performed dosage adjustment based on patient's renal function (19/30, 63.3%), drug-drug interactions (4/30, 13.3%), non-compliance (4/30, 13.3%), and overdose (3/30, 9%), respectively. Especially, 18 out of 19 non-performed dosage adjustment based on their renal function cases occurred in elderly. **Conclusions:** For medication safety use purpose, we suggest that a patient-specific creatinine clearance calculation or a computerized dosage adjustment warning system should be in place for reducing or preventing these adverse events in the future.

Key words: Adverse drug events, medication errors, renal insufficiency, adverse drug reaction, elderly

HPS-P-023

AUTOMATING HANDLING OF GOODS WITH AN AUTOMATED STORAGE MACHINE

M. Behzadi
Apoteket AB,
Sweden

Tomado is an automated storage machine installed in 2001 at the central hospital pharmacy, CSA, at Great Southern Hospital in Stockholm, Sweden. Tomado consists of two units with mobile shelves where restricted products are set aside on special shelves and can only be accessed by having an additional security clearing and a password. Casor can handle both traditional shelves as well as automated stock deposits.

The purpose of developing Casor was to simplify and increase efficiency when delivering goods to customers from both in-patient wards and out-patient wards. Casor collects automatically all information from an underlying system. By scanning goods labels, stock place labels and client labels we secure that the right products are delivered to the right customers.

Our experience shows that a combination between Casor and Tomado is the most efficient, generates minimizing, is economically justified and also ergonomically developed. Casor even supplies a more secure handling compared to today's system, no errors has been detected since startup in September 2003, because the control system for bar codes is built-in, starting from receiving the goods at the pharmacy to gathering products for client distribution. Higher efficiency has also been achieved by automating several work elements through Casor. Due to more compact storing of products in Tomado a better use of the stockroom has also been achieved. For us at CSA, Casor has increased the production by 44.1% in a year. A solely use of the Tomado resulted in improved quality and handling but not as high increase in productivity as combined with Casor.

HPS-P-024

TOTAL PARENTERAL NUTRITION SUPPORT FOR PRETERM INFANTS

Y.C. Tsai¹, M.J. Tsai², R.L. Jiang¹, Y.D. Cheng¹, S.T. Deag¹,
¹Chang Gung Memorial Hospital, ²Min Hwei CHCM,
China Taiwan

Aim: This study evaluated the total parenteral nutrition (TPN) prescription at the Pediatric Intensive Care Unit (PICU) at Chang Gung Memorial Hospital, Taiwan, to identify the logic of its prescription and thereby improve the quality of infant TPN.

Method: A review was performed of all PICU preterm infants supported with parenteral nutrition solutions between January 1 and June 30 2004. The TPN prescriptions and other relevant data from electronic medical records were gathered via the hospital's website and analyzed by retrospective longitudinal study.

Results: Fourteen preterm infants (9 male, 4 female), between 25–36 weeks old, were administered TPN for 4–45 days. The percentage of cases that met the recommended daily allowances and requirements (RDA) were as follows: 86% for individual dextrose; 93% for amino acid; 100% for lipid; 93% for total calories; 93% for calcium; 100% for phosphorus; 79% for sodium; and 14% for potassium. During nutrition support only 86% and 79% of these cases had normal serum calcium and phosphorus levels respectively, and 21% and 64% of the cases showed decreased serum sodium and potassium, respectively.

Conclusion: Administration of parenteral nutrition to the infant has decreased morbidity but has been associated with the development of complications. Thus, it is necessary to closely monitor nutritional values obtained by biochemical examination. When there is an electrolyte imbalance, a pharmacist can promptly suggest that a doctor adjust electrolyte content in infusion fluids. Monitoring the laboratory data support can prevent complications and achieve rationality, suitability and validity of care.

HOSPITAL PHARMACY SECTION - POSTER SESSION

HPS-P-025

TWO-YEAR COMPARISON OF ANTIMICROBIAL SPECTRA

C.L. Lin, R.L. Jiang, Y.D. Cheng, S.T. Deng,
Chang Gung Memorial Hospital,
China Taiwan

Aims: In vivo activities of antibiotics against common bacterial isolates were analyzed. Susceptibility rates were collected from all adult patients during the period from 2003 to 2004. First, 2004 data were compared with antimicrobial spectra in the 34th edition of the Sanford guide to antimicrobial therapy. Second, susceptibility rates from 2003 and 2004 data were compared to determine chronological changes.

Methods: Disk diffusion tests were performed.

Results: The susceptibility rate of *Staphylococcus aureus* to oxacillin was lower than that in the Sanford guide. Ampicillin showed a decreased potency against *Enterococcus faecium*, *H. influenzae*, *E. coli* and *Proteus vulgaris*. *Enterococcus faecium* and *H. influenzae* to ampicillin were lower than the 2003 data. Piperacillin showed a decreased potency against *E. coli*. *Aeromonas hydrophila* and *Bacteroides fragilis*. *Aeromonas hydrophila* and *Bacteroides fragilis* to piperacillin were lower than the 2003 data. Cefepime showed a decreased potency against *Enterobacter aerogenes* and *Serratia marcescens*. The susceptible rate of *Enterobacter aerogenes* declined from 100% (2003) to 25% (2004). That of *Serratia marcescens* declined from 63% to 14%. Erythromycin showed a decreased potency against gram-positive organisms. The susceptibility rate of *Acinetobacter baumannii* to ceftazidime, ciprofloxacin and cefepime were only 17%, 15% and 19%, respectively.

Conclusions: Inappropriate uses of extended spectrum antibiotics promote the development of drug resistance. Knowledge of antimicrobial susceptibility is useful to design strategies that maximize therapeutic efficacy of drugs and minimize emergence of resistance.

HPS-P-026

QUALITY IMPROVEMENT OF PHARMACY PRACTICE IN ALEXANDRIA HOSPITAL & RESULTING CLINICAL AND FINANCIAL OUTCOMES

M. Darwish¹, S.A. Mashally¹, S. Hassanin¹, D. Hamdy², H. Saad¹, M. Maher², D. Yehia², N. Alan¹, H. Osman¹,
¹Alexandria University Hospital, ²University of Alexandria,
Egypt

Before 2002, hospital pharmacist role involves dispensing of medications without medication related care with limited pharmacist educational activities.

As for 2002, delivery of pharmaceutical care services in different: 1-oncology, 2-hematology&bnr, 3-I.C.U., 4-toxicology.

These services include:

-medical chart review, reporting drug interactions, avoiding adverse reactions and medication errors.

-proper cytotoxic drugs handling&disposal

-educational activities for patients & working staff

-monitoring of poisons in bld. Using viva.

*outcomes included:

1-clinical (related to the quality of life of the pt.&optimising dose with lower possible side effects)

2-financial (saving medication cost)

3-documentary (full documentation of pt. Data)

4-sharing in international trials (stima)

*future plans include: tpo unite, pharmacokinetic lab,

Clinical pharmacy in all hospital departments

We have the power to be the best in our career with open budget & we can believe that what we made in only 3 years is something to be proud of & others in arabian world can have benefits from this still young experience & we can get more experience by international participation

HPS-P-027

THE RESEARCH OF HIGH RISK DRUGS SAFETY REGULATION IN REGION HOSPITAL

C.J. Wu¹, W.Y. Kuo²,
¹Taipei City Hospital, ²Wu-Yen Kuo,
China Taiwan

'High Risk Drugs Safety Regulation' is a quite high standard. All the specialists concerned can not accept any kind of mistake to occur. In this study, the achieving rate of the former measure (Comparison Group) and the latter measure (Experimental Group) is a little bit different, it is 87.79% and 100% separately. However, the wrong medicine rate of the two groups is all 'zero'. It means that all the pharmacists and nursing staff are doing very careful job and carry out medicine safety strictly. It is nothing to do with the education and training.

HPS-P-028

MULTICENTRE, MULTINATIONAL DISTANT LEARNING POST-GRADUATE DIPLOMA/MASTERS DEGREE IN CLINICAL PHARMACY

K. Sabra¹, L. Clarke¹, M. Teeling¹, J. Kennedy²,
¹CACT, ²UCC,
Ireland

A new Irish MSc/Higher Diploma in Clinical Pharmacy course by distance learning is expanding the range of options for pharmacists in Ireland and elsewhere who wish to acquire post-graduate qualifications in clinical pharmacy. Previously Irish-based pharmacists who wanted to undertake further studies in clinical pharmacy by distance learning had to look to courses outside the country and this has been the case in many other countries also.

This new course is innovative in many respects. It is a joint collaboration between the School of Pharmacy, University College Cork (www.ucc.ie) and the Centre for Advanced Clinical Therapeutics (www.cact.ie) based in St James's Hospital, Dublin, Ireland. It is the first distance learning clinical pharmacy course in Europe to utilize teleconference tutorial sessions to complement course materials. Extensive use is also made of Internet and email to teach and communicate.

In terms of content this MSc/Higher Diploma clinical pharmacy course represents a move away from rote-book learning into the application of knowledge in real-life situation. Students are also encouraged to think about their contribution to the broader healthcare system. As well as providing comprehensive training in clinical pharmacy, covering all major therapeutic areas, the course also aims to equip students with skills and knowledge necessary to develop new pharmacist-led services in their hospitals. Reflecting the strong multidisciplinary focus within the course, the module leaders who run the teleconference tutorial sessions, include senior clinical pharmacists, medical consultants, health economists, biostatisticians and clinical nutritionists.

HOSPITAL PHARMACY SECTION - POSTER SESSION

HPS-P-029

CHOOSING PRESERVATIVES FOR CARBOHYDRATE-CONTAINING ORAL GEL PRESERVATION

M. Toskic Radojicic
Military Medical Academy,
Serbia and Montenegro

Purpose: Glucose and sucrose-containing (15% each) oral gels were formulated, intended for managing the phase I of hypoglycaemia in patients suffering from type II diabetes mellitus. Cellulose derivatives were used as gelling agents: 3.5% sodium carboxymethylcellulose (NaCMC), 2.5% hydroxypropylmethylcellulose (HPMC) and 2.25% hydroxyethylcellulose (HEC). As the preparations contain 30% carbohydrates in a hydrosoluble oral gel, we tested which preservative and in what concentration should be utilized for obtaining a product of a satisfactory microbiological quality (category 3A according to PhEur IV), with a minimum shelf life of 60 days.

Methods: pH value was determined by potentiometry, directly immersing the pH-meter electrodes into the samples. Biological appropriateness was tested by applying 0.1 ml of each sample with a sterile syringe onto blood agar and Sabouraud agar, smearing it with a sterile loop, and incubating for 48 hours at 37°C.

Results: No bacterial strains were detected in non-preserved samples, however in each of them fungal strains were identified: *Penicillium* in NaCMC and HEC, *Candida* in NaCMC and HPMC and *Ventriculium* in HPMC. Measured pH values of the samples are as follows: NaCMC, 7.3; HPMC, 4.6, and HEC 5.8. Samples were made containing 0.1% parabens, which maintain best antimicrobial activity in the pH 4 to 8 range, where our samples pertain. Testing for biological appropriateness was performed on days 1, 30 and 60 after manufacturing and no bacterial or fungal strains were isolated.

Conclusion: Parabens content of 0.1% is sufficient for preserving oral hydrogels containing carbohydrates, if NaCMC, HPMC or HEC are used as gelling agents.

HPS-P-030

EFFECT OF TANNINE UPON THE STABILITY OF UNGUENTUM CONTRA PERNIONES

M. Toskic Radojicic, M. Boskovic,
Military Medical Academy,
Serbia and Montenegro

Formulari registrirani et reagentia(FM 79) prescribe contents including tannine and ichthamol, in the procedure of manufacturing Usg. contra pernioes.

AIM: test effect of tannine on preparation quality and stability, depending on the way tannine is admixed into the base.

METHOD

Sample manufacturing: a) procedure prescribed by FM 79; b) mixture of water-free lanoline and vaseline is made. Tannine is dissolved in water and admixed to the base. Further procedure is identical to the original one; c) procedure is identical to b); only the tannine solution is admixed after all the other active substances are admixed.

RESULTS

a) sample has good spreadability and homogeneous structure. b) grainy structure is formed on skin, drops of non-emulsified water with dissolved tannine are detected, c) on application upon skin, sticky grains are formed. Coalescences, aggregates and areas of 'free' water are seen.

DISCUSSION

Method a): tannine is suspended in the base; dissolution is delayed, achieving acid medium for incompatibility reaction with ichthamol. If tannine is first emulsified into the mixture of anhydrous lanoline and vaseline (method b), reaction between tannine and ichthamol will have slower rate, and if tannine is added in the end (method c), instantaneous reaction between ichthamol and tannine disables emulsification, forming 'free' water areas and an instable emulsifier layer on contact surface of two phases.

CONCLUSION

Incompatibility between tannine and ichthamol does exist and is the cause of poor spreadability of Usg. contra pernioes. Destabilization rate depends on technological procedure.

HPS-P-031

ASIRIN USE AND RECOMMENDATION FOR PATIENTS WITH DIABETES AT A MEDICAL CENTER IN EASTERN TAIWAN

T.Y. Liu¹, W.C. Hsieh²,

¹Buddhist Tzu Chi General Hospital, ²Taiwan Society of Health-System Pharmacists,
China Taiwan

Aims: The American Diabetes Association has recommended aspirin therapy for the diabetic individuals since 1997. However among 3790 diabetic patients treated at a medical center in eastern Taiwan, from January to June 2004, only 232 (6%) received additional aspirin therapy. To promote the aspirin therapy for patients with diabetes, our study examined the practices and the use of aspirin therapy for hospitalized patients in this medical center. **Method:** The study consisted of hospitalized diabetic patients, who have at least one diabetes-related ICD-9 code (250.x) or receive at least one hypoglycemics during January-March 2005. Recommendations for aspirin therapy (100mg/day) were pharmacy-directed intervention via physicians. The compliance and the effectiveness were examined and analyzed with SPSS program. **Results:** A total of 921 patients with diabetes were identified. 55 patients had been given aspirin therapy and 21 patients were intolerant to aspirin. Aspirin therapy was then recommended to a total of 844 patients during clinical intervention; 701(83%) accepted and were given daily aspirin. 655 discharged patients continued to receive aspirin therapy, and then 35 of 46 outpatients had accepted follow-up telephone intervention for the use of aspirin. **Conclusions:** A pharmacy-directed intervention increased prophylactic aspirin therapy in patients with diabetes from 6% at baseline to 83% at the end of the study. Most clinicians agree aspirin as an important treatment for patients with preexisting coronary disease. This intervention provided appropriate assistance to clinicians for the prevention of many cardiovascular events and deaths.

HPS-P-032

EFFECT OF A COMPUTER ALERT SYSTEM ON PRESCRIBING PRACTICE AND QUALITY OF HEALTH CARE IN A PAKISTANI TEACHING HOSPITAL

S.S. Raza, A.I. Sheikh,
The Aga Khan University Hospital,
Pakistan

Study assesses the impact of an Inpatient Computerized Physician Order Entry (POE) system on prescribing practices. Department of Pharmacy Services developed a system in collaboration with Information Technology of the Aga Khan University Hospital that alerts the dose adjustment when physician enters the order of drugs requiring the renal adjustment for patients whose serum creatinine is inappropriate. A six-month Pre & Post system modification data of calls on Drug Information Center was compared to see the impact. Before the system modification 420 calls were logged for renal dose adjustment in six months. After system modification number was increased to 1100 calls in six months that shows a 2.6 times increase in physician's alertness for adjusted doses. Similarly as the Physician enter the order for Vancomycin or Miconazole, the system displays the restriction policy approved by Pharmacy & Therapeutic Committee. A one-month pre and post system intervention data of the number of prescriptions was generated through system to see the impact. Before intervention 264 prescriptions of vancomycin were recorded in all wards of hospital. This number was reduced to 166/month after the intervention. This shows a 1.6 times decrease in vancomycin prescribing. In this regard hospital saved US \$ 78933 (1 US \$ = 60 Pak Rs.)/month. Similarly for miconazole the prescription numbers dropped to 70 from 166/month. This shows a 2.4 times decrease in the miconazole prescribing and in this regard the savings were US \$ 10298 (1 US \$ = 60 Pak Rs.)/month. POE powered by decision support systems is an effective tool for improving physician prescribing practices and quality of health care.

HOSPITAL PHARMACY SECTION - POSTER SESSION

HPS-P-033

FACILITY DESIGN FOR MANUFACTURE OF CELL THERAPY PRODUCTS

J. Gallenzi¹, K. Sabra², C. Carter¹,

¹National Institutes of Health, United States of America

²Pharmaceutical Services, Ireland

U.S. medical centers and hospitals manufacturing cell and gene therapy products, including products for clinical trials, are required by the Food and Drug Administration to follow current Good manufacturing Practice (cGMP) regulations. This provides assurance that there is consistency between lots and that adequate controls are in place to assure the safety, efficacy and potency of the product. These regulations also apply to the facilities and equipment in which the product is produced. Although these requirements are clearly identified, similar requirements are still under discussion in Europe. It should be noted that US-FDA does allow for a sliding scale of GMP compliance depending on the phase of clinical study—with validation and document completed during Phase 3 or commercial product. This allows for a reduction in costs of manufacture and handling of the product in its early studies. The design of these facilities for manufacture should be based on their intended use. Materials of construction, heating, ventilation and air conditioning (HVAC) systems; both for containment and product protection; aseptic processing area requirements; biosafety levels; gowning practices, moisture issues and environmental monitoring will be discussed with emphasis on ex vivo transduction of patient's cells and possible vector preparation if needed. GMP requirements in Europe and those in the U.S. will be compared and discussed.

HPS-P-035

CONSUMPTION OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MILITARY MEDICAL ACADEMY IN BELGRADE IN THE PERIOD OF 2001-2004

A. Orozovic, M. Toskic-Radojicic,
Military Medical Academy,
Serbia and Montenegro

Introduction: Nonsteroidal anti-inflammatory drugs (NSAID) are indicated for pain and relief of inflammatory rheumatologic diseases, the short-term management of pain in arthritis and for acute pain, inflammation and fever in various conditions. NSAIDs are frequently used in our hospital. The aim was to measure utilization of NSAID in Military Medical Academy in Belgrade, for the period from 2001 to 2004.

Material and methods: NSAID utilization was analyzed using the WHOAT methodology. We included NSAIDs with the ATC code M01A. The annual amount of DDDs was used to categorize the NSAIDs consumption. It was DDD/100 bed-days. **Results:** We had 40.77 DDD/100 bed-days in 2001, 41.35 DDD/100 bed-days in 2002, 36.64 DDD/100 bed-days in 2003 and 35.41 DDD/100 bed-days in 2004. Ibuprofen was the most frequently used drug, with the DDD% 87.74% in 2001, 78.02% in 2002, 74.50% in 2003 and 70.43% in 2004. It is also the cheapest drug. Ibuprofen, the NSAID drug regarding GI toxicity, was not the most prescribed. No coxibs have been used.

Conclusion: We should reduce the use of nonselective NSAIDs and follow the trend, in the light of serious adverse effects which could be caused by increased use and use of large daily doses of NSAIDs. The coxibs are new and expensive drugs. The DDD price for celecoxib is 35 times higher than DDD price for ibuprofen.

Conclusion: We should reduce the use of nonselective NSAIDs and follow the trend, in the light of serious adverse effects which could be caused by increased use and use of large daily doses of NSAIDs. The coxibs are new and expensive drugs. The DDD price for celecoxib is 35 times higher than DDD price for ibuprofen.

Keywords: non-steroidal anti-inflammatory drugs, drug consumption

HPS-P-034

A STUDY ON THE USAGE OF DRUGS THAT AFFECT THE RENAL FUNCTION OF CRITICALLY ILL PATIENTS

M. Aciu, D. Calina, L. Rosu, P. Nicolcescu, N.V. Calina,
University of Medicine and Pharmacy,
Romania

AIMS: Alterations of renal function are constantly associated with decreased renal blood flow, renal mass and creatinine clearance. These changes have a major impact on patient management in particular with respect to drug therapy.

METHODS: This retrospective study was conducted to review the usage of drugs that affect renal function, the relationship between the drugs and creatinine clearance and the degree of dose adjustment practice in the critically ill patients. Forty-two subjects (n=42) have been enrolled in the study. Drugs that known to cause increase in renal function will be classified as positive effect drugs whilst drugs that are known to deteriorate renal function will be classified as negative effect drugs.

RESULTS: Creatinine clearances of the subjects were highly reduced in both affecting drugs usage. The effects of positive effect drugs on improving the renal function and the effect of negative effect drugs on further deteriorating the renal function of the ICU subjects were not significantly showed any pattern. Dosage modifications of antibiotics among renal dysfunction patients in this studied were not being performed optimally based on established references.

CONCLUSIONS: The effects of drugs on the renal function were unpredictable, thus, close monitoring of renal function for critically ill patients with multiple drugs therapy is needed.

HPS-P-036

EVALUATION OF THE DIGOXIN TOXICITIES RELATED TO SERUM DIGOXIN CONCENTRATION IN A MEDICAL CENTER IN TAIWAN

M.J. Huang, C.Y. Wang,
Shin Kong WHS Memorial Hospital,
China Taiwan

Aims:

To evaluate the incidence of digoxin related toxicities in variant digoxin serum concentrations.

Method:

This retrospective chart review was conducted from September 2004 to December 2004. Patients who checked serum digoxin concentrations (SDCs) during this period were all included. We divided our patients into 5 groups: SDC less than 0.5 ng/ml, 0.5 to 0.99 ng/ml, 1.0 to 1.49 ng/ml, 1.5 to 2.0 ng/ml and greater than 2.0 ng/ml. We evaluated the association between SDCs and digoxin related toxicities. The digoxin related toxicities include: premature ventricular contractions, second or third atrioventricular block, sinus bradycardia < 60 beats/min, nausea, vomiting, anorexia, diarrhea, weakness and headache. The digoxin related toxicities are defined as disappearance after a week of digoxin withdrawal or dose reduction.

Result:

There were 192 patients included in our evaluation. Of the 192 patients, 29 patients had SDCs greater than 2.0 ng/ml and 19 patients had SDCs of 1.5 to 2.0 ng/ml. In the group of SDC greater than 2.0 ng/ml, 21 patients had digoxin related toxicities (72.41%, n=29), but in the group of SDC of 1.5 to 2.0 ng/ml, just 6 patients had digoxin related toxicities (31.58%, n=19).

Conclusion:

According to the preliminary result, a greater proportion of patients who had higher SDCs had higher rate of Digoxin related toxicities. This evaluation is still ongoing and will be finished on 30th April 2005.

HOSPITAL PHARMACY SECTION - POSTER SESSION

HPS-P-037

HEALTH INSURANCE IN FLUID MANAGEMENT OF FRACTURED EXTREMITY

T.C. Yen¹, T.H. Lan², S.P. Lee³, T.S. Cheng², T.M. Cham²,
¹Kaohsung Military General Hospital, ²Kaohsung Medical University,
³Kaohsung Pharmacists Association,
China Taiwan

Objective: This retrospective study discusses a routine work about the fluid management of Diagnosis-Related-Groups fractured cases in the regional hospital. There are extensive views to the whole national health insurance system.

Materials and Methods: There were totally 6017 cases, during January-2000 and December-2003, accepted orthopedic operations. The Diagnosis-Related-Groups cases were about 5902 (98%) people, the rest 115 (2%) cases got more severe conditions, combined trauma and poor nutrition. The blood samplings were done before and after the operation. Replacement of prior fluid losses based on known electrolyte composition of the body fluid, serum electrolyte measurement, and clinical assessment of intravascular volume status.

Result: In Diagnosis-Related-Groups cases, there was no obvious change of electrolyte. Average maintenance fluids were 1988.67 ml (1000-3000 ml/day) and maintain urine output of 0.5-1.0 ml/kg/hour (1000-1500 ml) reasonable. Hyponatremia were the most common condition in the non-Diagnosis-Related-Groups cases. The Asia infectious crisis, severe acute respiratory syndrome (SARS), was a major influence about the hospital data and prolongs hospital days (from March-2002 to December-2002).

Conclusion: Majority cases need the routine fluid input for intra-vascular drugs but the severe cases need the exactly fluid support for life saving even the nutrition support. The medical budget expensures year by year, the government must reasonably formulate the procedure to keep the quality of the health care. But it is very hard work.

HPS-P-038

INTRODUCTION OF A RE-CHECK METHOD TO ENSURE ACCURACY OF POWDERED DOSAGE FORMS OF TRADITIONAL CHINESE MEDICINES PRIOR TO DISPENSING

C.S.H. Shen, R.C. Yang,
Chang Gung Memorial Hospital,
China Taiwan

Purpose: The aim of this study is to introduce the use of a re-checking process to assure accuracy of powdered dosage forms of traditional Chinese medicines compounded prior to dispensing to patients within the Out-Patient Department (OPD) at our hospital. The objective of this process is to assure improvements in patient safety and achieve potential reductions in dispensing errors.

Method: A pre-weighed checking card was designed as a tool in this process. The checking card was designed to assist the pharmacist to ensure that the current weight of the mixed CCM was assured during the last step of the compounding process prior to dispensing. Using the checking card, the pharmacist will re-examine the mixed CCM's total weight compared with the total weight of the package. If there is a $\pm 2\%$ variation in the weight of the CCM, the prescription is re-dispensed correctly with the correct amounts, before being dispensed to the OPD patient.

Results: Following a ten-month study with the re-checking process, it was found that the rate of prescription errors detected was 0.023%. The errors were traced to pre-packing processes and the delivery or weighing steps in the dispensing processes.

Conclusion: Preliminary findings suggest the need to re-check or re-examine the dispensing of traditional Chinese medicines powdered dosage form prescriptions for accuracy in some or all medical dispensing clinics or hospitals. These steps would potentially enable healthcare professionals to verify that patients are receiving the right drug at the right dose.

HPS-P-039

THE COMBINED IMPACT OF PREVENTION CATEGORY AND CO-PAYMENT TIER ON STATIN NON-ADHERENCE AND DISCONTINUATION

J.G. Stevenson, J.J. Ellis,
University of Michigan Hospitals,
United States of America

The objectives of this analysis were to determine if statin non-adherence and discontinuation rates differ between levels of a combined prevention category/co-payment tier variable. The electronic medical and pharmacy records of managed care enrollees age 18 to 64 who filled at least 2 statin prescriptions during the study period were reviewed; n = 2,881. Patients were categorized as secondary or primary prevention based on published risk criteria and were further stratified to groups with monthly co-pay tiers of <\$10 or \$10-20. Patients with cumulative multiple refill-interval gap (CMIG) >10% were considered non-adherent. Discontinuation was defined as cessation of refills prior to the end of available claims data. Chi-square and Cox proportional hazard were used to analyze non-adherence and discontinuation, respectively. In bivariate analysis, a significant difference in non-adherence was observed across the prevention category/co-pay tier variable. Non-adherence in secondary/<\$10, secondary/\$10-\$20, primary/<\$10, and primary/\$10-\$20 were 50%, 61%, 53%, and 63%, respectively. Secondary/<\$10 patients were least likely to discontinue statin therapy (significantly < primary/<\$10). Though not statistically different, secondary/<\$10 tended toward lower discontinuation rates than secondary/\$10-\$20 and primary/\$10-\$20. Co-payment tier appears to have a significant impact on non-adherence and discontinuation rates, particularly in the secondary prevention population in whom the benefits of statins are most important. Strategies such as benefit based co-payment systems may be indicated in order to mitigate the negative impact of co-payment in the highest risk patients.

HPS-P-040

A TRADITIONAL HERBAL MEDICINE SHO-SAIKO-TO AFFECTS EXPRESSION AND FUNCTIONAL ACTIVITIES OF PEPT1 AND MRP2 IN CACO-2 CELLS

K. Naoa, A. Yamamoto, N. Nishimura, T. Uemura, K. Iwamoto,
Shimane University Hospital,
Japan

Aim: It has been known that many kinds of herbal medicines can cause pharmacokinetic interactions with synthetic drugs. We have already demonstrated that Sho-saiko-to (SST), a commonly prescribed herbal medicine, upregulates MDR1 leading to the increased activity of MDR1. The purpose of this study is to clarify the effects of SST on the other transporter proteins PEPT1 and MRP2 in Caco-2 cells.

Methods: Caco-2 cells were cultured according to the conventional method and exposed to SST in the culture medium for 1, 2, 7 and 14 days. The levels of PEPT1 and MRP2 mRNA in the cells were determined with the real-time PCR procedure. The uptake experiments of radiolabeled Gly-Sar and methotrexate in the cultured cells were carried out to evaluate the functional activities of PEPT1 and MRP2, respectively.

Results and Discussion: It was confirmed that SST exposure did not change the viability of the cells at all. In the expression level of PEPT1 mRNA, 50% to 100% increase was observed by 1- or 2-day exposure to SST, while there is no significant change in the cells treated for 7 or 14 days. Uptake amounts of Gly-Sar were significantly increased by SST exposure for 1 or 2 days, indicating the increased activity of PEPT1. On the other hand, enhancement of MRP2 mRNA expression was observed only in 14-day exposure. In this exposure condition, the uptake of methotrexate was also increased by 50%, meaning the reduction in the activity of the efflux transporter MRP2.

Conclusions: These results indicate that SST can upregulate PEPT1 expression, resulting in the enhanced functions, and that SST has the induction effect on MRP2 expression.

HOSPITAL PHARMACY SECTION - POSTER SESSION

HPS-P-041

DRUG INFORMATION LABELING ON PRESCRIPTION MEDICINE BAG

Y.C. Chou, C.C. Ho, F.H. Chao, A.C. Cheng, J.H. Tien, S.W. Chiang, C.Y. Chang, C.H. Chiang, C.Y. Lee, L.S. Lee, C.H. Lee, W.Y. Liu, Taipei Veterans General Hospital, China Taiwan

Introduction: The objectives of this study were to advance patient-centered pharmaceutical care and provide the ideal drug information labeling on prescription medicine bag. **Method:** This is a prospective study. The layout of the bag is 18.6cm width x 20.3cm long. All labeling text items and description are presented in both Mandarin and English; the new font size is 25% larger and neatly printed. Total labeling items included the bag number, patient name and history number, administration dosage, drug name, appearance, clinical uses, other instructions, physician, pharmacist, physician, date & time, expiration date, duration and quantity, and additional information. **Result:** The satisfactory resulted an 11% (74-85%) increase from February to May of 2004 and 13% (74-87%) increase in August when compared with the previous edition. The total time spending on communication between clinical staffs and patient counseling were decreased. About 1.6 staff pharmacist or an average 3,328 working hours or NTD \$2.32 million salary saved could be transferred and focused on clinical pharmaceutical services. **Discussion:** The automated labeling system serves in helping pharmacists to minimize handwriting omissions and most importantly to dispense accurately. All labeling descriptions are carefully deliberated and weighed on the relative importance between patient safety and treatment efficacy. **Conclusion:** Taipei VGH is the pioneer healthcare institute to implement the bilingual labeling innovation significantly facilitated our foreign friends and native citizens in properly taking their medications.

HPS-P-042

THE USAGE EVALUATION OF CELECOXIB

T.C. Tsai, C.H. Tseng, M.H. Chung, S.T. Deng, Chung Gung Memorial Hospital, China Taiwan

Aims:

Base on a medical center medication usage data, analyzing gastrointestinal, renal and cardiovascular system adverse reaction associated with long term use of celecoxib. Also compared these information found from literature research and our hospital data to establish the usage guideline for celecoxib.

Methods:

Record blood urea nitrogen, serum creatinine, hemoglobin, and hematocrit data changed before and after celecoxib used for rheumatoid arthritis patients from our rheumatologic clinic. Other data recorded include the time for adverse reaction occurred, patients' past medical history, concurrent medication used and treatment of adverse reaction occurred during study period.

Results:

During study period (Jan. 2003 to Feb. 2005), we found 854 rheumatoid arthritis patients use celecoxib. Adverse reaction were seen in 84 patients: 72 (8.43%) cases related to gastrointestinal system, 6 (0.7%) cases related to renal system and 4 (0.5%) cases related to cardiovascular system. The dose and using period of celecoxib and incidence for gastrointestinal adverse reaction are irrelevant. For those patients have past medical history of peptic ulcer are easier to have recurrent peptic ulcer after taking celecoxib.

Conclusion:

Base on this evaluation, the adverse reactions related to renal and cardiovascular systems are not very often. With normal dosage and within 2 years usage of celecoxib can still be safe. But safety of higher dose and longer period usage still need more data to evaluate.

HPS-P-043

DESIGNING DOSE REGIMEN FOR TEICOPLANIN BY USING NOMOGRAM

Y. Takeda, K. Matsumoto, T. Miyagoe, K. Miyauchi, S. Oiso, Y. Shimodono, K. Yamada, Kagoshima University, Japan

Objectives: Teicoplanin (TEIC) is one of the glycopeptide antibiotics and has been very useful to cure Methicillin-resistant *Staphylococcus Aureus* (MRSA) infection in Japan. Since TEIC has a long-term half life, many reports suggested that 400mg of TEIC could be administered twice in the first day as a loading dose to quickly increase its level up to therapeutic range (10-20 µg/mL). But there are little reports about the lasting dose for the following days. In this study, we established nomogram to determine the lasting dose of TEIC and evaluated its usefulness by simulation analysis.

Methods: Nomogram was estimated by values of creatinine clearance according to the Cockcroft-Gault formula and population parameters of Teicoplanin TDM analysis system software Ver 1.2'. The serum levels of TEIC were measured by fluorescence polarization immunoassay.

Results: We simulated trough levels of TEIC by using the parameter of 20 patients who had been treated with TEIC. Using by nomogram as a lasting dose for each patient, the simulated trough levels of TEIC in 15 patients were within the serum level of 10-20 µg/mL, but no more than 20 µg/mL in any patients. The lowest trough level among 15 patients was 7.3 µg/mL.

Conclusions: The maintained serum levels of TEIC in most patients were simulated within 10-20 µg/mL, which is an effective level, by using our nomogram. Therefore, our nomogram was very useful to determine the dose of TEIC as a lasting dose for most of MRSA patients.

HPS-P-044

NONOLIGURIC ACUTE RENAL FAILURE ASSOCIATED WITH CELECOXIB

C.T. Mao, S.T. Deng, Chung Gung Memorial Hospital, China Taiwan

OBJECTIVE: To report a case of nonoliguric acute renal failure associate with celecoxib therapy.

CASE SUMMARY: A 71-year-old woman with underlying hypertension, recent multiple infarctions with right hemisphere, chronic renal insufficiency, and gouty arthritis was treated with aspirin, allopurinol, magnesium, sesonide, enalapril, celecoxib. Ten days after celecoxib 200 mg/day initiating therapy, she developed nonoliguric acute renal failure include increased serum potassium, and serum creatinine at least two-fold. Celecoxib was discontinued. Renal function improved, but had not returned to baseline.

DISCUSSION: Patients considered at high risk for acute renal failure, such as those treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, hypovolemia, the elderly, and patients with congest heart failure, diabetes mellitus, hypertension, and chronic renal insufficiency. Only one case of nonoliguric acute renal failure have been reported after fourteen days therapy with celecoxib. But renal function had not returned to normal after 30 days.

CONCLUSIONS: Selective cyclooxygenase-2 inhibitor celecoxib may causing reversible, nonoliguric, acute renal failure, or hyperkalemia, especially in high risk patients. Although renal function improves after discontinuation of celecoxib, but it may not return to baseline.

HPS-P-045

SUSPECTED WARFARIN RELATED INTRACRANIAL HEMORRHAGE

C.T. Man, S.T. Deng,
Chang Gung Memorial Hospital,
China Taiwan

OBJECTIVE: To report a case with intracranial hemorrhage (ICH) related to warfarin therapy.

CASE SUMMARY: A 49-year-old woman who had been taking warfarin therapy for underlying rheumatic heart disease, and replaced prosthetic heart valve include mitral and aortic valve 10 years ago. She was sent to emergency department with suffered nausea, vomiting, seizure attack, and unconsciousness. She was found to have a right frontal hematoma with 30mm in diameter on brain computed tomography (CT). Her international normalized ratio (INR) was 2.37 on admission. Warfarin was stopped and anticoagulation was corrected with fresh frozen plasma and vitamin K therapy. Further evaluation by CT angiography and no vascular abnormality. She was discharged toward warfarin after two weeks when recovery completely was started with support care and had not surgical intervention.

DISCUSSION: Mechanical valve prosthesis patients who required intensive long-term anticoagulant therapy, and keep INR in 2.5-3.5. Anticoagulants treatment increases the risk of ICH 8-10 fold. Among patients given anticoagulant therapy during longer periods, the annual risk of ICH was 1% to 2% and mortality rate was 44% to 68%. Management of anticoagulant-related ICH requires cessation of anticoagulants, administration of vitamin K.

CONCLUSIONS: Patients with mechanical heart valve had been suffered ICH maybe maintaining the INR between 2.0-2.5 and needed strict monitor.

HPS-P-046

HYPOALBUMINEMIA IN PATIENT OF TRAUMATIC COMPARTMENT SYNDROME.

T.C. Yen¹, P.Ch. Yu², M.C. Lai³, T.M. Chen²,
¹KaoHsiung Military General Hospital, ²KaoHsiung Medical University,
³Pharmacists Association,
China Taiwan

Background: We have recently discovered that postoperative complications of compartment syndrome related to hypoalbuminemia.

Objective: The study was performed to elucidate the risk factors and complications of the patients who received the operation in order to release traumatic compartment syndrome.

Materials and Methods: This is a retrospective study. From January-2000 to December-2002, we have collected 4392 cases of fractured limb treated with open reduction and internal fixation. These were 615 cases received further fasciotomy due to acute compartment syndrome. Before and after the operation, the blood samplings of the patients were routine taken for the albumin level, the electrolytes, and blood cells count. **Results:** Most of patients suffered from hypoalbuminemia with average level of 2.9 ±0.43 (from 1.8 to 3.9) g/dl in the cases who received further fasciotomy. Beside the prolong hospital days, there were complications noted after the operation of fasciotomy including delayed wound healing (52%), ilias (10%), urinary tract infection (9%). The improved conditions of the patients were noted including urinary activity, subsided of edema of the patients who received intravenous human albumin for nutrition support after the operation.

Conclusion: Once the major operation done with massive body fluid loss, the albumin level of the human blood could have fallen below the standard level. The parenteral nutrition support to the patients with the human albumin seems play an important part of the recovery of the healing.

HPS-P-047

EVALUATION FOR PRESCRIBING PATTERNS OF MAJOR DEPRESSION PATIENTS IN A MEDICAL CENTER

P.Y. Lee¹, S.S. Wu², Y.H. Wen², H.L. Wen², C.L. Tai¹, Y.P. Hsing¹,
¹CGMH, ²Kaohsing Medical University,
China Taiwan

Aims: The study was to evaluate the prescribing patterns of antidepressants in a Medical Center.

Methods: Data were derived from the Psychiatric department in a medical center. The study included all outpatient users of antidepressants in the Psychiatric department in a medical center from October 1, 2003 to March 1, 2004.

Results: There were 888 patients in the research of the study. Paroxetine was the most used antidepressant (45%). 49.5% the patients stopped his first antidepressant in 1 month. The percentages of patients who had continuously used his first antidepressant for 4 months and 6 months, were 23% and 20.7% respectively. The range of effectively continuous treatment rate (ECTR) of the antidepressants was 9.4-66.7%. The averages of defined daily dose (DDD) of the antidepressants were all smaller than 1.00, except fluoxetine (1.13) and venlafaxine (1.17). The DDD (R27) of trazodone was the lowest of all. The reason that illness was not improved, for patients to stop continuous using first antidepressant of trazodone was the secondary high (22.7%) among all.

Conclusion: There was not significantly different among the ECTRs of antidepressants, except bupropion (9.4%, $P < 0.05$). We suggest that the doctors may increase the dose of trazodone in major depression patients to improve the efficacy of treatment.

HPS-P-048

FACTORS INFLUENCING THE HEALING OF PRESSURE ULCERS

S.Y. Yamamura
Toho University,
Japan

Purpose: There are many reports on risk factors for formation of pressure ulcers. However, there are few studies of factors influencing the healing process of an existing pressure ulcer. The aim of this study is to explore factors relating to the prognosis of existing pressure ulcers.

Method: Hospitalized patients in whom pressure ulcers had occurred after hospitalization were enrolled in this study. Patients were classified into two groups: one group consisted of patients whose pressure ulcer had improved for 3 months (the improved group), and another group consisted of the remaining patients (the unimproved group). Their pressure ulcers were evaluated by scoring depth, eschar, size, inflammation, granulation tissue and the necrotic tissue of lesions (the DESIGN score). The DESIGN score, laboratory data, and active daily life (ADL) score were collected before and after formation of the pressure ulcer.

Results and Discussion: The factors influencing the healing of pressure ulcers were the ADL score, rate of nutrition intake, serum cholesterol level and hemoglobin level. The mean cholesterol level of patients in the unimproved group before formation of the pressure ulcer was statistically lower than that in the improved group. This suggests that a patient's cholesterol level before formation of a pressure ulcer may be a prognostic indicator of healing of an existing pressure ulcer.

Conclusion: Pressure ulcers may be expected to repair poorly in patients whose cholesterol level is lower than the normal range. Pharmacists should concentrate on the care of pressure ulcers in association with other caregivers.

HOSPITAL PHARMACY SECTION - POSTER SESSION

HPS-P-049

TO STUDY THE INTEGRATION OF COMPUTERIZED-SYSTEM FOR KNOWLEDGE MANAGEMENT IN A MEDICAL CENTER

A. Yen chih ho
China Taiwan

Aims: In order to create the advantaged competition of hospitals, it is important to know how to manage the knowledge of pharmaceutical cares. It is necessary to set up and computerize the program of pharmaceutical standard procedures. The program will help the Bureau of National Health Insurance to decrease the cost in medications and increase the quality of patient care.

Methods: During January to October 2004, we designed the program of pharmaceutical standard procedures and used Visual Foxpro to design document center of pharmaceutical cares. The categories include drug utilization evaluation(DUE), total parenteral nutrition(TPN), therapeutic drug monitoring(TDM), drug information service(DIS), patient education and consultation in diabetes and renal transplantation, medication errors, database of drug information, updated clinical experiences, evaluation of serum creatinine clearance and dosage adjustments.

Results: During September to December 2004, pharmacist interventions of all the pharmaceutical cares categories are 1584 entries in the document center. These include DUE 1001 entries, TPN 61 entries, TDM 156 entries, DIS 134 entries, education and counseling of diabetic patients 206 entries and medication errors 26 entries. We estimated that these pharmaceutical interventions may have the potential to save about NTS 2405998.81 on medications. The system is user friendly and easy to perform search and analysis in the database for pharmaceutical cares.

Conclusions: The system serves not only a great resource for pharmacists acquiring information from others but also a useful pharmaceutical intervention tool associated with medication cost saving.

HPS-P-050

PRIOR INSPECTION INJECTION COMPOUNDING OF MEDICINES DUTIES IN IMCJ

S.R. Sensai, M.C. Chida, T.S. Sawa, A.K. Kubota, Y.S. Suzuki, N.Y. Yoshino,
International Medical Center of Japan,
Japan

Aims:

Injection duties in IMCJ use Automatic Injection Medical Dispenser basically. After a doctor inputs prescription, a pharmacist compounds it, and a nurse confirms mixture injection. And it is administered to a patient last. When the doctor inputs anticancer drug or poison, prior inspection by the pharmacist is done in the process as part of the malpractice prevention. We report on it.

Method:

A normal prescription is published with the input of a doctor, and data are transmitted promptly, and automatic compounding of medicines with Automatic Injection Medical Dispenser is done. However, the prescription is not to be compounded without prior inspection by a pharmacist when anticancer agent or poison was prescribed. When anticancer agent and poison of a high risk prescribed, it evade accident by a pharmacist inspects using technical knowledge in refer to information on the patient and a protocol of chemotherapy. A prescription is published after the prior inspection of a pharmacist, and a pharmacist compounds the medicine. After that mixture and administration of a medicine are enabled.

Result:

For a drug treatment by a doctor, the pharmacist who is an expert of medicine is concerned with prior inspection duties I think that we can contribute to reasonable use of medicine and security of safety for a patient thereby.

Consideration:

Now a pharmacist does prior inspection in some injection medicines in IMCJ.

However, all problems are not solved by a current method. I analyze contents and the number of inquiry and we want to do the duties aim at more and more improvement of prior inspection and measures of prevention of accident in future.

HPS-P-051

CLINICAL TRIAL INFORMATION MANAGEMENT BY DATABASE SOFTWARE ACCESS(?)

A.K. Kubota, M.S. Shirogami, N.K. Kondo, H.K. Kato, Y.S. Suzuki, N.Y. Yoshino, N.K. Koga, A.H. Hashimoto, O.O. Okazaki, N.U. Uemura,
International Medical Center of Japan,
Japan

Background

In the clinical trial business of Japan, which contains secretariat business, Clinical Research Coordinator(CRC) business and investigational medical products management, etc., there is huge information and a lot of essential documents are needed to manage it.

Aims

We report on the improvement of information management by the database software access in IMCJ.

Methods

We had input the essential information to the database of the software Access, which made the retrieval and the extraction of the clinical trial information easy.

Input information

Institutional Review Board(IRB)

Protocol title, Principal Investigator, Information of the pharmaceutical company, etc.

CRC business

Client information, Schedule management, etc.

Investigational medical products management

Delivery and return, Appropriate use, etc.

Result

We were repeatedly inputting same information to the computer for managing a lot of documents before. However, we were able to retrieve and extract promptly necessary information by using the database. And creation of IRB document, CRC business and progress report of clinical trial were managed efficiently. In addition, the investigational medical products management was improved accuracy.

Conclusion

Using the database reduced the amount of the clinical trial work.

Moreover, we were able to arrange necessary information efficiently and speed of reporting work was improved. We should take part in the reliability of the clinical trial and the safety of the patients based on these information in the future.

HPS-P-052

COMMUNITY ACQUIRED BACTEREMIC PNEUMONIA DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS—A CASE REPORT

Y.F. Yang¹, S.T. Deng²,

¹Chang-Gung Memorial Hospital, ²Chang Gung Memorial Hospital,
China Taiwan

Aim:

To present a case of community acquired methicillin-resistant staphylococcus aureus (MRSA) bacteremic pneumonia successfully treated with linezolid.

Case summary:

A 15 y/o girl was previously healthy except a past admission history of pneumonia when she was 5-6 y/o. This time she was referred from another hospital where CXR showed RML, RUL, and RLL pneumonia patch, sputum and blood culture all showed MRSA.

After admission, chest X-ray revealed consolidation with air-bronchogram over LUL, LLL & RLL. The laboratory data confirmed that influenza B Ab & PCR (+). Bone scan reported with no definite abnormal finding. We used linezolid for the MRSA infection control. The patient still got intermittent fever, productive cough with yellowish and blood stained sputum, mild shortness of breath. After linezolid treated 12 days, fever subsided and discharged on day 18.

Discussion:

Several retrospective studies appear to show an advantage of linezolid over vancomycin to treat MRSA infections. In this case, we use linezolid earlier to treat this patient's multiple lobe pneumonia that prevent from severe complications such as require intubation, chest tubes for drainage of pleural effusion.

Conclusion:

Because of increasing concerns about the efficacy of vancomycin, linezolid may be a better choice for MRSA pneumonia including nosocomial and community acquired.

HOSPITAL PHARMACY SECTION - POSTER SESSION

HPS-P-053

AN EVALUATION OF THE CLINICAL PHARMACY REPORTS PUBLISHED IN THE PHARMACEUTICAL SOCIETY OF CHINA-TAIWAN'S ANNUAL CONFERENCE ABSTRACT BOOK FROM 1998 TO 2004

C.C. Lin, C.M. Mao, E.K. Lee, P.L. Tseng, D.K. Lee,
Kaohsiung Veterans General Hospital,
China Taiwan

Aims: From 1998 to 2004, the Pharmaceutical Society of China-Taiwan held annual conferences that accepted reports from pharmacists and related professions. This making it possible to evaluate all of the structure and contents of the published abstracts, and to analyze and reflect the development of clinical pharmacy in Taiwan.

Methods: Over the 7 year period, a total of 276 abstracts were reviewed, including the academic background of the authors and the content details of the articles. Data Management was performed using the Microsoft Access Program.

Results: The no. of reports increased from 7 in 1998 to 107 in 2004. The % of papers relating to clinical pharmacy forum increased, whereas those relating to experimental research decreased. In the beginning the reports focused mainly on pharmacokinetics, therapeutics and drug utilization review. However the parameters of research and discussion were later widened to include case reports, adverse drug reports, pharmacoepidemiology, medication error, therapeutic drug monitoring and service quality. Furthermore, there was a trend towards producing results and conclusions based on more and more sophisticated statistical methodology. Hospital pharmacies that had their own affiliated colleges of pharmacy had a better opportunity to perform research work than those without. Another observable tendency was that non-pharmaceutical postgraduate institutes and government departments worked together in cooperation to produce more in-depth papers.

Conclusion: Our findings show that clinical pharmacy is both flourishing and diversifying in Taiwan; and that both the quantity and the quality of annual publications are clearly rising.

HPS-P-055

THE DRUG UTILIZATION FOR PATIENT WITH COPD IN TAIWAN

C.M. Mao, Y.S. Chen, E.K. Lee, C.C. Lin, D.K. Lee,
Kaohsiung Veterans General Hospital,
China Taiwan

Aims: To reveal the drug use pattern of COPD patients in Taiwan and to evaluate the use of anti-tussives which are not recommended in some countries because of its lacking well documents and evidences.

Methods: Using the claims data files of ambulatory care expenditure by visits (CD) and details of ambulatory care orders (OO) from the Taiwan National Health Insurance (NHI) Research Database of 2003, we analyzed the pattern and extent of the medication used in COPD patients (ICD-9-CM code:496) from a total of forty-two thousands systematic randomized patients. The drug codes of the merged CD and OO files were translated into their drug names using the drug file and grouped by the pharmacological system released from the NHI.

Results: The COPD patients visited more than 3 times in this year were included, which consisted a total of 1,244 patients, 0.349% cases from the whole claims database, with a mean age (SD) of 74.3(11.0) years. The pharmacological groups were respiratory smooth muscle relaxants(66.3%), sympathomimetics (58.6%), anti-tussives(56.1%), expectorants(20.5%), adrenergic(20.0%), mucolytics(19.3%), anti-cholinergics(14.0%), anti-inflammatory agents(12.9%), and common cold preparations(7.7%) respectively. Commonly prescribed anti-tussives comprising of its group were dextromethaphan, glycyrrhiza extract and potassium cresolsulfonate, benzonatate, platycodon extract, codeine, ephedrine.

Conclusions: A considerable reimbursement for the anti-tussives used in COPD was reported in this study. Since its clinical outcome has not been fully documented, drug use guideline could be established by the NHI to cope with the limited budget for the health insurance resource.

HPS-P-054

DRUG USE EVALUATION OF INSULIN GLARGINE IN A TAIWAN MEDICAL CENTER

Y.C. Tsai, C.H. Chen, P.L. Tsai, S.Y. Chien,
Changhua Christian Hospital,
China Taiwan

Aims: The hospital's Pharmacy and Therapeutics Committee has developed treatment guideline of insulin glargine in August 2004. The aim of this study was to measure and assess the safety and efficacy of insulin glargine.

Methods: This study was conducted from September 2004 to March 2005. Pharmacists reviewed each prescription and clinical record according to the Data collection and outcome assessment were based on the glycosylated hemoglobin (HbA1C), fasting plasma glucose (FPG), nocturnal hypoglycemia, and cost.

Results: A total of 76 patients (10 type 1, 66 type 2 diabetes) were enrolled. 25% (3 type 1, 16 type 2 diabetes) were evaluated during a 12-week consecutive insulin glargine treatment. Compared with previous therapy, glargine treatment produced significant reduction in FPG level ($p=0.002$). The FPG level less than 140 mg/dl were achieved in 63.2% of patients with insulin compared with 10.5% before insulin glargine therapy. The target HbA1C level ($\leq 8\%$) was achieved in 15.6% of patients with insulin glargine compared with before insulin glargine therapy, there was no significant improvement in mean value ($p=0.059$). The cost of new treatment is higher than the conventional therapy, however the new treatment reduced incidence of nocturnal hypoglycemia by 20%.

Conclusions: From this study insulin glargine appears to be more effective in lowering FPG and causes less nocturnal hypoglycemia than conventional therapy. We will conduct a long-term project for further evaluating the cost-effectiveness and quality of life with insulin glargine therapy.

HPS-P-056

THE UTILIZATION PATTERN OF THE THERAPEUTIC DRUG MONITORING IN TAIWAN - A 7-YEAR REVIEW FROM 1997 TO 2003

E.K.L. Lee¹, C.M. Mao², C.C. Lin², D.K. Lee², T.M. Cham¹,
¹Kaohsiung Medical University, ²KS Veterans General Hospital,
China Taiwan

Aims: Through years of clinical experience of Therapeutic Drug Monitoring (TDM) nowadays a growing clinical routine for the hospital pharmacy practice in Taiwan aimed to review the ambulatory utilization pattern of the TDM from 1997 to 2003.

Methods: All the TDM items based on 3 major research data files: the registration ambulatory care expenditures by visit and the details of ambulatory care orders over the 7 year period from the Taiwan National Health Research Institute, were accessed and analyzed. These files are systematic sampling files representing 0.2% of the database.

Results: During this period, a mean total of 2,385,397.6 cases and 231.6 TDM claims data per year were determined. About 63.8% TDM were ordered in six centers. The frequency and the reimbursement of TDM increased about 1.5-fold and 1.2-fold respectively within this period. Through the reimbursement covered 29 items, 12 was identified in the database that cyclosporine(21.1%), carbamazepine(17.1%), phenytoin(16.6%) were at the most. The most frequently prescribed TDM drugs theophylline 21,917.7 prescriptions/year, digoxin 1909.6 and carbamazepine 13, however, the proportion of their TDM was extremely low. The patient who cyclosporine and FK-506 performed a TDM at least once a month and these two have obviously tended to increase every year in comparison with the other items.

Conclusions: Only the TDM of the immunosuppressants were frequently ordered. It appears that some items i.e. aminityline, theophylline and lithium were ignored by clinicians. Thus, TDM should be re-emphasized its importance in the Taiwan society.

HOSPITAL PHARMACY SECTION - POSTER SESSION

HPS-P-057

IMPACT OF A PHARMACY INTERVENTION FOR PHYSICIANS TO IMPROVE PROPHYLACTIC TREATMENT OF CIO

C.Y. Tsai, Y.Y. Chan,
Chang Gung Memorial Hospital,
China Taiwan

Aim: The numerous side-effects associated with long-term corticosteroid treatment. Corticosteroid-induced osteoporosis (CIO) is the most serious side-effects which remains underdiagnosed and often inadequately managed. The objective of this study is to assess the effect associated with a pharmacy intervention aimed at physicians in order to improve the CIO-prophylactic treatment in a medical center in northern Taiwan.

Methods: The research using medical records of 1,432 patients from both the inpatient and outpatient populations who were receiving corticosteroid therapy for the period of April to November 2002. The impact of the pharmacy intervention was measured 6 months thereafter by changes in CIO-prophylactic-treatment prescribing behavior.

Results: Among all the 1,432 patients, only 430 patients (30.0%) used corticosteroids for up to 3 months were receiving CIO-prophylactic-treatment before pharmacy intervention. Review of ICD-9-CM diagnostic coding showed an osteoporotic patient population of 300, of whom only 204 (68%) received treatment; 906 patients (63.3%) needed to receive prophylaxis; 810 patients (56.6%) warranted bone densitometry evaluation. As a result of pharmacy intervention, 430 (30.0%) patients were increased to 695 (48.5%) patients receiving CIO-prophylactic-treatment.

Conclusions: The involvement of pharmacists in the team of care-providers can ensure that drugs are used safely and effectively. It is indeed laudable that this research has consequently been able to effectively improve quality of patient care and concluded that extension of pharmacy intervention from a focal level to district and even national level is worthwhile.

HPS-P-058

POINT OF CARE PHARMACIST; AN INNOVATION TO BETTER PATIENT CARE BY PHARMACIST.

Z. Ghous, A.Latif Sheikh, S.S. Raza, S.S. Ali,
Aga Khan University Hospital,
Pakistan

Objective: To determine the quantitative impact of Point of Care Pharmacist in a medical care unit. **Background:** Pharmacist is an active member of multidisciplinary team, but is being underutilized in a country like Pakistan. The study has been to determine the quantitative impact of point of care pharmacist in a tertiary hospital of Pakistan. **Methods:** A pharmacist was selected on the basis of his achievements and the feedback from his supervisor. Pharmacist was credited with supervision of Clinical Pharmacist. Pharmacist was then placed inside ward in collaboration of ward management staff. **Findings:** Over 6 months there were interventions by pharmacist with an average of 213 per month. Cost saving of thousand rupees has been documented with an average of 25 thousand rupees per month. There was a gradual decrease in number of interventions shown improvement in physician order entry by the presence of pharmacist inside ward were 580 queries replied during 6 months with an average of 88 per month. An average of 6 drug food interaction has been identified with a total of 35 in 6 months. 7 sessions has been taken by pharmacists on different topics, 35 missed doses been identified with an average of 6/month. 22 ADRs have also been reported. **Conclusion:** Pharmacist can play a vital role in management of hospital management and cost reduction. Study also shows an improvement in the physician order entry by the presence of pharmacist inside ward.

HPS-P-059

IMPACT OF COLLABORATIVE EFFORT BY PHARMACIST AND NURSES ON PATIENT CARE

S. Ali, Z. Ghous, S.S. Raza, F. Zaheer, A.Latif Sheikh,
Aga Khan University Hospital,
Pakistan

Objective: To determine the impact of a collaborative approach of Pharmacist and Nurses in prevention of missing doses and reporting of ADR.

Background: Disease state management is a latest concept introduced in the health care system. Pharmacist is already involved in multidisciplinary clinical rounds in our hospital. To improve the patient care different problems were identified where nurses and pharmacist can work together for the betterment of patient care. Two major areas were targeted, study has been designed to determine the impact.

1. Missing dose
2. Adverse Drug Reaction Reporting

Methodology: A pharmacist and nurse were appointed to check the medication bins of the patient after administration time of all the doses that is 1130 am at medicine ward, an extra dose was checked against medication administration sheet of the nurse and the missed doses were identified and administered where possible. Nursing staff of medicine ward were encouraged to report ADRs and the collective effort results in increase reporting of ADR.

Results: Total of 35 missed doses has been identified in a period of six months, the number decreased gradually, that shows a gradual improvement in the practice. Number of ADR reported increased from 1 per month to an average of 4 per month during 6 months.

Conclusion: Collaboration between nurses and pharmacists can result in better patient care.

HPS-P-060

HEALTH INSURANCE IN FLUID MANAGEMENT OF FRACTURED EXTREMITY

T.C. Yen¹, T.H. Lan², S.P. Lee³, T.S. Cheng², T.M. Cham²,
¹Kaohsiung Military General Hospital, ²Kaohsiung Medical University,
³Kaohsiung Pharmacists Association,
China Taiwan

Objective: This retrospective study discusses a routine work about the fluid management of Diagnosis-Related-Groups fractured cases in the regional hospital. There are extensive views to the whole national health insurance system.

Materials and Methods: There were totally 6017 cases, during January-2001 and December-2003, accepted orthopedic operation. The Diagnosis-Related-Groups cases were about 5902 (98%) people, the rest 115 (2%) cases got more severe condition, combined trauma and poor nutrition. The blood samplings were done before and after the operation. Replacement of prior fluid losses based on known electrolyte composition of the body fluid, serum electrolyte measurement, and clinical assessment of intravascular volume status.

Result: In Diagnosis-Related-Groups cases, there was no obvious change of electrolyte. Average maintenance fluids was 1988.67 ml (1000-3000 ml/day) and maintain urine output of 0.5-1.0 ml/kg/hour (1000-1500 ml) reasonable. Hyponatremia were the most common condition in the non-Diagnosis-Related-Groups cases. The Asia infectious crisis, and severe acute respiratory syndrome (SARS), was a major influence about the hospital data and prolongs hospital days (from March-2002 to December-2002).

Conclusion: Majority cases need the routine fluid input for intra-vascular dosage but the severe cases need the exactly fluid support for life saving even the nutrition support. The medical budget expenses year by year, the government must reasonably formulate the procedure to keep the quality of the health care, but it is very hard work.

HOSPITAL PHARMACY SECTION - POSTER SESSION

HPS-P-061

THE TECHNOLOGY APPLIED TO IMPROVE THE QUALITY OF DISPENSATION BY UNIT DOSE

V. Olmos, D. Deborah Szerman, M. Martín Daneri,
Asociación Española,
Uruguay

The amount spent on medication in our ambience is considered the second section of expenditure of all Hospitals; so that a method for reducing and improving the quality of dispensation is looked upon

The aim is to show how methods of dispensation by Unit Dose of tablets and liquids with the adequate technology and area can achieve an improvement in the quality and cost reduction.

The methodology is based in the incorporation of technology : d-blister machine, double disk tablet packaging, liquid packaging and new plant.

Analyzing the processes we see that the average speed by manual d-blising method versus the automatized is 50 % greater. The performance increases to the double with the double disk machine.

In the case of liquids a 36.3 % savings on the monthly cost was seen.

The plant was designed for the pharmacy's needs, with delimited areas reaching the conditions for each process.

We achieved a greater service and quality for patients and an important economical impact.

In conclusion technology alone isn't the fundamental issue but it's important to reach the objective.

HPS-P-062

QUALITY IMPROVEMENT OF HOSPITAL PHARMACY PRACTICE & MEDICAL SAFETY MANAGEMENT IN ALEXANDRIA UNIVERSITY TEACHING HOSPITAL

M. Dsrwish¹, S.A. Mashally², S. Hassanin¹, D. Hamdy³, H. Saad¹, M. Maher¹, D. Yehia¹, N. Alaa¹, H. Osman¹,

¹Alexandria University Hospital, ²Alex. University Hospital, ³University of Alexandria, Egypt

Health care environments worldwide are changing dramatically towards the delivery of high quality, cost effective patient care. At Alex. University Teaching Hospital, the role of pharmacists as legally responsible dispensers of medications (without medication-related care with limited pharmaceutical educational activities) has expanded in the recent 3 years to embrace the additional challenge of patient care. This was associated with the implementation of a postgraduate Pharm.D. Program at the Faculty of Pharmacy, University of Alexandria. The outcome of changes in pharmacy practice in four departments, namely Oncology, Hematology, ICU and Toxicology was monitored. Changes include establishment of a sterile area for the handling and dispensing of cytotoxic drugs by trained pharmacists, establishment of a computer-based documentation system, reviewing patient medical charts, reporting drug interactions, adverse drug reactions and medication errors, providing drug information to patients and other members of the health care team within an educational activity framework and toxic drug monitoring using VIVA apparatus. Positive outcomes include reduction in medication errors, improvement in nursing services, improved medication cost effectiveness translated as considerable financial savings, which collectively led to improved therapeutic outcomes and patient quality of life. Such changes motivated the Department of Pharmacy and hospital pharmacists to extend patient care services to the TPN unit and Therapeutic drug monitoring lab. & Clinical Pharmacies in all hospital departments.

HPS-P-063

USE/NON-USE OF HORMONE REPLACEMENT THERAPY IN THE CONTEXT OF WOMEN'S MENOPAUSAL EXPERIENCE.

A. Srivilai¹, P. Boonmongkon²,
¹Naresuan University, ²Mahidol University,
Thailand

Aims : To investigate the decision-making about use/non-use of hormone replacement therapy (HRT) in the context of women's menopausal experience.

Methods : Interviewed 22 women age 49-61 years with natural menopause from northern Thailand. Data collected from June to December 2002.

Results : A total of 9 (40.9%) women were currently being treated with HRT. A total of 8 (36.4%) women were not being treated with HRT and 5 (22.7%) women had been treated with HRT in the past. The reasons for starting treatment for alleviating menopausal symptoms, to prevent osteoporosis and physician offered it. The reasons for not taking HRT included the following : never had menopausal symptoms, the physicians never offered it, lacking of knowledge about HRT, fear of cancer, allergic symptoms and menstruation recurrence. The reasons for discontinuation was unbearable side effects, being bored in taking the hormone, taking the hormone for a long time, forgetting to take treatment and don't want to pay for the medication.

Conclusions : Most women who used HRT are under government health welfare. The women of low social status and low educational level tended to use HRT without participate in making decision about the use/non-use of HRT. On the contrary, the women with high social status and high educational level were more likely to participate in decision-making about use/non-use of HRT. The result of this study suggest that health service providers should provide information about benefits and adverse effects of HRT and a women must be able to make decision about the use/non-use of HRT.

HPS-P-064

USE/NON-USE OF HORMONE REPLACEMENT THERAPY IN THE CONTEXT OF WOMEN'S MENOPAUSAL EXPERIENCE.

A. Srivilai¹, P. Boonmongkon²,
¹Naresuan University, ²Mahidol University,
Thailand

Aims : To investigate the decision-making about use/non-use of hormone replacement therapy (HRT) in the context of women's menopausal experience.

Methods : Interviewed 22 women age 49-61 years with natural menopause from northern Thailand. Data collected from June to December 2002.

Results : A total of 9 (40.9%) women were currently being treated with HRT. A total of 8 (36.4%) women were not being treated with HRT and 5 (22.7%) women had been treated with HRT in the past. The reasons for starting treatment for alleviating menopausal symptoms, to prevent osteoporosis and physician offered it. The reasons for not taking HRT included the following : never had menopausal symptoms, the physicians never offered it, lacking of knowledge about HRT, fear of cancer, allergic symptoms and menstruation recurrence. The reasons for discontinuation was unbearable side effects, being bored in taking the hormone, taking the hormone for a long time, forgetting to take treatment and don't want to pay for the medication.

Conclusions : Most women who used HRT are under government health welfare. The women of low social status and low educational level tended to use HRT without participate in making decision about the use/non-use of HRT. On the contrary, the women with high social status and high educational level were more likely to participate in decision-making about use/non-use of HRT. The result of this study suggest that health service providers should provide information about benefits and adverse effects of HRT and a women must be able to make decision about the use/non-use of HRT.

HOSPITAL PHARMACY SECTION - POSTER SESSION

HPS-P-065

REVIEW OF ORAL HYPOGLYCEMIC AGENTS OF HOSPITAL IN TAIWAN

C.H. Feng, C.C. Tsai,
Mackay Memorial Hospital Tainung Branch,
China Taiwan

Objective: Type 2 diabetes mellitus is a common disease, affecting as much as 20% of elderly population. The total annual costs of treating type 2 diabetes were 13.5% in Taiwan. We investigate the current status of use oral hypoglycemic agents (OHA) of hospital in Taiwan. Discuss the rationality of use OHA. **Methods:** Retrospective method was used. ICD-9 code 250 was caught by our computer system. Included criteria were diagnosis, which is type 2 diabetes, and took the OHA, which for a month period. Use insulin alone was excluded. The rationality was reviewed and analyzed. **Results:** The total number of selected cases was 1057. Every patient was given 1.64 kinds of OHA on average. The rates of use kinds of OHA were 43.2% (462, one drug), 49.7% (530, two drugs), and 7% (75, three drugs). The absurdity orders had 2 cases (0.19%) and 35 cases (3.2%), which associated with dosage and contraindication. **Conclusions:** Two patients with type 2 diabetes were combined therapy with 2 sulfonylurea agents. Most patients with type 2 diabetes will eventually require combination therapy with 2 or more agents to maintain glycoemic control. Combining an insulin secretagogue (i.e. sulfonylurea or meglitinide) and an insulin sensitizer (i.e. metformin or glitazone) capitalizes on unique mechanisms of action and results in significant HbA1c lowering. Two insulin secretagogues (i.e. sulfonylurea) combining are not recommendation. If patient is unable to achieve glycoemic control, insulin therapy is an appropriate consideration and should be added to oral agents. The others 35 cases were prescribed metformin (31), Diamicon (3), and rosiglitazone (1).

HPS-P-066

APPROPRIATE USE OF DRUG INFORMATION THROUGH THE INTERNET

T. Orii¹, P. Kyung², S. In J.²,
¹Kanto Medical Center NTT EC, Japan ²Seoul National University Hosp.,
South-Korea

We conducted studies on organizing drug information and a system to offer such information, as well as methods to provide information included in the package insert for medicinal products. Specifically, the studies focused on electronic processing of information for the service system, the use of the Internet, and centralization of information. In 1998, a 'group to establish a format to offer information for correct use of pharmaceutical products' was instituted.

Method - In the more specialized area, the information contained in the package insert for medicinal products was electronically processed. During this process, an acronym, SGML/DTD (Standard Generalized Markup Language/Document Type Definition), was selected for the aforementioned system. Considering the overwhelming demand and usefulness of the information at the clinical setting, a study was also conducted on the feasibility of offering it as a PDF (Portable Document Format) file.

Results - The information in the package insert can be searched by generic name, trade name, or therapeutic category. At the moment (February 2005), 11,768 products (expressed in the number of sheets in the package insert, PDF 11,591 sheets) are registered in the system.

Conclusions - The 'Drug Information Offering System' (<http://www.pharmays.gr.jp/>, available since May 31, 1999) is a system that supplements the conventional information sources for those involved in medical services and employed at medical facilities (such as physicians and pharmacists). The use of the Internet means accurate and rapid dissemination of information uniformly without favoring any specific geographic areas.

HPS-P-067

DRUG-RELATED PROBLEMS IN THE INTENSIVE CARE UNIT

H.C. Huang, H.Y. Lin,
Cathay General Hospital,
China Taiwan

The patient care in intensive unit is multidisciplinary. These patients usually received treatments with enteral feeding tube. Drug therapy may be complicated in these cases. The aim of this study is to estimate the active interventions by pharmacists.

From July 2002 to March 2005, this study on drug-related problems (DRPs) was retrieved through chart review in the medical ICU, of an 800-bed medical center. The DRPs are divided into two parts. General DRPs: appropriate indication, efficacy, safety and compliance. And enteral feeding DRPs: change of dosage form, interactions between drugs and enteral feeding tube, or nutrition formulas, and the patients themselves.

With a total of 399 DRPs, the major problems were related to drug safety (168 events, 42.1%) and efficacy (172 events, 43.1%). Regarding dosage adjustment in the renal and hepatic insufficient patients and unsuitable dosage form, there were 182 events (45.6%) and 104 events (26.1%), respectively, and the acceptance rate was 81.0%. The desirable crushed drugs for enteral feeding found in 143 events, and the acceptance rate is 81.8%. The major recommendations (128 events, 89.5%) were the change of dosage form. Our interventions may prevent the detrimental results of the increased dissolution rate (63 events, 44.1%), side effects, and the destroyed active components.

Dosage form selection and appropriate administration methods recommended by pharmacists were crucial in patients with enteral feeding tube. The pharmacists' main recommendations favored dosage adjustments and avoidance of unsuitable dosage form. The pharmacists played an important role on the patients care in the intensive unit.

HPS-P-068

ANALYSIS OF AN ADVERSE DRUG REPORTING SURVEILLANCE

C.Y. Tsai, Y.Y. Chen, L. Chou,
Chang Gung Memorial Hospital,
China Taiwan

Aims: Both the effective spontaneous reporting of adverse drug reactions (ADRs) and the rapid identification of possible drug safety hazards are important to pharmacovigilance. This study is describing an current electronic ADR-reporting system involves several approaches in which care-providers are encouraged to report adverse events via the outpatient system, inpatient system, nursing system and the pharmacy system. In addition, clinical pharmacists will monitor and reply the reports routinely through this reporting system, and it will be recorded on the patient's chart.

Method: The number of reports had been collected two years before the system was implemented in 2002 and also two years thereafter. Besides, the classification such as majority damage of organ system, treating methods and patient outcomes were analyzed. **Result:** There were 614 cases had been reported after the system was implemented during 2002-2003, compared with only 124 cases without the system during 2000-2001. The majority damage of organ system were Skin(32%), CNS(14%), CV(12%), Blood(12%), Hepatic(9%), Renal(8%). Most of the treating methods were discontinuing treatment(33%), discontinuing treatment plus antidotes(26%), shifted to other agents(13%), shifted to other agents plus antidotes(11%). The patient outcomes were classified as symptoms improved(62%), shifted to outpatient(30%), symptoms unimproved(5%), non-ADR report(1%), expired(1%), expired due to underlined disease(1%).

Conclusions: The electronic ADR-reporting system is a technology being used to find a new way of improving signal generation procedures and enhanced methods for optimizing the collection of spontaneous reports.

HOSPITAL PHARMACY SECTION - POSTER SESSION

HPS-P-069

IMMEDIATE PHARMACIST'S INTERVENTION TO PHYSICIAN'S PRESCRIPTION OF FLUOROQUINOLONES WITH ANTACIDS

S.H. Lai, H.C. Lai, C.L. Huang, T.Y. Hsieh, Y.J. Lau,
Show-Chwan Memorial Hospital,
China Taiwan

Fluoroquinolones is a broad spectrum of antibiotics with good antibacterial effect to different organisms including G (+) and G (-) bacteria, anaerobe, Chlamydia, mycoplasma, legionella and beta-lactam-resistant organisms.

The oral absorption and tissue penetration of fluoroquinolones are good. However its bioavailability including absorption, area under the curve (AUC), C max, Tmax and drug urine output may decrease significantly when administered with di- and trivalent cations containing antacids. In such conditions, the reduction of bioavailability can potentially lead to treatment failure and development of quinolone-resistant strain.

In our retrospective study, 128 out-patient department patients who took levofloxacin/ofloxacin were included. In this study, 82 patients took levofloxacin/ofloxacin with antacids (such as aluminum and magnesium contained in antacids) simultaneously; another 46 patients took levofloxacin/ofloxacin 2 hours before or without antacids administration. Prescription accuracy rate increased from 35.9%(46/128) to 64.2%(70/109) (p<0.05, X² test) after immediate pharmacist's intervention for one month. Prescription accuracy rate was 58.6% (65/111, p<0.05) and 54.5% (55/101, p<0.05) in 3rd and 6th months, respectively in spite of pharmacist's intervention withdrawal after one month.

Conclusion: Immediate pharmacist's short term intervention could significantly promote efficacy of fluoroquinolones utilization in patients. The role of pharmacist in the intervention of drug prescription can indeed improve the quality of medical care.

HPS-P-070

PROVIDING QUALITY INFORMATION TO CHEMOTHERAPY PATIENTS

E.N. Doolin¹, T. Orii¹, K. Sakakibara², T. Yasumizu²,
¹Kusto Medical Center NTT EC, ²Gynecology Dept,
Japan

Introduction: Generally, patients receiving chemotherapy for the first time are anxious about possible strong adverse reactions because anticancer agents show severe adverse reactions in comparison to other drugs. For this reason, it is important to provide quality information to alleviate their concerns.

Methods: We prepared a leaflet about chemotherapy to provide the information that patients wanted based on the results of questionnaires to 45 patients involved in chemotherapy treatment. During the period January 2003 through June 2004, 44 patients were asked to evaluate these leaflets.

Results: We found that 100% of the patients understood the information about chemotherapy and 95% were satisfied with the relevant information about the adverse reactions of chemotherapy.

Conclusion: These results suggest that the use of information leaflets by a pharmacist can improve patients' understanding of chemotherapy and can alleviate their concern about adverse reactions of anticancer agents.

HPS-P-071

A SIMPLE INITIATION SCHEDULE OF ORAL WARFARIN TO PREDICT THE SUBSEQUENT CLINICAL RESPONSE IN THE MANAGEMENT OF THROMBOEMBOLISM

C.Y. Ray, S.T. Deng
China Taiwan

Abstract: Warfarin is an oral anticoagulant for the treatment of thromboembolism. However, it is inconvenient for the clinical evaluation. During initial treatment, the international normalized ratio (INR) response has to be monitored frequently, until a stable dose-response relationship is obtained. This study was aimed to design a simple warfarin initiation schedule and established the relationship of the initial INR and maintenance doses of warfarin during the follow-up period. The study included 46 in-hospital patients with deep vein thrombosis (28), pulmonary embolism (9), atrial fibrillation with stroke (7) or others(2), with age ranging from 26 to 90 years, 12 patients were excluded from the study due to they had prior warfarin treatment or baseline INR > 1.2 or less of followed up in clinic. Patients were initiated with 5 mg warfarin daily for 3 days (day 1 to day 3). The INR was measured on day 4. The subsequent dose of warfarin was given according to the data of INR and patients were discharged with the maintenance dose and measurement of INR was performed at least 1 week later. (Table 1)

Measurement of INR at day 4 and clinical follow-up (F/U)

No of patient (Day 4)	Mean dosage of warfarin(mg) (mean ± SD)	INR
8	1.33-1.49	4.82 ± 0.31
12	1.54-2	4.37 ± 0.76
6	2.12-2.5	5 ± 1.1
4	2.59-2.98	2.32 ± 0.22
4	3.03-3.76	2.5 ± 0

According to this study, about 82 % patients (28/34) could achieve the therapeutic level of INR (2.0-3.0), no complication was noted. In conclusion, this simple initiation schedule of oral warfarin to predict the maintenance dose is safety, and effectively.

HPS-P-072

INCIDENT REPORTS IN A PHARMACY DEPARTMENT

H.Y. Lin, W.T. Huang, C.F. Cheng, H.M. Chen,
Cathay General Hospital,
China Taiwan

Patient safety is a very important issue. To improve it, sharing incident reporting and learning from it is recognized to be an effective approach. In the current report, we reviewed the events associated with the practice in a pharmacy department.

We classified the types and evaluated the consequence and the likelihood of recurrence of the events by using the Safety Assessment Code (SAC) scoring system from January 2000 to December 2004 in an 800-bed medical center, with 3,500 outpatient prescriptions per day. Incident that ranks a SAC 1 represents highest risk and SAC 4 means lowest risk. For the potential events, the assigned severity is based on the most likely worst consequence.

There were 27 reports within 5 years, the incidence of actual adverse events was 37% and that of potential events or close calls was 63 %. Of the actual adverse events, 40% were belonged to SAC 2, 50% with SAC 3. In the potential events, the incidence of SAC 1 to SAC 4 was 23.5%, 41.2%, 39.4% and 5.9% respectively. Error rate due to poor staff performance was 74%, and the other 26% might be attributed to system problems.

The information gained from the reports may serve as a guide for determining appropriate procedures to improve patient safety, moreover it should not be used for accountability.

HPS-P-073

PRESCRIPTION DRUG USE IN PREGNANCY IN TAIWAN

C.W. Kuo¹, Y.M. Lu¹, C.M. Huang¹, C.P. Yu¹, Y.H. Yang Kao², J.S. Chen³,
¹Cheng Hsin Rehabilitation Medical Center, ²National Cheng Kung University, ³Taipei Pharmacists Association, China Taiwan

Aims: The purpose of this study was to provide information on the prevalence of the use of prescription drugs among pregnant women in Taiwan.

Methods: A retrospective study was conducted with the use of a database of two hundred thousands random subjects offered by The National Health Research Institute (NHRI). The sampling period was from 1997 through 2002. ATC classification and the US FDA risk classification system were used for evaluation. Gestational duration was assumed to be 270 days, with three 90-day trimesters of pregnancy. The due day was separated from the 3rd trimester and analyzed independently.

Results: During the study period, 9522 deliveries (from 7703 pregnant women) were identified that met the study criteria. A total of 120468 medications was prescribed during pregnancy, of which 60934 (50.6%) had US FDA risk classification with 0.93% as category A, 55.36% as category B, 9.66% as category C, 30.32% as category D, and 3.52% as category X. The three most frequently prescribed drug classes were antacid and drugs for treatment of peptic ulcer & flatulence (17.16%), cough & cold preparations (13.28%), and analgesics (10.18%).

Conclusions: Our finding that almost one half of the prescription medications during pregnancy belonged to categories C, D, or X. Many of these drug uses such as the systemic use of tetracyclines and iodinated glycerol should be avoided.

HPS-P-074

MEDICATION USE IN PEDIATRICS BY NON-PEDIATRICIANS

J.H. Lian¹, H.C. Chang¹, C.M. Huang¹, J.M. Liew²,
¹Cheng Hsin Rehabilitation Medical Center, ²Taipei Pharmacists Association, China Taiwan

Aims: To evaluate the prescription appropriateness including drug choices and doses for pediatric patients cared by non-pediatricians.

Methods: A retrospective study was conducted in a general teaching hospital from July through September in 2004. All pediatric inpatients aging 12 years or less not cared by the pediatricians were included. They were mainly cared by the General Surgery, Orthopedics or Otorhinolaryngology.

Results: A total of 57 cases was available for evaluation. Four medications were found to have the highest dosing guideline noncompliance rate, they were gestamycin, acetaminophen, cephalosin and cefuroxime with noncompliance rate of 100% (18/18), 66.7% (10/15), 57.1% (5/7) and 55.6% (5/9) respectively. Medications not approved for pediatric use were also found in the study.

Conclusions: Our finding that dosing guideline noncompliance was commonly seen in pediatric patients cared by non-pediatricians, especially in the use of antibiotics and acetaminophen.

HPS-P-075

DATA ANALYSIS OF THERAPEUTIC DRUG MONITORING OF THEOPHYLLINE IN A TEACHING MEDICAL CENTER IN TAIWAN

C.H. Lee, S.T. Deng,
 China Taiwan

Backgrounds

Theophylline has been placed as a second line bronchodilator as a result of expanding usage of β_2 agonist for the treatment of bronchial asthma and COPD. Theophylline is now prescribed in low-dose as an anti-inflammatory agent. Nevertheless, the therapeutic monitoring of theophylline serum level is still actively performed for inpatient in our hospital. This evaluation is performed to see if the practice of theophylline serum level monitoring is properly and we would like to look for a cut-off dose that beyond this dose doctor can safely prescribe this potentially toxic drug without routinely follow up the serum level.

Methods

A list of adult in-patients who had a serum theophylline level checked during 2005/1/1-2005/2/28 was selected. We reviewed the patients chart based on the list and collected patients' basic information, daily dose of theophylline used, sampling time, serum level, and drug interactions. The cut-off dose of theophylline was analyzed by ROC curve.

Results

181 patients were evaluated, 64% of them (116) were over 60 years old. 17% of the samples were collected at inappropriate time. 35% of the interpretable data were below 5 mg/L. Daily dose of theophylline under 270 mg were related to a serum level below 5 mg/L with a sensitivity of 88.5% and specificity of 77.8%.

Conclusions

The data of this evaluation suggest that pharmacist had a responsibility to educate related medical personnel about the proper sampling time of theophylline. Patients over 60 years old with no other factors affecting theophylline clearance may be given a daily dose under 270mg safely with no need of checking theophylline level regularly.

HPS-P-076

ACTIVITY AND GENOTYPE OF THIOPURINE S-METHYLTRANSFERASE(TPMT) RELATED TO ADVERSE REACTIONS IN LEUKEMIC CHILD PATIENTS UNDER THE MAINTENANCE THERAPY WITH 6-MERCAPTOPYRINE(6MP)

K. Iwamoto, K. Naora, N. Nishimura, H. Iwase, R. Kanai, T. Taketani, S. Yamaguchi,
 Shimane University Hospital, Japan

Aims: Activity and genotype of TPMT were studied to explain cause of severe adverse reactions in leukemic child patients under the maintenance therapy with 6MP.

Methods: Three patients(3, 4 and 14 y.o.) with acute ALL participated in this study after the informed consents were obtained, whereas one patient(15 y.o.) with ML participated these except genotype analysis. Maintenance therapy was started with 6MP at 50, 60 or 75 mg/m². Activity of TPMT in red blood cell(RBC) was measured according to the reported method. Genetic polymorphism of TPMT was distinguished by the allele specific-PCR, PCR-RFLP and the direct sequencing methods. The concentration of 6MP and its metabolites in RBC was also determined by HPLC method.

Results and Conclusions: Present study included 2 ALL patients who suffered from serious vomiting shortly after the maintenance therapy with 6MP and were obliged to discontinue the medication. TPMT activities in these patients tended to be lower than those in other two patients who did not experience any severe adverse reactions. Genotype of TPMT with both relatively low activity in two patients and high activity in one patient was distinguished as the wild type (TPMT*1), and any of known mutations (TPMT*2, *3A, *3B, *3C, *6) were not detected at all. Discontinued patients could resume low dose maintenance therapy accompanied with monitoring of 6MP and its metabolites in the RBC. Therefore, the estimation of TPMT activity may lead to a primary prediction to avoid severe adverse reactions in the maintenance therapy with 6MP. In addition, adjunct monitoring of 6MP and its metabolites may assist better dose adjustment.

HOSPITAL PHARMACY SECTION - POSTER SESSION

HPS-P-077

THE GENERAL SITUATION OF ORPHAN DRUGS USAGE IN TAIWAN

Y.W. Hsieh¹, C.C. Liao², M.C. Hsieh³, Y.D. Cheng³
¹Chang Gung Memorial Hospital Keelung, ²PTDC, ³Chang-Gung Memorial Hospital, China Taiwan

Aims: Rare disorders refer to those conditions that affected small numbers of individual. Drugs used to treat these disorders are commonly referred to as 'orphan drugs'. Usually those drugs are not easily obtained and the quantity is limited. In order to smoothly providing those medications, government's involvement for integrating those orphan drugs supply is very important. This research funded by Bureau of Pharmaceutical Affairs, Department of Health, Executive Yuan, Taiwan, R.O.C. collected orphan drugs used items and quantity in every hospital in Taiwan from 2003 to 2004. Base on the result of this evaluation, government and medical personnel can have an idea to distribute orphan drugs and to conduct further studies. At the end of our study period, a formulary of orphan drugs used in Taiwan was published to provide as a reference.

Methods: In order to collect information and publish formulary, we ask hospitals, Bureau of National Health Insurance, Foundation of Rare Disease and pharmaceutical companies to provide orphan drugs they used or other related information base on Bureau of Pharmaceutical Affairs' help.

Results and Conclusion
Until March 2005, government announces total 120 classes and 140 types of rare disorders since the Rare Disorders Prevention and Treatment Act put into practice. The total number of rare disorders patients reported to Bureau of National Health Insurance is 1747. Base on our survey, there are 76 items of orphan drugs included. Within those drugs, Azagrelide, Tetracycline, thalidomide and Kelfer are used most often.

HPS-P-079

ASSESSMENT OF MEDICATION ERRORS IN A MEDICAL CENTER UNDERGOING INTEGRATED PHARMACIST EDUCATION

C.Y. Tsai, Y.Y. Chan, H.Y. Chen,
Chang Gung Memorial Hospital,
China Taiwan

Aims: To identify the factors contributing to medication errors that occurred in a 3500-bed medical center which executing integrated pharmacist continued education program in order to examine the ability of detecting medication errors reported by the pharmacists through an electronic reporting system.

Method: The reported medication errors had been collected during January 2004 to January 2005. The causes of these medication errors were also been classified and evaluated.

Result: There were totally 15876 medication errors have been reported. The causes of these medication errors are multi-factorial including physician prescribing errors(40.4%), physician key-in errors(17%) and mistakes of control drug management(42.6%). Among the 6420 physician prescribing errors, it can be classified as wrong drug(21.4%), improper dosage(54.1%), drug-drug interactions(19.4%), wrong administration route(4.6%) and others(0.52%). Among those 2700 physician key-in errors, there were wrong units(11.6%), improper quantities(42.9%), wrong drug(16.7%), improper dosage(5.3%), improper therapeutic period(7.9%), wrong administration route(7.7%), wrong frequency(0.3%) and others(7.6%). In addition, there were 1923 medication errors reported about contraindication in renal insufficiency patients who need to discontinue the current therapy or need to adjust the dosage among all of the medication errors.

Conclusion: Pharmacists play an important role in preventing medication errors. Both effective education and reporting system will allow for the identification of processes that introduce the potential for errors and will lead to an open discussion about improving the quality of patient care.

HPS-P-078

USE OF PRESCRIPTION-REFILL RECORDS TO ASSESS PATIENT COMPLIANCE IN TAIWAN

J.Y. Chen, L.W. Chen, L.J. Huang,
Far Eastern Memorial Hospital,
China Taiwan

Aims: Lack of compliance with prescribed medication regimens contribute to preventable patient morbidity. The purpose of this study is to understand the behavior of patient and to know which factors contribute to the poor compliance. **Methods:** This study was a longitudinal survey. In a period of five months (from October, 2004), we used prescription-refill records from a computerized prescription database in FEMH to assess patient compliance and evaluated the factors associated with compliance. Compliance was defined as refill within the days' supply of the refill due date.

Results: A total of 7,566 out-patients were enrolled in this study. The mean age of subjects was 58.67 ± 14.84 years. The patient groups were almost equally distributed between men (n=3,657, 48.3%) and women (n=3,911, 51.7%). We found compliance was related to patient's age, prescription day and clinic service. In our survey, 5667 patients were refilled on time. The study revealed higher compliance was in patients increased age (0-19 years old: 61.1% v.s. >80 years old: 80.8%, p<0.001), 3512 patients (78.9%) with 28-day of prescription refilled scheduled, and 2223 patients (73.7%) day of prescription refilled scheduled (p < 0.001). Meanwhile, the patients for surgical and psychiatry services had better compliance than others.

Conclusion: Under the situation of Taiwanese government encouraging patients to prescribe refill prescription, the compliance was still quite low. Therefore, pharmacists can play important role in educating patients to use medications more correctly and safely.

HPS-P-080

STUDY OF NSAIDS USAGE PATTERN AFTER VIACC'S WITHDRAWAL

C.M. Mao, E.K. Lee, C.C. Lin, D.K. Lee,
Kaohsiung Veterans General Hospital,
China Taiwan

Aims: To reveal non-steroidal anti-inflammatory drugs (NSAIDs) use pattern after Viacc's withdrawal in Kaohsiung Veterans General Hospital (KVGH) after Rofecoxib (Viacc) withdrawal.

Methods: Using the claims data files of ambulatory care expenditure from the Database of 2004, we analyzed the pattern and extent of these patients' use of NSAIDs for pain relief.

Results: The 59,143 patients with a NSAIDs prescription in our practice had a mean age (±SD) of 52.3 (22.1) years. The subgroups were aspirin (37%), COX-2-selective drugs (63%) respectively. Commonly used NSAIDs comprising of its group were Diclofenac Pro. (22%), Piroxicam (13%), Etofenac (13%). However, only Celecoxib market increased up 8% in 2004 (Q4) than Q3.

Conclusions: After Viacc's withdrawal, these patients taking Viacc could switch to COX-2-selective drugs more than non-COX-2-selective drugs.

HPS-P-081

EFFECTS OF IMPACT (JAPAN) ON PERIOPERATIVE INFLAMMATORY AND IMMUNE RESPONSES IN PATIENTS UNDERGOING MAJOR SURGERY FOR CANCER

H. Kariyazono, K. Nakamura, T. Komokata, N. Nakamura, R. Sakata, K. Yamada,
Kagoshima University,
Japan

Preoperative nutritional support is a potentially beneficial strategy to improve perioperative morbidity. To investigate the influence of preoperative administration of arginine, n-3 fatty acids and RNA-enriched supplement (Impact, Japan) on inflammatory and immune responses in patients undergoing major surgery for cancer, we measured plasma levels of n-3 fatty acids (docosapentaenoic acid, docosahexaenoic acid, linolenic acid and docosapentaenoic acid), n-6 fatty acids (linoleic acid, arachidonic acid, etc.), thromboxane B2, prostaglandin E2, inflammatory markers, microbial markers and cytokines. Patients were classified into two groups; supplement group received 1 L/day of Impact (Japan) for 5 days before surgery, control group received an ordinary diet without Impact (Japan) before the operation. Blood samples were collected 5 days before operation at the starting point of supplementation, and on perioperative days (PODs) 0, 1, 3 and 7. After taking the supplement, n-3 fatty acid family and rapid turnover proteins significantly increased on POD-0, while the levels of thromboxane B2 and n-6 fatty acids significantly decreased on POD-0. On POD-0 only, inflammatory markers (CRP and alpha 1-acid glycoprotein) in supplement group were lower compared with the control group. Supplement group showed remarkably low levels of polymorphonuclear leukocyte-elastase on POD-1 and POD-3, and interleukin-8 on POD-3. Oral administration of a supplement enriched with n-3 fatty acids for 5 days before surgery would bring an improvement of perioperative inflammatory and immune responses as well as nutritional state in cancer patients.

HPS-P-082

THE QUALITY CONTROL OF CLINICAL PHARMACOKINETIC SERVICE

J.D. Chen, Y.J. Yu-Ju Chiao, J.B. Pan, W.S. Liou,
Tri-Service General Hospital,
China Taiwan

Aims

To develop the indicators to measure the outcomes assessment of TDM and the contribution of clinical pharmacokinetic service.

Methods

The five indicators to evaluate the outcomes assessment of TDM service were developed. The five indicators were: (1) timing of specimen collection, (2) timing of interpretation of TDM result by pharmacist, (3) dosage regimen adjusted by pharmacist, (4) physicians' action taken according to TDM interpretation, and (5) clinical impact on patient care. They were then used to evaluate the outcomes assessment of daily routine TDM cases that were provided clinical pharmacokinetic service by clinical pharmacists. A total of 364 TDM cases were included during 4-month period in a 1600-bed ward at the Tri-Service General Hospital.

Results

Of 364 TDM cases, 282 cases (77%) was correct time for specimen collection, 307 cases (84%) whose timing of interpretation of TDM result by pharmacist were within 24 hours. The dosage regimen need to be adjusted was 298 cases (82%). 226 cases (76%) of the 298 dosage regimen adjusted cases were physicians' action taken according to TDM interpretation. 245 cases (82%) of the 298 dosage regimen adjusted cases were improvement in clinical condition.

Conclusions

Outcomes assessment is an important component of the evaluation of therapeutic drug monitoring and the contribution of clinical pharmacokinetic service. The indicators in this study have provided a tool for monitoring the quality of therapeutic drug monitoring.

HPS-P-083

INVESTIGATING CUSTOMERS' EXPECTANCY AND SERVICE QUALITY OF OUT-PATIENT DEPARTMENT IN THE HOSPITALS BY QFD

Y.C. Sun¹, C.M. Huang¹, J.M. Lien².

¹Cheng Hsin Medical Center, ²Taipei Pharmacists Association,
China Taiwan

Objectives: To investigate the expectancy and the weighting on the quality of OPD (out-patient department) pharmacy services of the three parties: pharmacy administrators, pharmacists, and patients, and then try to propose the related information for further action on the improvement of service quality. **Methods:** We utilize the technique of QFD (quality function deployment) to evaluate the service quality and customers' satisfaction on OPD pharmacy. First, clarify the variables of OPD patients' demand and expectancy on the pharmacies by personal interview. Then investigate the customers' satisfaction and weighting on each variables by questionnaires. Finally we construct the matrix from two dimensions: patients' needs and the quality improvement activities that the pharmacy administrator plans to implement. According to the analysis of this matrix, the priority of service quality improvement activities can be decided. **Results:** The total QFD construction of OPD pharmacy was well-interpreted by following the steps of QCC (quality control circle). QFD also provided some advantages rather than the traditional way of customers' satisfaction survey. **Conclusion:** The results of the present study can be as the references to someone who wish to provide further excellent quality of pharmaceutical services.

INDUSTRIAL PHARMACY SECTION - POSTER SESSION

IPS-P-001

DEVELOPMENT OF METRONIDAZOLE COLON SPECIFIC DRUG DELIVERY SYSTEMS

M.A. Naser, M.A. El Massik, V.F. Naggur,
Pharmacy Faculty, Alexandria University,
Egypt

The ability of matrix, multilayer and compression coated tablets of metronidazole to reach the colon intact has been investigated *in vivo* using pectin as a carrier.

Matrix tablets containing various proportion of pectin in absence and presence of certain excipients were prepared by direct compression and wet granulation techniques.

Multilayer tablets were prepared using 50-100 mg of pectin matrix tablet of metronidazole.

Rapidly disintegrating metronidazole core tablets were also prepared and were compression coated with pectin.

The effect of coat: core ratio as well as the incorporation of 10% chitosan in pectin coat on drug release was investigated.

Results of *in vitro* release studies using conditions simulating the pH and times likely to be encountered during transit to colon indicated that matrix and multilayer tablets liberated 50-75% and 32-61% drug respectively in the physiological environment of stomach and small intestine.

On the other hand, coats consisting of pectin alone protected the cores from premature release when a high coat: core ratio (5:1) was used. Within 5 hours, the release was less than 1%.

In presence of chitosan protection occurred at lower coat: core ratio (3:1).

Selective delivery of metronidazole to colon can be achieved using pectin or pectin-chitosan mixture in the form of compression coated tablets.

IPS-P-002

BIOAVAILABILITY OF DESMOPRESSIN FROM A SUPERPOROUS HYDROGEL BASED DRUG DELIVERY SYSTEM

A. Polnok¹, J.C. Verhoeff², N. Sarisuta³, M.B. Peterson⁴, W. Leclama⁵,
H.E. Junginger⁶

¹Faculty of Pharmaceutical Sciences, Thailand ²Leiden University,
Netherlands ³Mahidol University, Thailand ⁴Ferring Pharmaceutical,
Sweden

The purpose of this study was to evaluate the bioavailability of desmopressin formulated in a superporous hydrogel based drug delivery system without and with N-trimethyl chitosan (TMC), an absorption enhancer, in juvenile pigs.

Six female pigs, average body weight of 30 kg, were operated to insert a silastic cannula at the jugular vein for blood sampling. One week after the surgery, the pigs were given desmopressin formulated in a superporous hydrogel based drug delivery system without and with TMC via oral administration in enteric coated hard gelatin capsule. To determine the bioavailability (F) values, desmopressin solution were given to the pigs intravenously. Blood samples were taken from the cannulated jugular vein and subsequently analyzed by radioimmunoassay.

Parental administration of 10 mg desmopressin formulated in a superporous hydrogel based drug delivery system without and with TMC resulted in the F values of 0.42 ± 0.05 and 0.63 ± 0.41% (mean ± SD), respectively. Administration of desmopressin in superporous hydrogel without and with TMC showed Tmax of 80.0 ± 34.6 and 162.0 ± 64.6 min, respectively, and Cmax of 2.481.3 ± 715.3 and 2676.5 ± 1266.3 pg/ml, respectively. The insignificant effect of TMC, an additional absorption enhancer, on bioavailability parameters of such drug delivery system may be attributed to the slow opening of most tight junctions by the effect from the superporous hydrogel.

The designed delivery systems appeared to possess very promising prospects for the development of effective oral dosage forms of peptide drug desmopressin.

IPS-P-003

EFFECT OF ZETAPOTENTIAL, PARTICLE SIZE AND OTHER PHYSICO-CHEMICAL FACTORS ON STABILITY OF NIOSOMES

P.K. Lakshmi¹, S. Gayathri Devi², S. Shyamala Bhaskaran²

¹Karnataka state pharmacy council, ²Al-Ameen College of Pharmacy,
India

Methotrexate niosomes were prepared by lipid layer hydration method using chloroform: ethanol combination using span 60 surfactant in 1:1 molar ratio with cholesterol with

15-micromolar quantity of DCP. The niosomes of Methotrexate prepared were studied for zeta potential, particle size, and leakage of drug through the niosomes on storage at room temperature and at refrigeration temperatures.

The stability of niosomes were studied for 6 weeks. There is increase in vesicle size of the niosomes stored and there was a change from 1micrometer to 40 microns. The zeta potential was measured using pH 7.4 buffer. The stable niosomes were found to be range between 38 mv to 45 mv. There was a change in the zeta potential upon storage and at the end of the 6 week the zetapotential was found to be in the range of 50mv-70mv. The scanning electron microscopy studies showed that there was a uniform shape and size of the vesicles seen. Up on storage there was coalescence noted with nonuniformity in the shape with increase in vesicle size. The poly dispersity index was increased upon storage.

The stability of niosomes is crucial factor and the physicochemical factors decide the stability of niosome.

IPS-P-004

COMPLEXATION OF CELECOXIB AND MELOXICAM WITH 2-HYDROXY PROPYL BETA-CYCLODEXTRIN USING DIFFERENT TECHNIQUES

O. Kamel¹, S. Murtada², H. El Maradny², A. Hikal¹

¹Amriya, ²Faculty of Pharmacy,
Egypt

The effect of hydroxypropyl β-cyclodextrin (HPB) on the aqueous solubility and dissolution of celecoxib and meloxicam was investigated. Solid complexes were prepared by freeze drying, evaporation, and kneading. Various ratios of drug to HPB were prepared ranging from 1:1 up to 1:10. The resulting complexes were characterized using differential scanning calorimetry (DSC), infrared spectroscopy (IR), and scanning electron microscopy. Solubility and dissolution profiles were also determined. Dissolution media included water, 0.1N HCl with or without tween 80 and buffer at pH 7.4. *In vitro* studies showed that the solubility and dissolution rate of celecoxib and meloxicam were significantly improved by complexation with HPB. DSC, IR and electron microscopy examinations also demonstrated clear differences between the parent drugs and the complexes. Solid dosage forms incorporating these complexes in presence of pvp showed better performance than drug alone. The dosage forms made from solid dispersions prepared by the solvent evaporation technique gave the highest improvement in dissolution rate and efficiency. This work has demonstrated that the formation of solid complexes of insoluble drugs with HPB can be applied to product dosage forms that could lead to better bioavailability of the insoluble drug.

IPS-P-005

PREPARATION, CHARACTERIZATION AND EVALUATION OF METHOTREXATE LIPOSOMES

S. Bhaskaran¹, C.G. Harish¹, P.K. Lakshmi², P.J. Hemant¹,¹Al-Ameen College of Pharmacy, ²Drug information center, KSPC, India

Aim: To prepare, characterize and evaluate Methotrexate liposomes for oral drug delivery.

Method: The Methotrexate liposomes were prepared using various ratios of Dimyristoyl phosphatidyl choline (DMPC), Soya lecithin, cholesterol with various weight ratios of the drug using lipid layer hydration method to get multilamellar and unilamellar liposomes. Both multilamellar vesicles and unilamellar vesicles were characterized by SEM analysis for their surface characteristics, zeta potential for surface charges and particle size analysis using Malvern Mastersizer. A short term stability studies was conducted for 2 months at 4°C and at room temperatures (25°C).

Results: DMPC liposomes showed a better entrapment than Soya lecithin liposomes. Both MLVs and ULVs showed uniform particle size distribution. The zeta potential was found to be satisfactory. Drug release from liposomes was in a biphasic manner with an initial fast release within 3 hrs and then an equilibrium state. SEM analysis showed a smooth outer surface.

Conclusion: Thus MLVs ULVs can be prepared for oral drug delivery for the drug Methotrexate. Final formulations were prepared after lyophilizing the selected liposomes in the form of dry syrup. The stability of liposomal methotrexate can be enhanced by using in the form of dry syrup.

IPS-P-006

NIOSOMAL UREA GEL-ADJUVANT TREATMENT OF PSORIASIS

P.K. Lakshmi¹, S. Gayathri Devi², S. Shyamala Bhaskaran³, S.Sachidananda³,¹Karnataka state pharmacy council, ²Al-Ameen College of Pharmacy, ³Victoria hospital, India

Aim: To prepare niosomes of urea by various methods. To incorporate urea niosomes in chitosan gel and to study release pattern of urea. To conduct HRIPT test of urea niosomes to study the irritation and sensitization of the gel on human skin.

Method: The Urea niosomes were prepared using various spans such as span 20, span 40, span 60, span 80 in combination with cholesterol by lipid layer hydration sonication and Trans -membrane pH gradient method. The dried film was rehydrated with 7.4 buffer solution. The hydrated solution was kept at 60°C with occasional shaking and niosomes thus prepared. The niosomes were characterized for particle size analysis, entrapment efficiency and in vitro release. Then a gel was formulated using chitosan as polymer. The skin irritation test, 'Repeated insult patch test protocol' (RIPT) was performed on human volunteers to study the cumulative irritation and or allergic contact sensitization potential of a test material.

Results & discussion: Trans -membrane pH gradient methods produced 45% entrapment of the urea. The span 40, 1:1 molar quantity with cholesterol gave 70% release was seen in 24 hours from the gel formulation. 1%, 1.5% concentrations of chitosans gave good urea gel and did not produce any irritation on the human volunteers by RIPT method.

Conclusion: The span 40, 1:1 molar quantity with cholesterol gave better release compare to other surfactants. Various concentrations of chitosan urea gel did not produce any irritation on the human volunteers by RIPT. This urea gel can be used as adjuvant treatment in psoriasis as well as in cosmetic area.

IPS-P-007

PHARMACOKINETICS AND ANTILEISHMANIAL ACTIVITY OF AMPHOTERICIN B ENCAPSULATED LONG CIRCULATING LIPID NANOSPHERES

V. Veerareddy¹, V. Vobalaboina², A. AR³,¹St.Peters Inst.Pharm.Sciences, ²University College Of Pharm.Scienc, ³Indian Institute of Chem. Bio., India

Amphotericin B lipid nanospheres (LN-A) and long circulating lipid nanospheres (LN-A-PEG) were prepared by Amphotericin B with Distearoylphosphatidylethanolamine-Polyethylene glycol (DSPE-PEG) (57.6 mg), egg lecithin and cholesterol were dissolved in soybean oil, heated to 70°C on a water bath. Glycerol, sucrose and sodium oleate were dissolved in sufficient amount of distilled water and the aqueous phase was added to the oil phase at the same temperature (70°C). A coarse emulsion was prepared by homogenization at 6000 rpm for 3 minutes was subjected to ultrasonication using ultrasonicator. The blank lipid nanosphere formulation (LN-PEG) was prepared in a similar manner without drug. The formulations were sterilized by autoclaving at 121°C. The pharmacokinetics of LN-A and LN-A-PEG were compared to the amphotericin B deoxycholate (Fungizone). The same dose of each formulation (5 mg/kg) of amphotericin B was injected in the male wistar rats via tail vein. Plasma samples were collected after 5, 10, 15, 30 min and 1, 2, 4, 6, 8, 16 and 24 h after the injection. Amphotericin B showed biphasic disposition. The pharmacokinetics of LN-A and LN-A-PEG were significantly different with high AUC_{0-t} and lower clearance than that of fungizone. The peak plasma concentration of LN-A-PEG was approximately 4 and 2.5 folds higher than fungizone and LN-A. Antileishmanial activity of LN-A and LN-A-PEG was assessed in BALB/c mice infected with *Leishmania donovani* AG83 for 60 days. A single dose (5 mg/kg) of LN-A and LN-A-PEG was injected intravenously. Mice were sacrificed after 15 days of treatment with fungizone, LN-A, LN-A-PEG and Leishman Donovan Unit (LDU) is counted.

IPS-P-008

ASSESSMENT OF PHARMACEUTICAL QUALITY AND ANTIFUNGAL ACTIVITY OF MICONAZOLE NITRATE CREAMS MARKETED IN EGYPT

A. El-Sayed, N.A. Boraie, F. A. Ismail, L.K. El-Khorragui, S.A. Khalil, Faculty of Pharmacy, Univ. of Alexandria,

Egypt

Miconazole nitrate (MCZ), a sparingly soluble antifungal agent is marketed in Egypt as topical cream and oral gel. This post-marketing surveillance study was conducted to assess the in-vitro performance and antifungal activity, against *C. albicans*, of three local brands of MCZ cream in comparison to the innovator product Dakarin® (two batches each). Creams were tested for: drug content both chemically (two-phase titration) and microbiologically (turbidimetry), pH, spreadability, shape and size of MCZ crystals in the cream and in-vitro drug release. A modified USP dissolution apparatus 5 (paddle over disk) and agar diffusion technique were compared for testing drug release. Results of drug content obtained chemically ranged from 95.2 to 100 % and those obtained microbiologically ranged from 125.4 to 153.6 %, due to interference of preservatives. In-vitro release results obtained over 8 hours (under sink condition) ranged from 2.2 to 10.8 % compared to 17.3 & 20.5 % for Dakarin® (samples analyzed by HPLC). Inhibition zone diameter ranged from 15.6 to 19.8 mm compared to 25.4 & 26.3 mm for Dakarin®. The size and shape of MCZ crystals in different creams proved major determinants of drug release. Inter-batch variability was generally low. Antifungal activity in terms of inhibition zone diameter could be correlated linearly with cumulative % MCZ released after 8 hrs ($r = 0.983$) and with in-vitro release rate in $\mu\text{g}/\text{cm}^2 \cdot \text{hr} \cdot 0.5$ ($r = 0.982$). In conclusion, products tested vary widely in their in-vitro performance and antifungal activity. Both of the in-vitro release and agar diffusion tests proposed are equally useful in estimating drug release from creams.

INDUSTRIAL PHARMACY SECTION - POSTER SESSION

IPS-P-009

ASSESSMENT OF PHARMACEUTICAL QUALITY OF OMEPRAZOLE CAPSULE PRODUCTS MARKETED IN EGYPT

A. El-Sayed, N.A. Bornaie, F. A. Ismail, L.K. El-Khorragui, S.A. Khalil,
Faculty of Pharmacy, Univ. of Alexandria,
Egypt

Omeprazole, a poorly soluble, acid labile, lipophilic drug, is marketed as enteric coated pellets in capsules. Generic products available in Egypt show more than 4-fold price difference. This work is a post-marketing surveillance study to compare the in-vitro performance (using validated HPLC methodology) of 7 local omeprazole generics relative to the innovator's product. Tests performed include drug content, content uniformity, USP drug release test for enteric coated articles and a modified release test (involving pre-exposure to pH 4 buffer rather than 0.1N HCl). Products were subjected to an accelerated stability study under ICH conditions (40°C and 75 % relative humidity) for 3 months.

Results indicate that 5 generic brands passed tests for drug content & content uniformity. All brands passed the USP drug release test (% release at 45 min. ranged from 91.5 to 114.6) despite different release rates as judged by t_{90} . The modified release test which better simulates in-vivo conditions proved more discriminative (% release at 45 min. ranged from 22.8 to 96.1). Stability data indicate that after 3 months storage, drug content of 3 generics remained above 90 % with only one brand maintaining drug release above 75 % and showing similar stability to the innovator's. Chemical degradation of omeprazole resulted in darkened pellets and amber glass bottles provided more protection than blisters, strips or plastic bottles.

In conclusion, omeprazole capsule products in Egypt show wide variation in in-vitro performance and the modified release procedure could be recommended as a discriminative test for omeprazole release from enteric coated articles.

IPS-P-010

MODULATION OF TENOXICAM RELEASE FROM HYDROPHILIC MATRIX: MODULATOR MEMBRANE VERSUS RATE CONTROLLING MEMBRANE

M.A. El-Nabarawi
Faculty of Pharmacy, Cairo University,
Egypt

Aim: to study the release pattern of tenoxicam from hydroxypropyl methylcellulose (HPMC) through the restriction of the releasing surface by addition of membrane layer. Also to explore the membrane layer is a rate controlling or modulator layer. Methods: Twelve devices were constructed based on bilaminated films which produced by a casting/solvent evaporation technique. The drug-HPMC layer was covered by drug free membrane layer composed of a mixture of HPMC and ethylcellulose (EC). Devices were evaluated for thickness, drug content, water absorption capacity and drug release. The films were evaluated for thickness, appearance, folding endurance and transparency. The influence of membrane layer composition and thickness on drug release pattern was studied. Results: The release of drug from HPMC matrices without the membrane layer was fast and follows diffusion controlled mechanism. Except four devices, the release of drug from other devices becomes linear with time (zero order) and extended for long time especially when thickness and the ratio of EC was increased in the membrane layer. Conclusions: changing the geometry of drug layer by addition of membrane layer and changing its composition and thickness plays an important role in determining whether the membrane layer is rate controlling (i.e. control drug release and no change in its release mechanism) or modulator membrane (i.e. control drug release and change in its release mechanism).

IPS-P-011

PREPARATION, CHARACTERIZATION AND EVALUATION OF SOLID LIPID NANOPARTICLES CONTAINING TENOXICAM

O.N. El-Gazayerly
Faculty of Pharmacy,
Egypt

Solid lipid nanoparticles (SLN) were prepared using tenoxicam as a model drug according to a 2³ factorial design, at two levels of lipid and surfactant concentration. The SLN were prepared by the modified high shear homogenization and ultrasonic method using Carpritol and cetyl palmitate as lipids, and poloxamer 188 as surfactant. The prepared SLN were characterized using DSC, X-ray diffraction, and zeta potential and were evaluated regarding particle size, drug encapsulation efficiency and in-vitro drug release. The DSC and X-ray studies showed that the prepared SLNs showed less orderly arrangement of crystals, which was favorable for increasing the drug loading capacity. The encapsulation efficiency of tenoxicam within the SLN was in the range 83-88% for the prepared SLN formulations. Zeta potential studies revealed the stability of the SLN preparations as indicated by the negative charges obtained for all the preparations, which ranged from -11.7 to -35.0 mV. Particle size analysis showed that mean particle size of the prepared SLNs was in the range of 250- 392 nm. The particle size decreased at the higher level of surfactant used. The obtained results from the in-vitro release studies revealed that SLNs could be used as modified release formulations for tenoxicam over a period of 12 hours.

IPS-P-012

LIPOSOMAL DIBUCAINE DELIVERY SYSTEM: DEVELOPMENT AND CHARACTERIZATION

M.M. Nounou, L.K. El-Khorragui, N.A. Khalafallah, S.A. Khalil,
Pharmacy Faculty, Alexandria University,
Egypt

Formulation of local anesthetics in controlled delivery systems provides safer and more effective anesthesia. The aim of this study was to develop a liposomal dibucaine base (DB) local anesthetic delivery system. DB-loaded multilamellar vesicles (MLVs) with different characteristics were obtained by varying lipid composition, drug loading, induced charge and pH of the hydration buffer. Liposomes were characterized for morphology, size, entrapment efficiency (EE) and stability including leakage stability. Results indicate that amongst formulations tested, negatively charged liposomes with the lipid composition phosphatidyl choline: cholesterol: diethyl phosphate 7:6:1 and drug: lipid ratio 90mg: 300mg prepared with pH 9 hydration medium showed good in vitro characteristics in terms of EE (> 90%), sustained drug release (> 20% in 12 hrs) and low burst effect. However, they exhibited relatively poor leakage stability. A delivery system was prepared by incorporating negatively charged DB-loaded liposomes in a 2% HPMC gel base. Gel formulations were assessed in vitro for drug leakage stability and in vivo using the pin prick test in Guinea pigs. Incorporation of liposomes in the gel enhanced their leakage stability. Release characteristics of the liposomal gel could be modulated by combining different proportions of free and liposomal DB. The in vivo performance of a combination gel provided a superior local anesthetic profile (fast onset and prolonged duration of action) compared to a non-liposomal DB gel and a liposomal gel formulation with no free drug added. The DB liposomal gel developed offers great potentials as a local anesthetic delivery system.

IPS-P-013

LIPOSOMAL 5-FLUOROURACIL FOR TOPICAL DRUG DELIVERY

M.M. Nounou, L.K. El-Khordagui, N.A. Khalafallah, S.A. Khalil,
Pharmacy Faculty, Alexandria University,
Egypt

Effective topical therapy with 5-Fluorouracil (5-FU) requires sustained availability of the drug at a minimum effective concentration in deeper skin layers with minimal systemic absorption. A liposomal 5-FU delivery system may fulfill such requirements although it presents formulation challenges because of the drug hydrophilicity and low molecular size. In this study, 5-FU was incorporated in multilamellar vesicles (MLVs) and stable plurilamellar vesicles (SPLVs) of different lipid composition and charge to modulate entrapment efficiency (EE), 5-FU-loaded liposomes were characterized for morphology, size, EE, release kinetics, stability including leakage stability and skin permeation through rabbit skin. Negatively charged 5-FU SPLVs exhibited good biopharmaceutical attributes in terms of appearance, size (70.32µ), EE (74%), release rate (80% in 12 hrs), with 31 fold increase in dermal retention of the drug. However, they showed poorer leakage stability relative to neutral liposomes. 5-FU-SPLVs were subjected to freeze drying with different cryoprotectants to improve their stability. This was achieved maximally with trehalose. A liposomal gel was prepared by incorporating trehalose-freeze dried 5-FU SPLVs in 2% hydroxypropyl methylcellulose gel. The gel showed good short term storage stability (one month at 4°C) with maximum drug release of 65% in 12 hrs and reduced burst effect. Incorporation of liposomal 5-FU in the gel base in different physical forms (fresh dispersion, freeze dried powder as such or after reconstitution) did not affect the release characteristics. The liposomal gel prepared offers promises as a 5-FU topical delivery system.

IPS-P-014

TRANSDERMAL DELIVERY OF NAPROXEN FROM ENHANCED NIOSOMES

G.M.M. El Maghraby
University of Auckland,
New Zealand

The study investigated the effect of fatty acid side chain in Span on the transdermal delivery of naproxen (model drug) from niosomes and monitored the effect of penetration enhancers when incorporated in niosomes. Niosomes were prepared from surfactant and cholesterol at 2:1 molar ratio. This was hydrated with 10% v/v ethanol in water to produce total lipid concentration of 50 mg/ml. The control was saturated aqueous drug solution. Full thickness skin prepared from the ventral side of freshly excised rabbit ears was mounted on vertical Franz diffusion cells. To ensure sink conditions, ethanol-water (30% v/v) was employed as a receptor. At different time intervals after occlusive application of the tested formulations, samples were taken from the receptor compartments and replaced with fresh receptor fluid. These were analyzed for drug content by HPLC. The steady state transdermal flux of naproxen was increased by 2.9, 2.7 and 1.3-fold after incorporation in Span 20, 40 and 60 niosomes, respectively. Employing Span 20 the effect of enhancers was tested. Incorporating menthol in niosomes augmented the niosomal skin drug delivery and increased the drug flux by 4.1-fold when incorporated at 20% w/w. In contrast, incorporating oleic acid in niosomes did not augment the skin drug delivery with the transdermal flux values being decreased by increasing oleic acid concentrations. Phase separation was visually evident for niosomes containing high concentrations of oleic acid. In conclusion, the fatty acid chain of surfactant can affect niosomal skin drug delivery and incorporation of menthol in niosomes can further enhance transdermal drug delivery.

IPS-P-015

ALBATIN® IN HEALING HIPERPIGMENTATED SKIN

M. Tasic¹, M. Tasic¹, L. Tomić Radovanović²,
¹Pharmacy Institution Belgrade, ²Student Health Care Institute,
Serbia and Montenegro

Besides already known substances (hydroquinon, lactic, kojic, AHA acids...) a new substance named Albatin® is also used in hiperpigmentated skin treatment and for skin lightening. It is used as an inhibitor of melanogenesis in lightening products, against age spots, and spots caused by long sunlight exposure. It is stable in pH 3-9, and the recommended concentration is 0.5-1.5%. It can be formulated without restriction into the aqueous phase of a gel, an emulsion or a solution. The substance is not cytotoxic, phototoxic, photosensitive, skin irritating. The mechanism of action is quite different from that of other skin lighteners. It does not act as inhibitor of tyrosinase, but contributes to melanogenesis inhibition, directly stabilizing DOPAchrome through inhibition of DOPAchrome tautomerase.

The paper gives account of the therapeutic observation of patients with circumscription hyperchromic dermatosis (CHD), where Albatin® was used as depigmentation product. Hydrogels with Albatin® concentration of 0.5% and 1.5% were produced, and thirty patients with different CHD (chloasma, melasma, Lentigo solaris, Lentigo senilis, ephelides, berlock dermatitis etc.) were treated and observed. The age of patients was 18-26 years. In the course of two months, therapeutic results were evaluated and recorded by medical checkup once in fifteen days. Besides depigmentation effects, the appearance of some possible contraindications (irritation and itch) was also observed. Astonishingly good results were obtained in ephelides therapy, good results in berlock dermatitis therapy, and poor results in solar and senil dermatitis therapy. Best results were obtained by 1.5% concentration.

IPS-P-016

AMOXICILLIN AND IBUPROFEN: DRUG INTERACTION, BACTERIOLOGICAL, CLINICAL AND PHARMACOKINETICS STUDY. PART I. COMBINED THERAPY FOR TREATMENT OF HUMAN BACTERIAL INFECTION.

N.A. Sahri
Ain Shams University,
Egypt

It was found that ibuprofen (IBU) influences the complex immune system to overcome a bacterial infection and possesses antibacterial activity, thus, its formulation with amoxicillin (AMX) in the same dosage form (capsule) worth to be studied. The aim of this combination is to obtain a higher antibacterial activity and increase patients' compliance. AMX and IBU physical mixture at ratios 1:1 and 2:1 were subjected to in-vitro examination for possible interactions using IR, UV scanning, DSC, TLC, results confirm absence of interaction. Effect of IBU on the antibacterial activity of AMX against certain bacterial species was investigated. The results showed that IBU potentiate the antibacterial activity of AMX towards certain micro-organisms. Sixteen A-I capsule formulations were prepared using a fractional factorial design (1/3) of 27 and tested for powder content characteristics and dissolution testing which showed that neither drug affect the dissolution process of the other. Data treatment and statistical analysis was performed. The chosen formulae; F4 and F15 were subjected to clinical study on 25 patients divided into 2 groups, one was treated with A-I capsules, the second was given AMX capsules. Data collected include: age, diagnosis, body temperature, total white blood cell count (W.B.C.), kidney and liver functions. Statistical analysis of W.B.C. data by using paired t-test revealed that there was a significant difference between before and after treatment and between AMX and A-I at p<0.001. There was no effect of sex on the percent decrease in W.B.C. at p<0.05. Thus, A-I combination proved to possess a higher clinical efficacy and microbiological activity than AMX alone.

INDUSTRIAL PHARMACY SECTION - POSTER SESSION

IPS-P-017

PROMISING ALTERNATIVE CARRIERS TO LACTOSE MONOHYDRATE FOR CROMOLYN SODIUM DRY POWDER INHALATION

H.M. EL. Laithy, A. Ahmed Abdelbary, M.I. Tadros,
Pharmacy college,
Egypt

To date, most Dry Powder Inhalation (DPI) rely on α -lactose monohydrate as the carrier of choice. However, interactions with many drugs with immunological and allergic problems were reported.

In this study, Coarse sieved fractions (63-80 μ m) of lactose, glucose, anhydrous lactose, avicel PH 101, spray dried lactose, mannitol and sorbitol have been evaluated as alternative carriers for cromolyn sodium (CS) that possess the positive aspects of lactose but overcome the above mentioned drawbacks. Their physicochemical properties (particle size, initial water content, microscopic optical image and moisture sorption capacity) were analyzed. Carriers that showed suitable physicochemical properties for use in DPIs (glucose and sorbitol) were further used to prepare CS-coarse carrier binary mixtures. Tertiary drug carrier mixtures were also prepared adopting two strategies. The first one includes the addition of micronized carrier particles in different ratios to coarse carrier CS-binary mixture. In the second one, micronized avicel 2000 as a high adsorbing material was premixed with CS before the addition of coarse sorbitol in a trial to overcome its detected high moisture sorption capacity. Finally all formulations were tested for their *in vitro* aerosol deposition using a twin stage impinger.

The results revealed that, no significant difference ($P < 0.05$) between the fine particle fractions (FPFs) of CS delivered from mixtures containing lactose (36.05 \pm 1.5%), glucose (35.00 \pm 1.2%) and sorbitol (33.33 \pm 1.2%).

This suggests that glucose & sorbitol are promising carriers for DPI where they possess acceptable aerodynamic properties and able to deliver CS efficiently as lactose.

IPS-P-018

DRUG CHECKING SYSTEM FOR THE SAFETY OF UNIT DOSE DRUG DISTRIBUTION SYSTEM—PRIMARY REPORT

R. Chen shyun yun
Taichung veterans general hospital,
China Taiwan

More attention had been placed on the topic of drug safety for patients in the past few years. In order to preserve the medication safety for hospitalized patients and prevent unnecessary and unknown source of human error, it is critical to implement an automatic drug dispensing system with Bar code Point-of Care (BPOC) which provide pharmacists the latest patient drug profiles with wireless connection, and also serves as an important tool to check drug names, dosages, doses, appearance and even the name of patients for nursing staffs during medication administration.

Therefore, we are actively discussing and communicating with the firm responsible for automatic dispensing machine on issues as re-integrating of dispensing protocol on updating the designs of the hardware and software. As for the pharmaceutical service and nursing procedures, a wireless updating system is designed for pharmacists who preparing prescriptions furthermore the system is adapted for nurses to administer or verify medication at patients' bedside in order to minimize error-prone and unknown source of human mistakes.

IPS-P-019

ENHANCEMENT OF DISSOLUTION RATE OF ACYCLOVIR BY COMPLEXATION WITH HYDROXYPROPYL β -CYCLODEXTRIN USING DIFFERENT TECHNIQUES

O.N. El-Gazayerly, N.M. Marsi, A.A.A. El-Wafa,
Faculty of Pharmacy,
Egypt

Aiming to increase the water solubility of the poorly soluble drug, acyclovir, complexes of the drug with hydroxypropyl β -cyclodextrin (HP β CD) were prepared. Complexes between the drug and HP β CD were prepared as physical mixtures and lyophilized forms. These solubility study was performed in phosphate buffer saline at concentrations 5, 10, 15 and 20% HP β CD. The complex was evaluated using differential scanning calorimetry (DSC), X-ray diffraction and thermal gravimetric analysis (TGA). The solubility studies showed that HP β CD-drug complexation was of the AL type, of stoichiometric ratio 1:1. This was confirmed by the continuous variation method. DSC studies shows that a complex existed between acyclovir and HP β CD as indicated by the disappearance of the characteristic endothermic peak of acyclovir. X-ray diffraction revealed the acyclovir existed in an amorphous state in the lyophilized inclusion complex. *In-vitro* release studies revealed enhanced dissolution of the poorly soluble drug when complexed with HP β CD (1:2). Such enhancement was more pronounced in the lyophilized form of the complex than the physical mixture.

IPS-P-020

PREPARATION AND EVALUATION OF RAPIDLY DISINTEGRATING TABLET IN THE ORAL CAVITY BY THE DRY GRANULATION AND COMPRESSION METHOD -AVAILABILITY OF POWDERED CELLULOSE AS AN EXCIPIENT

Y.Y. Yamada, Y. Yamada, N. Mariko, Y.S. Yasuhiro/Shimada, Y.
Yonezawa, S. Hisakazu,
Meijo University,
Japan

Introduction

A rapidly disintegrating tablet is known to be a form that can be swallowed easily because it is deformed by sputum in the human oral cavity. In this study, the tablet was prepared by the dry granulation and compression method using powdered cellulose (PC) as main excipients. Powdered cellulose is expected to be good for not only compressibility but also disintegration due to its swelling property. It also has the advantage of lower cost compared with other excipients such as microcrystalline cellulose.

Experimental

Batches contained some model drugs and PC, lactose (Lac), L-HPC as excipients were compressed to flakes by a roller compactor, then the flakes were crushed and sieved to granules. The granules were added to sucrose fatty acid esters (SE) as a lubricant or AEROSIL (AERO) then compressed to tablets by a rotary tableting machine. The tablets were evaluated mainly by tensile strength and disintegration time.

Results and Discussion

The rapidly disintegrating tablet containing PC were successfully prepared. Fluidity of the granules were improved and the tensile strength of tablets became higher using 0.7% AERO. As the amount of SE addition were increased, the tensile strength became lower and the disintegration time became later, but from the pressure transmission ratio, the optimal amount was 1-2%. The advantage of using PC was that it had very good compressibility and disintegrated faster after blending with L-HPC rather than using L-HPC alone. A disadvantage was that the evaluations on sensory cost worsened as the amounts of PC increased, although this was improved by using saccharides such as Lac.

INDUSTRIAL PHARMACY SECTION - POSTER SESSION

IPS-P-021

THE PHARMACEUTICAL MANUFACTURING OF CRUDE DRUG POWDER -THE EFFECT OF SOME DISINTEGRANTS ON THE PHYSICAL PROPERTIES OF THE TABLET-

K. Konishi, H. Sunada, Y. Yonezawa,
Meijo University,
Japan

Introduction

Crude drugs are very useful for health but these powders show various forms and properties that can become difficult to deal with qualities due to poor fluidity, strong adhesiveness and highly fibrous. Therefore we studied the pharmaceutical manufacturing of crude drug powder by the dry compacting method.

Experiment

Granules: Crude drug powders were mixed with some excipients, for example lactose or Micro Crystalline Cellulose (MCC), and compressed by a roller compactor into a flake form then the flakes were milled to produce granules. The physical properties of these granules were examined.

Tablets: The granules were compressed by a single or rotary tableting machine with a disintegrant, Kolidon CL and some binder, such as HPC, MCC and so on. The physical properties of those tablets such as tablet hardness, disintegration time and dissolution rate were examined.

Results and Discussion

As a result, tablets without a disintegrant showed a low hardness level below 1.0kgf and a long disintegration time over 1hr, but tablets with a disintegrant showed a lower hardness and shorter disintegration time. To increase the hardness, a binder, for example HPC or MCC, was added and the effect examined. Then the hardness was increased and the disintegration time was only slightly longer.

Furthermore, the optimal mixture ratio of binders and disintegrants was derived by multiple regression analysis.

This suggests that the formulation of tablets with ideal physical properties can be easily determined and that using these results allows the quantitative and rational manipulation of tableting.

IPS-P-022

COMPARATIVE EVALUATION OF MATRIX AND MINIMATRIX TABLETS OF CHLORPHENIRAMINE MALEATE

S. Bhaskaran, A.N Asha,
Al-Ameen College of Pharmacy,
India

Aim: To design extended release matrix and mini-matrix tablets of a water soluble model drug Chlorpheniramine maleate(CPM) using two native polysaccharides -xanthan gum(XG) and locust bean gum(LBG).

Methods: Granules of CPM were prepared by wet granulation technique using 50% of the polysaccharides comprising of XG and LBG in different ratios of 1:1, 1:2 and 1:3. Avicel PH101 was used as the diluent, alcoholic solution of either PVP K-30 or Ethyl cellulose(EC) as the binder. Matrix tablets were prepared by compressing 150mg of the granules on 8mm punches and Mini-matrix tablets on 4mm punches. The tablets were evaluated for their physical parameters and drug content. The in vitro drug release of the tablets was studied in 500ml of distilled water. Drug release data was fitted in the zero order, first order and Higuchi models.

Results: The drug release was extended upto eight hours for mini-matrices and upto 10 hours for matrix tablets. The drug release from mini-matrices followed first order kinetics whereas the release from matrix tablets followed zero-order kinetics.

Conclusions: The present study suggests that the matrices and mini-matrices of XG-LBG could be successfully used in extending the release of a water soluble drug like CPM.

IPS-P-023

STABILITY TESTING OF SILDENAFIL TABLETS

M. Lutina, S. Jurliina, L. Pozajic Pikeric, M. Mihoci,
PLIVA Research and Development Ltd.,
Croatia

Stability testing of Sildenafil tablets is performed as part of the drug development program.

During the stress test of Sildenafil tablets assay (HPLC), impurities (HPLC), water and appearance were tested. It was shown that the product is chemically stable, however significant physical changes were observed after exposure to high humidity.

Within the formal stability study, samples of Sildenafil tablets 25 mg, 50 mg and 100 mg in two types of packaging are tested: OPA/Al/PVC/Al blisters (packaging A) and PVC/PVDC/Al blisters (packaging B). Formal stability study is performed in line with ICH guidelines. Assay, impurities, dissolution, disintegration, hardness, appearance and microbiological quality are monitored.

After the first six months of stability testing the results obtained with samples in two types of packaging were compared. The samples in packaging B have shown slightly greater changes in physical parameters (water, disintegration, hardness, appearance), than the samples in packaging A. However, since all of the obtained results complied with the specification requirements, it was concluded that both types of packaging provide adequate protection for Sildenafil tablets. Therefore, the more economical type of packaging, PVC/PVDC/Al blisters, was chosen as the final packaging for Sildenafil tablets.

Up to now, 24 months of stability testing is completed. The obtained results confirm adequate chemical, physical and microbiological stability of Sildenafil tablets in the proposed packaging. According to CPMP Note for guidance on declaration of storage conditions (CPMP/QWP/60996/Rev 1) no labelling regarding storage conditions is required.

IPS-P-024

PREPARATION AND EVALUATION OF SOLID DISPERSION FOR NITRENDIPINE-AEROSIL SYSTEMS USING MELT-MIXING METHOD

L. Wang¹, F. Cui², H. Sunada³

¹-Japan, ²Shenyang Pharmaceutical Univ .China, ³Meijo University, Japan

Introduction

Nitrendipine (NTD), a dihydropyridine calcium channel blocking agent, is used to treat a variety of cardiovascular disorders. Due to its low aqueous solubility (about 2µg/mL), leading to the poor absorption of nitrendipine after oral administration, we prepared solid dispersions of nitrendipine to improve its dissolution rate and solubility.

Experiment

Solid dispersions (SD) of NTD were prepared by the melt-mixing method using fine silica particles having different particle size and specific surface area (Aerosil) as carriers. The physicochemical properties and dissolution properties of SDs were investigated.

Results and Discussion

Powder X-ray diffraction and differential scanning calorimetry evaluation showed that NTD in SDs was dispersed in the amorphous state when treated by the melt-mixing method. Fourier Transformation IR Spectroscopy obtained with SDs indicated the presence of hydrogen bonding between the secondary amine groups of NTD and silanol groups of silica particles. For NTD-Aerosil 200FAD (1:5) SD, specific surface area and water adsorbed amount on the surface of SD particles at 0.4 relative pressure were 223 times and 20 times that of original drug crystals respectively. The dissolution property of NTD in SDs was remarkably improved regardless of the grade of Aerosil. For NTD-Aerosil 200FAD, 300CF, 380 (1:5) SDs, at the end of dissolution test (60min) the concentration of NTD were 28, 27, 22 times that of original NTD crystals respectively. The rapid dissolution rate from SD was attributed to the amorphism of drug, improved specific surface area and wettability than original drug crystals.

INDUSTRIAL PHARMACY SECTION - POSTER SESSION

IPS-P-025

PREPARATION OF SOLID DISPERSION FOR PRANLUKAST HYDRATE AND HYDROXYPROPYLMETHYLCELLULOSE SYSTEM USING A TWIN SCREW EXTRUDER

S. Yasui, Y. Yonezawa, H. Sanada,
Meijo University,
Japan

Introduction

The solid dispersion method, by which a drug is dispersed in a carrier to make it amorphous, is one of the pharmaceutical approaches most commonly employed to increase bioavailability of poorly water soluble drugs. A pressurization/sealing/extruding method using a twin screw extruder is one of the methods used to facilitate solid dispersion. This extruder, originally designed as an extrusion/casting device for polymer alloys in the plastic or food industry, can be used for mass and continuous production of solid dispersion.

Materials and methods

In the present study, we prepared solid dispersion of Pranlukast hydrate (ONON) as a model drug and Hydroxypropylmethylcellulose (TC-5E) as the carrier using a twin screw extruder. Additionally, we investigated improvement of the solubility of the drug by changing the extrusion conditions, operation temperature and the kind and quantity of additive liquid. The degree of solid dispersion obtained was evaluated and the crystallinity, solubility and interaction between drug and carrier were compared with those of preparation made by the co-grinding method and physical mixing.

Result and discussion

The extrusion pressure increased as the operation temperature decreases, but there was no change in the crystallinity of ONON. However, the solubility of solid dispersion produced under higher pressure was better than that of preparations produced under lower pressure. Therefore, the solubility could be improved by selecting an appropriate extrusion temperature, and the solubility of ONON was improved by changing the kind and quantity of additive liquids.

IPS-P-027

EFFECT OF VARIABILITY OF PRIMARY ACTIVE MATERIAL ON THE PERFORMANCE OF CARBAMAZEPINE GENERIC PRODUCTS

S. Schic¹, H. Trobreadovic², G. Benz², S. Hadzidedic², S. Kocova El-Arim², H. Leuenberger¹

¹Institute of Pharmaceutical Technology, Switzerland ²Bosnalijek, Bosnia and Herzegovina ³National Research Centre, Egypt

The influence of the variability of primary active material on the dissolution behavior of carbamazepine (CBZ) generic products was studied using commercially available CBZ from different suppliers.

The differences between the commercial samples were determined by differential scanning calorimetry, X-Ray powder diffraction, hot stage microscopy, scanning electron microscopy, and dissolution rate.

The CBZ samples varied in their crystal modification or polymorphism, exhibiting different morphology, particle size and size distribution, all of which led to irregular dissolution behavior and affected short and long-term stability of the products.

The variations of the crystal properties are most likely due to the differences in the crystallization processes used by the different manufacturers of the drug.

The variability of the morphological properties was suggested to be due to the different conditions used in the manufacture and/or due to grinding.

The dissolution profiles of both, bulk powder and tablets, varied significantly from sample to sample. Furthermore, the mechanical properties were also influenced by the variability in the crystal modifications of the different samples.

The differences of primary active material were best described by powder dissolution profiles of bulk drug samples.

Conclusion: In order to maintain the quality of the final product either the characteristic properties of the drug have to be determined or a pretreatment has to be selected to eliminate the previous history of the active ingredient.

IPS-P-026

DESIGN AND IN-VITRO EVALUATION OF ALGINATE HYDROGEL PARTICLES OF GLICLAZIDE FOR ORAL CONTROLLED RELEASE: EFFECT OF POLYMER TYPE

M. Ghurab¹, H.M. Abdel salam², M. Abdel mosty²

¹College of pharmacy, Suez Canal Univ., ²Medical union pharmaceutical co., Egypt

Gliclazide, an effective antidiabetic drug, entrapped within gel microbeads using sodium alginate and systems containing mixtures of sodium alginate and various polymers were obtained by Orifice-Ionic gelation method. encapsulation efficiencies, bead size and drug release profile were evaluated. Increase in encapsulation efficiencies for the alginate beads from 69, to 76 and 84% were observed with the increase in drug ratio (sodium alginate: drug, 1:1, 1:3, and 1:5). The encapsulation efficiencies obtained for the gel beads in presence of different polymers were not affected significantly, except systems with xanthan gum where encapsulation efficiencies increased to 76% and systems with eudragit RL 30D and eudragit RS 30D decreased to 57 and 47% respectively. Also, increase in polymer concentration from 10 to 20% of total alginate polymer concentration had no effect on the encapsulation efficiencies. The majority of the studied systems showed no effect on the drug release except for xanthan gum that decreases the release significantly. Gel microbeads size distribution with and without polymers was approximately similar. However, increasing drug to polymer ratio increases beads size significantly. The morphological observations showed that the gel microbeads were spheroid with a homogenous distribution of the drug in the microbeads. From the previous work we can conclude that type, concentration of polymer, drug concentration and drug ratio to polymer, have effect on the characteristics of gliclazide hydrogel particles.

IPS-P-028

A NOVEL APPROACH TO THE PREPARATION AND SCALE UP PRODUCTION OF PENTOXIFYLLINE CONTROLLED RELEASE TABLETS: I. PREPARATION AND EVALUATION

M.A. Sharaf el Din¹, M.A. Shara², S.A. Elkhesen³, I. Khatib⁴, S.A. Nour¹

¹Five Fives Co., ²A. A. K. Co., ³Fac. of Pharmacy, Cairo Univ., ⁴Fac. of Pharmacy, Azhar Univ., Egypt

Aim: The purpose of this study was to prepare 600 mg pentoxifylline tablet formulation with acceptable controlled release (CR) profile and to scale it up to a pilot level.

Experimental: Tablets were prepared using wet granulation (WG), direct compression (DC) and hot melt (HM) techniques. The prepared formulae were subjected to various physicochemical and physicochemical testing to determine the most appropriate formulation with an acceptable CR profile. Factors affecting the release profile either related to the formulation (content and type of gum, tablet hardness, granules particle size and tablet surface area/shape) or the production technique (Method of preparation, type of granulating fluid and thermal treatment) were studied. Formulae showed satisfactory CR profiles were subjected to scale-up production up to 20 kg per batch.

Results: Seven formulae prepared by WG technique, two prepared by DC technique and one by hot melt technique showed satisfactory CR profiles. Water, as a granulating agent, showed superior CR behavior compared to isopropyl alcohol. Decreasing the granule particle size and the tablet surface area improved the CR behavior. Scaling-up the previous formulae affected the release profiles dramatically. Only three formulae prepared by WG technique gave acceptable profiles.

Conclusion: Pentoxifylline CR tablets using wet granulation technique and water as a granulating fluid with low granule particle size and either xanthan gum or HPMC E4 as gum type matrix and low tablet surface area gave satisfactory formulae with acceptable CR profiles comparable to the innovator product.

IPS-P-029

ELECTRICAL MUSCLE STIMULATION AS NEW METHOD FOR ENHANCED TRANSDERMAL DELIVERY OF TENOXICAM IN PATIENTS

M.A. El-Nabarawi
Faculty of Pharmacy, Cairo University,
Egypt

Aim: To investigate the accessibility of AB Tronic fitness device (electrical muscle stimulator) for the transdermal delivery of tenoxicam in patients. **Methods:** Tenoxicam gel was prepared by dispersing 1% of carbopol 940 in a mixture of water and polyethylene glycol with drug (2%) and then neutralized with triethanolamine and adjust pH to 7.4. Fifteen human patients, suffering from stiff and painful shoulder, were participated in this study under supervision of a physician and divided into three groups. Tenoxicam gel was applied to each patient shoulder in three different ways: method I) add gel to first group only (passive transport, PT); method II) add gel to second group and then applying AB Tronic device (1 pulse/second) for 10 minutes; method III) for third group applying AB Tronic device (1 pulse/second) for 10 minutes then removes the device and then adds gel. **Results:** Pain and stiffness was relieved in the following decreasing order: method II > method III > PT. The pharmacokinetic parameters and area under the curve were calculated from blood levels of the drug reveals that method II showed higher AUC than method III than PT. **Conclusion:** Addition of gel and then applying AB Tronic device was the most interesting way for the application, where lag time was markedly reduced suggesting a faster penetration of drug into the skin and relieve pain.

IPS-P-031

DEVELOPMENT OF PECTIN/CHITOSAN MATRIX TABLETS FOR COLONIC DELIVERY OF DEXAMETHASONE.

N.D. Mortada¹, S.S. Abd ElHady¹, L. Khairy², A.M. Coucha¹,
¹Pharmacy Faculty AinShams University, ²ADCO,
Egypt

Aim: Development of pectin-chitosan (P:C) based matrix tablets for colonic delivery of dexamethasone. **Methods:** Pectin and chitosan were mixed in different ratios viz 2:1, 6:1 and 10:1 P:C. In vitro release studies were done in pHs 1.2, 5.5, 7.4 and 6.8. The tablets were investigated concerning the % matrix erosion, the % water uptake and the unconstrained swelling behavior. In vivo evaluation was carried out in the cecum of conscious male rats with and without antibiotic treatment. **Results:** Tablets prepared with pectin only, failed to retain the drug enough period to reach the colon as 100 % of the drug was released after 4hrs. On the other hand, the addition of chitosan retarded the drug release. An inverse relationship was found between % drug released and % chitosan incorporated in the tablet. The 2:1 P:C tablet released 20% of its drug load after 5 hours before it reaches the colonic pH (6.8). The kinetic analysis of the release data showed variability in the order of drug release depending on the % of chitosan and the pH. The 2:1 P:C matrix tablet with the lowest rate of erosion and water uptake and the largest gel layer thickness, as well as the highest drug protection, was selected for in vivo studies which confirmed the ability of this matrix to deliver most of its dexamethasone content in the colon. **Conclusion:** The addition of chitosan to pectin was necessary to achieve colonic drug delivery of dexamethasone when formulated as matrix tablet. The optimum ratio of P:C was found to be 2:1.

IPS-P-030

FORMULATION, PHARMACOKINETICS AND CLINICAL EVALUATION OF NICARDIPINE HYDROCHLORIDE SUSTAINED RELEASE FLOATING TABLETS

N.A. Sabri
Faculty of Pharmacy Ain shams university,
Egypt

The aim of this study is to evaluate the prepared floating tablets of nicardipine HCl (NC) and determination of its pharmacokinetic parameters and hypotensive effect compared with a standard commercial capsules. Three hydrophilic polymers; NaCMC, HPMC and Avicel in combination with CO₂ generating mixture (NaHCO₃ and anhydrous citric acid in the ratio of 1:1) were used in the compounding process. The tablets/rate of water uptake, floatation performance and dissolution rate were evaluated. Two chosen formulae (the first consists of 25:25:100mg of NaCMC:HPMC:Avicel while the second of 75:75mg of HPMC:Avicel per matrix) were subjected to pharmacokinetics and bioavailability studies which showed that both floating tablets had lower C_{max} and longer T_{max} and Frel% of 87% and 119.4% compared to the conventional capsule. Clinical study was conducted on 16 male hypertensive patients, using formula of higher Frel% value and the conventional reference capsule for comparison, the obtained data showed that both evoked a hypotensive effect after 60 minutes and continued for 3 and 7hr for the capsule and the tablet respectively. The significant acute hypotensive maximum effect (E_{max}) were 10.85±0.14 and 9.87±0.359mmHg with a tmax of 2 and 6hr respectively. The mean values of the decrease in blood pressure at each interval for each administration were evaluated by ANOVA one way statistical analysis showing no significant difference between the prepared tablets and the conventional capsules at p<0.05. Sustained release effect of NC floating tablets was achieved which could increase patient compliance due to the reduction in vasodilatation-related effects such as flushing, headache, and peripheral edema.

IPS-P-032

PECTIN/CHITOSAN COMPRESSION COATED DEXAMETHASONE TABLETS FOR COLONIC DELIVERY: AN IN VITRO IN VIVO EVALUATION

N.D. Meetada¹, S.S. Abd ElHady¹, L. Khairy², A.M. Coucha¹,
¹Pharmacy Faculty AinShams University, ²ADCO,
Egypt

Aim: The preparation of compression-coated tablets containing dexamethasone in the core by dry coating with either pectin alone or pectin-chitosan (P:C) mixture for colonic delivery. **Methods:** The P:C mixture was used in the following ratios: 2:1, 6:1 and 10:1. The coat was applied into 3 layers to give different core:coat (ct:cr) ratios viz 1:1, 2:1 and 3:1. The in vitro release of the tablets in a gradient pH. In vivo evaluation was done in the cecum of conscious male rats with and without antibiotic treatment. **Results:** Pectin alone was unable to protect the tablet core from premature release even with 3 coating layers. Addition of chitosan to pectin offered better tablet protection. The formula with 2:1 P:C coat and 3:1 ct:cr ratio showed maximum drug protection. The dexamethasone release exhibited always an initial lag period followed by a stage of controlled drug release. The mechanism of release was complex as it was dependent on P:C and ct:cr ratios except in case of 2:1 P:C where the order of drug release was by diffusion at all coating levels, indicating that the number of coats had no effect on the mechanism of drug release at this P:C ratio. The formula with 2:1 P:C coat and 3:1 ct:cr ratio was subjected to further in vivo studies. The coat undergoes biodegradation in the presence of colonic microflora of the rat leading to higher drug release than in vitro. **Conclusion:** The addition of chitosan with pectin increased its protection ability until it reaches the colon. A successful colonic controlled drug delivery was achieved with 2:1 P:C at 3:1 ct:cr. Results were more prominent after in vivo studies as the colonic microflora plays a major role in drug release.

INDUSTRIAL PHARMACY SECTION - POSTER SESSION

IPS-P-033

MEASUREMENT AND EVALUATION OF THE ADHESIVE FORCE BETWEEN FINE PARTICLES BY THE DIRECT SEPARATION METHOD AND THE INFLUENCE OF ELECTRIFICATION

Y. Shimada, H. Sunada, Y. Yonetsawa, R. Yamada,
Meijo University,
Japan

A new apparatus was developed to measure the adhesive force between particles with a high resolution of approximately 2nN. The force was measured directly by pulling the particles with a contact needle. Also, the separation processes were observed with a CCD camera during the measurement. Here, the adhesive force of six kinds of pharmaceutical particles and glass beads were measured, and the effects of moisture, shape and triboelectrification of the particles on the force were investigated. In the case of moisture adsorptive particles, the force of adhesion increased rapidly with the moisture content under high relative humidity. In the case of moisture non-adsorptive particles, the force was affected by particle shape and triboelectrification. The adhesive force of particles having sharp corners was greatly affected by triboelectrification at the corner of the particles. So, the distribution of triboelectrification affects the adhesive force of the particle. The adhering of finer particles to the surface such as lactose caused an increase in the distance between particles, and a marked decrease in adhesive force. A knowledge of the adhesive force of particles and factors influencing the force is of advantage to development of new drugs, for instance, dry powder inhaler, and to prevent pharmaceutical manufacturing troubles.

IPS-P-034

PREPARATION AND EVALUATION OF CHITOSAN MICROSPHERES OF DILTIAZEM HYDROCHLORIDE

B.A. Vishwanath¹, S. Shyamala Bhaskaran²,
¹Krupanidhi college of pharmacy, ²Al-Ameen College of Pharmacy,
India

Microspheres of diltiazem hydrochloride were prepared by spray drying and solvent extraction technique using biodegradable and biocompatible polymer chitosan. Prepared formulations by both the methods yielded microspheres with good encapsulation efficiency, further an increase in the stirring rate, concentration of an emulsifier and temperature were found to reduce the particle size. The release of drug from the microspheres was found to follow biphasic pattern, including initial burst effect followed by slower release. Formulations were found to have no interaction with the excipients used in the formulations. SEM studies revealed that chitosan microspheres were spherical when prepared by solvent extraction method and appeared shrunken when prepared by spray drying irrespective of drug polymer ratio; further surface folding was also seen. The mechanism of drug release was studied by fitting the data into Korsmeyer peppas and Higuchi Model, according to which the formulations were found to follow fickian diffusion releasing the drug upto 12h. Thus prepared formulations by both the methods were found to be promising in terms of successfully extending the release of diltiazem hydrochloride

IPS-P-035

FORMULATION AND EVALUATION OF ACYCLOVIR OCULAR INSERTS

A.N. Allam, S.S. El Gamal, V.F. Naggat,
Pharmacy Faculty, Alexandria University,
Egypt

A common cause of blindness in developed countries is due to Herpes Simplex Virus(HSV) Type I infections.

Acyclovir selectively inhibits the replication of this virus. Therefore, it deemed necessary to develop Acyclovir formulations of prolonged ocular residence time. This can be achieved via development of ocular inserts.

Acyclovir inserts were prepared by casting method using polyvinyl alcohol (PVA) and methylcellulose (MC) mixtures. Inserts were subjected to the following studies:

in vitro release, water absorption capacity (swelling index), effect of different additives (osmotic, viscosity imparting and hydrophobic agents) on drug release as well as differential scanning calorimetry (DSC).

Results showed significant increase in drug release from all formulations except in presence of hydrophobic agents which decreased the release significantly.

Increase in release was partially attributed to the presence of the drug in amorphous form as confirmed by DSC studies.

Statistical analysis of data was performed through Student t-test.

The best fit of release data for most formulae was obtained using Higuchi equation, although relaxation of polymers caused a slight deviation from Fickian diffusion. Release from some inserts was controlled by zero order mechanism.

Swelling index (using diameter method) of all the formulations did not exceed 25%.

In conclusion, polymeric ocular Acyclovir inserts are easily prepared; the rate and pattern of drug release can be modified using different additives.

This would ensure long residence time, better patient compliance, suitable drug level at target site and consequently less side effects

IPS-P-036

FORMULATION AND EVALUATION OF ACYCLOVIR OPHTHALMIC GELS

A.N. Allam, V.F. Naggat, S.S. El Gamal,
Pharmacy Faculty, Alexandria University,
Egypt

Acyclovir, an antiviral agent, is successfully used to treat localized and systemic HSV infections. Commercially, it is available as tablets, suspension, ophthalmic ointment and skin cream.

Ophthalmic ointment is applied 4-5 times daily causing side effects and poor patient compliance.

The aim of this study is the formulation of Acyclovir gels in a way to reduce the frequency of application, ensuring better bioavailability and patient compliance.

Acyclovir gels were prepared using three different concentrations of each of the following polymers: Methylcellulose (MC), sodium alginate, Carbopol, Chitosan, Hydroxypropylmethylcellulose (HPMC) and Hydroxyethylcellulose (HEC).

Formulations were subjected to release and rheological studies, differential scanning calorimetry (DSC) and Infrared (IR) analysis on drug, polymers and physical mixture (1:1).

Results showed higher release rate with the lowest polymer concentration used.

Rheological studies indicated that the incorporation of drug into the polymer base increased the viscosity except for HPMC and Carbopol.

No interactions between drug and gel bases occurred as confirmed by DSC and IR studies.

Storage decreased the viscosity of all gel formulations except in case of sodium alginate. It also reduced the release rate for all formulations except for gels prepared with chitosan.

From the results obtained, we can conclude that good and prolonged release of the drug from gel formulations compared to ointment would ensure better bioavailability and patient compliance.

IPS-P-037

IMPROVED BIOAVAILABILITY OF CELECOXIB WITH SMEDDS

V.M. Joshi, J. Shaji,
KMK college of pharmacy,
India

Objective: The objective of the present investigation is to develop and optimize self-emulsifying drug delivery system of poorly water-soluble drug celecoxib and to improve its oral bioavailability.

Introduction: SMEDDS is isotropic mixture of oil, surfactant and cosurfactant, when introduced in

GI fluid, which rapidly disperse to form particles of nanosize range enhancing absorption and GI permeation. SMEDDS is very good approach to overcome dissolution limited release of poorly water-soluble drugs. In the present investigation celecoxib has been chosen as a poorly water-soluble drug (6.18±0.25 µg/ml). SMEDDS of celecoxib has been developed and optimized on the basis of particle size.

Experimental: Different oils, surfactants and co-surfactants were screened for the development of SMEDDS based on saturation solubility study. Approximate limit were set based on pseudoternary phase diagram. SMEDDS was optimized with the help of 2³ factorial design. Analytical method of celecoxib was developed on HPLC both for human and rabbit plasma. In-vivo study in rabbits of optimized formulation was carried out.

Result and Discussion: Optimized system was found to be self-emulsifying in 10 sec with optimum viscosity and surface tension and with Particle size of 230nm. In vitro dissolution of optimized batch showed more than 95% release in 10 min. In-vivo study has shown enhanced oral bioavailability of SMEDDS compared to marketed preparation.

Conclusion: Celecoxib capsule in SMEDDS was successfully developed to overcome dissolution limited release and hence enhance absorption of the drug through GIT.

IPS-P-038

DEVELOPMENT OF A MICROBIOLOGICAL SPF DETERMINATION METHOD

Y. Abdou, E. Aboulmagd, N.A. Boraie, I.A. Darwish, L.K. El-Khordagui,
Pharmacy Faculty, Alexandria University,
Egypt

A microbiological method for SPF determination is validated as a simple quality control tool for assessing the photoprotective effect during sunscreen product development. Sunscreen preparations were applied as a continuous film on a UV-transparent membrane (2mg/cm²) covering nutrient agar plates on which *E. coli* was spread. Plates were irradiated by a UV lamp for different exposure times. After overnight incubation, colonies were counted and the decimal reduction time (DRT) determined. The method was validated by assessing the effect of selected experimental variables on DRT using a market SPF 12 product as standard and by correlating the DRT for a variety of commercial sunscreen products with their SPF values (ranging from 12 to 100). The method was then tested as a quality control tool by assessing the influence of formulation variables on the photoprotective effect of a series of O/W emulsion lotion formulations with different composition.

The method proved valid for detecting changes in the photoprotective effect of the standard product as a result of modifying experimental conditions. It proved also valid for ranking market sunscreens products according to their protective effect. Equally important, the method could successfully detect the change in the photoprotective effect of a sunscreen test formulation as a function of concentration of the sunscreen agent, benzophenone-3 and the synergistic photoprotective effect produced by combining this agent with chemical and physical sunscreen agents. An additional advantage was the ability of the method to detect the effect of physicochemical interactions on photoprotection provided by the test formulation.

IPS-P-039

BENZOPHENONE-3 SOLID LIPID MICROSPHERES : DEVELOPMENT AND IN VITRO CHARACTERIZATION

Y. Abdou, N.A. Boraie, I.A. Darwish, L.K. El-Khordagui,
Pharmacy Faculty, Alexandria University,
Egypt

Effective photoprotection by sunscreen products implies sustained availability of the sunscreen agent(s) to the outer layers of the skin in an effective concentration. Sunscreen controlled delivery systems offer promises in this respect. The aim of this study was to develop a controlled delivery microsphere system for the lipophilic sunscreen agent benzophenone-3 (BZ-3) with optimum pharmaceutical attributes. Microspheres (MS) were prepared using carnuba wax (CW) by a melt solidification technique. A full factorial design (2⁴) was used to assess the combined effects of four independent variables (BZ-3:CW ratio, type and concentration of emulsifier and emulsification speed) on MS in vitro characteristics (particle size, drug loading, incorporation efficiency, and % drug release at 1 hour) as dependent variables. BZ-3 loaded MS of size ranging from 50 to 85 µm were obtained with more than 90% yield. Maximum drug loading and incorporation efficiency were 39% and 100% respectively. Drug release occurred according to combined first order and Higuchi kinetics and ranged from 34 to 84% at 1 hour.

All independent variables tested did affect MS in vitro characteristics. Statistical data obtained were used for the selection of MS formulations with optimum in vitro characteristics. These MS were incorporated in a W/O cream base. The protective effect of the cream against UVB radiation was assessed using two in vitro SPF spectrophotometric methods and a microbiological method developed in our laboratory. Combined results indicate that the sunscreen MS developed exerted a prolonged photoprotective effect which was potentiated by the microsphere carrier system.

LABORATORIES AND MEDICINES CONTROL SERVICES SECTION - POSTER SESSION

LMCS-P-001

COMPARATIVE STUDY OF AMOXICILLIN-SULBACTAM WITH OTHER FOUR ANTIMICROBIAL AGENTS IN VITRO.

M. Acie, D. Calina, L. Bejenaru,
University of Medicine and Pharmacy,
Romania

Aims: To evaluate the antibacterial activity of amoxicillin-sulbactam compared with other four antimicrobial agents in vitro.

Methods: The antibacterial activity of amoxicillin-sulbactam against clinical isolated strains were compared with amoxicillin, ampicillin-sulbactam, amoxicillin-clavulanic acid and ceftriaxone. Minimal inhibitory concentrations were determined by use of agar dilution method.

Results: The susceptible rate of amoxicillin-sulbactam against gram positive bacilli strains was 91,28%, higher than those of amoxicillin and ceftriaxone. The susceptible rate of amoxicillin-sulbactam against *Escherichia coli*, *Klebsiella pneumoniae* and *Proteus mirabilis* was 81,28%, 84,12% and 100%, similar with those of amoxicillin-clavulanic acid, ampicillin-sulbactam and ceftriaxone, higher than that of amoxicillin. The susceptible rate of amoxicillin-sulbactam against *Enterobacter cloacae* was 84,23%, higher than that of amoxicillin significantly and better than other two agents containing beta lactamases inhibitors and ceftriaxone. The antimicrobial activity of amoxicillin-sulbactam against common clinical isolated bacterial strains was better than that of amoxicillin, especially to beta lactamases positive strains.

Conclusions: Amoxicillin-sulbactam is an effective antibiotic containing beta lactamases inhibitor and a powerful antimicrobial agent for clinical bacterial infections especially to *Enterobacter*.

LMCS-P-002

LITHUANIA'S OFFICIAL MEDICINES LABORATORY'S FUNCTIONS, TASKS AND PERSPECTIVES IN PREVENTION OF LITHUANIA'S PHARMACEUTICAL MARKET FROM REJECTED MEDICINES AND PHARMACEUTICAL SUBSTANCES

M.J. Jakimavicius¹, R. Mockute¹, M. Jakimavicius², M. Juzenas²,
¹State medicines control agency, ²Kaunas university of medicine,
Lithuania

Aims:

This work involves the activity of LT-OMCL in 2001-2003. The main questions are:

- Does LT-OMCL fully perform its functions, which are indicated in its official regulations?
- How does LT-OMCL prevent Lithuania's pharmaceutical market from rejected medicines and pharmaceutical substances?
- Which drug defects were found?
- What are the perspectives of LT-OMCL?

Methods:

The work refers to:

1. Statistical data of LT-OMCL activity in 2001-2003.
2. The survey of reliable sources of information OMCLs activities in other countries.

Results:

1. The average number of investigated samples per year in all given period is: 7130 made by pharmaceutical industry, 2424 made by pharmacies and 9554 of total samples.

2. The average percent of defects found per year in all given period is: 0.14% of samples made by pharmaceutical industry, 0.20% of samples made by pharmacies and 0.16% of total samples.

3. There was almost no biological profile investigations performed in LT-OMCL in all given period.

Conclusions:

The most effective ways to optimize LT-OMCL work and to guarantee the best prevention of Lithuania's pharmaceutical market from rejected medicines and pharmaceutical substances are:

1. To make the LT-OMCL investigation project for the next year considering to the data of the last year LT-OMCL investigations and rejected medicines and pharmaceutical substances.
2. To expand variety of investigated drug forms.
3. To perform more modern biological profile analysis methods.

LMCS-P-003

IMPROVING REGULATORY REACH AND CAPACITY: DEVELOPING A NATIONAL REGULATORY PROJECTION SCHEME

M. Ndomondo-Sigonda, M. Ndomondo-Sigonda, O. Kowero, Z. Msuya, E. Masha,
Tanzania Food and Drugs Authority,
Tanzania

The Tanzania Food and Drugs Authority (TFDA) has implemented a six-zone regulatory administrative structure in the 21 governmental regions to coordinate and focus programs into a more manageable structure. The zonal centers provide a focus for training, collection of TFDA program data and regulatory extension by incorporating on a part-time basis other governmental health workers to perform on behalf of TFDA compliance assessments. Any out of compliance findings are then referred to the TFDA for follow-up and action. The TFDA has appointed a desk officer who among other duties is to liaise with the zonal centers ensuring good flow of information. For the pharmaceuticals control segment the training is focused on raising awareness on product quality attributes, performing structured product physical examinations, and inspecting both public and private drug dispensing outlet facilities. In addition a selected group of health workers were trained on Minilab® drug quality screening procedures to manage testing sites serving the various zones. An overview and current status of this effort will be presented.

LMCS-P-004

PROFICIENCY TESTING AS A TOOL TO ASSESS THE PERFORMANCE OF VISUAL TLC QUANTITATION ESTIMATES

M. Ndomondo-Sigonda¹, P. Rishi², Z. Msuya¹, M. Ndomondo-Sigonda¹, T. Layloff²,
¹Tanzania Food and Drugs Authority, ²Management Sciences for Health,
Tanzania

Thin-Layer Chromatography (TLC) has been used as a separation tool for an array of analytical applications. For example, TLC visual detection test procedures to assess pharmaceutical product quality has been included in a very convenient kit concept developed by the German Pharma Health Fund (GPHF) called the Minilab®. The Tanzania Food and Drugs Authority (TFDA) has established a drug product screening program using the Minilab® testing technology. All of the inspectors who participated in this program are pharmaceutical technicians or pharmacists who have had prior laboratory training in volumetric procedures. Prior to performing the screening procedures the inspectors completed a one-week training program after which each of the inspectors was sent with a Minilab® to perform the product screening tests at various locations in the country. As a part of the TFDA Quality Assurance (QA) program a proficiency test procedure was established to provide assurance that the Minilab® screening tests were being competently performed. The results of the first proficiency test indicated that most inspectors had difficulty discerning the differences of substandard products. A performance qualification test set was developed to reinforce the inspectors ability to discern the differences and their performance on a second proficiency test was markedly improved. It is important to include proficiency testing into the Minilab® implementation plan to provide an added measure of confidence in these screening tests and to identify additional training needs or other interventions to assure quality performance.

LABORATORIES AND MEDICINES CONTROL SERVICES SECTION - POSTER SESSION

LMCS-P-005

QUALITY ASSURANCE: INSPECTION TRAINING

M. Ndomondo-Sigonda¹, M. Ndomondo-Sigonda¹, O. Kowero¹, E. Mosha¹, Z. Msuya¹, E. Msuga², M. Chambuso¹, O. Ngassapa², P. Risha¹, T. Layloff²,
¹Tanzania Food and Drugs Authority, ²Muhimbili University, ³Management Sciences for Health, Tanzania

The flow-chart decision tree standard operating procedures and forms were used to develop a training manual, daily study guides, and examination materials for a one-week inspection training program, which includes inspection of import documents, compliance with labeling requirements, physical examination of products, etc., and outlines procedures for inspection at both ports-of-entry and dispensing outlets. In addition, a one-week Minilab-based screening test training program was developed for inspectors to field-test products to assess their quality. These programs were initiated in October, 2002 and have been fine-tuned in subsequent presentations. An overview of this program discussing successes and problems will be presented.

LMCS-P-006

DETERMINATION OF BENZOIC AND SALICYLIC ACID IN WHITFIELD'S OINTMENT BY DERIVATIVE SPECTROPHOTOMETRY

O. Dzikić, O. Džikić, T. Zorić, I. J. Milovanović,
Pharmacy Institution Belgrade, Serbia and Montenegro

Whitfield's Ointment contained 6% benzoic and 3% salicylic acid. Benzoic acid has a long history of use as an antifungal. Salicylic acid also possesses fungicidal properties and is used topically in the treatment of fungal skin infections.

A second-order derivative spectrophotometric method was suggested for the simultaneous determination of benzoic and salicylic acid in Whitfield's Ointment. Benzoic acid was measured at 289nm and salicylic acid at 304nm (peak-baseline). Validation of the method confirmed that linearity concentration range lies between 20-60 µg/ml for benzoic and 10-30 µg/ml for salicylic acid. The corresponding regression equation was: $2D289 = 0,00004 + 0,00004C$ ($r = 0,9999$), for benzoic acid and $2D304 = -0,00002 + 0,00007C$ ($r = 0,9992$), for salicylic acid. LOD was 3 µg/ml and 0,857 µg/ml; LOQ was 10 µg/ml and 2,857 µg/ml for benzoic and salicylic acid, respectively.

The validity of the method was tested by an assay of benzoic and salicylic acid in Whitfield's Ointment. The mean value of the content of benzoic acid was 5,898% (98,30% of the labeled claim) and of the content of salicylic acid was 3,049% (101,63% of the labeled claim).

The developed method is suitable for fast and reliable identification and quantification of both components.

LMCS-P-007

QUALITY ASSURANCE: ESTABLISHING STANDARD OPERATING PROCEDURES

M. Ndomondo-Sigonda¹, M. Ndomondo-Sigonda¹, O. Kowero¹, E. Mosha¹, Z. Msuya¹, E. Nyeura¹, A. Elias¹, L. Mshana¹, M. Hajji¹, D. Simon¹, W. Mfuko², P. Risha¹, T. Layloff²,
¹Tanzania Food and Drugs Authority, ²Management Sciences for Health, Tanzania

The Tanzania Food and Drugs Authority compliance decision tree provides structure for inspectional standard operating procedures (SOPs) and reporting forms. The SOPs and forms outline how to conduct and record the examination of products and premises to determine their compliance or non-compliance with the laws and regulations. To establish standard operating procedures (SOPs), the following steps were taken—

- Each inspectional function was defined and reviewed together by a group of key managers and experienced inspectors.
- Step-by-step procedures on what actions are required to achieve each decision point were discussed and documented.
- These step-by-step procedures were developed into SOP format, and checklists were prepared to guide inspectors through the SOP process.

An overview of this process will be presented.

LMCS-P-008

QUALITY ASSURANCE: THE DRUG INSPECTION AND TESTING PROGRAM

M. Ndomondo-Sigonda¹, M. Ndomondo-Sigonda¹, O. Kowero¹, Z. Msuya¹, W. Mfuko², T. Layloff²,
¹Tanzania Food and Drugs Authority, ²Management Sciences for Health, Tanzania

The Government of Tanzania has enacted legislation and regulations to help assure the quality of pharmaceutical products available in the market. To help improve market compliance, a market inventory of requirements and policies was prepared to guide all stakeholders. This inventory was used to develop a flow chart compliance decision tree, which directs the inspection process to regulatory decision points. These process revisions were presented at a stakeholders' workshop for wholesalers and importers to make them aware of the changes in regulatory expectations. Following the initial workshop in Dar es Salaam, the Minister of Health formally launched the new inspection program, in October 2002. Subsequently stakeholders' workshops have been conducted throughout the country to apprise them of the legal requirements and possible regulatory actions to be taken for non-compliance. The decision tree will be presented.

LABORATORIES AND MEDICINES CONTROL SERVICES SECTION - POSTER SESSION

LMCS-P-009

SIMULTANEOUS DETERMINATION OF SOME ANTIFUNGALS AND CORTICOSTEROIDS IN BINARY MIXTURES BY UV-SPECTROPHOTOMETRIC AND CHEMOMETRIC METHODS

A.M. Abou El-Alamein¹, M.Y. Salem¹, A.M. Abou El Alamein¹, K.M. Kelani², S.A. Abdel Fattah³,

¹Faculty of Pharmacy Cairo University, ²Faculty of Pharmacy, Cairo University, Egypt

This work is concerned with the simultaneous determination of econazole nitrate (EZ)-triamcinolone acetonide (TA) and micronazole nitrate (MZ)-hydrocortisone (HC) in binary drug mixtures without previous separation by two different techniques. The first technique is the application of the derivative spectrophotometric methods, where the mixture of EZ-TA was determined using the first derivative of the ratio spectra. EZ can also be determined using the second derivative spectrophotometry. The mixture MZ-HC was also assayed for MZ using second derivative spectrophotometry and the first derivative of the ratio spectra. HC can be alternatively determined in binary mixture with MZ using the first derivative spectrophotometry.

The second technique is based on the application of different chemometric methods, namely classical least squares (CLS) calibration model, partial least squares (PLS) and principle component regression (PCR) models. These models were used after their validation for the prediction of the concentration of the analyzed drugs in their mixtures. The validity of the proposed methods was further assessed by applying standard addition technique. The obtained results of the suggested methods agreed statistically with those obtained by the official methods.

LMCS-P-010

SEPARATION AND VALIDATION OF FIVE PRINCIPAL ALKALOIDS IN OPIUM AND OPIUM TINCTURE BY GRADIENT REVERSED-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY-PHOTODIODE ARRAY DETECTION

R.L. Shih, C.Y. Chen, F.S. Chin,
National Bureau of Controlled Drugs,
China Taiwan

The separation of five alkaloids (morphine, codeine, thebaine, papaverine, noscapine) in opium and opium tincture samples has been achieved on a reversed-phase octadecyl column by gradient high-performance liquid chromatography-photodiode array detection. The multiple linear gradient program was started at 12% acetonitrile in potassium dihydrogen phosphate buffer to elute morphine, then hold at 16% acetonitrile to elute codeine, then hold at 22% acetonitrile to elute the remained three alkaloids. Heptane-1-sulfonic acid sodium salt was used as ion pair reagent to increase the resolution between morphine and morphine N-oxide. All of the peaks of five alkaloids in opium and opium tincture samples have good peak purity. The sample preparation was simplified by treating with methanol to removed flocculent precipitate of plant fragments in opium. The method validation involved system suitability, specificity, linearity, accuracy, precision, detection limit and quantitation limit.

LMCS-P-011

SALIVA AND SERUM LITHIUM MONITORING IN HOSPITALIZED PATIENTS AND A POSSIBILITY TO DSSUBSTITUTE SALIVA FOR SERUM

N. Serdarevic¹, F. Kozjek², I. Malesic²,

¹Clinical center Sarajevo, Bosnia and Herzegovina
²Faculty of Pharmacy, Slovenia

ABSTRACT

Aim of work

The aim of our study was to compare results of lithium ions concentration from two body fluids saliva and serum.

Methods

Lithium concentration was determined in saliva and serum of 25 patients treated with lithium carbonate (3x 300 mg) Jadran, Galen Laboratory Rijeka. Saliva and blood were taken 2 and 12 hours after the last dose. Lithium ion determination was done using the dry-slide technology Vitrus 250 Analyser (Ortho Clinical Diagnostic) and atomic absorption spectrometry (AAS) method Perkin Elmer 403. At the same time samples of blood and saliva were determined with these methods, which showed a high level of correlation.

Results and discussion

The mean difference between serum and saliva was statistically significant for $p < 0.05$ using t student test. The saliva/serum ratio after 12 hours was 1.24 ± 0.269 , while after 2 hours it was 2.15 ± 0.179 using dry-slide technology; after 12 hours it was 1.22 ± 0.314 , and after 2 hours 2.17 ± 0.170 by AAS method.

At saliva we got $K_i = 0.02 \text{ h}^{-1}$ and half-life of saliva was $t_{1/2} = 34.6$ hours. For serum half-life was $t_{1/2} = 24$ hours, which means that the lithium ions elimination is slower from saliva than from serum. That is the reason why probably the concentration in saliva is higher than in serum.

Conclusion

The lithium elimination is a two-compartment pharmacokinetic model, where saliva and salivary glands are an important part of the compartment. At a certain point in medical treatment, it could be expected to use controlled determination of lithium ions in saliva and in serum as control.

Key Words: Lithium, Serum, Saliva

LMCS-P-012

VITROS DRY SLIDE TECHNOLOGY METHOD FOR THE DETERMINATION OF LITHIUM IONS IN HUMAN SERUM

N. Serdarevic¹, F. Kozjek², I. Malesic²,

¹Clinical center Sarajevo, Bosnia and Herzegovina
²Faculty of Pharmacy, Slovenia

ABSTRACT

Aim of work

The medical treatment with lithium preparations demands the determination of the lithium ions concentration 12 hours after the last dose when the excretion of lithium ions has already started. The aim of work was to compare lithium ions concentration analyzed by dry-slide technology Vitrus 250 Analyser (Ortho Clinical Diagnostic) atomic absorption spectrometry (AAS) method Perkin Elmer 403 and ion-selective electrode (ISE) potentiometry AVL 9181.

Methods

The Vitrus 250 Analyser consists of a colorimetric end-point reaction where the crown ether chromophore binds the lithium in the sample; the resultant dye complex is measured using reflectance spectrophotometry at a wave-length of 600nm after 2.5 minutes at 37° C. We analyzed lithium ions in 23 serum specimens of patients after oral administration of lithium carbonate (3x 300mg) Jadran, Galen Laboratory Rijeka by dry-slide technology, AAS and ISE methods.

Results and discussion

The precision of dry-slide technology, variation coefficient (CV) varied from 2.45 to 4.64 %. The reproducibility of the method determined CV to be from 0.60 to 1.81% over a ten-day period. The accuracy of the assay in the concentration range examined was from 3.60 to 6.12%. The limit of detection was 0.20 mmol/L.

Conclusion

The Vitrus dry slide technology gave a good coefficient of correlation (r) with AAS and ISE method. Dry slide technology is a practical method of interest in the therapeutic monitoring of patients receiving lithium salts. It may also be an useful alternative or it could even change other methods such as AAS.

Key Words: dry slide technology, AAS, ISE and lithium.

LABORATORIES AND MEDICINES CONTROL SERVICES SECTION - POSTER SESSION

LMCS-P-013

DETERMINATION OF LACIDIPINE IN THE PRESENCE OF ITS ACID DEGRADATE BY DERIVATIVE,UV- SPECTROPHOTOMETRY AND COUPLED HPTLC DENSITOMETRY

S.A. Elhayomy, F.H. Metwa, M.N. El-Leithy, K.M. Kefani,
Faculty of Pharmacy, Cairo University,
Egypt

Two sensitive and selective spectrophotometric and coupled HPTLC-densitometric methods have been established for determination of Lacidipine in the presence of its acid degradate. Derivative,UV-spectrophotometric techniques were carried out by measuring the absorbance of (1D) at 271.2nm,(2D) at 285nm and (1DD) at 229.6nm. The concentration range was 5-30 µg/ml for the three techniques, with the corresponding mean accuracies of 100.118±0.743,99.41±0.946 and 99.59±1.04 respectively.

For coupled HPTLC-densitometry, the separation was done on silica gel plates (10x20cm) with H₂O:methanol:30%NH₃(4:6:0.05,v/v) as the mobile phase, developing time was 20min, R_f =0.52 and scanned at 240nm. The concentration range was 5-60µg/spot, with the mean accuracy of 99.615±1.4315.

The results obtained were statistically compared with those obtained by the company method.

The degradate was confirmed by IR and mass-spectrometry.

LMCS-P-014

SOLUBILITY OPTIMIZATION AND FORMULATION OF NIMESULIDE INJECTION

K. Rathore¹, G.D. Gupta¹, Y.S. Tanwar¹, R.S. Goad², G.K. Jani³,
¹B.N.College of Pharmacy, ²Member, AICTE, ³L.M.College of Pharmacy,
India

AIM: The aim of the study was to solubilize nimesulide a water insoluble analgesic, anti-inflammatory and antipyretic drug by the use of physiologically compatible hydrotopes and to attempt their injectable formulation and evaluations.

METHODS: UV method was selected for the analysis of nimesulide in solubilized systems. For solubility enhancement hydrotopes solubilization method was proved to be successful for nimesulide in the study, using sodium benzoate (SB), sodium-o-hydroxy benzoate (SS) and sodium-p-hydroxy benzoate (SP). Physical parameters like viscosity, relative density, conductivity, diffusion study, interaction study, pH study, refractive index, gel study etc was done. A greater solubilization capacity was noted for SB than SS and SP, which has been explained on the basis of possible steric factor. The solubility determination was carried out at 25°C and 37°C.

RESULTS AND CONCLUSIONS: The solubility increased up to 93 times at 37°C in sodium benzoate (25% w/v solution) solution while upto 87 times at 25°C in sodium benzoate (20% w/v) solution. The solubilizing power of different hydrotopes could be ranked as: SB > SS > SP.

Formulation was prepared with sodium benzoate (20%) using Sodium metabisulphite (0.1%) and EDTA (0.1%) as antioxidant and chelating agents. Physical and chemical stability study was conducted and found that injection with sodium benzoate was stable for 108 days.

LMCS-P-015

RP-HPLC METHOD FOR ASSAY OF FOLIC ACID IN CHEWABLE TABLETS

M. Bodiroga, J. Ognjanovic, V. Markovic, A. Orozovic,
Military Medical Academy,
Serbia and Montenegro

Introduction: Folic acid, N-[4-[(2-amino-1,4-dihydro-4-oxo-6-pteridinyl)-methyl]amino]benzoyl]-glutamic acid, is a member of the vitamin B group. Folic acid is reduced in the body to tetrahydrofolate, which is a coenzyme for various metabolic processes.

Methods: The chromatographic system consisted of a Shimadzu LC-10ADvp pump, a Rheodyne 7725 injector with a 20 µl sample loop and a Shimadzu SPD-10AVvp UV-VIS detector. Separations were performed on a Fusospher® STAR RP-18 endcapped column (150mm x 4.6mm; 5µm) at room temperature using 0.1 M sodium acetate : acetonitrile (940:60 v/v), adjusted to pH 5.7 with acetic acid as mobile phase. Flow rate was 1.0 ml/min. UV detection was performed at 254 nm.

Results: The aim of this work was to find optimal conditions for HPLC method determination of folic acid in chewable iron and folic acid tablets. Each chewable tablet contains 350 µg (mcg) of folic acid and iron(II)hydroxydic polymaltose complex equivalent to 100 mg elemental iron. Validation of applied method was carried out by determination of linearity range, accuracy, precision (repeatability, reproducibility). The sensitivity of method was demonstrated with determined LOD and LOQ for active component.

Conclusion: The obtained results show that applied HPLC method may be used for determination of folic acid in chewable iron and folic acid tablets.

LMCS-P-016

DETERMINATION OF LACIDIPINE IN THE PRESENCE OF ITS ACID DEGRADATE BY DERIVATIVE,UV- SPECTROPHOTOMETRY AND COUPLED HPTLC DENSITOMETRY

S.A. Tawfik
Faculty of Pharmacy, Cairo University,
Egypt

M.N. Eleithy, K.M. Kefani, F.M. Metwally, S.A. Elhayomy
Department of Analytical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt

Abstract

Two sensitive and selective spectrophotometric and coupled HPTLC-densitometric methods have been established for determination of Lacidipine in the presence of its acid degradate. Derivative,UV-spectrophotometric techniques were carried out by measuring the absorbance of (1D) at 271.2nm,(2D) at 285nm and (1DD) at 229.6nm. The concentration range was 5-30 µg/ml for the three techniques, with the corresponding mean accuracies of 100.118±0.743,99.41±0.946 and 99.59±1.04 respectively.

For coupled HPTLC-densitometry, the separation was done on silica gel plates (10x20cm) with H₂O:methanol:30%NH₃(4:6:0.05,v/v) as the mobile phase, developing time was 20min, R_f =0.52 and scanned at 240nm. The concentration range was 5-60µg/spot, with the mean accuracy of 99.615±1.4315.

The results obtained were statistically compared with those obtained by the company method.

The degradate was confirmed by IR and mass.

MILITARY & EMERGENCY PHARMACY SECTION - POSTER SESSION

MEPS-P-001

RATIONAL AND COST EFFECTIVE USE OF PROTON PUMP INHIBITORS

A.I. Awle¹, K. Malcom², A. Twahir³, S.M. Kairu¹

¹Armed forces memorial hospital, Kenya ²Queens University, United Kingdom ³Aga Khan Hospital, Kenya

ABSTRACT

Title: Rational and cost-effective prescription of proton pump inhibitors (PPIs) in the Armed Forces Memorial Hospital-Kenya.

Objective: (1) To determine the relationship between prescriptions for PPIs and gastro-intestinal conditions.

(2) To compare the usage of different PPIs and cost implications.

(3) To compare the pattern of PPI prescriptions with the recommendations of the National Institute of Clinical Excellence.

Design: Retrospective, cross-sectional study evaluating the utilization of PPIs.

Setting: Armed Forces Memorial Hospital-Kenya

Subjects: Dispensed PPIs for 104 patients from the hospital pharmacy over eight consecutive weeks (15 January to 15 March 2004).

Results: 67 patients (64.4%) had no appropriate upper gastro-intestinal tract investigations and 52 patients (75.4%) did receive trial of H₂ - antagonist therapy before commencement of a PPI. The major indication for use of PPIs in the study patients were gastro-oesophageal reflux in 68 patients (65.4%), peptic ulcer disease in 19 patients (18.3%), NSAID induced ulcer in 9 patients (8.7%) and non-ulcer dyspepsia in 8 patients (7.7%). 81 patients (77.9%) were treated at a cost below Kshs 3000. In only 45 patients (43.3%) did prescriptions comply with the NICE guidelines. Clinical indication that failed highly in meeting the guideline was gastro oesophageal reflux disease.

Conclusion: Drug utilization data indicate high costs that were incurred as a result of not using the guidelines. Many patients were put on PPI without any investigations. These findings explain the irrational use of these drugs and associated hospital expenditure.

MEPS-P-002

ASSESSMENT OF RISKS ASSOCIATED WITH SHORT-TERM USE OF MEfloQUINE IN CANADIAN FORCES MEMBERS: A DESCRIPTIVE CROSS-SECTIONAL STUDY

R. Vaillancourt¹, J. Ma¹, J. Sampalis²

¹Canadian Forces Health Services, ²JSS Medical Research, Canada

Methods

Medical records of Regular Canadian Forces personnel who served in Somalia between 1992 and 1993 were reviewed by trained data extractors. All health effects recorded during treatment with mefloquine were assigned ICD-10-CA codes. Data extractors also noted if the effect has been reported with mefloquine, and rated the severity of the effect. Cohen's kappa was calculated to determine concordance between extractors, and descriptive statistics used to report the health effects seen.

Results

The majority of the 1413 subjects identified were male (96%). A total of 5019 adverse health effects were recorded in the medical records, most of which were mild in severity. At least one adverse effect which could potentially have been related to mefloquine was reported in 39.2% of subjects. Of the adverse effects recorded, 21 were classified by the data extractors as major (18 affecting the nervous system and 3 cardiovascular system effects). These results are consistent with those reported in other populations.

Conclusions

The results of this study have been applied to guide development of policies governing the provision of chemoprophylaxis for subsequent military missions. In particular, resources have been allocated to formalize the counselling provided to members regarding antimalarials and the prevention of malaria.

MEPS-P-003

A CANADIAN FORCES CERTIFICATION PROGRAM FOR NON-TRADITIONAL HEALTH CARE PROVIDERS

R. Vaillancourt¹, F. Hall¹, R. Sylvestre¹, J. Ma¹, N. Winslade²

¹Canadian Forces Health Services, ²Winslade Consulting Inc, Canada

Background

In contrast to provincial health care systems, the Canadian Forces (CF) relies heavily upon alternative professionals to provide health care in challenging environments. Medical Technicians (Med Techs) provide non-prescriptions (OTC) medications to CF members to manage both minor self-limiting illnesses and urgent or emergent conditions.

Purpose

To develop an evidence-based process to assess the competency of Med Techs to supply selected OTC medications safely and appropriately.

Process

Existing provision of medications policies were reviewed. Following an extensive literature review, the policy framework was reconfigured to meet the CF's unique needs. A decision was made by consensus to apply a model allowing delegation of tasks defined in the Med Tech scope of practice. A certification examination was used as a screening tool to ensure that Med Techs have maintained their competence to supply OTC medications.

Output

A variable option multiple-choice examination was developed based on critical decisions required of Med Techs in this practice area. Components of the examination process include: development of an exam blueprint; defining the scope of practice; development of questions by Med Techs and expert item writers; establishing a pass standard using modified Angoff method pass standard; rigorous psychometric analysis.

Conclusions

A valid examination is now used to assess the competency of CF Med Techs to supply OTC medications. The exam identifies those who have maintained their competency, and highlights those who require additional assessment, educational or training to demonstrate such competency.

MEPS-P-004

UPDATING AND TENDENCIES OF BIOAVAILABILITY (BA) AND BIOEQUIVALENCE (BE), REGULATORY ASPECTS IN URUGUAY AND THE LATIN AMERICAN REGION.

W. Diaz, M. Ricca,

DNSFFAA,

Uruguay

The use of Generics, the responsibility assumed at the time of interchanging medicines with the efficiency and safety which must be given to the patient in his treatment, lead to necessity of having regulations according to the reality of the country and the International Norms.

OBJECTIVES:

* Revision of the regulatory aspects of BA and BE of the medicines in Uruguay and tendencies in the region within the frame of harmonization and integration programs promoted by PAHO.

* Analysis of the impact of the generic prescription and pharmaceutical substitution, and the need to demand BA and BE studies within the regulatory practice in our country.

METHODOLOGY:

* OMS Documents

* Guidelines for the FDA Industry

* UE Norms

* Norms in regions

* Documents issued in Conferences of the PAHO

* National Bibliography

CONCLUSIONS:

I) The PAHO has strongly developed the concept of 'generics' in the region in order to make medicines accessible, but national authorities have faced certain failures regarding this issue. In the pharmaceutical market there are a number of 'similar ones', which have been interchanged and it is unknown whether they are equivalent or not. At the Military Hospital, medicines are traditionally interchanged based on costs.

II) The costs of the BA and BE studies should be no obstacle

III) There is a Regulation Project on the rational use of medicines in Uruguay which has as its main objective to know the degree of interchange of the different medicines, with the premise that the GMP are the basis of assurance of the quality. The implementation of this practice is still in process.

MILITARY & EMERGENCY PHARMACY SECTION - POSTER SESSION

MEPS-P-005

HOW CANADIAN FORCES (CF) PHYSICIAN ASSISTANTS (PA) MET THE MEDICATION NEEDS OF CF MEMBERS.

R. Vaillancourt¹, F. Hall¹, J. Ma¹, R. Sylvestre¹, N. Winslade²,
¹Canadian Forces Health Services, ²Winslade Consulting Inc,
Canada

Background

The CF has an obligation to provide quality health care to CF members often in very distinctive settings. Unlike most health care systems the Canadian Forces (CF) relies heavily upon unique health care providers such as Physician Assistants (PAs). PAs provide care, including prescription medications to CF members for urgent emergent conditions where a delay in treatment would be harmful. CF members in operational settings need medications provided in a safe and effective manner by a competent provider.

Objective

To develop an evidence-based process to assess the competency of PAs to provide selected medications safely and appropriately.

Methods

In order to assess competency, a variable option multiple-choice, critical decision, key question type examination was developed. Steps involved in this process included: exam blueprint development (disease states/therapeutics); scope of practice (SOP) definition; question development by practicing PAs and expert item writers according to practice-based blueprint; modified Angoff methodology utilized to set the pass standard; psychometrical analysis prior to release of results

Conclusion

A validated examination is now used to assess the competency of PAs to provide prescription medications. This exam is used to identify those who have maintained their competency, and to highlight those who require additional assessment, educational or training to demonstrate such competency.

MEPS-P-007

ROLES OF THROMBOXANE A₂ IN OLEIC ACID-INDUCED LUNG INJURY

H. Moriuchi
Sojyo University,
Japan

[OBJECTIVES] Acute respiratory distress syndrome (ARDS) is a severe lung injury with hypoxemia. We are trying to elucidate the mechanism of ARDS and to find candidate drugs against the disease, by using an animal model, oleic acid (OA)-induced lung injury. Although precise mechanism of ARDS is not clear, thromboxane A₂ (TXA₂) is suggested to play an important role. On the other hand, participation of TXA₂ in the OA-lung injury is unclear. Therefore, we examined the participation of TXA₂ in the OA-lung injury. [RESULTS] An intravenous injection of OA to guinea pigs caused hypoxemia, and an increase in TXB₂, a stable metabolite of TXA₂ in bronchoalveolar lavage fluid (BALF). Both ozagrel, an inhibitor of TXA₂ synthetase and EPC-K, an inhibitor of phospholipase A₂, prevented the hypoxemia and the increase in TXB₂. OA injection induced hyperpermeability of pulmonary blood vessels and also induced an increase in macrophages and neutrophils in the BALF, while eosinophiles and lymphocytes were not increased. The expressions of mRNAs of chemokines which activate macrophages and neutrophils were increased with OA, but those of chemokines that activate eosinophiles were not increased. Ozagrel inhibited the expressions and the increase in macrophages and neutrophils in the BALF. RAW264 cells derived from macrophages released TXA₂ with an application of OA. [DISCUSSION] These results suggest that an increase in TXA₂ in the lungs induced by OA, facilitates the expressions of mRNAs of chemokines, which leads to an activation and infiltration of macrophages and neutrophils into alveolus.

MEPS-P-006

PHARMACIST-MANAGED, PHYSICIAN-DIRECTED MANAGEMENT OF ALLERGIC RHINITIS IN THE CANADIAN FORCES - A TRIAL

R. Vaillancourt¹, M. Kearney¹, J. Ma¹, A. Gervais¹, C. Ma¹, J. Taylor²,
¹Canadian Forces Health Services, ²University of Saskatchewan,
Canada

Background

According to the 2000 Canadian Forces Health and Lifestyle Information Survey, 21% of male and 32% of female Canadian Forces (CF) members suffer from allergic rhinitis (AR).

Objective

To evaluate the impact of pharmacist-managed care on the quality of life of AR patients in the CF.

Study Design

CF members with a confirmed diagnosis of AR who presented to sick parade, physician appointments or a base pharmacy at 4 CF bases between September 2003 and December 2004 were included in the study. Patients at the 2 control bases received standard pharmacist care while patients at the 2 treatment bases received enhanced pharmacist care including: monthly follow-up consultations, detailed counselling and modification of medication therapy via a collaborative prescribing protocol. As the primary outcome, study participants completed the Rhinocconjunctivitis Quality of Life Questionnaire (RQLQ(S)) at 4 week intervals, patients were followed for 12 weeks.

Results

Ninety-two patients were recruited (39 control, 53 intervention). Results indicate that CF members receiving enhanced care from pharmacists report a clinically-significant improvement in allergy symptoms and related RQLQ(S) scores at week 4. These improvements were sustained for the entire study period. Patients receiving enhanced pharmacist-managed care showed a more rapid progression to clinically relevant improvements in emotional and non-ocular symptoms versus the control group.

Conclusion

Regular interaction with a pharmacist over a 12-week period, where counselling can be provided and pharmacotherapy adjusted, appears to positively impact AR symptoms and quality of life.

PHARMACY INFORMATION SECTION - POSTER SESSION

PI-P-001

EFFECT OF ATP-SENSITIVE POTASSIUM CHANNEL MODULATORS ON INDOMETHACIN-INDUCED GASTRIC LESIONS

H.I. Ismail, M.M. Khalifa, M.A. Kassem, O. Ashour,
Minia University,
Egypt

Mechanisms like decreased gastric mucosal blood flow, increased motility, acidity and apoptosis have been proposed for the pathophysiology of indomethacin-induced gastric lesions (IGL). It seems probable that ATP-sensitive potassium (KATP) channels have a regulatory effect on them. AIM: Investigation of the effects of KATP channel modulators, nicorandil as a channel opener and glibenclamide as a channel antagonist, on IGL. METHODS: Gastric lesions were induced by injection of indomethacin (40 mg/kg s.c.). Nicorandil (2 and 10 mg/kg i.p.) was given to 2 groups and a third group received glibenclamide (6 mg/kg i.p.). Another 2 groups received glibenclamide, concomitantly, with either doses of nicorandil. Nicorandil and glibenclamide were always given thirty minutes and one hour, respectively, before indomethacin. The rats were killed 5 hours after indomethacin and the stomachs were removed. Macroscopic gastric lesions in each stomach were measured and the ulcer index and preventive index was calculated. RESULTS: Indomethacin produced ischemic lesions in 96% of the rats with an ulcer index of 20.4. Nicorandil protected by up to 51.2% against indomethacin-induced lesions and glibenclamide aggravated the lesions by 55.1%. CONCLUSION: 1) Nicorandil has an ulcer-protective action which is, assumingly, completely attributable to its KATP channel opening action. 2) It is suggested that antagonism of KATP channels is an important pathway for tissue injury by noxious agents and that KATP channel antagonists may play a permissive role in damage produced by other ulcerogens. 3) KATP channel openers may prove to be important candidates for developing new effective anti-ulcer drugs.

PI-P-003

PHARMACOGENOMICS AND PHARMACEUTICAL CARE

V. Radonjic
Medicines and Medical Devices Agency,
Serbia and Montenegro

Pharmacogenomics is relatively new science. The complete sequencing of the human genome will result in improved understanding of the role of genes in disease and drug response. Genetic profiling will become an integral part of the prescription process whereby drugs will be prescribed based on a patient's genotype. Pharmacists will need to understand the concepts and promise of pharmacogenomics in order to adapt to the demands of genotype-based prescribing.

The aim of this presentation is to emphasize how pharmacogenomics might influence pharmaceutical care in the future. The surge of interest in pharmacogenomics stems from growing knowledge that individual responses to drugs vary considerably. We are consider the potential benefits of pharmacogenomics to pharmaceutical care in the future like as:

- more powerful medicines
- better, safer drugs the first time
- more accurate methods of determining appropriate drug dosages
- improvements in the drug discovery and approval process and
- decrease in the overall cost of health care.

Impact of pharmacogenomics will be allow medical practitioners and pharmacist to avoid the prescription of drugs to non-responders or those patients who are predisposed to adverse reactions. Pharmacogenomics aims to provide the right prescription immediately for the maximum benefit of the patient. Pharmacist are likely to be key players in the dispensing of drugs based on an individual's gene profile.

PI-P-002

MAKING EFFORTS TO PROMOTE CLINICAL PHARMACY BETTER IN ROMANIA

M. Aciu, D. Calina,
University of Medicine and Pharmacy,
Romania

AIMS: To develop the hospital pharmacy as a service system where the patient can meet professional pharmacists and get advice about medication usage in an easy and inspiring way.

METHODS: A new style for drug dispensary as well as drug information service have been implemented for the outpatients.

RESULTS:

1. Pharmacy was reconstructed completely into a patient-centered service. The dispensary was changed from 'window style service' to 'counter style service', which is so called face-to-face service for the patients.
 2. The individual drug list is proved to help the patients to understand the whole medicines treatment and the cost of every medicine.
 3. The drug usage labeling is combined with a simple oral explanation to make sure the patients can follow the important usage directions exactly.
 4. Specialized counseling pharmacists are available to answer the special questions based on each patient's disease history and background.
 5. The 'Drug usage booklet' is delivered for recording the medication history and informing patients severer adverse effects and drug interactions with some precautions. This is especially useful for the elderly patients with chronic diseases.
- CONCLUSIONS: The concept of pharmaceutical care has been prevailing accepted in Romania for many years. Our practice has been promoted by many hospital pharmacies, and will contribute to improve rational use of medicine in Romania.

PI-P-004

PHARMACEUTICAL EXPENDITURES IN ARMENIA

I. Kazaryan Ghazaryan
Drug Utilization Research Group,
Armenia

Pharmaceutical expenditures are very different depends on countries. There is no official data about drug spending in Armenia. The aim of this work was to study the situation of pharmaceutical expenditures and to develop appropriate recommendations.

Methods: documents review; collecting information from records and the National Statistical Service; interviewing key staff.

Analysis of the State Budget shows that the sums planned for medicines centralized procurement were very low (about a half of USD per capita) for the period up to 2003 when it is sharply increased reaching almost 2.2 US dollar in per capita terms. Since 2004 public drug expenditures again twice decreased. Real expenditures were always less than planned. Private expenditures are also sharply increased since 2002, and the trend is kept. The private expenditures made up 7 USD per capita without taking into account shadow economy. Drug donations were significantly reduced since 2000.

Comparison demonstrates that pharmaceutical expenditures in Armenia are very low. In the OECD on average, the public pharmaceutical expenditures in 1996 was 137 USD per capita, in developing countries it is usually less than 30 USD, and only in 38 countries it is less than 2 USD. This leads to the situation when many patients lack access to essential medicines. Recommendations on increasing public pharmaceutical expenditures and other strategies for improving affordability of medicines were presented to the Ministry of Health. Access to information should also be amended. Accountability and transparency mechanisms have to be introduced.

This work was supported by the OSI - with the contribution of the IPF of OSI-Budget.

PHARMACY INFORMATION SECTION - POSTER SESSION

PI-P-005

QOL OF PATIENTS WITH UNIPOLAR MAJOR DEPRESSIVE DISORDER WITH SOME SELECTED ANTIDEPRESSANTS.

M. Triveni¹, M. Ramesh², G. Parthasarathi², P.K. Lakshmi¹, S. Shyamala Bhaskaran³,

¹Karnataka state pharmacy council, ²JSS College of Pharmacy, ³AI-Ameen College of Pharmacy, India

Aim: To assess the changes in Quality of life (QOL) of patients with unipolar major depressive disorder receiving either single or combination of selected antidepressant drugs.

Method: The study was open labeled, prospective study conducted over a period of nine months at the department of psychiatry of J.S.S. Medical College Hospital, Mysore. Total five drug groups were selected. The different drug groups were i.e. citalopram, sertraline, dothiepin, citalopram in combination with dothiepin and sertraline in combination with dothiepin group. Patients of either sex who were diagnosed as having unipolar major depressive illness as per DSM-IV criteria and patients who gave their written consent to participate in the study were included in the study. Institutional Human Ethical Committee of J.S.S. College of Pharmacy, Mysore, has approved the study. WHO-BREF Quality of Life questionnaire was used to assess the quality of life.

Results: Among all the five drug groups, statistically significant ($p < 0.05$) improvement in quality of life at the end of 8 weeks was seen in sertraline plus dothiepin combination compared to other groups.

Conclusion: Improvement in quality of life scores of patients with unipolar major depression was found in all the study groups. The maximum improvement in quality of life scores was seen with sertraline plus dothiepin group followed by citalopram group.

PI-P-006

COMPARATIVE STUDY OF SAFETY AND EFFICACY OF SOME SELECTED ANTIDEPRESSANTS IN UNIPOLAR MAJOR DEPRESSIVE DISORDER

M. Triveni¹, M. Ramesh², G. Parthasarathi², P.K. Lakshmi¹, S. Shyamala Bhaskaran³,

¹Karnataka state pharmacy council, ²JSS College of Pharmacy, ³AI-Ameen College of Pharmacy, India

Aim: To assess and compare the safety and efficacy of selected antidepressants and their combinations in unipolar major depressive patients.

Method: The study was open labeled, prospective study conducted over a period of nine months at the department of psychiatry of J.S.S. Medical College Hospital, Mysore. Total five drug groups were selected. The different drug groups were i.e. citalopram, sertraline, dothiepin, citalopram in combination with dothiepin and sertraline in combination with dothiepin group. Patients of either sex who were diagnosed as having unipolar major depressive illness as per DSM-IV/ICD-10 criteria and patients who gave their written consent to participate in the study were included in the study. Institutional Human Ethical Committee of J.S.S. College of Pharmacy, Mysore, has approved the study. Hamilton rating scale for depression - 17 items and somatic symptom questionnaire were used to assess the efficacy. Udvalg for Kliniske Undersogelser side effect rating scale was used to assess the safety.

Results: Results of this study showed that citalopram was most efficacious drug ($p < 0.05$) showing 93% reduction in HAM-D scores and 98% reduction in somatic symptoms followed by sertraline plus dothiepin combination. Upon assessment of safety parameter study showed that citalopram was safest drug with only decrease in salivation as an ADR while sertraline plus dothiepin combination showed maximum number of ADRs.

Conclusion: All the study drugs were effective in treating unipolar major depression. The results suggest that citalopram was found to be most efficacious and better tolerated drug among all the study groups.

PI-P-007

ANTIMICROBIAL DRUG RESISTANCE (AMR): AN INCREASING CONCERN FOR TREATMENT FAILURE

D. Seyoum
The US Pharmacopela,
United States of America

The devastating effects of HIV infection, tuberculosis, malaria, and many other infectious diseases, especially in resource-poor countries, has led to local, regional, and international public efforts in the prevention and treatment of infectious diseases. However, the scale of infectious diseases is changing rapidly because of emerging infections and AMR. AMR results in increased morbidity, mortality and costs of health care. AMR has been observed since the 1940s with penicillin resistant *Escherichia coli* and *Staphylococcus aureus*. Resistance has also been detected in both gram-positive and gram-negative organisms immediately after the introduction of penicillin. Recently, more and more pathogens are showing multiple drug resistance. Examples are multiple drug-resistant *Mycobacterium tuberculosis* (MDR-TB), penicillin-resistant *Streptococcus pneumoniae*, fluconazole-resistant *Candida*, methicillin-resistant *S. aureus* (MRSA), vancomycin-resistant *Enterococci* (VRE) and more recently, vancomycin-resistant *S. aureus* (VRSA) with reduced susceptibility to vancomycin. Given the spectacular increase in the incidence of multiple drug-resistant organisms and the growing resistance transfer from one organism to another, we will certainly witness pathogens for which there are no antibiotic solutions. Both prescribers and patients should appreciate and understand the problem and the magnitude of AMR. Therefore, appropriate infection control measures designed to curb the problem of AMR should also include the development and dissemination of drug information in relation to AMR.

PI-P-008

MARKETING STRATEGIES TO INCREASE CONSUMER AWARENESS OF IMPROVED ACCESS TO MEDICINES IN UNDERSERVED POPULATIONS

J. Vivaldo
Management Sciences for Health,
United States of America

Three models for improving access to medicines through use of private sector drug sellers have been implemented under the SIAM Program. The goal of these initiatives was to improve overall access to medicines; with access being defined as geographic accessibility, affordability, availability and acceptability of quality drug products and services. In each initiative, strategies were implemented to address access gaps. Substantial marketing efforts were needed to inform consumers of the changes taking place.

Key marketing messages for consumers were defined using input from stakeholders and consumers. These included: 1) only buy medicines from drug sellers that are properly trained, licensed, and regulated; 2) recognize the dangers posed by buying medicines of unknown quality; 3) understand how to take your medicine; and 4) know what to expect from drug dispensers, including good service and a fair price.

The facilities involved with these initiatives are in rural areas with limited service availability. As a result, this limited the usage of some traditional marketing strategies and alternative, culturally-adapted marketing strategies were employed. These included re-branding or re-naming old facilities, extensive radio and billboard campaigns, elaborate program launches, public skills and presentations, traveling road shows, and 'word of mouth' promotion.

Preliminary data collected for the final evaluation of the project indicate these strategies have played a major role informing people of the improved access. The strategies used have been key to the successful implementation and will be critical for continued expansion to other regions of the countries.

PHARMACY INFORMATION SECTION - POSTER SESSION

PI-P-009

MAXIMIZING THE IMPACT OF DONOR INITIATIVES FOR INCREASING ACCESS TO MEDICINES

A.C. Speed, G. Phumtim, K. Johnson,
Management Sciences for Health,
United States of America

Aims: Coordination of donated funds and commodities is a key step to ensuring uninterrupted and rational commodity disbursement within an underdeveloped country. Making this information readily available for program management, especially those donor programs dealing in drugs and supplies used in the prevention, diagnosis, and treatment of HIV/AIDS, is essential. The introduction of a shared, Web-enabled database has facilitated this access.

Methods: MSH collaborated with Synergy International Systems using their Intelligent Data Manager™ software to create the Commodities Tracking Tool (CTT). The database, which currently focuses only on HIV/AIDS drugs and supplies, is being used in countries targeted by the U.S. President's Emergency Plan for AIDS Relief where MSH has a presence. Piloting of the tool was done with data from the Haiti program.

Results: Use of the CTT depends heavily on good coordination of data gathering efforts in-country, as was discovered during the experience in Haiti. Based on the results of the pilot phase, use of the tool allowed the donor organization and the Ministry of Health to help answer the questions of what is coming into Haiti, how much is coming in, and where the gaps are in drug supplies for national treatment programs. Knowing the answers to these questions will help to more appropriately redirect donor initiatives to maximize public health impact.

Conclusion: A Web-enabled database is an effective way to share information about donor initiatives. As the database grows, it is hoped that more donors will see the CTT as a valuable source of information and opt to include their program funding information.

PI-P-010

BOT-PLUS: THE SANITARY KNOWLEDGE DATA BASE : INNOVATIONS

P. Capilla, C. Peña, J. Herradón, J. Carbonell, M. Fuentes, I. Linaza, L. Amaro,
General Council of Pharmacists of Spain,
Spain

Aims:

For more than twenty years, the Database of the General Council has served the information needs of pharmacists in Spain. Advances in the pharmaceutical world have led the Council to consider the continuous updating of its computing tools in order to meet current requirements and those which might arise in the short and medium term. This has been the origin of the new Database of the General Council BOT Plus.

Methods and results:

In order to meet the needs of the pharmaceutical sector, BOT-Plus incorporates a series of advantages over its previous version:

- New information blocks:
 - Pharmaceutical care: permits the development of Pharmaceutical Care.
 - Pathologies: information referring to illness and their treatment
 - Medicines for animal use.
 - Herbal Medicines: information on more than 200 active principles and over 600 products.
 - Homeopathy.
- Foreign medicines: correspondences between Spanish and foreign medicines.
- Incorporation of multimedia contents: annex documents that enrich the information (technical files, information files for the patient, documents from the magazine *Panorama*, etc.).
- Searches and lists: direct and fast gathering of the most common lists of various types of medicines required by the pharmacist in his daily labour.

Conclusion:

BOT-PLUS constitutes an essential element for developing the pharmacotherapeutic monitoring of the patient, thereby improving the rational use of medicines.

PI-P-011

USE OF PHARMACEUTICAL MANAGEMENT SOFTWARE IN RESOURCE-LIMITED SETTINGS

A.C. Speed, K. Johnson,
Management Sciences for Health,
United States of America

Aims: Resource-limited countries rarely have adequate infrastructure to manage pharmaceutical procurement, inventory, and distribution effectively. They also lack ready access to resources needed to build this capacity. Low-cost software, specific to their needs, is required.

Methods: MSH, in collaboration with 3i Infotech, created software to address this gap. ORION@MSH incorporates pharmaceutical supply best practices for resource-limited settings and is comprised of six interlinked modules spanning from accounting to warehousing. This software was successfully piloted at the Pharmaceutical Procurement Service of the Organization of Eastern Caribbean States (PECS/OECS) and St. Lucia's Central Medical Store in May 2004 and then rolled out to six other island nations over the following 14 months.

Results: In order to effectively integrate new software into a site where old or no software currently exists, many conditions must be understood and met beforehand. Some key items: 1) buy-in and agreement from the sites regarding the effort required from local resources and its provision, 2) clear understanding how the program operates and changes required (both in the software and in the processes of the beneficiary) to ensure maximum benefit, and 3) available and accessible support for the clients. User response (both from the managerial and support levels) is positive.

Conclusions: Affordable pharmaceutical management software built on best practices for resource-limited environments is a sustainable alternative that countries can consider in building their pharmaceutical management infrastructure.

PI-P-012

IMPORTANCE OF INFORMATION IN HERBAL MEDICINES USAGE

D.D. Djurovic, U.D. Urošev,
Medicinal Agency of Serbia,
Serbia and Montenegro

Herbal medicines are used in traditional treatment but there are lack of evidence in efficacy, toxicity and safety. Despite potential risk, monitoring of side effects is still developing.

According with this well-timed and precise information about herbal medicines became an imperative. Usage of herbal medicines is very important for patient because it makes symptoms easier in minor illnesses. How to make this more safety? Generally, this treatment requests high level of health education and social status than the role of community pharmacist is significant.

The aim was to emphasize importance of precise and well-timed information for usage of herbal medicines.

In this work, we presented examples of herbal drug which efficacy is confirmed in controlled pharmacology and clinical trials, and examples of some herbal medicines side effects and interactions. The exact examples of information that community pharmacist give at dispensing are shown. Data Base and Report of Adverse Effects are used.

We emphasize that instruction for usage for herbal medicine has to be in concordance with SPC but adjusted for patients.

Today, knowing of existence of side effects, interactions and cautions with herbal medicines it is very important to include them in instruction for usage.

Analyzing results, we concluded that responsibility of community pharmacist is enlarged while dispensing herbal medicines. The difference of giving complex information in community pharmacy and in instruction for usage is significant.

To make this service more professional, the importance of communication, counseling and continuing education have to be stressed in permanent education of pharmacist.

PI-P-013

APPLICABILITY OF INFORMATION PROVIDED BY A DRUG- INFORMATION CENTRE (DIC) FOR COMMUNITY PHARMACY DAILY PRACTICE

A.M. Nogueira, A. Nogueira, C. Antunes, M. Fernandes, J. Guerreiro,
ANF,
Portugal

Aims: To evaluate if the information provided by CEDIME (DIC) is useful for community pharmacists and applicable to their daily practice.

Methods:

Study design: descriptive cross-sectional study

Period of data collection: data will be collected over a one-month period (April 2005)

Tools for data collection: information will be collected through telephone interviews performed by an independent person, registering such information on a data collection sheet. This information will be entered into a database specifically developed for the purpose of the study. Checking data entering will be performed prior to its analysis as a means to ensure validity.

Study participants: all community pharmacists calling CEDIME for pharmacotherapy-related queries will be included in the sample, when agreeing to participate (until 48 hours later). **Data analysis:** Variables allowing concluding on daily applicability (main outcome) will be evaluated by descriptive statistics. Bivariate analysis will be used to explore the association of socio-demographic data, origin of the query (e.g. patient request) with the main outcome of the study.

Results: will be available for the congress.

Discussion: we believe these studies are important to detect improvement opportunities in order to better align theory and practice.

PI-P-014

DEVELOPMENT OF DRUG INFORMATION DATABASE FOR NONPRESCRIPTION DRUGS AND SUPPLEMENTS

T.O. Oshima
Kinjo-gakain University,
Japan

From the viewpoint of the proper use of nonprescription drugs and supplements, we have developed a drug information database for nonprescription drugs and supplements with drug interaction check system. This database is set up by using the Microsoft® Access 2002 for Windows. There are a total of eight tables: drug information, ingredients, product information, drug interactions, contraindications, and therapeutic category. Each table is linked mutually by using the Japanese Article Number (JAN) Code and generic name. The up-to-date data required to develop the database were taken from resources such as 'Japan Self-Medication Database Center', 'The Medical Information System Development Center', 'Japan Pharmaceutical Information Center', and 'Hansten and Horn's Drug Interactions (Facts and Comparisons)'. The degree of drug interaction were classified into three levels: avoid combination, avoid unless benefit outweighs risk, and monitor.

The database consists of 14,003 items of nonprescription drugs and 19,210 items of prescription drugs and 179 ingredients of supplements. A total of 2,096 drug interactions are showed 875 of nonprescription-nonprescription interactions, 1094 of nonprescription-prescription interactions, 44 of nonprescription-supplement interactions, 83 of prescription-supplement interactions. Sixty-two ingredients are found in both supplements and drugs (prescription and nonprescription), whereas 218 ingredients of nonprescription drugs contain contraindication when used as prescription drugs. In conclusion, we consider our database to be a useful tool for the proper use of medications and for the promotion of self-medication.

PI-P-015

THE CONSUMPTION OF INSULIN PREPARATIONS IN THE REGION OF BANJA LUKA FROM JANUARY 2002 TO DECEMBER 2004

V. Todic, T. Djuric,
Apotekarska Ustanova Banjaluka,
Bosnia and Herzegovina

The aim of this research was to present the increase of insulin dependent diabetes mellitus in the region of Banja Luka, the area with population of almost 300000 people. The research was made in Apotekarska Ustanova Banja Luka from January 2002 to December 2004, using the data from 18 pharmacies. This is the only institution where patients can get the preparations of insulin on a prescription.

According to the contract with the RS Health Fund, the data and prescriptions of insulin preparations since 2002 have been taken separately from other medicines. The data included Novo Nordisk preparations, the only one on this market permitted by the RS Health Fund. They were compared by years and types.

We found that the number of used insulin preparations had been 11342 in 2002, 13230 in 2003 and 14232 in 2004. According to these results almost 5% of population are insulin dependent. The results also revealed that the use of insulin preparations had significantly increased from 2002 to 2003 of 16,65% and of 7,57% from 2003 to 2004.

Genetic factors, inappropriate nutrition and stress can be the causes of this increase, but the post traumatic syndrome specific for this region even years after the war is probably the leading factor.

Considering a large number of registered patients and probably more uncovered cases, we constantly pay attention how to prevent the further development of this illness by having the workshops among the pharmacists and continuous education among the patients.

PI-P-016

USE OF INTERNATIONAL PHARMACEUTICAL PRICE COMPARISON INFORMATION

A.C. Speed, J.E. McFadyen,
Management Sciences for Health,
United States of America

Aim: Access to a central, independent, updated source of comparative pharmaceutical price information should greatly facilitate procurement of medicines of assured quality for the lowest price.

Method: The International Drug Price Indicator Guide provides an indication of pharmaceutical prices on the international market. Updated annually and published by Management Sciences for Health (MSH) in collaboration with the World Health Organization, the Guide contains a spectrum of prices from pharmaceutical suppliers, international development organizations, and government agencies. The latest edition of the Guide contains prices for more than 900 pharmaceuticals, contraceptives, and vaccines. The Guide, in English, French, and Spanish, is available in print, on CD-ROM, and through the MSH Electronic Resource Center (<http://ec.msh.org>).

Results: A 2004 survey of more than 50 users of the International Drug Price Indicator Guide found that 68% of them use the Guide for comparing prices recently obtained from suppliers and 42% use it to plan their budget or tender. Sixty-four percent of the survey respondents stated that they do not have access to any other source of comparative international price information. Of the survey respondents, 44% said that using the Guide has contributed to better acquisition prices or other savings for them, with half saving 11-30%.

Conclusions: Access to independent comparative price information assists in price negotiations, in locating new supply sources, and in assessing the efficiency of local procurement systems.

PHARMACY INFORMATION SECTION - POSTER SESSION

PI-P-017

TO PROMOTE THE PATIENT SAFETY THROUGH A RADIO PROGRAM-'HOW TO BE A WISE PATIENT'

D.J. Shiao, S.Y. Hsiao, C.S. Gau, L. Shue,
Ching-Kang Foundation,
China Taiwan

Aim:

People in Taiwan are not only seeing doctors more than they really need to, but also taking too much over-the-counter (OTC) medicine and so-called healthy food supplements. It is important to educate people understanding the danger of that, and the right approach to use non-prescribed medicine. To achieve this goal, we must help people learning the correct ways to use the OTC medicine and understanding the food supplements that are advertised everywhere in Taiwan. We will convey the message that the patient is the centre in medical practice, patients and their relatives should be educated and informed thoroughly to assure patients' safety.

Method:

Playlets, which introduce patient's safety to the audience of all ages and backgrounds, were aired on the News Channel of the Broadcasting Corporation of China (BCC). The scripts were written by junior pharmacists and reviewed by experienced senior pharmacists, doctors and professors. The scripts were posted on websites of BCC and CKF foundation.

Result:

Short plays of 2 to 3 minutes were aired at noon or dusk on weekdays. A total of 66 playlets were aired within three month span. The subjects are, but not limited to, counterfeit medicines, differentiating exaggerated advertisements of medicine and healthy food supplements, storing medicine properly, asking questions regarding to your medicine, and being a participating patient.

Conclusion:

In a society bombarded by all kinds of OTC medicines and healthy food advertisements, it is important for pharmacists to educate the general public through mass media to be 'wise patients'.

PI-P-019

FREE CONSULTATION PHONE CENTRE AS A SOURCE OF INFORMATION ABOUT RATIONAL USE AND CHOICE OF MEDICINE FOR CONSUMERS AND SPECIALISTS

H.G. Dunagulyan, L. Grigoryan, H.CH. Harutyunyan, Ch. Shakaryan,
Pharmprogress NGO,
Armenia

Background: According to the data of investigations made in Yerevan among 7200 medicine consumers, 55% of medicine consumers lack information about rules of medicine use because of refusing to visit a specialist before taking medicines or buying the medicine without leaflet. 82% of medicine consumers are unaware of possible minimization of medicine expenses by using generics.

Aims: Create an available source of information about the rules of rational choice and use of medicines for Yerevan population.

Methods: We created a free consultation phone center (the staff of which includes licensed doctors and pharmacists) with an informational base including the rules of safely using the medicines, registered in Armenia and an opportunity of filtering generics by active substance.

The spread of information about phone center was realized by means of providing policlinics and pharmacies with posters, as well as by means of mass media.

Results: In the period of October 1, 2004- March 1, 2005 (150 days) there were 9981 calls. 55% (5549 calls) needed information about the rules of medicine use, 42% (4202 calls) were interested in different generics registered in Armenia. Of 4202 calls for generics 58% (1597 calls) were made by doctors or pharmacists.

Conclusions: We created and developed free phone consultation center that can be an effective source of information about rational choice and use of the medicines for medicine consumers, as well as for specialists.

PI-P-018

PHARMACEUTICAL JOURNALS IN SERBIA

G.M. Mihajlovic
Medicines and Medical Devices Agency,
Serbia and Montenegro

Any profession, but especially pharmacy is abundant with the information which are meaningful to colleagues and patients. In our country several journals are published, of which some are strictly professional and some mainly popular, such as:

ARCHIVES OF PHARMACY, founded in 1950, and published bimonthly by the Serbian Pharmaceutical Society (YU ISSN 0004-163). It publishes the papers in Serbian with summary in English, based on original research, as well as general reviews.

APOTHECARY PRACTICE, published monthly by Pharmaceutical Chamber (ISSN 1451-1827). It presents the news from Pharmaceutical Chamber, details from the pharmacy practice, review of new books and news in pharmacotherapy.

PHARMACY, monthly journal for popular medicine and pharmacy, published by BB-Soft. It is distributed to the individuals free of charge to the private-owned Pharmacies.

INFORMANT, Journal published monthly by BB-Soft assigned to the Pharmacies-members of the Serbian Society of Private Pharmacies.

PI-P-020

PATIENT INFORMATION ADMINISTRATE SYSTEM FOR A PHARMACIST-YAKUREKI-

Y.N. Nanaumi
Seven Pharmacy,
Japan

We use a tool saying 'Administration guidance and recording sheet of medication history' routinely to promote proper usage of medicine at a Japanese community pharmacy. We call a popular name 'YAKUREKI'.

YAKUREKI is a paper media which made to a patient individual by pharmacist as record of at community pharmacy, and a full name of the patient, an address, product names are specified. And this is made when pharmacist fills a prescription, hands products to a patient, and counsels about medication.

This YAKUREKI was carried out since separation system-Bungyo- was introduced in Japan, but the contents, the purpose, the format changed with promotion of Bungyo.

Now administration of YAKUREKI in pharmacist duties is evaluated as required duties as a medical worker.

In other words contents and information of YAKUREKI are necessary indispensability so that a pharmacist achieves a duty as a medical job.

Therefore a tool of this YAKUREKI was introduced and used to analyze a point of revision of YAKUREKI which it continued having been lasted for at my community pharmacy for about 10 several years and a change of YAKUREKI after process and revision of revision.

I think that the result that they are analytical show a change of a social role of a pharmacist and a change of consciousness to the patient and a change of consciousness to a pharmacist of the patient.

I propose that the system of the patient information administrate duties that using YAKUREKI is a very effective system for promotes patient-centered medical care, and for approach a distance of a pharmacist and the patient.

PI-P-021

COCAINE USE IN METHADONE PATIENTS IN THE HEALTH SERVICE EXECUTIVE, NORTHERN AREA DUBLIN, IRELAND

N. Zayed, B. Kirby, Z. Ramtoola,
Health Service Executive,
Ireland

Aims: To examine the use of cocaine among methadone patients in the Health Service Executive (HSE) Northern Area Dublin, Ireland. **Methods:** A survey was carried out on 451 patients receiving methadone treatment for opiate addiction. Patients reported the incidence and frequency of cocaine use. **Results:** Data showed that 77% of the participants had a history of cocaine use. Of these, a significant percent, 34%, represented cocaine use within the last month, with 12% reporting a daily frequency of use. Of all the patients surveyed, 72% were receiving a daily dose of methadone of 60 mg or greater. Examination of the data from one of the largest Drug Treatment Centres surveyed, D1, showed that the participants had a cocaine incidence of 68%, with 29% having used cocaine within the last month. Of these participants, 30% were in the 20-29 years age range. The survey showed that 71% of the participants who had used cocaine in the last month were receiving a daily dose of methadone of 60mg or greater. **Conclusions:** The survey concluded that cocaine abuse is emerging as a problem in the Irish drug scene among opiate users receiving methadone treatment in Dublin City. The figure of cocaine use observed in this survey is an important indicator of the level and extent of cocaine use in methadone patients and is valuable from a public health perspective in order to assess needs, and to plan and evaluate education, prevention, treatment and harm reduction services.

PI-P-022

PREVALENCE OF CANNABIS USE AMONG METHADONE PATIENTS IN THE ADDICTION SERVICES OF THE HEALTH SERVICES EXECUTIVE (HSE), NORTH AREA DUBLIN, IRELAND

N. Zayed, Z. Ramtoola,
Health Service Executive,
Ireland

Aims: To examine the use of cannabis among methadone patients in North Dublin. **Method:** A survey was carried in 869 methadone patients of six drug treatment centres of North Dublin. **Results:** Prevalence of cannabis use among the participants was high at 83% and was consistent across all drug treatment centres (78-88%). Of the participants using cannabis, 42% reported a daily frequency of use and 19% reported using cannabis once or twice weekly. A high proportion of the participants surveyed, 46%, were receiving a medium to high dose of methadone (70-100mg) daily. The prevalence of cannabis use was not found to be related to the methadone daily dose received by the participants. A high incidence of cocaine use was previously shown in the same population of patients suggesting a high level of poly-drug use among these patients. **Conclusions:** The survey showed that the majority of methadone patients were using cannabis, with a high proportion of the patients using it on a daily basis. Although cannabis is perceived as a safe drug, it is known to have both acute and chronic health effects and does produce dependence.

PI-P-023

INFORMATION ON TRAVEL HEALTH

L.M. Azzopardi, A. Serracino-Inglott, M. Zarb-Adami, M. Camilleri,
University of Malta,
Malta

Information on travel health empowers individuals to understand prevention and management of health conditions that can occur when travelling. The aim of the study was to develop and evaluate a travel health information booklet to be distributed from community pharmacies.

A booklet was prepared to present information on travel health. A self-administered questionnaire was developed to determine the knowledge of participants on travel health before and after the use of the booklet. The questionnaire was administered to 433 adults recruited from shopping localities (test 1). The booklet was presented to the participants after test 1 was completed and they were asked to complete the questionnaire again 15 days after reading the booklet (test 2).

Out of the 433 participants who participated in test 1, 96% (414) had traveled at least once and 13% (56) claimed that they had a health problem during travel. The majority (68%, 293) do not seek advice on travel health prior to traveling. Participants (98%, 425) were aware of the methods to prevent HIV infections. Knowledge about Hepatitis A and Hepatitis B infection was lower with only 21% (93) and 39% (168) respectively having the correct knowledge. Test 2 was completed by 323 participants (75%). There was an overall significant improvement in the knowledge reported ($p=0$). Participants (79%, 256) assessed the booklet as useful, understandable, well presented and informative.

Few persons seek advice on travel health. The presentation of a booklet on travel health creates an awareness on health travel in prospective travellers who can then seek advice from the pharmacist.

PI-P-024

GUIDES TO HELP COMMUNITY PHARMACISTS IN HIV/AIDS AND STDs COUNSELING

J.O.S. Naves¹, L.L.C. Castro¹, E.V. da Silva², C.C.F. Vidotti², C.A.L. Vicira³,
V.A. Melo⁴, J.B. Oliveira Filho⁴,
¹Brasilia University (UnB/FS), ²CEBRIM/CFF, ³Community pharmacist,
⁴CRF-DF,
Brazil

Introduction: Sexually transmitted diseases (STD) are a major public health issue. According to estimates of WHO, 70% of those infected by STDs in Brazil do not seek for treatment. Community pharmacies are an important site where people seek for primary health services. The purpose of this work is to develop and test guides to help both pharmacists and pharmacy-sales-person in community pharmacies.

Methodology: The guides were developed based on previous ones published by Brazilian Ministry of Health, updated by a multidisciplinary team - pharmacists and physicians. The guides were distributed and evaluated in a course on HIV/AIDS and STDs in community pharmacies, which was attended by both pharmacists and pharmacy-sales-persons.

Results: It was produced the two guide's that include information about: The impact of STDs; their clinical issues and measures to prevent and control; the importance of community pharmacies in public health system; pharmacist responsibilities and counseling in STDs; patients' instructions about use of drugs in STDs; useful websites. It was held a course attended by 78 persons. Out of these, only 19 answered the questionnaire. The guides are 'very good' for 16(84%) and 'good' for 3(16%).

Conclusion: It was possible to develop the guides using the proposed methodology and to verify the opinion of their users. Limitations of this study include: evaluation of the guides by few people. In this moment is in processing the evaluation if the course, combined with the guides, change the current practices in community pharmacies. These results will be in the congress.

Thanks: To UNESCO, to CFF and to SES/DF.

PHARMACY INFORMATION SECTION - POSTER SESSION

PI-P-025

AIMING AT EXCELLENCE IN ADOPTING AND USING DRUG GENERIC NAMES

C.C.F. Vidotti¹, L.B. de Moraes²,
¹Federal Council of Pharmacy, ²ANVISA/MS,
Brazil

Introduction: Drugs are identified by many names and codes, according to their developing status and use. This causes confusion over the pharmaceutical chain, including harm to users of drugs and loss of money due to market of a same drug with different names. Considering this situation, Brazilian authorities have adopted regulations to harmonize the generic names of the drugs.

Objectives: Describe regulations approved in Brazil to harmonize the generic drug names.

Methodology: Search and describe regulations approved in Brazil to harmonize the generic drug names, specifying their role in a system to adopt generic names in the Portuguese language.

Results: Six officially adopted regulations related to drug nomenclature were identified: 1. the Portuguese drug nomenclature rules; 2. the English - Portuguese translation rules; 3. the labeling regulation; 4. the database that stores drug nomenclature approved, their synonyms, English names and C.A.S. registry number; 5. the Brazilian Nonproprietary (generic) Names Official list and 6. the resolution to update, to correct and to delete official generic drug names.

Conclusion: In recent years, regulations approved can help users, professionals and the Brazilian government to use the same drug name over the pharmaceutical chain. That can avoid misunderstanding, promote rational use of drugs and reduce unnecessary costs and loss of time. The last mentioned regulation links all the other five ones, building a professional framework that can lead to an excellence in adopting and using generic drug names. Further works should study the correct use of generic names over the pharmaceutical chain.

PI-P-026

USING SELECTIVE SEROTONIN RECEPTOR INHIBITOR IN PREGNANT WOMEN AND NURSING MOTHERS

J. Chiang¹, N. Chen²,
¹, ²Kaohsiung Medical University,
China Taiwan

Aims: depression has become a modern disease, and it involved a great number of young women. We try to figure out the influence of sari for them, especially they are in the age of planning parenthood. We hope that every patient will have a thoughtful suggestion from pharmacist. **Methods:** we collected the results of several clinical trials, from 2000 to 2004. **Results:** although no evidence approved the teratogenic effects in appearance of newborns, we still need more research followed to assess the mental difference of children. For those mothers who has taken sari during pregnancy, we realized those sari attend to the withdrawal syndrome of their babies. Until now, we may say that few sari is absorbed by infant from breast-feeding, the safety of using sari in breast-feeding infant is more than we estimated before. But we still suggest that some sari of high protein-binding rate should have a bigger clinical trial. Not only stop the administration of sari, but also stop the treatment of sari, we strongly recommend the pharmacist and the patient of depression, to judge the benefits of treatment of sari with the clinician.

PI-P-027

A NEW METHOD TO PROVIDE DRUG INFORMATION BY '2D-BARCODE' WITH CAMERA PHONES

K. Takunaka, K. Uno, K. Osada, C. Endou,
Niigata College of pharmacy,
Japan

[aims] Over 75% percent of mobile phones in Japan are camera phones which enable new services based on QR-code (2D-barcode) input leading to a variety of new transactions. Patients, for example, use their camera phones to take a printed QR code and automatically access a corresponding website. Using this technology, patients are accessible to information on their prescribed drugs.

[methods]

Firstly, we made a database on representative medicines in Japanese as well as English. The database consist of following elements on each drugs. 'What is this medicine used for?' 'Usage of this medicine' 'When you forgot to take the medicine?' 'When you take too much medicine?' 'What is the adverse reaction?' 'Symptoms that require attention' 'Essential information you should tell your doctor' 'The government established code name of the drug'. QR codes corresponding to prescribed drugs for patients were printed on drug container, so that patients scan a QR code and access the specific drug website.

[results and conclusions]

Some people may stop taking their medicine, take a lower dose, or skip doses if they are having side effects. To avoid these medication errors, it is important to give the information not only by paper but also digital information. We could establish a new drug information system using '2D-barcode' with camera phones. Although the QR code is a JIS Standard as well as an ISO standard, it is only widely used in Japan. For foreigners in Japan, we are also able to provide English instructions on prescribed drugs.

PI-P-028

HOPADOM HAUTE NORMANDIE 76000 ROUEN - FRANCE REGIONAL HEALTH NETWORK FOR THE COORDINATION OF KEEPING SICK PEOPLE AT HOME.

D. Briessier
Ordre des Pharmaciens,
France

AIM

To allow patients who have reduced physical and mental autonomy to be taken care of at home whatever their age or illness by their usual medical staff.

METHOD

Thanks to public finance by the « Fond d'Aide à la Qualité des Soins de Ville » (quality health care in town aid fund) run by the « Unions Régionales des Caisses d'Allocations Familiales » (grouping of regional National Health agencies) and by regional donations for the development of networks run with the help of the regional hospital departments Hopadom has set up a team of co-ordinators and social workers to help patients who want to stay at home as well as people from the medical field specialised in hospital and town medicine. The association provides material and human resources necessary for health care at home while coordinating the different types of health care, social help and psychological help needed by the patients. Its operation and data management are run via Hopadom's Internet site.

RESULTS

25% of the patients are under 60, 30 % are over 80 and 42 % of them suffer from cancer. The association gives free health care. Hopadom, an independent neutral association, guarantees quality, safety and impartiality to the patients.

CONCLUSION

Hopadom, an organisation whose aim is to take care of sick people at home is an answer to those who want to be taken care of at home. It also fulfils a need to reduce the number and the duration of hospital visits as well as organizing patients return home after being in hospital and the doctors visits in the patients home.

PHARMACY INFORMATION SECTION - POSTER SESSION

PI-P-029

CHARACTERIZATION OF KNOWLEDGE AND ACCESSIBILITY OF SELF-MEDICATION USE IN UNDERGRADUATE STUDENT: A TEACHING PROVINCE

C. Sithiworatan¹, N. Kitikannakorn²,

¹Faculty of pharmaceutical sciences, ²Faculty of Pharmaceutical Sciences, NARE, Thailand

Aims

To design appropriate drug information service of self-medication for undergraduate student

Methods

Questionnaire was designed and approved by specialists (comprised of 4 sections: personal data, self-medication use, information accessibility and general knowledge test of self-medication use). The approved questionnaire was handed to a random sample of undergraduate student in a teaching province, Northern of Thailand.

Results

One hundred and fifty questionnaires were completed. Mean age (SD) of respondents was 21.43 (2.06) years old, 70% were female and 77.4% lived in dormitories. Result presented 93.3% were using self-medication. Most of self-medication uses were analgesics (87.3%), cosmetics (52.7%), first aid kit (46.7%) and home remedies (44.7%). The most of provided self-medication place was community pharmacy (90%) and only 38.7% were absolute recovered of chief-complaint. More than 50% agreed the most of drug information resources were television broadcast and community pharmacist and 68.7% preferred television broadcast for their most convenient accessibility. Most of drug information demands were primary health care medication and home remedies. An average score (SD) of general knowledge test was 14.78 (5.53) out of 28. Recommendations, adverse drug reaction and administration of drug use were particular topics of less right scores.

Conclusions

Drug information service of self-medication use should be included recommendation, adverse drug reaction and administration. Television broadcast and community pharmacist are generally agreed the most drug information resource. Further study of self-medication use in other provinces is characterized.

PI-P-030

THE PHARMACIST'S ROLE IN WRITING THE BASIC GUIDEBOOK FOR RATIONAL PHARMACOTHERAPY

L. Djukić¹, N. Ugresić², T.S. Tomislav Solarić¹, V.S. Violeta Stanimirović¹, B.T. Braška Terzić³,

¹Medic and Medical Devices Agency, ²Faculty of Pharmacy, ³Clinical Center of Serbia, Serbia and Montenegro

Synthesis of pharmaceutical, pharmacological and therapy attitudes with the application of key information for health-care professionals, is raising the drugs knowledge level and enhancing the pharmacotherapy. Clinical pharmacy, clinical pharmacology and pharmacological information technology are the sources for the advancement of pharmaceutical and medical practice.

Project development survey of writing an operative Pharmacotherapy Guide which makes the practical pharmacotherapy easier is accord with the latest scientific and expert achievements.

The book was made at the Pharmacy Institute of Serbia. The data were collected from reference sources: relevant literature official positions of the regulatory organs, doctrinaire positions, expert opinions, and manufacturers' data.

The methodology has been adjusted to the international classification which provides keeping up with the main pharmacoepidemiological parameters. Up-to-date information and attitudes have been cited for the essential medicines; there has been made a more detailed description for new ones. In its supplements there were given abridged information from the field of pharmacokinetics, pharmacogeny, toxicology and other related disciplines.

There are brief, scientifically verified and practical information gathered in it. Commitment of the multi-disciplinary team of health experts is opening a space for a higher level of cooperation between pharmacists and doctors.

This book was reviewed very well by the health-care public imposing the need it to be published annually. With this study, we are emphasizing the very significant role of pharmacist is creating a rational pharmacotherapy.

PHARMACY INFORMATION SECTION - SHORT ORAL PRESENTATIONS

PI-O-001

HOW WELL DO UK ADULTS UNDERSTAND MEDICINE PICTOGRAMS?

P. Knapp, D.K. Raynor, A.H. Jebar, S. Price,
University of Leeds,
United Kingdom

Patients' ability to understand information about medicines is crucial for safety and effectiveness. Rates of illiteracy mean that written information alone cannot meet patients' needs. Medicine pictograms are an alternative, but may be culturally sensitive. Previous testing has used large pictograms which are impractical for conventional information formats.

Study aims were:

to compare two sets of pictograms (from the USA and RSA) for understandability by UK adults.

to examine the effects of pictogram size and repeat presentation on understandability among older adults.

In the first part of the study, 160 adults (aged 17-83) saw 10 pictograms, and gave their interpretation. In the second, 67 adults (aged 65-96) were randomly assigned to see 10 small or large pictograms. After giving their interpretation they were told the meaning. One week later they saw the same pictograms and gave their interpretation.

The pictograms for the 10 different instructions and warnings showed great variation in interpretation rates (7.5% to 90%), with few significant differences between the US and South African versions. Only 3 were understood by 85% or more. Pictograms performed significantly better if they were larger and at the second presentation.

Pictograms have the potential to help patients to understand information. This study shows that some existing pictograms are not easily interpreted and that testing is needed before their implementation. A reduction in their size to allow incorporation into conventional written formats may cause additional problems for patients.

NB I would be happy to submit this paper as a poster if an oral presentation is not possible.

PI-O-002

DEATHS AND USE OF CNS DEPRESSANTS IN COMBINATION WITH ASTHMA MEDICATIONS

R. Correa-de-Araujo, M. Hindi-Alexander, W. Escarosa,
Agency Healthcare Research & Quality,
United States of America

Background: Deaths from chronic lower respiratory diseases, of which asthma is one, remains the 4th leading cause of death in the United States. Sedatives and tranquilizers are still being prescribed to asthma patients despite knowledge of death-associated risks in asthma: hormonal/circadian differences, use/abuse of sedatives/tranquilizers, antihistamines, gender-related prevalence of underlying causes of death (i.e. men more often diagnosed with chronic bronchitis; women more often diagnosed with asthma), time of death, nocturnal asthma, melatonin coadministration.

Methods: Data from 2002 MarketScan Commercial Claims and Encounter Database (Medstat Group, Inc). Claims and prescription drugs for 5.6 million enrollees under age 65 were evaluated as part of employer-sponsored benefit plans for 45 large employers in all 50 states.

Results: 170.8 million individuals < 65 years enrolled in employer-sponsored benefit plans. 92,502 individuals took concomitantly asthma medication plus CNS-depressants for at least 30 days. Asthma medication combined with tranquilizers, sedatives, antipsychotics, and/or benzodiazepines was associated with odds of death 97% higher compared to any other asthma-CNS-depressant combination. Any asthma-CNS-depressant combination for 110-132 days was 45.4% more likely to lead to death compared to 30-40 days. Men taking asthma medications plus any combination type had twice the death rate compared to women. Men and women age 45-64 taking any asthma-CNS-depressant combination had 3 times the death rate compared to those ages 18-44. Persons taking = 4 combinations at once were > 3.5 times more likely to be hospitalized.

Conclusions: Further studies are required to clarify how combination of asthma medications and CNS depressants taken simultaneously contribute to death in asthma patients.

PI-O-003

DIFFERENCES IN LABELING PRACTICE OF OTC BETWEEN JAPAN AND OTHER COUNTRIES

M.I. Izumisawa¹, E.S. Eric M. Skier², N.S. Naokata Shimizu³, T.E. Toru Ebitara³

¹Tokyo Univ. of Pharmacy and life science, ²Tokyo Univ of Pharm and Life Sci, ³Sch of Med, Univ of Tokyo, Japan

[Objective] In various countries, OTC medicine labels play an important role in providing information for consumers. However, OTC labeling regulations differ based on the laws of each country. We surveyed to what extent consumers consider labeling practices to be important in Japan and other countries.

[Method] The labelings of painkillers, antacids, and antihistamines from Japan, the U.S., Britain, Australia, and France were compared. In addition, a survey of Japanese consumers' perceptions of OTC labels was conducted.

[Results] In Japan, only ingredients, directions, and warnings are provided on labelings based on a Pharmaceutical Affairs Law. On the other hand, the FDA has detailed regulations regarding labeling, including drug interactions with prescription drugs and warnings for consumers with pre-existing conditions. Moreover, labeling in the U.S. has been standardized for all OTC medicines (Drug Facts Label). In Australia, where OTC medicines are graded into two categories, a labeling system delineating a medicine as a 'Pharmacy Medicine' or a 'Pharmacist Only Medicine' exists. In addition, in Australia, a priority is given to package inserts over outside box information. The content of the labeling differed in Britain depending on the medicine and the maker. In France, labels are extremely simple even in the case of Rx-to-OTC medicines.

From our recent survey, Japanese consumers are becoming more concerned about adverse reactions and drug interactions of OTC medicines.

[Conclusions] From our study, it has become obvious that there is much need for improvement in Japanese labeling requirements.

PI-O-004

IDENTICAL TABLETS FROM THE SAME COMPANY - BUT DIFFERENT NAMES AND INFORMATION

S. Lyftingsmo
Hospital Pharmacy of Elverum,
Norway

Medicine is not only active substance and pharmaceutical formulation. Information is an indispensable component.

Some companies market tablets that are pharmaceutically identical under different brand names.

- Rofecoxib (until 2004) as Vioxx® for treatment of osteoarthritis, and as Vioxx AC®, Vioxxolot®, Vioxxalt®, Vioxxdolor® for treatment of acute pain.
- Bisoprolol fumarate as Emconcor® for angina pectoris and hypertension, and as Cardicor®, Emconcor® CHF, Concor®COR for heart failure.
- Bupropion as Zyban® for smoking cessation and Wellbutrin® for depression.
- Fluoxetine as Prozac® for depression and Sarafem® for premenstrual dysphoric syndrome.

Not only do they differ in indications for use. The patient information/package inserts are also different.

Doctors, nurses, pharmacists, and patients get confused.

Generic substitution is difficult, because the package inserts have different texts, and do not cover the same indications.

Sometimes original brand names are stigmatized, so it is difficult to use them for other indications.

©

Regulatory authorities should be very restrictive in allowing a company to use more than one brand name on a medicine.

When such permission is given, it should be demanded that

- information in formularies and package insert should not differ significantly.
- The second brand name should be generic

PHARMACY INFORMATION SECTION - SHORT ORAL PRESENTATIONS

PI-O-005

IMPACT OF USE OF PDAS ON DRUG REGULATORY EFFORTS

A.C. Speed¹, M. Ndomondo-Sigonda², B. Kosarus², H. Krushnar¹, P. Risha¹,
G. Phumtim³,

¹Management Sciences for Health, ²TFDA, ³SATELLIFE,
United States of America Tanzania United States of America

Aims: Collection of correct and timely drug inspection and testing data is critical in drug regulation. Tanzanian Food and Drug Authority (TFDA) field inspectors require ready access to TFDA's drug marketing authorization database and need to efficiently collect and submit inspection data.

Methods: Together with Management Sciences for Health, the TFDA devised and implemented a system using personal digital assistants (PDAs). The first steps consisted of defining standard operating procedures for inspections, data entry, and data transfer and identifying setting up a method for the monthly data transfer (both for data collected by inspectors to the TFDA and updated drug authorization lists to inspectors from TFDA). Concurrently, the TFDA mounted an effort to ensure the currency and accuracy of its drug authorization database. Existing paper-based forms used for inspection and postmarket surveillance were then programmed into a PDA-ready format to guide inspectors through the data-gathering process.

Results: Over the past eight months, inspectors have used PDAs to gather data. The program has allowed them to expand the number of premises visited, helped increase accuracy of data entry, and provided a mechanism for getting more timely and definitive information to the TFDA for regulatory action. Results show a decrease in time needed to perform inspections and enter data, a significant reduction in data entry errors, and the ability to create reports quickly.

Conclusions: Coupled with appropriate support from management, the use of PDAs can serve as an effective tool for building and maintaining regulatory efforts.

PI-O-006

DEVELOPMENT OF THE FIRST CLINICAL CLASSIFICATION OF DRUGS USED DURING LACTATION.

G. Hussein

Loma Linda University School of Pharmacy,
United States of America

The infant is recognized as the unintended recipient of drugs administered to the lactating mother. While a letter classification exists for drug use during pregnancy, a similar one is not available for lactation. Our objective was to create a classification system, to collect and evaluate available drug data, and to apply our classification on the collected data. Drug information on more than eleven hundred drugs were collected from primary, secondary, and tertiary resources. Data included drug excretion in breast milk, reported adverse effects on the infant, as well as the compatibility of the drug with breast-feeding. The classification represented each drug with two letters and two symbols. The first letter indicated compatibility with breast-feeding which was denoted by C (Compatible), I (Incompatible), or U (Unknown). The second letter indicated excretion in breast milk which was denoted by e (excreted), n (not excreted), or u (unknown). Four symbols (*, **, #, and ##) indicated potential adverse effects and their severity on both the infant and the lactation process. Fifty seven percent of the drugs evaluated were compatible and 22% were incompatible with breast-feeding; data on the remaining 20% were unreported. While 18% of the drugs evaluated were excreted in breast milk and less than 1% were not excreted; data on the remaining 81% were unreported. The presented data, simplified in a readily attainable pattern, may offer a valuable and quick initial source of information for the healthcare provider. Data will be continuously updated in the authors web site which may allow for timely updates as well as feedback by researchers and clinicians worldwide.

BB-P-001

C_{MAX}/AUC FOR DEMONSTRATING THE BIOEQUIVALENCE OF TWO DRUG PRODUCTS CONTAINING LEVODOPA-BENSERAZIDE

P.S. Schaiquevich¹, R. Rubio Garcia²,
¹Lab. Raffo- Univ. Nac. La Plata, ²Lab. Raffo,
 Argentina

For evaluating the bioequivalence of two drug products, both the rate and extent of absorption of the two products are expected to be the same within a statistical tolerance. For the rate of absorption, C_{max} is often used, an ambiguous measure of the absorption rate for also being affected by the extent of absorption. In the present work we assessed the feasibility of C_{max}/AUC for demonstrating the bioequivalence of two drug products containing Levodopa-Benserazide for registration purposes.

An open, randomized, 2-period crossover study with 1-week washout interval between doses was conducted in male healthy volunteers. Blood samples were taken at predetermined times up to 8 h after oral dose and assayed for levodopa by HPLC. Parametric analysis on log-transformed pharmacokinetic data were performed.

The percentage geometric mean ratios and 90% CI of Test/Reference were 105.1 % (76.3-144.7 %) for C_{max}, 102.2 % (80.5-129.7%) for C_{max}/AUC, 102.9 % (90.1-117.5%) for AUC_{last} and 102.7% (89.9-117.4%) for AUC_{inf}, respectively.

AUC but not C_{max} demonstrated bioequivalence between the two formulations evaluated considering the 80-125 % interval defined by the US-FDA. However, the percentage C_{max} ratios were found to be between 80-125%. Moreover, equivalence of the two drug product absorption rates could be declared as the 90% CI for the percentage ratio of C_{max} /AUC was found to be between 75-133% as previously recommended by others (Einfrey L., 1991).

Thus it is concluded that the test formulation of Levodopa-Benserazide is bioequivalent in terms of both rate and extent of absorption to the reference drug product.

BB-P-002

RAPID AND SELECTIVE ANALYSIS OF CLOZAPINE IN HUMAN PLASMA USING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY AND ULTRAVIOLET DETECTION

A.H. Elshafey, G. Abdelbary, A. Abdelbary,
 Faculty of Pharmacy, Cairo University,
 Egypt

A rapid high performance liquid chromatographic method has been developed for the determination of clozapine in human plasma. A simple extraction step with acetonitrile was done. The analysis was performed on a C18 (3.9 x 150 mm) reversed phase analytical column with the wavelength fixed at 280 nm. The mobile phase consists of methanol-water-triethylamine, 70:30:0.05 (v/v/v), flowing at a rate of 0.6 ml/minute, using celecoxib as an internal standard. Calibration curves were linear in the range of 20-300 ng/ml and the lower detection limit was 5 ng/ml. The intra-assay and inter-assay precision as well as recovery and reproducibility values were satisfactory. The developed method was used to compare between two commercially available products of clozapine in 24 healthy volunteers.

Keywords: clozapine, HPLC, plasma, bioequivalence.

BB-P-003

THE DEVELOPMENT OF A NEW METHOD FOR THE DETERMINATION OF RACECADOTRIL IN HUMAN PLASMA BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

G. Abdelbary, A.H. Elshafey, A. Abdelbary,
 Faculty of Pharmacy, Cairo University,
 Egypt

A simple, rapid, specific high performance liquid chromatographic assay of racecadotril in human plasma has been developed. The method is based on extraction by precipitation with acetonitrile and reversed phase chromatography using a C18 (3.9 x 150 mm) analytical column and UV spectrophotometer detection at 230 nm. The mobile phase consists of acetonitrile:phosphate buffer [65:35 (v/v), flowing at a rate of 1 ml/minute]. Methyl paraben was used as an internal standard. The assay was linear in the concentration range of 100-1000 ng/ml, and the lower limit of detection was 30 ng/ml. Within-day and between-day precision expressed by relative standard deviation as well as recovery and inaccuracy were calculated and were within permitted limits. Blood levels have been measured with good precision in 24 healthy volunteers following the administration of 120 mg of racecadotril powder in water. This method was applied to study the bioequivalence of two commercial products using a two way open randomized cross-over design.

Keywords: racecadotril, HPLC, plasma, bioequivalence.

BB-P-004

COMPARATIVE BIOAVAILABILITY STUDY OF FORMULATED AND MARKETED GLIMEPIRIDE

Z.M.K. Ebeid¹, F.M. Hashem², W. Sakran², M. Al Shafay¹,
¹MOH, ²Pharmaceutics Dept Helwan Univ, ³Faculty of Med, Ain Shams
 Univ,
 Egypt

Eight formulas of glimepiride capsules were prepared by changing the weights of additives used. Results of in-vitro study revealed that no interaction was found between the drug and the selected additives. Moreover, the results of in-vitro dissolution indicated that there were two formulas showing better dissolution than the others. The marketed glimepiride tablets 2 mg (Amary, Aventis) and the best two formulas were subjected to a random cross over bioavailability study in 6 healthy human volunteers with one week wash out period. After administering oral single dose, blood samples were collected over a period of 12 hours and were analyzed by HPLC. Pharmacokinetic parameters of the formulated capsules were C_{max} 1.4, 1.3 µg/ml, t_{max} 2.5, 2.5 hr, and AUC₀₋₈ 7.71, 8.15 µg.hr/ml respectively, while the marketed tablets produced C_{max} 1.5 µg/ml, t_{max} 2.5 hr, and AUC₀₋₈ 9.9 µg.hr/ml. Statistical evaluation of measured pharmacokinetic parameters using ANOVA revealed insignificant differences between the two formulas as well as the marketed tablets (p>0.05). This indicated that the marketed tablets and formulated capsules are bioequivalent.

BB-P-005

LPS-INDUCED INFLAMMATION ALTERS THE DISPOSITION OF FEXOFENADINE IN THE ISOLATED PERFUSED RAT LIVER.

A.K. Davey, Y. Tong, R. Zhang, S.N.T. Ngo,
University of South Australia,
Australia

AIM: To examine the effect of bacterial lipopolysaccharide (LPS) on the pharmacokinetics of fexofenadine (an OATP and P-gp substrate) in the isolated perfused liver. **METHODS:** Male SD rats were divided into 4 groups (n=4): 1 control group and 3 treatment groups. Inflammation was induced in the 3 treatment groups by either 5, 2.5 or 1mg/kg i.p. of E.coli LPS in sterile saline. The control rats received an equivalent volume of saline (1ml/kg). At 24h following treatment, the rats were euthanased, the liver isolated and perfused with fexofenadine (initial concentration = 2000ug/ml). Perfusate samples were collected at times 0, 1, 3, 5, 10, 15, 20, 25, 30, 40, 50 and 60mins. Bile samples were obtained at 10min intervals and the liver collected at the end of the perfusion. All samples were stored at -4°C until analysis with HPLC. Clearance of drug from the perfusate, biliary clearance (CL_b), and the final liver:perfusate (L:P) and bile:liver (B:L) concentration ratios were determined. Statistical evaluation was conducted using the student's t-test. **RESULTS:** Significant (p<0.05) differences from the controls were observed in all treatment groups. This was most marked in the 5mg/kg LPS treatment group where CL = 0.024 (+/- 0.002) ml/min; CL_b = 1.25 (+/- 0.20) ml/min; L:P = 44 (+/- 11); and B:L = 17 (+/- 2) compared with controls where CL = 0.040 (+/- 0.004) ml/min; CL_b = 2.70 (+/- 0.48) ml/min; L:P = 88 (+/- 14); and B:L = 30 (+/- 4). **CONCLUSIONS:** Clearance from the perfusate and into the bile was reduced following treatment with LPS. The changes in the L:P and B:L ratios suggest that the reduced clearance is due to down regulation of both canalicular and sinusoidal transport.

BB-P-006

FACTORS AFFECTING ATENOLOL BIOAVAILABILITY IN NORMAL VOLUNTEERS

M.A. Hedaya, S.M. El-Haggag, S.A. El-Gizawy,
Tanta University,
Egypt

Atenolol is a widely used beta-blocker which has bioavailability of less than 50%. The objective of this research was to investigate the effect of dose, modification of gastric pH and food composition on atenolol bioavailability in normal volunteers. Our results demonstrated that the bioavailability of atenolol was dose independent in the range of 50-100 mg. Also, administration of atenolol with alkaline antacid solution significantly reduced atenolol bioavailability which was reflected by the 20% reduction of atenolol AUC and 40% reduction in its C_{max}. The results also demonstrated that administration of atenolol after eating fat-rich meal resulted in significant delay in atenolol absorption. The t_{lag} increased from 0.55 ± 0.31 hr to 1.04 ± 0.35 hr and t_{max} from 2.86±0.94 hr to 3.57±0.65 hr. Also, the bioavailability of atenolol was significantly reduced by administration after fat-rich meal. The AUC decreased from 5760± 732 ug-hr/L to 4179±777 ug-hr/L and the C_{max} from 552.3 ± 160 ug/L to 415.7 ± 88.5 ug/L. Administration of atenolol after protein-rich meal also affected the rate and extent of atenolol absorption significantly. The t_{lag} increased from 0.55 ± 0.31 hr to 1.58± 0.68 hr and t_{max} from 2.86±0.94 hr to 3.26±1.31hr, while the AUC decreased from 5760± 732 ug-hr/L to 3377±1062 ug-hr/L and the C_{max} from 552.3 ± 160 ug/L to 255.6± 45.8 ug/L. The effect of fat-rich meal and protein-rich meal explained by delayed gastric emptying and reduced atenolol dissolution. Based on these results, it is advisable not to take atenolol with food or with beverage to decrease the variability in absorption and hence atenolol therapeutic effect.

BB-P-007

IN VITRO AND IN VIVO STUDIES ON RECTAL SUPPOSITORIES CONTAINING ACETAMINOPHEN

N. Bergisadi¹, I. Kabesakal², G. Uzunkaya¹, S. Gungor¹, T. Yurdun², M. Keyer Uysal²,¹Istanbul university, ²Marmara University,
Turkey

Acetaminophen, a non-steroidal anti-inflammatory drug with analgesic and anti-inflammatory properties, is glycolic acid ester of indomethacin. Metabolic studies of acetaminophen suggest that the drug is rapidly absorbed orally and hydrolyzed by the liver to produce indomethacin as its major active metabolite. Currently acetaminophen is used orally for the treatment of arthritis and rheumatic diseases in capsule form.

The aim of this study was to formulate acetaminophen suppositories with lipophilic (Suppocire AIM and Witepsol H15) and hydrophilic bases (PEG 1500 and a blend of PEG 1500 : PEG 400 (90:10, (w/w)) and to evaluate in vitro drug release from these formulations. Suppository formulations were prepared by the melting technique to contain 60 mg of acetaminophen. In vitro release studies were performed with dynamic membrane diffusion method using a dialysis tube and acetaminophen was assayed by spectrophotometrically at 318 nm. Based on the in vitro studies, the release of drug increased in the following order: Suppocire AIM > PEG 1500 > Witepsol H15 > PEG1500 : PEG400. According to in vitro release study results, the formulation showing the highest the drug release was selected for further in vivo evaluations. Suppositories containing 10 mg/kg as acetaminophen were adjusted to fit the anatomical size of rats rectum. In vivo studies were performed with Sprag-Dowley rats. The amounts of acetaminophen and indomethacin its active metabolite in plasma were analyzed by high-performance liquid chromatography with diode array detector. Comparative studies were run with acetaminophen suspension given orally.

BB-P-008

FORMULATION AND BIOLOGICAL EVALUATION OF GLIMEPIRIDE - CYCLODEXTRIN - POLYMER SYSTEMS

A. Mahmoud¹, H.O. Ammar², H.A. Salama², M. Ghorab³, A.A. Mahmoud²,
¹Dokki, National Research Center, ²Department of Pharmaceutical Sciences,
N, ³Faculty of Pharmacy, Cairo University,
Egypt

Glimepiride is one of the third generation sulfonylureas used for treatment of type 2 diabetes. Poor aqueous solubility and slow dissolution rate of the drug lead to irreproducible clinical response or therapeutic failure in some cases due to subtherapeutic plasma drug levels. Consequently, the rationale of this study was to improve the biological performance of this drug through enhancing its solubility and dissolution rate. Inclusion complexes of glimepiride in β-cyclodextrin (β-CD), HP-β-CD, DM-β-CD and SBE-β-CD, with or without water soluble polymers (HPMC, PVP, PEG4000, PEG6000) were prepared by the kneading method. Phase solubility diagrams revealed increase in solubility of the drug upon cyclodextrin addition showing Ap type plot indicating high ordered complexation. In the dissolution study of binary systems, DM-β-CD complex showed highest dissolution rate. All the ternary systems utilizing β-CD or HP-β-CD showed higher dissolution efficiency compared to the corresponding binary systems. This result indicates that these polymers enhanced glimepiride complexation in these cyclodextrins. Conversely, these polymers didn't enhance dissolution of drug complexes in DM-β-CD or SBE-β-CD. The hypoglycemic effect of the most rapidly dissolving ternary system of glimepiride-HP-β-CD-PEG4000 was evaluated after oral administration in diabetic rats by measuring plasma glucose levels. The results indicate that this ternary system enhanced significantly the biological performance of the drug. In conclusion, the association of water soluble polymers to glimepiride-CD systems would lead to reduction in the dose of glimepiride as well as in the amount of cyclodextrin utilized.

BB-P-009

AMOXICILLIN AND IBUPROFEN: DRUG INTERACTION, BACTERIOLOGICAL, CLINICAL AND PHARMACOKINETICS STUDY. PART 1. COMBINED THERAPY FOR TREATMENT OF HUMAN BACTERIAL INFECTION.

N.A. Sabri
Faculty of Pharmacy Ain shams university,
Egypt

Amoxicillin (AMX)-ibuprofen(A)-physical mixture(1:1and2:1)were subjected to in-vitro examination for possible interactions using IR,UV scanning,DSC,TLC,results confirm absence of interaction. Effect of ibuprofen (IBU) on the antibacterial activity of AMX against certain bacterial species was investigated.The results showed that IBU potentiate the antibacterial activity of AMX towards certain micro-organisms.Sixteen A-I capsule formulations were prepared using a fractional factorial design (1/8) of 27 and tested for powder content characteristics and dissolution testing which showed that neither drug affect the dissolution process of the other.Data treatment and statistical analysis of data was performed.The chosen formulae; F4 and F15 were subjected to clinical study on 25 patients divided into 2 groups,one was treated with A-I capsules,the second was given AMX capsules.Data collected include:age,diagnosis,body temperature,total white blood cell count (W.B.C.),kidney and liver functions.Statistical analysis of W.B.C.data by using paired t-test revealed that there was a significant difference between before and after treatment and between AMX and A-I at $p < 0.001$.There was no effect of sex on the percent decrease in W.B.C.at $p < 0.05$.A-I combination proved to posses a higher clinical efficacy and microbiological activity than AMX alone.

BB-P-010

AMOXICILLIN AND IBUPROFEN: DRUG INTERACTION, BACTERIOLOGICAL, CLINICAL AND PHARMACOKINETICS STUDY. PART2. PHARMACOKINETICS OF AMOXICILLIN AND IBUPROFEN ADMINISTERED ALONE AND IN COMBINATION.

N.A. Sabri
Faculty of Pharmacy Ain shams university,
Egypt

Studying the pharmacokinetics and reactivity of amoxicillin(AMX) and ibuprofen(IBU)in plasma required an analytical method for their simultaneous determination.A simple,rapid,specific and reliable HPLC assay is described using a mobile phase of acetonitrile:water(50:50)v/v,pH 3.5,UV detection at 230nm.Regression analysis for the calibration plot for plasma standards obtained on 3 different days indicated excellent linearity($r > 0.999$).Quantification of AMX and IBU from a single oral dose was conducted on 4 different drug formulations(A,B,C,D)in a latin square crossover design involving sixteen male adult volunteers. Formulation A(A-I capsules chosen formula(F15)AMX500mg+IBU400mg),formulation B(AMX500mg),formulationC(IBU 400mg),and formulation D(reference products of AMX capsules and IBU tablets).Criteria used to assess this pharmacokinetic study were: C_{max} , T_{max} , $AUC(0-24)$, $AUC(0-11)$, $t_{1/2el}$, K_{el} ,MRTand $F_{rel}\%$. C_{max} of AMX from formulations A and D were 19.95±1.83 and 18.23±1.291 μ g/ml.While C_{max} of IBU for formulations A,D and C were 14.49±0.492,15.57±0.910 and 16.54±0.709 μ g/ml respectively.Formulation A showed a greater values of $AUC(0-24)$, $AUC(0-11)$ for AMX and IBU,than when each drug was administered alone.The MRT of AMX and IBU in formulation A were significantly higher than those of formulations B,C and D. $F_{rel}\%$ of AMX from formulations A and B were 110.21±5.077% and 94.28±7.739%.While that of IBU in formulations A and C were 213.56±7.030% and 132.04±5.685%.The data were analysed statistically according to one way ANOVA representing a significant difference between formulations A, B and D,for AMX, and between formulations A,C and D,for IBU, at $p < 0.001$.

BB-P-011

THE PREPARATION OF FAMOTIDINE ORALLY DISINTEGRATING TABLETS.

R.H. Fahmy¹, M.A. Kassem²,

¹Faculty of Pharmacy, ²Faculty of Pharmacy, Cairo University,
Egypt

Elderly people, children, and most disabled patients often suffer swallowing difficulties, thus, the demand for rapidly disintegrating tablets (RDT) has been growing fast. The problem concerning most of co-dispersible tablets is to achieve an optimal balance between their physical strength and stability and their rapid disintegration when placed in the oral cavity.

In this work, to make RDT with sufficient mechanical integrity as well as rapid disintegration, Ac-di-sol as superdisintegrant, Avicel PH102 as binder, Mg stearate as lubricant, and mannitol or lactose as diluents were formulated. Sixteen tablet formulations were prepared according to a full factorial experimental design to investigate the effects of these excipients on the formulation of directly compressed co-dispersible tablets.

Tablet properties such as tensile strength, in-vitro disintegration, wetting time, dissolution and mouth dissolving time were determined and compared for the prepared formulae. A selected formula was then evaluated in-vivo compared to conventional tablets. For the prepared formulations, the tensile strength ranged between 94.64 and 27.45 N/cm², while the in-vitro disintegration time ranged from 12 minutes to 23 seconds. The preparations showing tensile strength above 52 N/cm² and in-vitro disintegration time less than 2 minutes were selected for further investigations. All showed wetting time less than 26 seconds, mouth disintegration time of less than 40 seconds, and drug release in 15 min. ranged from 75.4 to 100.17%. In conclusion, RDT with acceptable hardness and desirable disintegration properties could be prepared within the obtained optimum region.

BB-P-012

PREPARATION AND EVALUATION OF TIMOLOL MALEATE NANOPARTICLES FOR OCULAR DRUG TARGETING.

R.H. Fahmy¹, M.A. Kassem², A. Abdelsabood³,

¹Faculty of Pharmacy, ²Faculty of Pharmacy, Cairo University,
Egypt

Nanoparticles (NP) are known to increase the efficacy and/ or to reduce the toxicity of drugs, thus attracted interest in the last decade. Timolol maleate-loaded ocular nanodispersions were prepared by a new technique based on salting-out process between two completely miscible solvents. Eudragit S-100 used as the nanoparticles-forming polymer while polyvinyl alcohol (PVA) was selected as the protective colloid and stabilizer agent to stabilize both the emulsification process and the final dispersion. The influence of changing PVA concentration on the ocular NP prepared was evaluated through drug loading capacity, particle size analysis, morphological characters examination, and drug release profile. A selected formula was then evaluated in-vivo compared to conventional eye drops. The results indicated an increase in the drug loading efficiency with the increase in PVA concentration; the loading of timolol into nanoparticles prepared using PVA concentrations higher than 1% exhibited a linear relationship with a correlation coefficient of 0.998. Regarding the NP size, increasing the concentration of the hydrocolloid (PVA) in the external aqueous phase led to a consequent decrease in the particle size of the produced nanoparticles. Formulation of timolol maleate-loaded nanodispersion resulted in significant improvements in the maximum intra-ocular pressure reduction effect, the time of maximum response and the duration of the IOP reduction effect of timolol maleate when compared to control conventional eye drops. In conclusion, preparation of ocular nanoparticles colloidal dispersion to achieve a controlled release of timolol maleate proved to be of promising potential.

BB-P-013

FORMULATION AND EVALUATION OF FELODIPINE IN SOFTGELS WITH SOLUBILIZED CORE

M.H. Aboul-Einien
Faculty of Pharmacy,
Egypt

Felodipine, an antihypertensive and antianginal calcium channel antagonist, is considered to be water insoluble (about 1mg/L) and only 15% bioavailable. In this study softgels, with solubilized-drug core, were used to improve the solubility of felodipine. Drug solutions were prepared using both cosolvency and micellar solubilization.

The optimum dielectric constant (DEC) for maximum drug solubility was first determined using dioxane/ water mixtures of different proportions. The optimum DEC was found to be 16.3, so felodipine was dissolved in either glycerin/ PEG400 mixture or propylene glycol (PG)/ PEG400 mixture (containing 90% & 80% PEG respectively). The drug solutions were filled in softgels, which were subjected to dissolution testing & evaluated for their drug content, weight uniformity & moisture absorption behavior.

Dissolution tests revealed a significant improvement of felodipine dissolution characteristics using cosolvency. After 90 minutes, more than 95% of the drug was dissolved from softgels containing solutions.

To study the effect of micellar solubilization on felodipine dissolution parameters, three different surfactants were investigated (0.5% sodium lauryl sulfate (SLS), 0.5% CTAB & 10% Tween80). All surfactants were found to increase the rate of felodipine dissolution where the time required for 100% drug dissolution was 60, 45 & 45 minutes for Tween, SLS & CTAB in glycerin/PEG & 75, 60 & 45 minutes for Tween, SLS & CTAB in PG/PEG respectively.

It could be concluded that felodipine softgels succeeded in enhancing the rate & extent of dissolution of such insoluble drug.

BB-P-014

ENHANCED BIOAVAILABILITY OF THE LUTEOLIN OF ARTEMISIA AFRA PLANT MATERIAL IN THE VERVET MONKEY (CHLOROCEBUS AETHIOPS).

J.A. Syce¹, R. Mugsanga¹, J. Seier², M. Mdhuli²,
¹University of the Western Cape, ²MRC Primate Unit,
South Africa

Aim: To investigate the bioavailability of luteolin contained in an aqueous extract of *Artemisia afra* to ascertain the influence of plant matrix on flavonoid absorption. **Methods:** A freeze-dried aqueous extract of *A. afra* was prepared and evaluated for luteolin content by validated HPLC assay. In a two-period cross over design bioequivalence study, six healthy vervet monkeys received, on two different occasions, the equivalent of 1mg luteolin/kg body weight of luteolin or *A. afra* aqueous extract via oral route (gastric tube). Blood samples (2ml) were drawn at 0, 15, 30, 60, 120, 240 and 360 min after administration and hydrolysed, extracted with ethyl acetate and assessed for luteolin using HPLC assay. From the luteolin plasma concentration vs. time data AUC₀₋₃₆₀, AUC_{0-inf}, C_{max}, T_{max} and Kel were calculated and bioequivalence assessed applying individual ANOVA analysis on the ln-transformed data of AUC₀₋₃₆₀, AUC_{0-inf} and C_{max}, point ratios and 90% CI of the ln-transformed data. **Results:** The aqueous extract of *A. afra* contained 2.5ug luteolin / mg plant material. The AUC_{0-inf}, C_{max} and Kel for luteolin pure and in *A. afra* were: 20.34 ± 4.524 and 37.69 ± 3.049 µg/ml.min; 140.8 ± 20.15 and 258.8 ± 9.735 ng/ml and 96.99 ± 51.19 and 63.33 ± 14.28/min, respectively and the point ratios and 90% CI for AUC_{0-inf} and C_{max} 188.8 (CI = 163.6 - 217.8%) and 185.3 % (CI = 163.9 - 209.5%), respectively. **Conclusion:** The bioavailability of luteolin was better in *A. afra* aqueous extract than in pure form suggesting that either plant matrix constituents improved the absorption of luteolin or luteolin was better absorbed in the plant (i.e. glycoside) form.

BB-P-015

RAPID DETERMINATION OF CLOBAZAM AND DESMETHYLCLOBAZAM IN HUMAN PLASMA BY HPLC

M.R. Rouini, Y. Hosseinzadeh Ardakani, M. Makhberi, Gh. Badri,
Tehran U of Medical Sciences,
Iran

Aim: The study was designed to develop a rapid HPLC method using Chromolith TM column for sensitive determination of clobazam (CLB) and its main metabolite N-desmethylclobazam (NDCLB) in human plasma with an acceptable LOQ for pharmacokinetic studies.

Methods: The chromatographic apparatus consisted of a low-pressure gradient HPLC pump, a UV detector and an online degasser, all from Knauer (Berlin, Germany). Chromatographic separation was achieved with a ChromolithRP-18e (100x4.6mm) column (Merck, Darmstadt, Germany). A mixture of a phosphate buffer (pH 3.5; 10 mM)-acetonitrile (70:30, v/v) was delivered at 2 ml/min. UV detector was set at 228 nm.

The plasma samples (0.5 ml) were extracted with 1.5 ml toluene after addition of 20 µl alprazolam (internal standard). The mixture was vortex and centrifuged at 10000 rpm (1 min each). The organic layer was evaporated under a gentle stream of nitrogen and reconstituted in 150 µl of mobile phase and a 100 µl aliquot was injected on to the HPLC system.

Results: The regression equations showed intercepts of -0.0135 and 0.0297, slopes of 0.0004 and 0.0076, and r² of 0.9988 and 9986 for CLB and NDCLB respectively. The mean intra and inter day reproducibility was shown to be less than 10% for both compounds (n=5).

The limit of quantitation (LOQ) of the method as signal/noise of 5 was equal to 25 and 10 ng/ml for CLB and NDCLB respectively. Each complete run time lasted 3.5 minutes. **Conclusion:** The developed method is applicable in Pharmacokinetic and bioequivalence studies.

BB-P-016

THE PHARMACOKINETICS OF RIBAVIRIN IN TAIWANESE

C.C. Tseng¹, L.H. Wang¹, Y.S. Uang², J. Hsu³, K.Y. Hsu⁴,
¹Taipei Medical University, ²Rosetta Pharmaceutical Co., Ltd., ³TTY Biopharm
Co., Ltd.,
China Taiwan

As a broad-spectrum antiviral agent, ribavirin is used in treating hepatitis C combined with interferon-α. Pharmacokinetics of ribavirin has been reported in papers, but there are many differences, such as T_{1/2} of ribavirin varies from 37h to 100h. Besides, no pharmacokinetic data about ribavirin in Taiwanese was found, either. This study was to provide pharmacokinetics of ribavirin in Taiwanese. 22 healthy volunteers (Female=9, Male=13) were enrolled in this study. 600mg ribavirin (Rebetol®) was given with 240 ml of water orally. Blood sample was taken from 0 to 372 h after dosing. Plasma concentration of ribavirin was assayed by LC/MS/MS. Pharmacokinetic parameters were determined by non-compartment model. The results were as following: Ribavirin was fast absorbed with the T_{max} and C_{max} were 1.42 h and 791.15 ng/mL which agreed with published data. The clearance was 22.43 mL/hr. The AUC_{0-t} and AUC_{0-∞} were 22827.19 h*ng/mL and 28274.78 h*ng/mL. The T_{1/2} was 176.96 h, significantly longer than it used to be known. This showed the extended blood sampling time was necessary in studying ribavirin pharmacokinetics because of its easily accumulation in erythrocytes. Higher absorption extent was obtained resulted from the AUC_{0-t} / AUC_{0-∞} ratio (81%). The CV% was 22.42% in average for all pharmacokinetic parameters showed a major individual variation was among Taiwan residents. Based on this study, no significant difference in the absorption rate of ribavirin is between Taiwanese and Caucasians. However, with different study design and better analytical sensitivity, longer half-life and higher absorption extent were obtained in the study.

BB-P-017

BUCCAL SILYMARIN LIPOSOMAL DELIVERY SYSTEM: PREPARATION AND INVESTIGATION APPLYING FACTORIAL DESIGN

E.A. Mahmood¹, M.S. El-Samaly², N.N. Afifi²,
^{1,2}Faculty of pharmacy, Cairo University,
Egypt

Silymarin, a natural lipotropic agent of low bioavailability from oral products, is prepared in a buccal liposomal delivery system. Silymarin liposomes were prepared using lecithin/cholesterol mixtures. Additives were explored in a full 2(3) factorial experimental design regarding drug entrapment efficiency. Additives used to optimize liposomal product were also investigated for their optimal concentrations considering release properties and in vitro permeation and absorption through chicken cheek pouch. The results showed an optimal liposomal performance at 7:4 lecithin to cholesterol molar ratio. Decrease in entrapment efficiency with increasing cholesterol content was observed. Tween 20 or Tween 80 decreased the entrapment efficiency after 0.5 molar ratios. Positively charged liposomes showed superior entrapment efficiency over neutral and negatively charged liposomes. The product containing lecithin, cholesterol, stearyl amine and Tween 20 in molar ratios 9:1:1:0.5 gave the best drug absorption and permeation. It showed steady state permeation through chicken pouch for 6 hours.

BB-P-018

COMPARATIVE IN VITRO RELEASE OF KETOPROFEN FROM COMMERCIAL GEL FORMULATIONS THROUGH SILICONE MEMBRANE UTILIZING EUROPEAN PHARMACOPOEIA AND FRANZ DIFFUSION CELLS

J.M. Haigh, R.N.O. Tetley-Amlalo,
Rhodes University,
South Africa

Three commercially available ketoprofen gels, from the United Kingdom, France and South Africa were used in these diffusion experiments. The purpose of this study was to evaluate the in vitro release of ketoprofen from these gels and to compare the release profiles using two different diffusion techniques, Franz diffusion cells and those of the European Pharmacopoeia (EP).

The diffusion cells of the EP were immersed in 1l of receptor fluid maintained at 32°C and stirred at 100 rpm. Silicone membrane was used which was cut to size to cover the aperture. One millilitre of receptor fluid was withdrawn at intervals sufficient to generate a release profile. Jacketed Franz cells maintained at 32°C were also utilized for this experiment. At pre-defined times the cells were emptied and refilled with pre-warmed receptor solution. The receptor solution used for both techniques was 0.2M phosphate buffer solution at pH 6.8. All runs were performed on five replicates for both techniques. The receptor fluid was analysed for ketoprofen using HPLC.

The best release profiles observed were for the French and SA formulations using the EP cells. Next were the release profiles for the French and SA gels using the Franz diffusion cells. The UK formulation showed a very low release profile using both diffusion techniques. On examination it was found that the French and SA formulations were very elegant gels which spread evenly whereas the UK formulation was very thick and sticky and did not spread well. It is interesting to note that for all three formulations, the Franz diffusion cells always produced a lower release profile than that obtained from the EP cells.

BB-P-019

EVALUATION OF DOUBLE-PEAK PHENOMENON OF GLICLAZIDE AFTER ORAL ADMINISTRATION TO HEALTHY VOLUNTEERS

S. Sadry, S. Safari, M. Rouini, S.M.H. Tahami,
Tehran University of Medical Sciences,
Iran

The pharmacokinetics (PK) of gliclazide after oral administration in healthy volunteers was studied. The concentration-time profiles after administration of 80 mg Gliclazide exhibited a double-peak phenomenon in some of the volunteers (in test product n=6, in reference product n=10). This phenomenon was not seen clearly in the mean concentration-time profiles. The time between the two peaks was different in volunteers. We concluded that the mechanism underlying the double-peak phenomenon is due to either enterohepatic recirculation or two sites of absorption of gliclazide in the healthy volunteers. This is the first report of double peaks for oral gliclazide in healthy volunteers. The double-peak phenomenon caused by the hypothesized mechanism may have important therapeutic effects. The double-peak phenomenon was also seen in the decrease of blood glucose level (dBGL) in pharmacodynamic (PD) studies.

BB-P-020

A NOVEL APPROACH TO THE PREPARATION AND SCALE UP PRODUCTION OF PENTOXIFYLLINE CONTROLLED RELEASE TABLETS-II. BIOEQUIVALENCE STUDY

M.A. Sharaf el Din¹, M.A. Shariq², S.A. Elkheser³, I. Khatib⁴, S.A. Nour⁵,
¹Five Fives Co., ²A. A. K. Co., ³Fac. of Pharmacy, Cairo Univ., ⁴Fac. of Pharmacy, Azhar Univ.,
Egypt

Aim: The bioequivalence of a single 600-mg doses of pentoxifylline, newly formulated controlled release tablets, (Treatment A) and Trental® tablets (Treatment B) were evaluated in a crossover study in 12 healthy volunteers under fasting conditions.

Experimental: In vitro dissolution profiles were determined for the new formulation and Trental® at 100 rpm using USP paddle (apparatus II) employing simulated gastric fluid and simulated intestinal fluid. Twelve healthy volunteers received single oral doses of each formulation with a washout period of one-week in a randomized double blind, crossover study. Concentrations of pentoxifylline in plasma were measured by high-performance liquid chromatography. Typical ANOVA for crossover studies was applied to the area under the plasma concentration versus time curve (AUC) and the maximum concentration (C_{max}) and the log transformed data. Bioequivalence of the two formulations in each comparison was assessed using the 90% confidence intervals (CI). In vitro dissolution profiles were also characterized and compared with corresponding human bioavailability study results.

Results: No statistically significant difference was found in the mean bioavailability parameters between Treatments A and B. The ratio of the mean bioavailability parameters and the logarithmically transformed AUC_{0-inf} and C_{max} values of treatment A over those of Trental® was calculated to be within the acceptable limit of 0.80-1.25 and 0.80-1.25, respectively. There was a good correlation between the in vitro and in vivo results.

Conclusion: These two products were bioequivalent and can be considered interchangeable in medical practice.

BB-P-021**COMPARISON OF THE IN VITRO RELEASE OF KETOPROFEN FROM EXTEMPORANEOUSLY PREPARED GELS CONTAINING DIFFERENT CONCENTRATIONS OF CARBOPOL**J.M. Haigh, R.N.O. Teney-Amlalo,
Rhodes University,
South Africa

There are a large number of proprietary topical ibuprofen formulations on the market, but in South Africa there is only one topical gel formulation available. The purpose of this study was to evaluate the in vitro release of ketoprofen from three extemporaneously prepared topical gel formulations containing different concentrations of carbopol (Ultec 10NP) and compare the release with that produced by the commercially available formulation. All formulations contained 2.5% ketoprofen.

Jacketed Franz cells maintained at 32°C were utilized for this experiment, each being replicated five times. Silicone membrane was cut to size to cover the aperture. The receptor solution used was 0.2M phosphate buffer solution at pH 6.8. At pre-defined intervals sufficient to generate a release profile, the cells were emptied and refilled with pre-warmed receptor solution. The fluid was analysed for ketoprofen by hplc and cumulative release curves were plotted.

The formulations containing 1.5% and 2.0% carbopol produced virtually identical release profiles. The commercial gel produced a slightly higher release profile but it was very similar to the carbopol formulations. The gel containing 1% carbopol produced a much higher release profile than the other formulations. This is because gelling did not appear to be complete when using 1% of carbopol, whereas using 1.5% and 2.0% resulted in an elegant gel formulation with release profiles very similar to the commercially available formulation.

BB-P-022**RAPID INTRANASAL DELIVERY OF METOCLOPRAMIDE HYDROCHLORIDE: EFFICACY AND SAFETY OF VARIOUS ABSORPTION ENHANCERS AND PHARMACOKINETIC EVALUATION**G. Awad, S.S. Abdel Hady, N.D. Mortada, N. Zaki,
Pharmacy Faculty AinShams University,
Egypt

Aims: Evaluation of efficacy and safety of different absorption enhancers used in the preparation of nasal solution (NS) of metoclopramide hydrochloride (MCP HCl) and determination of pharmacokinetics parameters of the drug in the formula containing the safest enhancer. **Methods:** Different enhancers viz: sodium deoxycholate (SDC), sodium cholate (SC), chitosan low and high molecular weight (CS L, CS H), protargin sulphate (Prot) and poly-L-arginine (Pol arg) were evaluated as nasal absorption enhancers for (MCP HCl) in anaesthetized rats. The safety of enhancers was assessed in vitro using human erythrocytes lysis experiment and in vivo by leaching of biological markers: total protein and enzyme lactate dehydrogenase (LDH) from the rat nasal epithelium. Furthermore, the pharmacokinetics of the MCP HCl in the NS with higher apparent first-order absorption rate constant (K_{app}) and better safety, were evaluated in rabbits and were compared to those obtained after intravenous (IV) and peroral administrations. **Results:** Based on the obtained K_{app}, the enhancers were ranked as follows: SDC> SC> CS H> CS L> Poly arg > Prot > control (no enhancer). SC proved to be a safe enhancer with < 15 % hemolysis and insignificant protein and LDH leaching (P<0.05). This same NS has a T_{max} of 23.3min, compared to 50 min in case of the oral drug solution while the AUC 0-C were 505.1, 434.9 and 278.7 $\mu\text{g/ml}\cdot\text{min}$ for IV, NS and oral solutions respectively. These values corresponded to absolute bioavailabilities of 87.21 and 55.61 % for the nasal and per oral solutions respectively. **Conclusion:** MCP HCl NS containing SC represents a successful approach for achieving a rapid control of emesis.

BB-P-023**COMPARATIVE IN VITRO RELEASE OF KETOPROFEN AND IBUPROFEN FROM COMMERCIALY AVAILABLE TOPICAL GELS FROM THREE COUNTRIES**J.M. Haigh, R.N.O. Teney-Amlalo, C.H. Pardon,
Rhodes University,
South Africa

The purpose of this study was to compare the diffusion rates of ketoprofen and ibuprofen from commercially available topical gels manufactured in three different countries (France, United Kingdom and South Africa) using the diffusion cells described in the European Pharmacopoeia (EP). The gels contained either 2.5% ketoprofen or 5% ibuprofen.

The diffusion cells of the EP (5 replicates) were immersed in 1l of receptor fluid maintained at 32°C and stirred at 100 rpm. Silicone membrane was used which was cut to size to cover the aperture. One millilitre of receptor fluid was withdrawn at pre-determined time intervals sufficient to generate a release profile. The receptor fluid was not replaced. Both ketoprofen and ibuprofen were determined in the receptor fluid using hplc.

The ibuprofen formulations showed the highest diffusion rates. This is probably due to the fact that there is more ibuprofen than ketoprofen present in the formulations. Another factor is that the ibuprofen molecule is smaller than ketoprofen. The French and UK products showed very similar release rates, with the SA formulation displaying a much lower diffusion rate. In the case of the ketoprofen formulations, the French and SA formulations displayed the highest diffusion rate and were almost identical, with the UK formulation displaying a much lower diffusion rate. The formulations manufactured in France and the UK were imported into South Africa in the hand luggage of one of our investigators to reduce any temperature fluctuations. This is another example of formulations from different countries showing different release rates of the active ingredient.

NRP-P-001**IMPLEMENTATION OF AN INTERNAL MONITORING PROGRAMME IN OCCUPATIONALLY EXPOSED WORKERS**M.A. Terán¹, A. Paolino¹, E.O. Savio¹, J.C. Hermida²,
¹Facultad de Química, ²Centro de Medicina Nuclear,
Uruguay

Radionuclides incorporation may occur as a result of diverse activities; these include the work associated with the different stages of nuclear fuel cycle, the use of radioactive sources in medicine, scientific research, agriculture and the industry. In many countries, legal regulation exists that establishes the form in which incorporation studies must be performed, but in Uruguay these kind of studies had not been implemented up to now. Nevertheless within the framework of an AECAL Project (International Atomic Energy Agency collaboration with Latin American Governments), based on the Safety Guides of the AEA, a pilot program was implemented by our group. The target group were occupationally exposed staff from Nuclear Medicine Services (both public and private). This program initially was circumscribed to a reduced group of 9 volunteers. The pilot program was followed during 1 year, assessing biweekly internal activity of thyroid using a NaI (Tl) scintillation probe associated with a EG&G Ortec spectrometer. The measures were performed during 15 minutes to determine ¹³¹I and ^{99m}Tc and urine samples were collected the same day.

Incorporated doses were estimated using specific software provided by the IAEA. Internal contaminations were found and correction actions were taken. The pilot program is being extended to 20 workers and its generalisation to the whole population involved in Nuclear Medicine Services is being considered by national nuclear regulatory authorities. Different procedures must be revised in order to improve safe management of the radiopharmaceuticals.

NRP-P-002**EVALUATION OF ¹⁸⁸RE-Sn RADIOPHARMACEUTICAL SAFETY FOR RADIOSINOVECTOMY**E.O. Savio¹, C. Ures¹, V. Trindade¹, A. Paolino¹, J. Gaudiano², J. López³,
¹Facultad de Química, ²Centro de Medicina Nuclear, ³Dpto de Hematología,
Hosp.de Clínicas, F,
Uruguay

The ¹⁸⁸Re-Sn is a radiopharmaceutical used with therapeutic purposes in patients with rheumatoid arthritis (AR) or hemophilic joint disease. The procedure consists a intraarticular administration of the radiopharmaceutical, keeping the treated joint immobilized and in rest during 72 hrs. ¹⁸⁸Re is a suitable beta-emitting radionuclide with a maximum energy of 2.12 MeV and a 155 KeV gamma emission that enable scintigraphic image acquisition to follow leakage from the administration site. The aim of the study was to evaluate the safety of a radiosinovectomy treatment for the patient, the family and the staff. The protocol was previously approved by the Committee of Ethics of the University Hospital. Four patients with informed consent received the treatment (three young hemophilic patients and one adult woman with AR). Radiopharmaceutical leakage was assessed for blood and urine samples during 72 hrs in a solid scintillation counter NaI(Tl) (crystal of 3x3"). Radioactivity at one meter of distance from the knee, measured with a portable detector, was registered. Scintigraphic images (0, 24, 48 and 72 hrs) in a SOPHIA SDX gamma-camera were acquired. A maximum of 11 % by urine elimination was determined, and 8% of administered dose was found in blood after the 72 hrs. The activity registered at 1 m of distance was always below the recommended limits. Scintigraphic images did not show significant levels of activity, except in the injection site.

Radiosinovectomy with ¹⁸⁸Re-Sn is a safe procedure, from a radioprotection point of view, for the patient and the involved staff.

Acknowledgments: To Comisión Sectorial de Investigaciones Científicas, Universidad de la República

PB-P-001

STABILITY OF INSULIN IN PLGA NANOPARTICLES AFTER COMPLEXATION WITH PROTAMINE

Y. Chen, F. Wang, H.A.E. Benson,
Curtin University of Technology,
Australia

Aims: To investigate the effect of complexation on the stability of insulin in biodegradable nanoparticles of poly (D, L-lactic-co-glycolic acid) (PLGA). **Methods:** Bovine insulin was incorporated into PLGA nanoparticles by a solvent evaporation and a solvent diffusion method following its complexation with protamine. A stability-indicating high performance liquid chromatography (HPLC) method was developed and validated for analysis of insulin in the presence of nanoparticle matrix materials. Insulin loading in nanoparticles was determined by the HPLC assay after solvent extraction using acetonitrile:0.01M HCl (1:2, v/v). The stability of insulin within nanoparticles, in PBS (pH 7.4, containing 0.05% sodium azide and 0.2% BSA), and in extraction solvent was evaluated by HPLC at both the room temperature and 37 °C. Nanoparticles were also characterised for morphology, particles size and surface charge. The *in vitro* release of insulin from particles was investigated in PBS. **Results:** HPLC analyses indicate that insulin is very unstable in acidic solution and high temperature increases the speed of insulin degradation. However, in PBS, less than 1% increase of insulin degradation was detected after 3 days and about 2% increase in degradation products after 7 days storage at 37°C. The investigation of insulin-loaded PLGA nanoparticles after 7 days of release study at 37°C showed no significant insulin degradation occurred within nanoparticles compared to that of the control (insulin solution). **Conclusion:** Our study suggests that the formation of insulin-protamine complexes can effectively stabilize insulin, leading to the higher stability of insulin in PLGA matrix.

PB-P-002

SKIN PENETRATION OF BIODEGRADABLE POLYMERIC MICRO/NANOPARTICLES

Y. Chen, F. Wang, H.A.E. Benson,
Curtin University of Technology,
Australia

Aims: To establish the relationship between physicochemical characteristics of micro- and nanoparticle formulations and particle skin penetration. **Methods:** Rhodamine 6G (R6G) was chosen as a model drug and as a fluorescence label. Micro- and nanoparticle carriers were prepared from two different types of polymers. Hydrophilic particles were manufactured from chitosan (CS) by a coacervation method and hydrophobic particles were made of poly (D,L-lactic-co-glycolic acid) (PLGA) by both solvent evaporation and solvent diffusion methods. The mean particle size and zeta potential were determined by the Malvern Zetasizer 3000HS. Morphology of particles was characterized by FESEM. The *in vitro* release of R6G from particles was investigated in PBS. The penetration and distribution of nanoparticles in human skin were investigated by using Franz's cells and skin cryosectioning. The skin sections were examined under a fluorescence microscope. **Results:** Characteristics of CS particles such as size and charge were determined by the charge ratio of oppositely charged polymers whereas the size of PLGA particles was influenced by the method of preparation. Fluorescence images of skin penetration samples indicated that only hydrophobic PLGA particles showed significant penetration into the skin while hydrophilic CS particles did not show any penetration. Size of PLGA particles played an important role on penetration. Microparticles with size above 7 µm remained on the skin surface but nanoparticles (<1 µm) showed penetration into the viable epidermis and dermis of skin. **Conclusions:** This work suggests that both the nature and size of particles influence their skin penetration.

PB-P-003

PARTIALLY BENZYLATED DECAPEPTIDE OF POLYASPARTIC ACID TO REDUCE AMPHOTERICIN B TOXICITY

B.K. Yoo¹, M.A. Miah², K. Han³, J.D. Rhee³

¹Yeungnam University, ²Changbuk Natl University, ³College of Pharmacy, Yeungnam University, South-Korea

Polyaspartic acid (PAA) has been extensively studied to protect renal toxicity of aminoglycoside antibiotics both *in vivo* and *in vitro*. However, PAA has not been examined if it has similar effect on the nephrotoxicity of amphotericin B (AmB). As a new method to reduce renal toxicity of AmB, we synthesized partially benzylated decapeptide of PAA and examined self-aggregation status along with acute toxicity of AmB after interaction of the drug with the polymer. Transmission electron microscopy of AmB solution after the interaction showed nano-sized spherical micelles with mean diameter of about 20 nm. Molar absorptivity of AmB after the interaction was significantly higher than that of AmB only, indicating low degree of self-aggregation of the drug. In acute toxicity test, all of the six mice survived seven days in 6 mg/kg AmB as of the drug interacted with the polymer, and only one mice died in 8 mg/kg dose. In contrast, AmB without the interaction was very toxic showing only one and three mice survived in 3 and 2 mg/kg dose, respectively. Mechanism for the reduced toxicity is unclear at present, but it appears that the micelles of AmB and the partially benzylated decapeptide of PAA get around the acute tubular damage in kidney.

PB-P-004

GENE TRANSFER SYSTEM INTO HUMAN PLACENTAL CELLS BY FIBER-MODIFIED ADENOVIRUS VECTORS

Y. Watanabe¹, N. Koizumi¹, M. Kondoh², M. Fujii¹, H. Mizuguchi², T. Hayakawa², T. Nakanishi³, K. Tanaka³

¹Showa Pharmaceutical University, ²National Institute of Health Sciences, ³Osaka University, Japan

[Purpose] Aim of this study was evaluate the ability of fiber-modified adenovirus (Ad) vectors, which can be effective in cells lacking the coxsackievirus and adenovirus receptor (CAR), to transduce human trophoblast cell lines used as *in vitro* models of human placenta.

[Methods] Human trophoblast cell lines, JEG-3, JAR and BeWo cells were used. Ad vectors, wild-type Ad-L2, Ad-RGD(III)-L2 containing an Arg-Gly-Asp motif, Ad-K7(C)-L2 containing a 7-tandem lysine motif and Ad535 containing a chimeric Ad type 5 and 35 fiber protein were prepared. Luciferase gene was used as a reporter gene. For Ad-mediated gene transduction into cultured cells, the luciferase production was measured after culture of cells with vector particles for 48 h.

[Results and Discussion] Compared to the amount of luciferase produced by wild-type Ad-L2, Ad-RGD(III)-L2 had the largest infectious potential and mediated 8-fold the amount of luciferase in JEG-3 cells, 14-fold in JAR cells and 77-fold in BeWo cells. Ad535 vector had greater gene transfer efficiency than wild-type Ad-L2 in three trophoblast cell lines (1.8-fold in JAR cells, 5-fold in BeWo cells and 6-fold in JEG-3 cells). Thus, Ad-RGD(III)-L2 can be a potential tool for gene transfer into human trophoblast cell lines. Furthermore, Ad535 is a promising vector for mediating efficient gene transfer into human trophoblast cells which expressed CD46 of receptors for Ad535.

PB-P-005

IN SEARCH OF ACTIVE AZATYROSINAMIDE METABOLITES AS ANTI-ANGIOGENESIS AGENTS

H.P. Wang¹, C.C. Wen¹, S.L. Hsiao², K.C. Wen³, J.H. Guh³,
¹Chang Gung University, ²China Medical University, ³National Taiwan University,
 China Taiwan

HPW98-1, synthesized in this laboratory, showed inhibitory activities on the growth of human colon, pancreatic and prostate cancer cells. It also demonstrated anti-angiogenesis effect in nude mice with VEGF-induced angiogenesis. As this compound exhibited short half-life, it is suspected that the antitumor activity might be resulted from its possible metabolites. Therefore, the investigation of bioactive metabolites was conducted in this study. HPW98-1 was orally administered to Wistar rats. Two phase II metabolites, namely HPW071x001 glucuronide and HPW071x004 glucuronide / sulfate were identified from rat urine by LC/MS/MS analysis. Three phase I metabolites, namely HPW071x001, HPW071x002 and HPW071x003, were identified by hydrolysis of the urine samples with glucuronidase or sulfatase. The metabolites were chemically synthesized for the evaluation of cytotoxic activity on HL-60 human leukemia and SW480 human adenocarcinoma cancer cell lines. All three metabolites exhibited anti-angiogenesis effect in mice, with HPW071x001 showing highest activity at a low dose (10 mg/kg, oral), indicating its potential as an antitumor agent.

PB-P-006

FORMULATION OF A FAST-DISSOLVING KETOPROFEN LYOPHILIZED TABLET AS A NOVEL DOSAGE FORM

I.S. Ahmed¹, M.M. Nafadi¹, F.A. Fatahalla²,
¹Cairo University, ²NODCAR,
 Egypt

To improve the solubility and dissolution rate of poorly water-soluble ketoprofen, novel fast-dissolving tablet of ketoprofen was developed using freeze-drying technique. Enhancers of solubility of ketoprofen was obtained by preparing its lyophilized tablet (LT) with highly water-soluble carrier materials consisting of gelatin, glycine, as sorbitol. Results obtained showed that the solubility of ketoprofen in its LT was nearly times greater than the solubility of the plain drug and 2 times greater than the solubility of its physical mixture (PM). Results obtained from dissolution studies showed that LT of ketoprofen significantly improved the dissolution rate of the drug compared with LT PM and the plain drug. More than 95% of ketoprofen in LT dissolved within 5 min compared to only 45% of ketoprofen plain drug dissolved during 60 min. In its dissolution rate of ketoprofen in LT was almost tenfold higher than that of ketoprofen powder alone. Differential scanning calorimetry (DSC), X-ray powder diffraction, an scanning electron microscopic (SEM) analysis revealed that amorphous drug was dissolved in the carrier matrix of the LT.

PB-P-007

SIMPLE AND RAPID EFFICIENT METHODS FOR REGENERATION OF ARTEMISIA ANNUA L.

W. Luatun
 Khon Kaen University,
 Thailand

Artemisia annua L., an important medicinal plant of the family Asteraceae contains an antimalarial, artemisinin. However, the relative low yield (0.01-0.6%) of artemisinin in *A. annua* greatly limits the commercialization of the drug. This work aimed to apply plant tissue culture techniques for high-frequency shoot regeneration in *A. annua*. In vivo efficient method for shoot organogenesis of *A. annua* L. were obtained from culture in different media to evaluate the frequency of regeneration. The result in variation of NAA, BA, 2,4-D and Kinetin was observed when stem segments culture for 4 weeks on Murashige and Skoog (MS) medium supplement with combination of NAA (0.05-1.0 mg/l) and BA (0.5-1.0 mg/l) and then transferred into hormone-free MS medium for 8 weeks for rooting. MS medium supplement with NAA 1.0 mg/l and BA 1.0 mg/l mostly stimulated shoot formation and regeneration. In order to study effect of MS with only TDZ, the highest percentage of shoot formation (100% with >50 shoots/explant) was found when stem segments culture for 2 weeks on MS medium with TDZ 0.1 mg/l, and then transferred onto hormone-free MS medium for 8 weeks. Combination of TDZ with NAA and BA concentration in different ratio were performed to obtain high frequency of shoot formation (75% with 3 shoots/explant) when stem segments culture for 4 weeks on TDZ 0.1 mg/l, and BA 1.0 mg/l, and then transferred onto hormone-free MS medium for 8 weeks. Finally the suitable conditions of three experiments could be the basal for genetic transformation with *Agrobacterium tumefaciens*.

PB-P-008

RELEASE STABILITY OF 5-FLUOROURACIL LIPOSOMAL CONCENTRATES, GELS AND LYOPHILIZED POWDER

M.M. Nounou, L.K. El-Khorragi, N.A. Khalafallah, S.A. Khalil,
 Pharmacy Faculty, Alexandria University,
 Egypt

Possible leakage of 5-Fluorouracil from stable pluramellar vesicles was monitored during storage of the liposomal concentrates, gels and lyophilized powders. Charge and release profile of dibocaine were taken as indicator of instability. Release profiles were obtained using the dialysis technique for a freshly prepared liposomal concentrate, gel and reconstituted lyophilized powder (zero time) and storage for one, two and four weeks in well closed tubes at 4 °C for the liposomal concentrate or gel and at 25 °C for liposomes lyophilized powder. Aiming at increasing stability of 5-Fluorouracil liposomal dispersion, freshly prepared liposomal concentrates were directly incorporated in hydroxypropyl methylcellulose gel. Stability release profiles of liposomal gels and concentrates indicated a significant increase in stability of liposomal formulations. Also, lyophilization increases the shelf life of liposomes by preserving it in a dry form and a lyophilized cake to be reconstituted immediately prior to administration or drug incorporation into a final dosage form. Release and physico-chemical stability studies showed superior potentials of the lyophilized product after reconstitution in comparison to concentrate and gel forms. It could be concluded that lyophilization of liposomes loaded with a water-soluble drug such as 5-Fluorouracil could significantly increase the stability of the liposomal vesicle and decrease leakage from it.

PB-P-009

DEVELOPMENT AND VALIDATION OF A DRUG RELEASE RATE TECHNIQUE FOR HYDROPHILIC AND HYDROPHOBIC DRUG ENTITIES IN LIPOSOMAL DISPERSIONS AND GELS

M.M. Nounou, L.K. El-Khoedagui, N.A. Khalafallah, S.A. Khalil,
Pharmacy Faculty, Alexandria University,
Egypt

The development, evaluation and validation of a method for determining the rate of hydrophilic and hydrophobic drug entities release from different types of liposomal dispersions and gels using a dialysis method are described. Dibucaine base and 5-fluorouracil were used as model drugs for a hydrophobic and hydrophilic drug respectively. Aliquots of liposomal dispersions were dispensed into dialysis bags of fixed length and size. The dialysis bags were fixed on the tablet dissolution tester paddle by attaching a stainless steel part to allow fixing the dialysis bags to it. The dialysis bag was attached horizontally fully stretched to the paddle, which was then immersed in the tablet dissolution tester beaker containing the release medium. The bag was fully immersed under the surface. Control bags were prepared and tested along with the liposomal dispersions. In case of liposomal gels, a known weight of each gel formulation was filled in stainless steel cups. The surface of the gel was made flat, the cups were fitted with the dialysis sheet by a rubber band and fixed at the bottom of the beakers of the tablet dissolution tester filled with the release medium. The paddles were positioned in the beakers of the tablet dissolution tester under the surface of the dialysis medium. Release rates were affected by the rate of rotation of the paddles of the tablet dissolution tester, temperature, and volume of release medium. The method was reproducible and precise. The method applied was proved to evaluate the in-vitro drug release from hydrophilic and hydrophobic drug entities from liposomal dispersions and gels.

PB-P-011

A STATISTICAL MODEL-BASED APPROACH TO PLATFORM COMPARISONS AND MICRO ARRAY QUALITY ASSESSMENT

J.D. Rešec, Y. Terpez, E. Hubbell,
Affymetrix,
United States of America

The ideal platform comparison is a disciplined, statistical approach based on a model of platform behavior. We use an ANOVA model which describes the variability in the measured transcript as a combination of the variability of the platform, sample, replicates and transcripts. This approach has the significant benefit of providing estimates of the relative contribution to variability of each component in a system. In addition the analysis is objective and avoids the over-conservative behavior of intersecting lists. For such an analysis the dataset must consist of the same samples run in replicate on different platforms and the same transcripts should be detected by all the platforms. This model can be extended to include additional quality control variables such as different operators, different reagent batches, and different manufacturing batches. This approach allows the investigator to systematically identify and quantify all sources of variability in a micro array experiment.

PB-P-010

OCTAARGININE-MODIFIED ENVELOPE-TYPE NANO PARTICLES FOR EFFICIENT AND SAFE GENE DELIVERY

L.A. Khalil, K. Kogure, H. Harashima,
Hokkaido University,
Japan

Protein transduction domains (PTDs) like TAT, penetratin and VP22 peptides are promising devices for efficient cellular uptake of associated peptides, proteins and other bioactive molecules. These peptides share the presence of several arginine residues in their sequences and it was shown that the arginine residues play an important role in the internalization. Here, we used the octaarginine (R8) peptide as an optimized arginine rich peptide to achieve high intracellular delivery of relatively large drug carriers such as liposomes.

We prepared R8-modified liposomes (R8-Lip) using a simple procedure in which the peptide is attached to a stearyl moiety that acts as an anchor to the lipid surface of the liposomes. The cellular uptake and intracellular trafficking of the R8-Lip were examined using confocal microscopy and flow cytometry.

R8-Lip were extensively internalized into cells mainly in the form of intact vesicles as judged by confocal microscopy. The presence of cell surface proteoglycans was found to be important for cellular binding and internalization. R8-Lip were internalized using different endocytic pathways depending on the density and the topology of the peptide on the liposomal surface. Furthermore, condensed DNA particles coated with a lipid envelope modified with R8 were highly internalized and were not subject to high lysosomal degradation. The R8-modified nano particles produced highly efficient transfection activities with a minimum cytotoxicity. The virus-like core-shell structure developed here is highly promising for gene therapy.

PB-P-012

THE USE OF BIODEGRADABLE LACTIDE- CO- γ -CAPROLACTONE FOR CONTROLLED DNA GENE DELIVERY

H.M. EL-Laithy¹, A.E. Abd Elhalim Elzassay², S.A. Tayel², M.M. Amin²,
Pharmacy college, ¹Pharmacy College,
Egypt

The success of gene therapy is largely dependent on the development of safe and effective systems that deliver DNA for sufficient time to target cells. Non-viral delivery systems, such as biodegradable polymeric microspheres have been increasingly proposed as alternatives to viral vectors.

In this study, *in vitro* double emulsion solvent evaporation technique was adapted for the preparation of controlled release calf thymus DNA microspheres using two lactide copolymers with varying viscosities and lactide residues namely (D,L-lactide-co-glycolide) PLGA (50/50) (RG502) & poly(D,L-lactide-co- γ -caprolactone) PLCL(75/25).

The prepared microspheres were evaluated for their surface morphology, average particle size, DNA loading efficiency and their release pattern in phosphate buffered saline pH 7.4. Agarose gel electrophoresis (AGE) and Differential scanning calorimetry (DSC) were applied to assess DNA structural integrity.

The Electron microscopy revealed that, DNA microspheres were round, spherical and smooth with average particle size of 3.1 and 4.2 μ m and entrapment efficiencies of 53.09% & 60.55% for PLGA and PLCL, respectively. AGE and DSC showed no additional bands or extensive smearing and no significant change in DNA melting temperature. This would prove that lactide copolymer is an efficient polymer system for DNA protection. Both polymers successfully controlled DNA release for 7 days with more delayed pattern (30.2%) and low initial burst release (9.2%) from PLCL than PLGA (65.2% & 29.4%) respectively.

The physicochemical properties of microspheres are greatly affected by the lactide residue, viscosity and lactide copolymer composition used.

PB-P-013

SENNOSIDE A AND SENNOSIDE B PRODUCTION BY HAIRY ROOTS OF SENNA ALATA (L) ROXB.W. Pitalun
Khon Kaen University,
Thailand

Senna alata (L.) Roxb. (Family Leguminosae) is known to contain anthraquinone glycosides including sennoside A and B which act as purgative properties. Recently, hairy root cultures were useful for the production and biosynthesis of plant secondary metabolites in many plant species because of biochemical stability and rapid growth rate. In the process of our study on the production of sennoside A and B from *S. alata*, we established hairy roots of *S. alata* and described the effect of culture conditions for the formation of sennoside A and B.

Hairy roots of *Senna alata* transformed with *Agrobacterium rhizogenes*, strain ATCC 15834 were induced and grown in half strength of Murashige and Skoog (MS) medium. Yellowish hairy roots of *S. alata* generated from the wounded sites after 2 weeks of inoculation on half-strength MS medium containing 500 mg ml⁻¹ cefotaxime. The time course study of the growth of hairy roots was carried out by using the shaking culture, and sennoside A and B contents were quantified simultaneously by ELISA using anti-sennoside A and sennoside B monoclonal antibodies. Hairy roots cultured on half-strength MS medium containing 5 % (w/v) sucrose under dark condition mostly stimulated the growth of hairy roots and increased the concentration of sennosides A and B yielding 168.94 \pm 4.30 and 34.16 \pm 3.64 μ g g⁻¹ dry wt, respectively.

In conclusion, the hairy root cultures of *S. alata* on hormone-free half-strength MS medium containing 5% (w/v) sucrose under the dark condition is the optimum condition for producing sennosides A and B by the shaking culture system.

SIG PHARMACOEPIDEMOLOGY/PHARMACOECONOMICS - POSTER SESSION

PP-P-001

KNOWLEDGE ON DRUGS USED TO TREAT ASTHMA

J. Moisan¹, L. Line Gagné¹, Y. Yves Bolduc², M. Turcotte², E. Elieles Dorval³, J-P Gégouire¹

¹Faculté de pharmacie, ²Centre hospitalier Le Jeannois, ³Merk Frost Canada, Canada

Aims : To compare knowledge on drugs used to treat asthma between teenagers (aged less than 20) and adults (aged 20 to 45 years).

Methods : Participants were recruited by community pharmacists who identified among their clients those who were aged 12 to 45 years, had had a previous diagnosis of asthma and were using a short-acting beta 2 agonist more than three times a week or an inhaled corticosteroid. We interviewed participants by telephone to obtain information on the medications they used to treat their asthma and on their knowledge on short-acting beta 2 agonists and on inhaled corticosteroid using a four item questionnaire. We computed a score for each class of drugs by adding one point for each correct answer. Mean scores were calculated for teenagers and for adults. Differences between the two groups were assessed using Student's t tests.

Results : A total of 220 individuals were included (57 (25.9%) teenagers and 163 (90.1%) adults). In all, 195 (88.6%) said they were using a short-acting beta 2 agonist. Adults had a higher mean score (2.84) than teenagers (2.39) (p-value = 0.001) for the knowledge on these drugs. Similar results were observed among the 156 participants who reported using an inhaled corticosteroid (adults mean score = 2.69; teenagers mean score = 2.16; p-value = 0.005).

Conclusion : In this population, knowledge on drugs is not optimal. Pharmacists could help improve asthma control by educating asthmatic people on their medication, in particular teenagers.

PP-P-002

EVALUATION OF A CLINICAL PHARMACOKINETICS MONITORING SYSTEM

Y.Y. Chan¹, C.Y. Tsai¹, HM Tseng²

¹Chang Gung Memorial Hospital, ²Chang Gung University, China Taiwan

Background: Concentrations of some drugs appear to have inappropriate indications or suboptimal timing, particularly in the inpatient setting. The appropriate use of pharmacokinetic drug monitoring, particularly in conjunction with a clinical pharmacokinetic monitoring (CPM) service, is both efficient and cost-effective. **Objective:** The aim of this study is to evaluate the effectiveness of a computerized CPM system which was implemented in a medical center. Indicators of medication outcome were collected prior to and after the CPM system was introduced. **Methods:** The drug Digoxin is representative and being evaluated in this study. Several objective indicators were used to estimate cost-effectiveness of this CPM. **Results:** After introducing the CPM system, day intervals of abnormality in serum concentration are significantly reduced by 3.53 days/patient. Average length of stay significantly decreases after the CPM, from 32.15 to 27.92 days in average. The cost of laboratory blood test can be saved is US\$33.27/patient. In addition, the cost of toxicity therapy was found significantly reduced by US\$9.68/patient (US\$23.76/patient vs. US\$14.08/patient; p<0.05), due to reducing the use of Lidocaine, Phenytoin and anti-diarhea drugs. Similarly, significant reduction was found as US\$9.42/patient (from US\$22.82/patient to US\$13.41/patient; p<0.05) for the cost of combined therapy in the over-optimal group. **Conclusion:** This study provides the evidence for the implementation of the CPM system is meaningful in pharmaceutical care that can improve quality of patient care as well as enhance patient safety.

PP-P-003

PHARMACOEPIDEMOLOGICAL STUDIES IN ANIMAL BITES: WHAT DO THEY SHOW?

M. Aciu, D. Calina, L. Bejenaru, J. Neamtu,
University of Medicine and Pharmacy,
Romania

AIMS: The goal of our pharmacoepidemiological studies was to following the multiple problems concerning the prophylaxis, therapy and pharmacoeconomics problems caused by animal bites.

METHODS: Patients who were diagnosed having animal bites during July to December 2004 were included. It was studied and statistical analysed some different aspects: medico-pharmaceutical, medico-veterinary, the protection of environmental medium and pharmacoeconomics related to cases of animal bites.

RESULTS: A total of 261 patients were included. There were 152 patients (58.2%) with bites produced by dogs, 69 patients (26.4%) bitten by cats and 40 patients (15.3%) bitten by wild animals. The common interest in human and veterinary physicians was to avoid rabies. The medico-pharmaceutical problems concerning the complex treatment, a local care of the wounds and a general therapy such as: immunizations, prophylactic antibioticotherapy, in easy cases with Cephotetam and Clindamicin, in severe cases with Ampicillin and Clindamicin. The costs of the wound care are different, varying from 5 EU to 1500 EU.

CONCLUSIONS: In the light of these results, the prevention on animal bites depends on education and civilisation, pharmacoepidemiology and public health services, ecological environmental protection.

PP-P-004

FLUOROQUINOLONES CONSUMPTION IN CLINICAL EMERGENCY HOSPITAL OF CRAIOVA

M. Aciu, D. Calina, L. Bejenaru,
University of Medicine and Pharmacy,
Romania

AIMS: Excessive use of fluoroquinolones contributes to the development of antibiotic resistance and increase hospital costs. The aim of this study is to evaluate the impact of the fluoroquinolones controlled use on the consumption and the bacterial susceptibility.

METHODS: The study was performed between May 2003 and December 2004 and screened prescriptions of Ciprofloxacin, Ofloxacin, Norfloxacin and Pefloxacin. The following data were collected, recorded and analysed using Epi-info software:

- consumption of antibiotics in euros, number of day of treatment
- clinical data (duration of therapy, administration route, germs, resistance),
- pharmacist interventions.

RESULTS: The consumption of fluoroquinolones decreased between 2003 and 2004 (18%) but increased in 2004 (3%). 5757 patients were enrolled in this study. The main medication used were Ciprofloxacin (40%) and Ofloxacin (39%). Oral therapy represented 64% of cases. Fluoroquinolones were used for infection treatment (50%), empiric therapy (38%) or prophylaxis 918%. Most frequent germs were Escherichia coli (35%), Pseudomonas aeruginosa (14%) or Staphylococcus aureus (11%). Susceptibility to fluoroquinolones remain high (92%-82%-80%). Patients were treated for urinary tract infections (48%), respiratory tract infections (20%), bone or joint infections (7%). In 6.3% of cases, pharmacist interventions led to change the route of administration, to replace fluoroquinolone by another one or by another antibiotic.

CONCLUSIONS: The controlled use led to a large decrease of consumption during the first 6 month, a slowing down was observed after, probably due to the turn-over of resident physicians.

SIG PHARMACOEPIDEMIOLOGY/PHARMACOECONOMICS - POSTER SESSION

PP-P-005

DISCORDANCE OF UPPER RESPIRATORY TRACT INFECTION DIAGNOSIS AND TREATMENT BASED ON TAIWAN'S NATIONAL HEALTH INSURANCE DATA

W.F. Huang¹, F.Y. Hsiao², Y.W. Tsai³

¹Institute of Health and Welfare Policy, ²Institute of Public Health, ³National
Health Research Inst.,
China Taiwan

Background: Pharmacoepidemiologic study using administrative data relies on the correct classification of diagnosis. In Feb. 2001, the Bureau of National Health Insurance (BNHI) in Taiwan started a new policy for controlling antibiotic usage in upper respiratory tract infections (URI). However, lack of explicit definition of URI could induce bias in policy evaluation.

Objectives: This study investigates patterns in antibiotics prescription for URI using different classification of diagnosis to assess the potential impact on policy evaluation.

Method: The study draws its data from 6,284,760 outpatient visit claim records for 2002 from Taiwan's BNHI. Two definitions of URI were used in this study: single diagnosis (ICD9 code=465) and extended diagnosis (ICD9 code=461,463,464,465,466) of URI. Different definitions of diagnosis were hypothesized to reflect discordance in antibiotic prescribing rate and pattern.

Results: Contrast to the hypothesis, similar proportion (16.59% vs. 16.87%) of antibiotic prescriptions using different URI definitions fell outside of published guideline. The prescribing patterns were also identical. Variation was only shown in percentage of each antibiotic category. Cephalosporins (39.39% vs. 36.50%, $p<0.001$), penicillins (34.77% vs. 31.13%, $p<0.001$), and clindamycin (13.86% vs. 20.15%, $p<0.001$), were the most common prescribed antibiotics in both comparison groups.

Conclusion: A lack of appropriate definition of URI was shown in this study. Evidence-based prescribing evaluation using administrative data and followed policy implication should not be performed unless coding classification of diseases is improved.

PP-P-006

PATIENT PERCEPTION ON TREATMENT FOR ACNE

M. Zarb-Adami, A. Serracino-Inglott, L.M. Azzopardi, D. Fernandez,
University of Malta,
Malta

The aim of the study was to investigate the perception of patients regarding treatment of acne.

Patients attending for a consultation with a dermatologist and who had been receiving treatment for at least 4 months were asked to participate. Patients were interviewed using a questionnaire intended to analyse patients' perception with regards to treatment and occurrence of side effects. The Acne Disability Index (ADI) was administered. Data was analysed using Microsoft Excel, and Anova and t-tests were carried out.

The severity of acne for the 53 participants (26 males, 27 females; mean age 20 years age range 13-38 years) was: 10 mild, 30 moderate, 13 severe. Treatment for acne included: topical treatment- 13, systemic antibiotics- 4, oral isotretinoin-21, both oral and topical treatment- 15. The majority of patients described the degree of improvement as moderate (22) and slight (18). Thirty-nine patients found their treatment expensive. Occurrence of side effects did not affect the quality of life for 34 patients. Patients with severe acne were willing to pay either 125 -250 Euro (50%) or more than 250 Euro (50%) for a hypothetical cure. Patients with mild to moderate acne were willing to pay 25-125 Euro (28%), 125-250 Euro (50%) and more than 250 Euro (22%) ($p<0.05$).

Participants feel that their treatment is expensive, the side effects experienced affect their quality of life and the improvement is only moderate slight. However patients are willing to spend more money for a hypothetical cure and the amount of money they are willing to pay varies proportionately with the severity of acne.

QP-P-001

SIMULTANEOUS DETERMINATION OF MICONAZOLE NITRATE AND TRIAMCINOLONE ACETONIDE IN A TOPICAL PREPARATION BY LIQUID CHROMATOGRAPHY

A. Mansour, H. Mokhtar,
Medical Union Pharmaceuticals,
Egypt

Miconazole nitrate is an antifungal agent. It is applied as 0.2% cream in the treatment of fungal infections of skin and nails. Triamcinolone acetonide is also applied topically as a 0.1% cream or ointment for treatment of various skin disorders. Combination of the two drug substances is applied in the formulation of a pharmaceutical topical preparation incorporating methyl paraben sodium and propyl paraben sodium as preservatives. Most of the reported chromatographic methods for determination of miconazole nitrate and triamcinolone acetonide are either dealing with each drug in separate or in different combinations. In this work, we determined simultaneously both active ingredients together with both preservatives by a validated gradient elution chromatographic method. Analysis was conducted on a C18 column (10µm) with a mobile phase, (A) acetonitrile-methanol (80-20), and (B) 20mM ammonium acetate, with a programmable gradient elution at a flow rate of 1.0 ml.min⁻¹, and at a detection wavelength of 238 nm. The method was validated to linearity, precision, accuracy and selectivity. Correlation coefficient (rs) were 0.9998, 0.99998, 0.99997, 0.99995 in the ranges of 5-50 µg.ml⁻¹, 0.53-5.3µg.ml⁻¹, 0.9-9.0µg.ml⁻¹ and 0.22-2.2µg.ml⁻¹ for miconazole nitrate, triamcinolone acetonide, methyl paraben sodium and propyl paraben sodium, respectively. Recoveries of the method ranged from 99.82% to 100.88% for miconazole nitrate and from 99.76 to 100.46% for triamcinolone acetonide in the range of 80-120% of the labeled claim. Recoveries for methyl paraben sodium and propyl paraben sodium were ranged from 100.66% to 100.97% and from 100.36% to 100.90%, respectively.

QP-P-003

CHEMOMETRIC AND CHROMATOGRAPHIC METHODS FOR SIMULTANEOUS DETERMINATION OF ISOPROPAMIDE IODIDE, DIPHENYLPYRALINE HYDROCHLORIDE AND PHENYLPROPANOLAMINE HYDROCHLORIDE IN PHARMACEUTICAL MIXTURES

H.A. Nagy¹, H.M. Mahgoub¹, H.M. Kocany¹, R.H. Fahmy², H.M. Maher²,
¹Faculty of pharmacy, ²Faculty of Pharmacy,
Egypt

General chemometric methods are outlined for the use of orthogonal polynomials for unequal intervals (OPU) to eliminate interferences in multi-component spectrophotometric analysis. The methods are useful when the absorption spectra of the analytes show considerable overlap. The unequal interval wavelengths are selected according to the shape of a specified segment on the absorption curve, thus the optimum values of the calculated OPU coefficients reflect exactly the fine structure of the absorption curve for each analyte in the mixture. The work utilized these coefficients in two approaches. The first involves matrix calculation for a number of source equations equal to the number of analytes in the mixture, a method named the unique orthogonal polynomials for unequal intervals (U-OPU method). In the second the OPU is applied under least squares approach, a method termed LS-OPU method. In the latter the number of source equations exceeds the number of mixture components. The mathematical explanation behind the methods is presented. The methods are illustrated by analyzing a mixture of isopropamide iodide, diphenylpyraline hydrochloride and phenylpropranolamine hydrochloride. In addition, an HPLC method was developed for resolving such ternary mixture using a 250mmX4.6mm C-18 column. The mobile phase is a mixture of acetonitrile and 0.025M NaH2PO3 (60:40v/v) containing 0.1% sodium laurylsulfate and 0.1% triethylamine (pH 3.5), flow rate 1ml/min, with UV detection at 223nm and ambient temperature. The proposed methods were successfully applied to the determination of the drugs in their capsules. The results obtained are statistically compared.

QP-P-002

QUANTITATIVE ANALYSIS OF ESTROGEN DERIVATIVE RESIDUE IN POLIOMYELITIS VACCINE BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY WITH FLUORESCENCE DETECTION

D.H. Tjahjono, R.E. Kartasasmita, R. Kanis,
Institut Teknologi Bandung,
Indonesia

A quantitative HPLC-fluorescence method for estrogen derivative residue in poliomyelitis vaccine was developed and validated. Sample pretreatment included ethyl acetate extraction and solid-phase extraction on a C18 column. LC separation was performed on a column of Zorbax SB C18 (150 mm x 4.6 mm id, 5 µm of particle size), a fluorescence detector at an excitation wavelength of 280 nm and an emission wavelength of 310 nm, and a mixture of methanol-phosphoric acid 10 mM (7:3) as mobile phase with a flow rate of 1.0 ml/min. Identification and quantitation were based on retention time and fluorescence intensity, respectively. Limits of detection and quantitation (LOQ) had values of 1.17 and 3.91 µg/g, respectively. Linearity was obtained with an average coefficient of determination (R²) higher than 0.997, over a dynamic range from the LOQ value up to 65 µg/g. The recoveries of estradiol, estrone and estradiol from poliomyelitis vaccine were in the range of 93.5 to 96.3%.

QP-P-004

FORCED DEGRADATION - A SUITABLE METHOD FOR THE SYNTHESIS OF IMPURITIES IN LIFE SAVING DRUGS

A.A. D' Souza, V.S. Velingkar,
Prin.K.M.Kundnani College of Pharmacy,
India

AIM: A state of absolute purity of any pharmaceutical substance is almost impossible, but approached as closely as possible. The US FDA drafted guidance states that all related impurities of the drug are to be identified, characterized, qualified and studied for its impact on safety and stability of its products. A standard is thus needed to:

1. Detect impurities in drug
 2. Decide the presence/absence of degradation/related substances
 3. Standardize the impurity substance
 4. Control strength/ potency of Active Pharmaceutical Ingredient.
- Such official impurity reference standards are costly and not freely available in Asian market. Hence, an economical method for producing these impurities, which can be used as working standards, is designed. The drugs selected for the study are Glibenclamide and Nifedipine. METHODS: Hydrolysis of Glibenclamide produced BP Impurity-I while carbonylation of Impurity-I gave BP Impurity-II. Nitrophenyl pyridine and Nitrophenyl pyridine analogs of Nifedipine were synthesized using two basic reactions: oxidation and reduction. Exposure of dilute solution of drug to visible light can also be used, but is a slow process. The synthesized impurities were purified by specialized techniques of recrystallization & column chromatography.

RESULTS AND CONCLUSIONS: The synthesis of Glibenclamide and Nifedipine impurities have been successfully carried out and process-standardized. The purity (99-99.9%) of the substances was checked by TLC, HPLC and characterized by physical, chemical and spectral analysis (Elemental, NMR, Mass, IR, UV).

ACKNOWLEDGMENT: Thanks are due to Deputy Drug Controller (WZ).

SIG QUALITY OF PHARMACEUTICALS - POSTER SESSION

QP-P-005

SPECTROPHOTOMETRIC AND SPECTROFLUORIMETRIC METHODS FOR THE DETERMINATION OF FLUVOXAMINE MALEATE WITH NINHYDRIN IN DRUG FORMULATION

M.A. El-Sayed, R.M. Youssef, E.F. Khamis, H.A. Mahgoub, A.A. Gazy,
Faculty of Pharmacy, Aik. University,
Egypt

Two sensitive and selective spectrophotometric and spectrofluorimetric methods have been developed for the determination of Fluvoxamine maleate in pure form and in pharmaceutical preparation. The methods are based on the reaction of the primary amino group of the drug with ninhydrin in N,N - dimethyl formamide (DMF) medium producing a blue colored complex measured spectrophotometrically at 600 nm and the first derivative value (peak to peak) at 553 and 646 nm. The fluorophore exhibits excitation λ_{max} at 308 nm and emission λ_{max} at 624 nm. The composition of product was found to be 2:1 (Reagent: Drug). The reaction obeys Beer's law over the ranges of 15-55 and 10-50 $\mu\text{g/ml}$ for the absorption and first derivative measurement and over the ranges of 0.1-0.5 $\mu\text{g/ml}$ for spectrofluorimetric method. The detection limits were found to be 4.36, 2.37 and 0.04 $\mu\text{g/ml}$ for the spectrophotometric and spectrofluorimetric methods, respectively. The proposed methods have been applied successfully to the analysis of the drug in tablet form. No interference was observed from common pharmaceutical adjuvant. Statistical comparison of the results with the reference method showed excellent agreement which indicated no significant difference in accuracy and precision.

QP-P-006

ENZYME KINETIC ANALYTICAL METHOD FOR ANGIOTENSIN CONVERTING ENZYME INHIBITOR DRUGS DETERMINATION IN PLASMA USING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

P. Thongsopnon¹, C. Poeknapo²,
¹Chulalongkorn university, ²Martin-Luther Universität,
Thailand Germany

Based on enzyme kinetic principle, angiotensin converting enzyme inhibitor drugs plasma, demonstrated by captopril and enalapril were determined via the analysis hippuric acid, the product of reaction between hippuryl-histidyl-leucine and zink angiotensin converting enzyme from drug inhibition. The developed high performance liquid chromatographic technique consists of C18 column and the mixture of acetonitrile and 40 mM phosphate buffer with sodium dodecylsulfate at the pH of 2.3 as the mobile phase operated at the flow rate of 1 ml/min. The detector wavelength was 228 nm. The sensitivity of the method for enalapril as enalaprilat was 3 ng/ml or 10 ng/ml (captopril in plasma). Acceptable accuracy as average %bias was -0.45% for enalapril and 0.27% for captopril. The %RSD of intra-day and inter-day precision for enalapril and captopril were all within 9%. Since none endogenous interference was detected supporting the specificity of this method. The stability of plasma enalaprilat as captopril at laboratory temperature were 10 and 5 h and at frozen temperature (-40°C) were 30 d and 14 d, respectively. Plasma enalapril could be restored within two freeze thaw cycles while only one cycle for captopril. However, the processed analytes were still stable within the autosampler at 0°C up to 40 h. This developed method was successfully used for analyzing plasma sample from twelve volunteer subjects throughout 14 h after administered enalapril tablets.

QP-P-007

APPLICATION OF DERIVATIVE RATIO SPECTROPHOTOMETRY AND PARTIAL LEAST SQUARES PLS TO THE DETERMINATION OF DISSOCIATION CONSTANTS.

A. Wahbi, O.T. Fahmy, M.S. Moneeb,
University of Alexandria,
Egypt

Dissociation constants of some compounds have been determined using (i) derivative ratio spectrophotometry, (ii) multivariate methods using absorbances and absorbance ratio data. For the PLS method, the training set was constructed by computation using a general formula $U_{Aa} + D_{Ab}$ where $U+D=1$ and A_a and A_b are the absorbances of the completely dissociated acidic and basic forms. Trisulf buffer solutions were used. At a given pH, any of the studied compounds behaves as a mixture of two components (dissociated and undissociated forms). Accordingly, first and second order ratio spectrophotometry have been applied to obtain the dissociated and undissociated concentrations at different pH values. Substituting in the Henderson equation, the pKa values were obtained. Using the same principle PLS has been applied to obtain the concentrations at different pHs.

Compound Reported pKa 1D 2D PLS
Theophylline 8.6 8.60 8.61 8.61
Chlorpheniramine 4.0 4.00 4.02 4.01
Trimethoprim 7.2 7.23 7.25 7.26
Paracetamol 9.5 9.53 9.50 9.51
Chlorzoxazone 8.0 8.13 8.09 8.10
Benzoic acid 4.2 4.15 4.18 4.17

QP-P-008

APPLICATION OF CHEMOMETRICS, PLS, TO SECOND-ORDER DERIVATIVE SPECTROPHOTOMETRIC DETERMINATION OF BENZENE AS IMPURITY IN ETHANOL AND ISOPROPYL ALCOHOL.

A. Wahbi, E. Hassan, O. Fahmy, D. Hamdy,
University of Alexandria,
Egypt

Benzene is assayed as an impurity in ethanol, I and isopropyl alcohol, II at a level of ppm using GC methods (B.P. 2004). The multivariate method of analysis (PLS) has been applied to develop a rapid, simple and direct spectrophotometric method for this purpose. Second-order derivative data has been recorded for I and II in 5 cm and 1 cm path lengths, respectively against water as blank over the wavelength range 240 - 298 nm at 1nm intervals. Training sets containing benzene in I and II have been constructed over the concentration range 1.2 to 3.6 ppm at 0.4 ppm increments. Absorbance and second order-derivative data have been recorded. Applying PLS for both data revealed that using second-order derivative readings was more appropriate than using direct absorbance data as a quantitative measure of benzene as impurity. Validation set prepared to contain benzene in I and II over the concentration range 1.4 to 3.4 ppm at 0.4 ppm increments were similarly measured and chemometrically treated. Mean percentage recoveries were found to be 99.93±0.67% and 100.41±1.22% for benzene in I and II, respectively using PLS. Four different samples of I and II containing variable amounts of benzene as impurity have been analyzed using second-order derivative PLS method. The same samples were determined using the tangential graphical technique applied to second order derivative curves (B.P. 1998) as a reference method. The amount of benzene in I and II were found to range from 1.36 to 2.51 ppm and 1.38 to 2.53 ppm, respectively using the official method. The PLS method gave results ranging from 1.37 to 2.47 ppm and 1.34 to 2.48 ppm for I and II, respectively.

QP-P-009

DETERMINATION OF OMEPRAZOLE, LANZOPRAZOLE AND PANTOPRAZOLE IN PRESENCE OF THEIR ACID-INDUCED DEGRADATION PRODUCTS USING DERIVATIVE-RATIO SPECTROPHOTOMETRY AND PARTIAL LEAST SQUARES METHODS.

A. Wahhi, O.T. Fahmy, M.S. Moneeb,
University of Alexandria,
Egypt

Omeprazole I, lansoprazole II, and pantoprazole III, have been determined trially in presence of their acid-induced degradation products using (i) first and second order-derivative ratios and (ii) PLS applied to absorbance and absorbance ratio data. Laboratory prepared mixtures of the intact compounds with the corresponding acid induced degradation products were prepared in 0.1M NaOH to contain 2.0 to 65% degradation product and measured over the wavelength range 220 - 340 nm at 2nm intervals. The derivative ratio, first and second order methods as well as the PLS method applied to absorbance ratio and absorbance data gave mean percentage recoveries 99.9 ± 0.30 , 100.0 ± 0.23 , 100.1 ± 0.33 , and 99.9 ± 0.25 for I, respectively; and 100.1 ± 0.36 , 100.2 ± 0.31 , 100.3 ± 0.32 , and 100.1 ± 0.29 for II, respectively; and 100.4 ± 0.28 , 100.1 ± 0.45 , 100.3 ± 0.36 , and 100.5 ± 0.31 , for III, respectively. The PLS method when applied to absorbance ratio data to give concordant results to absorbance data expresses its specificity to the investigated compounds I, II, and III.

Capsules of I (Gastrazole, 20 mg), II (Lanzor 15 mg) and tablets of III (Controloc; 40 mg) have been analyzed using the proposed methods. Mean percentage found from the labeled were 100.5 ± 0.36 , 100.3 ± 0.4 , 100.5 ± 0.33 and 100.7 ± 0.25 , for I, respectively; 98.6 ± 0.43 , 98.6 ± 0.48 , 99.0 ± 0.45 and 98.9 ± 0.35 for II, respectively; and 100.3 ± 0.46 , 99.9 ± 0.43 , 100.0 ± 0.33 and 100.0 ± 0.39 for III, respectively. The PLS method is fast, easy simple and do not require any prerequisite. It is a one step calculation.

QP-P-011

DETERMINATION OF ARISTOLOCHIC ACID IN CHINESE MEDICINAL FORMULAS CONTAINING MU TUNG, FANG JI, XI XIN BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

L.L. Hong, S.T. Deng,
Chang Gung Memorial Hospital,
China Taiwan

Some herbs Mu Tung, Fang Ji, Xi Xin which always to be mistaken another species plants that contain aristolochic acid. The aristolochic acid can induce progressive fibrosing interstitial nephritis had been obvious. To ensuring patient's safety of using medicine, we investigated the commonly used traditional Chinese medicinal formulas that contain Mu Tung, Fang Ji and Xi Xin, carried in the pharmacy of certain medical center, to determine whether these formulas contain aristolochic acid. We selected 22 commonly used traditional Chinese medicinal formulas and randomly inspected 5 batches for each formula. The samples were analyzed by high performance liquid chromatographic on a silica gel RP-18 reversed-phase column and detected at 254 nm with 2% acetic acid-acetonitrile (55:45, v/v) in 0.8ml/min. The HPLC method can separate aristolochic acids I, II clearly within 30 min and all samples didn't find the aristolochic acids. We use photodiode array detector to further confirm the reality of existence of the aristolochic acids. It is useful to develop an effective system for monitoring the quality of traditional Chinese medicinal formulas in hospital.

QP-P-010

POLAROGRAPHIC AND VOLTAMMETRIC CHARACTERISTICS OF *o*-OXO-*l*-BUTYROLACTONE-ARYLHYDRAZONES- DETERMINATION OF SULFA DRUGS THROUGH JAPP-KLINGEMANN REACTION

S.S. Sabry
Faculty of Pharmacy,
Egypt

The electrochemical behavior of *o*-oxo-*l*-butyrolactone arylhydrazones in aqueous solution was studied by differential pulse polarography (DPP) at dropping mercury electrode (DME), differential pulse voltammetry (DPV) at hanging mercury electrode (HMDE) and cyclic voltammetry (CV). The adsorptive stripping characteristics at HMDE were also considered. *o*-Oxo-*l*-butyrolactone arylhydrazones are formed as a result of Japp-Klingemann coupling transformation reaction of 2-acylbutyrolactone (ABL) with diazotized aromatic amines. In this study, sulfadiazine (SD) and sulfamethoxazole (SMX) were used as models of aromatic amines. Analogous study on sulfa-azo derivatives formed after diazo-coupling reaction with ethyl acetoacetate (EAA) was also of interest. Similar features in electrochemical characteristics of hydrazono- and azo- compounds were demonstrated. In aqueous acidic solution, the reduction of azomethine center of *o*-oxo-*l*-butyrolactone arylhydrazones and azo-center of sulfa/EAA-azo derivatives (pH > 4) occurs in one 2e/2H⁺ reaction step, to give the corresponding hydrozo group. The redox system of either compound is irreversible. Based on the study performed, DPP, DPV and adsorptive stripping voltammetric (ADSV) methods were evaluated for determination of SD and SMX in pharmaceutical preparations. Further, SMX was determined in plasma and urine samples, spiked with clinically relevant levels, through voltammetric measurements of *o*-oxo-*l*-butyrolactone arylhydrazones. Real analysis of female urine samples was also done.

QP-P-012

OPTIMIZATION OF HPLC METHOD FOR SIMULTANEOUS ANALYSIS OF NIACIN, ANHYDROUS CAFFEINE, PYRIDOXINE HYDROCHLORIDE, RIBOFLAVIN AND THIOCTIC ACID IN PHARMACEUTICAL PREPARATION

M.J. Kim, K.R. Chae, D.G. Leem, M.K. Kim, M.H. Shin, J.H. Baek, M.J. Jung, J.Y. Park, J.S. Kim,
Busan regional KFDA,
South-Korea

This study was going to offer an improvement proposal about the simultaneous analytical method for niacin(NA), anhydrous caffeine(AC), pyridoxine hydrochloride(PH), riboflavin(RF) and thioctic acid(TA) in solution and capsule preparation by high performance liquid chromatography. For assay of solution and capsule preparation containing NA, AC, PH, RF, TA, chromatography was performed under gradient condition using a mixture of acetonitrile-Sodium sodium 1-heptane sulfonate with 0.1% phosphoric acid as mobile phase into UV 211 nm. Separations were performed on Capcellpak C18 column (5 μ , 4.6 \times 250mm) and flow rate was 1ml/min. Under above conditions the retention time of NA, AC, PH, RF, TA was 6.500, 10.620, 11.684, 13.453 and 30.380min, respectively. This new proposed method was validated following the analytical performance parameters, i.e. linearity, precision, accuracy and system suitability, required by the U.S. Pharmacopoeia (USP) and the international conference on harmonization (ICH) guidance. Using development method, commercially available preparations (solutions and capsules) were assayed and all of the results were within their drug specification for assay. Due to their simplicity and accuracy, this method is suitable for the compendial method.

SIG QUALITY OF PHARMACEUTICALS - POSTER SESSION

QP-P-013

DEVELOPMENT OF SIMULTANEOUS ANALYTICAL METHOD BY HPLC FOR THE COMPONENTS IN HERBAL MEDICINE PREPARATION 'GUPHUNGJIBODAN'

J.H. Baek, K.R. Chae, D.G. Leem, M.K. Kim, M.H. Shin, M.J. Kim, M.I. Jung, J.S. Kim.
Busan regional KFDA,
South-Korea

The purpose of this study is the development of a simultaneous analysis for the components in herbal medicine preparation 'Guphungjibodan' using high performance liquid chromatography without derivatization. 'Guphungjibodan' should contain not less than 90.0% of the labeled amounts of ginsenoside(GS) in *Gardeniae Fructus*, paeoniflosin(PF) in *Paeoniae Radix*, ephedrine(ED) in *Ephedrae Herba*, baicalin(IC) in *Scutellariae Radix*, total berberine(BB) in *Coptidis Rhizoma* and *Phellodendri Cortex*, glycyrrhizic acid(GA) in *Glycyrrhizae Radix*, decursin(DS) in *Angelicae Gigantis Radix* according to Korean Pharmaceutical Codes (KPC), but each component has individual identification and quantification method. Simultaneous analysis using high performance liquid chromatography for contents assay of GS, PF, ED, IC, BB, GA and DS has been developed and validated. Sample preparation was extracted and individual standard was prepared using methanol. The simultaneous separation of GS, PF, ED, IC, BB, GA and DS was achieved on reversed-phase C18 column (Capcellpak C18, 5 μ , 4.6 \times 250mm) with acetonitrile gradient system from 5% acetonitrile to 70% acetonitrile in 5mM sodium 1-hexane sulfonate with 0.1% phosphoric acid as mobile phase into UV 254 nm. According to this method, all of the compounds showed good results in linearity, precision, accuracy and recovery. This method was successfully applied to the identification and quantitative analysis of all compounds, except for the PF and ED in Guphungjibodan were mixed other ingredients, as revealed by the UV spectrum.

QP-P-014

SCREENING OF THE MECHANICAL PROPERTIES OF THERMOREVERSIBLE MUCOADHESIVE PHYSICAL HYDROGELS USING TEXTURE PROFILE ANALYSIS AND ARTIFICIAL NEURON NETWORKS

N.M.Z. Gouda¹, P. Hildgen²,
¹University of Alexandria, Egypt ²Faculty of pharmacy, University of Montz, Canada

Aim. Based on the assessment of mechanical properties, texture profile analysis(TPA) assisted by artificial neurons network(ANN) are used to select the optimum thermoreversible hydrogel formulation intended for mucosal application.

Methods. Aqueous solutions of different concentrations of thermoreversible polymer pluronicF127 (F127) and pluronicP68 (P68) with or without the mucoadhesive polymer carbopol 934P (CP934P) or polyacrylamide (PC) were prepared. Their gelatin temperatures were determined using the inverted test method. Three replicates from each free flowing liquid formulation were kept at 34 \pm 0.5 for 30 minutes prior testing to allow gelation. TPA was then performed where 2cm diameter cylindrical acrylic probe was twice compressed into each formulation at 34 \pm 0.5 to 5.0mm depth, at pre-test speed of 5.0mm/s, test and post-test speed of 1.0mm/s, and recovery period of 15s between the 2 compression cycles. From the resultant force-time curve, values of hardness adhesiveness and cohesiveness were determined and analysed using ANN.

Results. Formulation with optimum mechanical properties appeared to be the containing F127/P68/PC of concentrations 15.0/25.0/0.1 (%w/w) where the values of hardness, adhesiveness, and cohesiveness were 2.03 N, 7.20 Nmm, 1.06 Nmm respectively. These properties were negligible for formulations not gelling at body temperature. PC proved to play a considerable role in cohesiveness (relative importance 83%, R2 0.946 and MSE 0.001).

Conclusion. Combined TPA-ANN has shown its efficiency in screening mechanical characteristics of thermoreversible hydrogel formulations to obtain the most suitable candidate for mucosal application.

SIG NATURAL SUBSTANCES - POSTER SESSION

NS-P-001

NOVEL SORBICILLINOID DERIVATIVES FROM THE MARINE FUNGUS TRICHODERMA VIRIDE ASSOCIATED WITH THE CARIBBEAN SPONGE AGELAS DISPAR

A.L. Abdel-Lateff¹, S.K. Stefan Kehraus², A.K. Anja Krick³, A.D. Wright⁴, G.M. König⁴

¹Faculty of Pharmacy, Egypt; ²University of Bonn, Germany

³Pharmaceutical Biology, Germany

⁴Institute for Pharmaceutical Biology, Germany

The fungus *Trichoderma viride* isolated from the Caribbean sponge *Agelas dispar*, collected on Dominica, was mass cultivated and found to produce four novel sorbicillinoid polyketide derivatives, trichodermanones A-D and the trichopyranone. In addition to these compounds two known hexaketide derivatives, epoxysorbicillinol, vertinolide and three known dodecaketides trichodimerol, bislongiquinolide (trichostroazine), and bisvertinol, were isolated. Finally, a known fungal metabolite, 2-furancarboxylic acid was obtained. The structures of all compounds were determined by interpretation of their spectroscopic data (1D and 2D NMR, MS, UV and IR). Total extract and all compounds except 2-furancarboxylic acid have DPPH radical scavenging effects (12.5, 43.8, 15.5, 37.2, and 23.8 % respectively at 230 µmol/L), with epoxysorbicillinol, vertinolide, and trichodimerol being also able to inhibit peroxidation of linoleic acid (17.8, 5.2 and 19.9, respectively at 164 µmol/L). Epoxysorbicillinol showed moderate HIV-1 reverse transcriptase inhibitory activity (63.8 % at 200 µg/mL). All compounds and the total extract except 2-furancarboxylic acid were tested for their estrogenic, antitumor and antimicrobial effects and no significant activities were observed.

NS-P-003

IN VITRO EVALUATION OF ACACIA NILOTICA PODS FOR ANTI-HIV ACTIVITY

T.A. Khan¹, P.A. Taithe², S.Y. Gabbe¹, K. Mahajan³, S. Kothare², R. Deshmukh²

¹C.U. Shah College of Pharmacy, ²Haffkine Research Institute, India

INTRODUCTION

Traditional and folklore medicines play an important role in health services. Ayurveda, the traditional medicinal system of India provides remedial treatment for a variety of disease conditions. Rational design of novel drugs from traditional medicine offers new prospects in modern healthcare. Our current research work is an effort towards finding a cheaper and safer option in alternative medicine to existing HIV therapy.

OBJECTIVE

The present study aims at screening the extracts of the pods of *Acacia nilotica* (Family: Mimosaceae) for potential anti-HIV activity. The methanol and water extracts of the ripe pods of *Acacia nilotica* were used in this study.

METHODS

The anti-HIV activity of these extracts was measured in terms of their effects on viral infection and replication in-vitro. Infection was measured by the microtiter syncytium formation assay. Replication was measured by virus-associated Reverse Transcriptase activity. The H9 cell line was used for the infectivity assay and for virus-associated Reverse Transcriptase inhibition.

RESULTS

The methanol and water extracts of *Acacia nilotica* exhibited a dose related inhibition of the enzyme Reverse Transcriptase. The methanol and water extracts exhibited a 98.32% and 99.07% inhibition of Reverse Transcriptase.

CONCLUSIONS

The extracts of the pods of *Acacia nilotica* possess a statistically significant inhibitory activity against the novel enzyme Reverse Transcriptase. These results provide a rationale for further studies on isolation of active principles and pharmacological evaluation of *Acacia nilotica* pods.

NS-P-002

ANTIMICROBIAL AND ANTIFUNGAL ACTIVITY IN LABURNUM ANAGYROIDES L.

M. Aciu, D. Calina, F. Popescu, L. Bejenaru, J. Neamtu, University of Medicine and Pharmacy, Romania

AIMS: To make evident the antimicrobial and antifungal effect of ethanolic extract of the species *Laburnum anagyroides* L. (Leguminosae), golden chain, against human pathogenic microbes.

METHODS: The flowers, leaves, bark and seeds of the species *Laburnum anagyroides* L. air-dried were ground into fine powders and extracted in a Soxhlet extractor with 90% ethanol. The ethanolic extract at concentrations 83,25% were tested using filter paper discs sterilized impregnated with 100µmicrog extract. It was assessed sensibility/resistance of bacterial strains derived from 50 pathological biological samples; taken from subjects living in community or hospitalized. The investigated species are follows: *Escherichia coli*, *Staphylococcus aureus* methicillin sensitive and resistant, *Staphylococcus epidermidis*, *Streptococcus pyogenes*, *Klebsiella*, *Enterobacter aerogenes*, *Salmonella cholerae* sals, *Proteus mirabilis*, *Candida albicans*. The extracts were tested using classic diffusimetric method Kirby-Bauer and observing area of microbial growth inhibition (mm) on specific solid mediums. Reading was done by comparison with standard strains and using in the same time antibiotics from standard medical pouch (Becton-Dickinson).

RESULTS: It was observed an antibacterial activity from different parts of the plant. Thus, extracts from seeds and flowers was efficiently on Gram positive cocci. The leaves and bark's extracts were efficiently on Enterobacteriaceae and *Candida albicans*.

CONCLUSIONS: The antimicrobial and antifungal activities of the ethanolic extract can be used in association with classic antimicrobial and antimycotic drugs therapy for a synergic effect.

NS-P-004

PHYTOCHEMICAL INVESTIGATION AND PHARMACOLOGICAL SCREENING OF TAGETES ERECTA LINN FOR NEPHROTOXICITY

K.P. Manohara, R. Ramesh, T.V. Narayana, G. Krishna Murthy, R.V. Savadi, V.I. Hukkeri, R.V. Karadi, Dr.H.L.T.College of Pharmacy, India

AIM: To evaluate *Tagetes erecta* Linn ethanolic leaf extract for nephrotoxicity

Method: Gentamicin and Cisplatin induced nephrotoxicity models are used.

Results:

In traditional system of medicine the juice extracted from the leaves of *Tagetes erecta* Linn was reported to be useful in treating Nephrotoxicity.

Gentamicin induced Nephrotoxicity

Gentamicin 60mg/kg.b.w/day for 13 days s.c in rats induced acute renal failure. This was evidenced by significant increase in blood urea nitrogen (BUN) and Serum creatinine levels (SCL). Which persisted even after 10days of cessation of therapy. Treatment with ethanolic extract after Gentamicin induced damage caused a marked decrease in BUN & SCL. The co-administration of the extract also showed the same effect indicating its protective activity.

Cisplatin Induced Nephrotoxicity

At 5mg/kg i.p Cisplatin induced renal injury. Extract treated groups showed decrease in BUN levels however no change in SCL levels. In curative regimen decrease in BUN and SCL were observed however in preventive regimen no change in SCL levels.

Conclusion:

Phytochemical investigation revealed the presence of flavonoids, phyosterols and triterpenoids. There may be chances of flavonoids will help in BUN & SCL levels. From the above results *Tagetes erecta* leaf proves to be beneficial in the management of nephrotoxicity.

SIG NATURAL SUBSTANCES - POSTER SESSION

NS-P-005

ORGANOCHLORINE AND ORGANOPHOSPHORUS PESTICIDES IN VARIOUS HERBAL TEAS

D. Djukic
Faculty of Pharmacy,
Serbia and Montenegro

Due to its beneficial effects, different herbal teas are recommended and widely consumed all over the world. Anyhow, some literature data reported increased levels of pesticides in certain tea species, green tea being one of them.

The current study was undertaken to determine organochlorine and organophosphorus pesticides in 5 domestic herbal teas originated from the wild and field production in Serbia (*Urticae folium*, *Hyperici herba*, *Thymi herba*, *Rosae fructus* and *Hibisci flos*) and 2 imported teas (Nack Indian tea and green tea). The herbal samples were purchased randomly from a local pharmacy.

Samples of herbal teas were extracted and purified according to Ph.Yug.V procedure, and the content of 18 organochlorine and 15 organophosphorus pesticides was determined by GC/MS (apparatus Shimadzu QP 5050).

None of the investigated herbal teas contained increased organochlorine or organophosphorus levels. The obtained results were even under the level of detection for organochlorine (0.01 mg/l) and organophosphorus compounds (0.005 mg/l).

We can conclude that examined herbal teas fulfill the requirements for pesticides content given by our Drug Law (Ph. Yug. V), as well as standards given by European Union.

NS-P-006

A NEW HERBAL COLORANT FROM INDIAN PLANT

K.M. Khambholja, P.M. D'Mello,
KMK college of pharmacy,
India

OBJECTIVE: Colors have always been an essential constituent of pharmaceutical and food products. With the course of time approved synthetic colorants are coming under scientific and regulatory scrutiny for their toxicity and other reasons, thus developing the need for alternatives to these synthetic colorants. The use of organic plant materials as a source of colorant is now inclining due to varied reasons like cost effectiveness, safety, ease of availability, eco friendly nature and wide applications. The objective of our project was to develop new herbal colorant, having above characteristics, which can replace yellow colored synthetic colorants like tartrazine.

METHOD: The new colorant was obtained from flowers of Indian origin plant *Butea*. This paper describes about the raw material retrieval, its pretreatment and optimized novel extraction procedure for getting high yield. The most important part of the project is the extraction procedure using hydro-alcoholic solvent rendering a high yield with batch to batch reproducibility. The color was characterized using spectrophotometry and chromatographic methods. It was assessed for its stability and toxicity. Applications of this newly developed colorant were studied in different formulations like liquids dosage forms-syrup, elixir and solid dosage forms like tablets, granules, granules to be reconstituted and for coloring the coating solutions.

RESULTS AND DISCUSSIONS: Our studies have revealed that this new herbal colorant is safe and can be easily obtained with high yields economically. The color is also sufficiently stable thereby indicating that this can be a better substitute for yellow synthetic colors and dyes.

NS-P-007

EXTRACTION AND CHARACTERISATION OF THE POLYSACCHARIDES IN SCAPHIUM SCAPHIGERUM G.DON

S. Proepram¹, A. Pundech²,
¹Faculty of Pharmaceutical Sciences, ²Wang Yai Hospital,
Thailand

Nowaday many polysaccharides from plants have been showed interested properties. The glucomannan from *Konnyaku* inhibit cholesterol and sugar absorption to human intestine and has been us as dietary fiber. The fruit of *Scaphium scaphigerum* is rich with polysaccharide and has been used as food and traditional medicine for anti-inflammation. This study aims to extract the polysaccharides from the fruits of *Scaphium scaphigerum* and characterization of sugar component in the crude extract. The fruits of *Scaphium scaphigerum* have been extracted by three methods; extracted with boiling water, extracted with cold water and extracted with organic solvent and then boiling water. The three crude extracts were further purification by sepharose 6B gel filtration chromatography and DEAE column chromatography. The elution profile of the polysaccharides from these extraction methods were similar. Extract obtained by using organic solvent and boiling water give the most percent yields and good appearance. Characterization of the polysaccharides has been perform by hydrolyze the polysaccharides and identify sugar composition comparison with standard monosaccharide thin layer chromatography and gas chromatography. The sugar compositions are major monosaccharide which found in pectin. The detail of the structure and bioactivity study will be performing later.

NS-P-008

POSSIBLE RISK OF DRUG INTERACTIONS CAUSED BY HEPATIC ENZYME REGULATORS FROM DAILY FOODS

O. Hu, C.H. Hsiang, P.C. Kuo, M.T. Wang, L.F. Hsu,
National Defense Medical Center,
China Taiwan

The purpose of this study is to address the risk related to the effects of food or pharmacokinetics in drug development. We had successfully screened the potential inhibitors and enhancers from 62 food components. Highly inhibiting case of CYP450 and UGT7 modulating ability was found for these pure food components. For UGT2B7, HUCHE011, HUCHE002 and HUCHE025 were the most potent components to reduce the activity of UGT2B7, which are contained richly in onions, parsley, oranges and orange juice. It was found that 30 grams of raw onions, 15 grams of oranges, 36 grams of bottled lemon juice or 7 grams of tangelo juice will greatly reduce the activity of UGT2B7 range from 36% to 100%. For CYP3A4, HUCHE015, HUCHE019, HUCHE059 and HUCHE060 were the most potent components to reduce the activity of CYP3A4, which are contained richly in tea, chocolate, red wine and grapes. It was found that 7.3 mg of green tea leaves, 27 mg of oolong tea leaves, 485 grams of dark chocolate or 763 grams of red wine will greatly reduce the activity of CYP3A4 range from 40% to 90%. For CYP2D6, HUCHE066 was the most potent component to reduce the activity of CYP2D6, which is contained richly in tea, fennel, parsley and cranberries. It was found that 200 grams of dry green tea leaves, 300 grams of fennel leaves or 1200 grams of cranberries will greatly reduce about 86% of the activity of CYP2D6. Possible high risk is concluded that many foods uptake in daily life will possess the potential to affect the absorption and metabolism of drugs metabolized by CYP450 or UGT, such as simvastatin, nalfurafine, carvedilol and so on.

SIG NATURAL SUBSTANCES - POSTER SESSION

NS-P-009

PHARMACOGNOSTICAL, PHYTOCHEMICAL AND HEPATOPROTECTIVE ACTIVITY OF ZIZIPHUS OENOPHIA (L.) MILL.

A. Shantha¹, Saraswathy²,
¹C.I.Baid Metha college of pharmacy, ²,
India

A detailed study of a folklore medicinal plant in India - *Ziziphus oenopia* (L.) Mill, has been carried out. Detailed phytochemical tests were carried out on different extracts obtained from the aerial parts of the plant. Extracts were obtained using six different solvents of increasing polarity. Prior to this, standard physicochemical constants - ash value, total ash, acid insoluble ash, water soluble ash, sulphated ash were determined. Extractive values of ethanol and water soluble extractives are determined. Estimation of crude protein was also carried out. Qualitative organic analysis was also performed. There are no reports of study on the methanolic extract of aerial parts of the said plant. Following the extraction using methanol, fractionation, isolation was attempted. In-depth detailed analysis of the compound obtained by subjecting it to HPTLC, IR, UV analysis, NMR spectral analysis and mass spectroscopy, RUTIN was identified. Further to the isolation from the aerial parts, methanolic extract was subjected to acute oral toxicity studies and hepatoprotective activity. All these had proper ethical committee approval. Hepatoprotective activity was carried out using the carbon tetrachloride challenge method and silymarin was the standard. Biochemical parameters - SGOT, SGPT, ALP, total protein content and bilirubin were determined. Histopathological studies were also carried out. Analysis of the result shows significant hepatoprotective action when compared with standard as determined by subjecting result to ANOVA test.

To conclude methanolic extract of aerial parts of the plant contains rutin and has significant hepatoprotective activity.

NS-P-010

PHARMACOLOGICAL STUDY OF TRADITIONAL CHINESE MEDICINE- DANG-GUI-SHAO-YAO-SAN

A.Y. Shen¹, T.S. Wang¹, L.F. Liao¹, C.H. Liao², C.C. Lin³,
¹Fooyin University, ²Chang Gung University, ³Kaohsiung Medical
University,
China Taiwan

Dang-Gui-Shao-Yao-San (DGSYS) is a mixture of medicinal herbs, which has long been used in the traditional Chinese medicine for treating anemia and ovulatory disorders. Its preparation comprises *Angelica sinensis* (Oliv.) Diels, *Ligustrum chinensis* Hort, *Paeonia lactiflora* pall, *Portia cocos* (Schw.) Wolf, *Arctostaphylos macrocephala* Koidz and *Alisma orientalis* (Sam.) Juzep. The present study examined the anti-superoxide formation, free radical scavenging and anti-lipid peroxidation activities of DGSYS by xanthine oxidase inhibition, cytochrome C system with superoxide anion releasing by FMLP or PMA activating pathway in human neutrophils, and Fe-Cl₂-ascorbic acid-induced lipid peroxidation effects on lipids in rat liver homogenate, respectively. DGSYS showed anti-superoxide formation and free radical scavenger activity in a concentration-dependent manner. It also inhibited PMA- but not FMLP-induced superoxide anion releasing from human neutrophils. These antioxidant actions of DGSYS showed beneficial cytoprotective effect against lipid peroxidation in rat liver homogenate, human platelet aggregation induced by AA and ADP, and mitomycin C-mediated hemolytic in human erythrocytes.

NS-P-011

ANTIOVULATORY ACTIVITY OF AQUEOUS EXTRACT OF DAUCUS CAROTA LINN. SEEDS IN ALBINO MICE.

P.A. Tatke, S.G. Mohanty,
C.U. Shah College of Pharmacy,
India

Aims

Carrot or *Daucus carota* Linn. Seeds (family : Umbelliferae) have been known as 'Garbhapatana' in Ayurveda, the ancient system of Indian medicine, which means 'causing abortion'. The present study includes preparation of aqueous extract of carrot seeds and its evaluation for antiovlatory activity.

Methods

The aqueous extract was prepared by refluxing the dried, powdered seeds with distilled water for 8 hours. The extract was administered intraperitoneally to albino mice at 10 mg/kg and 20 mg/kg for 15 days and the estrous cycles were observed daily for 30 days. The activity was compared with control group and vehicle control group animals which showed normal estrous cycles.

Results

The aqueous extract (at doses of 10mg/kg and 20mg/kg body weight) arrested the estrous cycle at diestrous stage on 7th and 5th day of dose administration respectively indicating antiovlatory activity. This activity was found to be reversible as the cycles returned to normal pattern after the treatment has been stopped. The aqueous extract indicated presence of tannins, saponins, proteins, steroids and reducing sugars.

Conclusion

The aqueous extract of carrot seeds showed significant antiovlatory activity in mice at 10mg/kg and 20mg/kg body weight. The activity was found to be reversible in action.

NS-P-012

IN-VITRO ANTIMICROBIAL ACTIVITY OF BARK OF ACACIA NILOTICA LINN.

P.A. Tatke, A. Phadnis, K.K. Singh,
C.U. Shah College of Pharmacy,
India

Aims

The bark of the plant *Acacia nilotica* Linn. (Family: Mimosaceae), commonly known as 'babul' has traditionally been used since ancient days as a 'chewing stick', for maintenance of oral hygiene. However its antimicrobial activity, with emphasis on dental microflora has not yet been reported. The present study aims at in-vitro antimicrobial activity of *Acacia nilotica* Linn.

Methods

Dried powdered bark of *Acacia nilotica* Linn. was extracted successively with various solvents. These extracts were studied for antimicrobial activity against various gram positive and gram negative bacteria, *Candida albicans*, and organisms isolated from tooth tartar of dental patients.

Results

Acetone extract was found to exhibit maximum activity with a Minimum Inhibitory Concentration (MIC) of 2.5 mg. 100 mg of acetone extract showed antimicrobial activity comparable to that of the standard used, Chloramphenicol-100mg. The extract was found to exhibit greater zones of inhibition for some of the cultures isolated from tooth tartar than the standard antimicrobial agent. Preliminary phytochemical screening of acetone extract revealed presence of tannins, phenolic compounds, flavonoids, reducing sugars and carbohydrates. TLC profiles and HPTLC fingerprinting were developed for the extract and the numbers of peaks obtained were recorded.

Conclusion

Acetone extract of bark of *Acacia nilotica* Linn. possesses good antimicrobial activity against dental pathogens confirming the traditional claim.

Acknowledgements

Hi-Media Laboratories Ltd, Mumbai.
Nair Dental College, Mumbai.

NS-P-013

EVALUATION OF HEALTH PRODUCTS USED BY THE CANADIAN FORCES HEALTH AND LIFESTYLE INFORMATION SURVEY RESPONDENTS

R. Vaillancourt¹, M. Roy², J. Sampalis¹, S. Groves¹,

¹Canadian Forces Health Services, ²CSHP, ³JSS Medical Research, Canada

Objectives

To identify the patterns of natural health product (NHP) use among Canadian Forces (CF) members. The secondary objective was to compare NHP use with first language (English/French), gender, age, marital status, education, rank, duration of service, Non NHP medication use, chronic conditions, weight (Body Mass Index BMI), and self reported health status.

Methods

A cross-sectional survey of CF members was performed and all 6,841 respondents to version B of the CF 2000 Health and Lifestyle Information Survey (HLIS) were included in the study. Descriptive statistics, using SPSS software, were determined for the demographics of the study sample and the frequencies of health products use. Odds ratios and 95% confidence intervals were determined for the association between the independent and dependent variables. A logistic regression analysis was done for independent characteristics associated with health products use.

Results

Data from the 6,841 respondents was analyzed: mean age was 37.2 years (7.52) with the majority of respondents rating their health status (41.3%) as very good. Of the respondents, 44.1% used health products on a regular basis and 2134 (31.2%) used a NHP in the previous two days.

Conclusions

CF members, in common with the general population, utilize the full range of NHP. All CF health care providers need to be knowledgeable about NHP and be able to provide accurate information to their patients. Further follow up studies should be conducted to determine when CF members obtain their NHP and from whom they obtain information on NHP.

NS-P-015

EFFECTS OF THYMOL, A NATURAL PRODUCT, ON IONIC CURRENTS IN PITUITARY GH3 CELLS

A.Y. Shen¹, M.H. Hwang¹, T.S. Cheng², M.C. Lai³, C.S. Tang³, S.N. Wu³,

¹Fooyin University, ²Kanhsing Pharmacists' Association, ³National Cheng Kung University, China Taiwan

Drugs with the opening of potassium (K⁺) channels, causing hyperpolarization of cell membrane, possess a clinical potential. The large-conductance Ca²⁺-activated K⁺ (BK) channel is highly selective for K⁺. Activation of this channel is Ca²⁺ and voltage dependent. We here investigated the effects of thymol, a natural product, on ion currents in pituitary GH3 cells. The patch-clamp technique was used to investigate the effect of thymol (100 µM) in these cells. Thymol reversibly stimulated Ca²⁺-activated K⁺ current with an IC₅₀ value of 75 µM. In cell-attached configuration, application of thymol to the bath increased the activity of BK channels. BAFTA (1 mM) attenuated thymol-stimulated channel activity. In inside-out configuration, thymol exposed to the intracellular face of excised patches did not modify the single-channel conductance of these channels, however, it did enhance the channel activity. Neither menthol (100 µM) nor zingiberone (100 µM) had any effects on BK-channel activity, while AAPH (100 µM) suppressed it significantly. The stimulatory actions of thymol on Ca²⁺-activated K⁺ currents may be associated with the underlying cellular mechanisms through which it affects neuronal or neuroendocrine functions.

NS-P-014

THE STUDY OF ANTISEPTIC EFFECTS IN ADONIS VERNALIS L.

M. Aciu, D. Calina, L. Rosu, P. Nicolicescu, D. Trasca,

University of Medicine and Pharmacy, Romania

Adonis vernalis L. belong to Ranunculaceae family and consist several famous species that all of them have medicinal uses. This plant compounds are useful in fever, cough, epilepsy, asthma, spasm and rheumatism.

In this research, the plant organs (vegetative organs: leaves, stems and roots) and generative organs (flowers and fruits) was desiccated and powdered, separately. The powders were sterilized by Tinsdallization method. Then we prepared ethanolic, methanolic 80% and aqueous extracts. The study of antiseptic effect was evaluated by diffusimetric Kirby-Bauer method, adopted by N.C.C.L.S., USA, on six microorganisms (Staphylococcus aureus, Staphylococcus epidermidis, Enterobacter aerogenes, Klebsiella pneumoniae, E. coli, Candida albicans)

The results showed that aqueous extract had not any antimicrobial effect. Extract of generative organs showed antimicrobial effect more strongly than vegetative organs extracts. The antiseptic effect of mentioned plant on Gram positive bacteria was greater than Gram negative bacteria. In comparative with Amikacine antibiotic, inhibitory areole diameter of this plant extracts approximately was corresponded.

NS-P-016

REPRESENTATION OF RARE AND PROTECTED PLANTS SPECIES IN MONTENEGRO WITH SPECIAL CONSIDERATION ON MEDICINAL AND AROMATIC PLANTS AND THEIR USE IN FOLK MEDICINE

K. Milosevic Kostadinovic
Apoteka Medicor,
Serbia and Montenegro

The aim of this research was to represent a unique and rich flora of Montenegro and its folk medicine, which is used in cases of self-medication for centuries. Montenegro have rich flora with more than 3000 species. Surface of 13812 km² with more than 3000 species represent one of richest flora in Europe continent. Special signal to our flora gives lots of endemic, endemismicous, rare, medical, aromatic and honeyed plants. In Montenegro flora there is 220 endemic species of Balkanic peninsula and southeast Dardanis. 165 taxons are with locus classicus in Montenegro. Republic of Montenegro has protected 50 endemic, rare and jeopardized species and 25 of them are described like medicinal and aromatic plants and are used in folk medicine for variety of indications for centuries.

NS-P-017

INVESTIGATION OF MUTAGENICITY EFFECTS OF CARUM CARVI

B.S. Fazly Bazzaz¹, B.S. Fazly Bazzaz², S.M. Bahari Saravi¹, Z. Sabeti Noghabi¹,

¹School of Pharmacy, ²Biotechnology Research Center, Iran

Introduction

A considerable number of mutagens have been shown to be carcinogenic. Therefore it is useful to detect mutagens through simple, rapid tests such as the Ames test. Carum carvi is one of the herbal plants widely used in Iranian traditional medicine. In this paper, the mutagenic activity of this plant is investigated using the Ames test.

Materials and Methods

Carum carvi was collected in Spring and dried in the proper conditions. Seeds of Carum carvi were then extracted with ethanol. Afterward ethanolic extracts were concentrated in the vacuum. In order to complete the extraction, different solvents were used. The classic protocol described by Maron and Ames (1983) was adopted for the mutagenicity test. Tester strains of *Salmonella typhimurium* were TA97, TA98, TA100 and TA 102. These strains contain mutations in the histidine operon, so that they can not synthesize histidine. They also have additional mutations which increase the sensitivity of the system. Different samples were incorporated on plates containing agar in both the presence and absence of mammalian liver extract (S9), with tester strains. After incubation for 2 days the number of revertant colonies were counted and compared with control plates.

Results and Conclusion

After analysis of the results, it was observed that plant extracts have no mutagenicity effects in the Ames plate system.

Reference

1. Maron, D. M. and Ames, B. N. (1983). Revised methods for the *Salmonella* mutagenicity test. *Mutat. Res.* 113, 173-215
2. Samsam Shariat H. Extraction of effective constituents of herbal medicines and their identification and evaluation. Masti publication, Isfahan, (1982), pp. 1-30

NS-P-018

REDISCOVERY OF POTENTIAL OF HONEY IN SKIN DISEASES AND ITS CHARACTERISATION

S.B. Jadhav¹, M.S. Honrao², S.P. Dhat²,

¹Modern College of Pharmacy, Pune, ²Sinhagad College of Pharmacy, India

Aim is to present a comprehensive review on types, sources, composition and properties of honey, which reveals its potential as therapeutic agent. Also to compile methods of evaluation like HPLC and enzyme activity determination; explore areas yet open for investigation such as HPTLC and to present the use of Honey on acne, pimples and eczema on the basis of study on 120 volunteers.

Ayurveda and Unani systems of medicine mention Honey to have antibiotic, wound healing and nutritive properties. Worldwide various official standards are available for honey. There are two streams of thought regarding whether to have an expiry date for honey or not. Authors have tried to compile this data. In this regard thought is given to presence of hydrogen peroxide, HMF (hydroxymethyl furfural) and high sugar content in honey.

Methodology: Topical effect of honey with cinnamon and *Rubia Cordifolia* was studied by the authors on 60 candidates each, which showed that cinnamon-honey combination had faster and better effects. This combination showed effect in the ratio of 20:45:35 in terms of fair-good/excellent, whereas Honey-*Rubia Cordifolia* showed effect in the ratio of 20:35:45. The pimples, acne and even eczema subsided to a large extent in both combinations, with a bit of improvement in complexion with *Rubia Cordifolia* combination.

Authors feel that various data of evaluation available combined with HPTLC analysis can give universal reference standard protocol for honey. The promising results of honey with cinnamon and *Rubia Cordifolia* on acne and eczema makes the author state that potential of Honey in various medicinal areas should be rediscovered and brought into practice.

SIG INDIVIDUALIZED MEDICINES - POSTER SESSION

IM-P-001

CLINICAL INVESTIGATION OF SILYBUM MARIANUM SEED EXTRACT (SILYMARIN) TREATMENT IN TYPE II DIABETIC PATIENTS

W.M.Y. Yousefi¹, F. Hussieni²,

¹Faculty of Medicine, Egypt ²Institute Medic, Iran

Introduction: The free radical production and consequently metabolic oxidative stress disorder is hallmark of chronic disease particularly in uncontrolled hyperinsulinemic type II diabetic patients. Inhibition of free radical production, its neutralization or correction of oxidative metabolic abnormality in diabetic patients following antioxidant therapy may influence the glycaemic control.

Aim: The present study was designed to investigate the efficacy of silymarin treatment with known antioxidant property on glycaemic control in type II diabetic patients.

Methods: A 12 month randomized double blind clinical trial was conducted in 80 non-insulin dependent diabetic patients in two well - matched groups. One group (n=48) received 200mg silymarin tablet 3 times a day plus standard therapy, while the control group (n=32) received placebo plus standard therapy. The patients were visited every two month and glycosylated hemoglobin (HbA1c), fasting blood glucose, total cholesterol, LDL and HDL, triglyceride, SGOT and SGPT levels were determined at the beginning, after four month and at the end of the study.

Results: There were significant decrease in HbA1c, fasting blood glucose, total cholesterol, LDL, SGOT and SGPT levels in silymarin treated patients as compared to placebo group.

Conclusion: In present study the silymarin treatment to hyperglycemic type II diabetic patients for twelve months improved glycaemic as well as lipid profile.

Key words: Silymarin, Herbal medicine, Antioxidant, Type II diabetes.

IM-P-002

CEFUROXIME VERSUS AMOXYCILLIN IN TREATMENT OF URINARY TRACT INFECTION IN CHILDREN

M. Aciu, D. Calina, F. Popescu, L. Bejenaru,

University of Medicine and Pharmacy,
Romania

AIMS: To investigate the clinical effect of parenteral Cefuroxime (CFX) and Amoxicillin (AMX) in children admitted to hospital for infection of urinary tract.

METHODS: 34 children (age 2 to 13 years) were selected for this study. The clinical criteria for selection were: fever, bacteriuria assessed by bladder puncture, positive C reactivity protein reaction. 20 subjects were treated with CFX and 14 with AMX (there were no intergroup differences in relation to age distribution or clinical data). The duration of the treatment was 7 days.

RESULTS: The etiological agent was *Escherichia coli* in 32 cases, there was 1 *Enterobacter* strain and 1 *Streptococcus aureus* strain. The treatment was considered good in 15 from 20 cases and fair in 4 from 20 cases in the CFX group. It was good in 10 from 14 cases, and fair in 4 from 14 cases in the AMX group. There was one culture of *E. coli* resistant to CFX and 12 from 34 cultures resistant (as well as 4 intermediate) to AMX. Although the study protocol was initially randomized 10 of the AMX resistant cases appeared in the CFX group.

CONCLUSIONS: We conclude that although the results bear evidence of equal clinical response, the Cefuroxime appears superior to Amoxicillin, because of the higher incidence of AMX resistance.

IM-P-003

PREDICTION CYA DOSAGE IN KIDNEY TRANSPLANTATION USING DATA OBTAINED FROM FIRST DOSE

H. Tajerzadeh, N. Adib,

Faculty of Pharmacy,
Iran

Cyclosporin A (CyA) a selective and potent immunosuppressive extensively metabolized by the liver cytochrom P450 iso-enzymes M17 is the most important metabolite with 10% of CyA activity. The therapeutic level is highly variable so high risks of organ rejection/ toxic effects are existed. The common methods of TDM are trough level, AUC method and single concentration measurement other than trough level, all suffer either having a weak relationship to total drug exposure or not feasible to daily clinical use.

AIM: The aim of present study is to experience an individual dosage adjustment applicable in clinical centers.

METHODS: 10mg/kg CyA was orally administered to eight kidney transplant candidates 12 hrs before and 12 hrs after transplantation. The serum concentration of CyA and M17 were determined spontaneously by developed HPLC method at room temperature. The concentration/time profile for both, CyA and M17 was evaluated.

RESULTS: There was very poor correlation using Cmax, AUC and Cmax/AUC M 17 against dose ($r^2 = 0.03, 0.3$ and 0.12 respectively). The AUC M17/ AUC CyA against mid point CyA concentration approached plateau in patients over 60 kg the ratio of AUC M17/AUC CyA in female was higher than those in male, 0.33 and 0.19 respectively. Finally there was a good correlation between concentrations at 8, 10 and 12 hrs with AUC inf. of CyA (0.9, 0.98, & 0.90), and M17, 0.78, .80 & 0.70 respectively.

CONCLUSION: The calculated steady-state concentration using parameters obtained from 8, 10 and 12 hrs level following CyA first administered dose. AUCM17/AUCCyA above 0.50 would be considered as high metabolism so dose reduction is not recommended.

IM-P-004

ESTROGENIC AND UTERINETONIC ACTIVITY OF SIDHA FORMULATION AMURI

G. Krishna Murthy, T.V. Narayana, R. Ramesh, K.P. Manohara, B.

Jainkash, R.V. Savadi, V.I. Hukkeri, R.V. Karadi,
Dr.H.L.T.College of Pharmacy,
India

Aim : To evaluate the estrogenic and uterine tonic activity of Amuri in *in vivo* and *in vitro* experimental models.

Method: Estrogenic activity was studied in normal and ovariectomized rats. Amuri was administered orally for a period of 21 days. The parameters studied in both *in vivo* models includes change in uterine weight, histometric changes of uterus. The effect was also studied on normal and regular estrous cycle. *In vitro* studies with amari non-primed, estrogen-primed and amari pretreated uterus were carried out to findout whether it possess any oxytocin like activity.

Results: Administration of Amuri in normal rats significantly increased the uterine wt, diameter of uterus and thickness of endometrium. Amuri treatment in ovariectomized rats didnot show any change in uterine wt. The rats from both control and treated groups showed normal estrous cycle and produced significant contractile response on non-primed, estrogen primed and amari treated rat uterus when exposed *in vitro*.

Conclusion: Siddha formulation Amuri proves to be beneficial in the management of gynaecological problems. Hence it justifies its traditional claim.

IM-P-005

PREVENTION OF REINSTATEMENT OF FEAR MEMORY BY CANNABINOIDS

P. Gean
National Cheng Kung University,
China Taiwan

The treatment of choice for a number of anxiety disorders is exposure therapy. However, successful reduction of fear through exposure is often followed by a return of fear which poses a challenge for both research and clinical practice. Reinstatement, the recovery of fear that occurs when the subject is exposed to the unconditioned stimulus (US) after extinction, is one possible source of relapse. Here we show that pre-training administration of CB1 agonists WIN55212-2 or HU210 impaired fear memory measured with fear-potentiated startle while post-testing application had no effect. The effects of WIN55212-2 and HU210 were blocked by AM251, a specific CB1 receptor antagonist. CB1 receptor agonists also blocked re-consolidation when applied after memory reactivation and facilitated conditioned stimulus (CS) alone-induced extinction of fear memory. Using a protocol to induce reinstatement of fear memory, we found that WIN55212-2-induced amnesia did not recover after a reminder shock. The absence of recovery was not attributable to permanent damage to the amygdala in WIN55212-2-treated rats because they could be re-trained. Taken together, these results suggest that CB1 agonists may be useful for the treatment of patients with inadequate reaction to potentially dangerous situation (e.g. patients with phobias or with posttraumatic stress disorders). More importantly, patients taken CB1 agonists may be less likely to relapse following successful completion of treatment.

AUTHOR INDEX

Author	Code	Page	Author	Code	Page
Abad, R.	CPS-P-020	92	Alaa, N.	HPS-P-062	128
Abd ElHady, S.S.	IPS-P-031	141	Alboul-Younes, A.M.	AS-O-001	76
Abd ElHady, S.S.	IPS-P-032	141	Ali, S.S.	APS-O-006	84
Abd Elhalim Elassasy, A.E.	PB-P-012	169	Ali, S.S.	HPS-P-058	127
Abdel Fattah, S.A.	LMCS-P-009	146	Ali, S.	HPS-P-059	127
Abdel Hady, S.S.	BB-P-022	165	Ali, A.	IPS-P-007	135
Abdel Hamid Ibrahim, A.I.E.	HPS-P-013	116	Aliaga, A.	CPS-P-023	93
Abdel moaty, M.	IPS-P-026	140	Alkofahi, A.	AS-O-001	76
Abdel salam, H.M.	IPS-P-026	140	Allam, A.N.	IPS-P-035	142
Abdelbary, A.	BB-P-002	160	Allam, A.N.	IPS-P-036	142
Abdelbary, G.	BB-P-002	160	Almarsdóttir, A.B.	CPS-P-084	108
Abdelbary, A.	BB-P-003	160	Alphonse, E.	CPS-P-058	102
Abdelbary, G.	BB-P-003	160	Al-Saffar, N.	APS-O-004	83
Abdel-Galil, A.A.M.	CBS-P-007	86	Alshaeqi, K.	CBS-P-005	86
Abdel-Lateff, A.A.M.	B S5-002	28	Altagracia-Martinez, M.	APS-P-002	79
Abdel-Lateff, A.L.	NS-P-001	177	Altagracia-Martinez, M.	APS-O-002	83
Abdelmaaboud, A.	BB-P-012	162	Altagracia-Martinez, M.	CPS-P-004	88
Abdou, Y.	IPS-P-038	143	Altubuly, Reda	CBS-P-005	86
Abdou, Y.	IPS-P-039	143	Al-Wazailiy, M.	AS-O-001	76
Abela, T.	CPS-P-072	105	Amaro, L.	CPS-P-008	89
Abou El Alamein, A.M.	LMCS-P-009	146	Amaro, L.	CPS-P-009	90
Abou El-Alamein, A.M.	LMCS-P-009	146	Amaro, L.	CPS-P-020	92
Aboul-Einien, M.H.	BB-P-013	163	Amaro, L.	PI-P-010	152
Aboumagd, E.	IPS-P-038	143	Amin, M.A.	B IPCD-003	69
Aburawi, S.M.	CBS-P-005	86	Amin, M.M.	PB-P-012	169
Aciu, M.	AS-P-001	72	Amirkhanyan, A.	AS-P-009	74
Aciu, M.	AS-P-002	72	Ammar, H.O.	BB-P-008	161
Aciu, M.	AS-P-006	73	Anderson, B.	CPS-P-030	95
Aciu, M.	APS-O-001	83	Anderson, C.W.	B G02-002	35
Aciu, M.	HPS-P-002	113	Anderson, C.W.	G02-001	36
Aciu, M.	HPS-P-003	113	Anderson, C.W.	B G13-002	60
Aciu, M.	HPS-P-004	113	Anderson, C.W.	G13-001	62
Aciu, M.	HPS-P-034	121	Antolovic-Amidzic, A.A-A.	HPS-P-015	116
Aciu, M.	LMCS-P-001	144	Antolovic-Amidzic, A.A-A.	HPS-P-019	117
Aciu, M.	PI-P-002	150	Antolovic-Amidzic, A.A-A.	HPS-P-020	117
Aciu, M.	PP-P-003	171	Antunes, C.	PI-P-013	153
Aciu, M.	PP-P-004	171	Aranda da Silva, J.A.	AS-O-007	77
Aciu, M.	NS-P-002	177	Archer, J.M.	AS-O-004	76
Aciu, M.	NS-P-014	180	Arhinful, K.	CPS-P-061	103
Aciu, M.	IM-P-002	182	Arteta, M.	CPS-P-020	92
Adedeji, A.O.	CPS-P-001	88	Asha, A.N	IPS-P-022	139
Adib, N.	IM-P-003	182	Ashour, O.	AS-P-004	72
Affli, N.N	BB-P-017	164	Ashour, O.	CBS-P-002	85
Ahmed, I.S.	PB-P-006	168	Ashour, O.	PI-P-001	150
Ahmed Abdelbary, A.	IPS-P-017	138	Asiri, Y.	B G03-002	37
Airaksinen, M.S.A.	B G02-001	35	Asiri, Y.	G03-001	38
Airaksinen, M.S.A.	B G07-005	46	Aslani, A.	HPS-P-008	114
Airaksinen, M.S.A.	G07-005	48	Åslund, B.	CPS-P-080	107
Airaksinen, M.S.A.	B G18-002	67	Austin, Z.	AS-P-007	73
Airaksinen, M.S.A.	G18-001	68	Avenati, T.	CPS-P-081	108
Airaksinen, M.S.A.	G18-002	68	Awad, A.	AS-O-002	76
Akita, H.	B S2-007	20	Awad, G.	BB-P-022	165
Akita, H.	S2-005	22	Awle, A.I.	MEPS-P-001	148
Al Sayed Hussain, A.	B G12-001	58	Ax, F.	CPS-P-078	107
Al Shafay, M.	BB-P-004	160	Ax, F.	CPS-P-080	107
Alaa, N.	HPS-P-026	119	Azzopardi, L.M.	AS-O-005	77

AUTHOR INDEX

Author	Code	Page	Author	Code	Page
Azzopardi, L.M.	CPS-P-071	105	Boateng, S.	G09-002	52
Azzopardi, L.M.	CPS-P-072	105	Bodiroga, M.	LMCS-P-015	147
Azzopardi, L.M.	PI-P-023	155	Bolduc, Y.	PP-P-001	171
Azzopardi, L.M.	PP-P-006	172	Bonny, O.M.	G09-003	52
Badri, Gh.	BB-P-015	163	Boonmongkon, P.	HPS-P-063	128
Baek, J.H.	QP-P-012	175	Boonmongkon, P.	HPS-P-064	128
Baek, J.H.	QP-P-013	178	Boraie, N.A.	IPS-P-008	135
Bahari Saravi, S.M.	NS-P-017	181	Boraie, N.A.	IPS-P-009	136
Bakhtiarian, A.	CBS-P-003	85	Boraie, N.A.	IPS-P-038	143
Bale, Jr., H.E.	B P2-004	7	Boraie, N.A.	IPS-P-039	143
Bale, Jr., H.E.	P2-004	8	Borsting, A.	CPS-P-042	98
Ball, D.E.	AS-O-002	76	Boskovic, M.	HPS-P-030	120
Ball, D.E.	APS-O-004	83	Bourdeau, G.B.	B G12-002	58
Bandal, R.S.	APS-P-005	80	Bourdeau, G.B.	G12-001	59
Barratt, S.McG.	HPS-P-008	114	Brånstad, J-O	CPS-P-078	107
Barrio, A.	CPS-P-020	92	Brånstad, J-O	CPS-P-080	107
Batel-Marques, F.	CPS-P-082	108	Bras, M.	CPS-P-032	95
Bates, I.	CPS-P-076	106	Brasseur, D.	PI-P-028	156
Baxter, R.C.	HPS-P-008	114	Brien, J.E.	G11-003	57
Beales, J.D.	AS-P-007	73	Brien, J.E.	HPS-P-018	117
Becket, G.	CPS-P-005	89	Brooks, G.	B S2-001	19
Behzadi, M.	HPS-P-023	118	Brooks, G.	S2-004	21
Bejenaru, L.	AS-P-002	72	Buabeng, K.O.	CPS-O-002	110
Bejenaru, L.	APS-O-001	83	Buabeng, K.O.	HPS-P-010	115
Bejenaru, L.	HPS-P-003	113	Buchmann, M.	CPS-P-069	105
Bejenaru, L.	HPS-P-004	113	Bugnon, O.	CPS-P-069	105
Bejenaru, L.	LMCS-P-001	144	Bugnon, O.	CPS-P-070	105
Bejenaru, L.	PP-P-003	171	Bugnon, O.	CPS-P-081	108
Bejenaru, L.	PP-P-004	171	Bugnon, O.	CPS-O-007	111
Bejenaru, L.	NS-P-002	177	Buil, P.	CPS-P-020	92
Bejenaru, L.	IM-P-002	182	Burnier, M.	CPS-P-081	108
Bell, S.	B G15-004	64	Bušelić, R.	CPS-P-064	103
Bell, S.	G15-003	66	Caldeira, C.	CPS-P-062	103
Bell, S.	G18-002	68	Calina, D.	AS-P-001	72
Benet, L.Z.	B P5-003	13	Calina, D.	AS-P-002	72
Benet, L.Z.	P5-002	14	Calina, D.	AS-P-006	73
Benrimoj, S.I.	CPS-O-009	112	Calina, D.	APS-O-001	83
Benson, H.A.E.	PB-P-001	167	Calina, D.	HPS-P-002	113
Benson, H.A.E.	PB-P-002	167	Calina, D.	HPS-P-003	113
Berbatis, C.G.	CPS-P-067	104	Calina, D.	HPS-P-004	113
Bergisadi, N.	BB-P-007	161	Calina, D.	HPS-P-034	121
Betz, G.	IPS-P-027	140	Calina, N.V.	HPS-P-034	121
Bhaskaran, S.	IPS-P-005	135	Calina, D.	LMCS-P-001	144
Bhaskaran, S.	IPS-P-022	139	Calina, D.	PI-P-002	150
Bheekie, A.	AS-P-013	75	Calina, D.	PP-P-003	171
Bica, A.	B S3-004	23	Calina, D.	PP-P-004	171
Bica, A.	S3-001	25	Calina, D.	NS-P-002	177
Bicknell, K.A.	S2-004	21	Calina, D.	NS-P-014	180
Bishay, D.B.	B S5-006	29	Calina, D.	IM-P-002	182
Bishay, D.B.	S5-004	30	Camilleri, M.	PI-P-023	155
Björnsdóttir, I.	CPS-P-084	108	Capan, Y.	B S1-007	16
Björnsdóttir, I.	CPS-P-085	109	Capan, Y.	S1-006	18
Blanc, A.	CPS-P-036	96	Capilla, P.C.	CPS-P-008	89
Blanchet, F.	CPS-P-036	96	Capilla, P.C.	CPS-P-009	90
Blanchet, F.	CPS-P-073	106	Capilla, P.C.	CPS-P-020	92
Blekic, J.	CPS-P-032	85	Capilla, P.	CPS-P-023	93

AUTHOR INDEX

Author	Code	Page	Author	Code	Page
Capilla, P.	PI-P-010	152	Chen, Y.	PB-P-001	167
Capps, P.	APS-O-004	83	Chen, Y.	PB-P-002	167
Carapinha, J.L.	B G15-005	85	Chen shyue yuan, R.	IPS-P-018	138
Carbonell, J.	CPS-P-008	89	Cheng, Y.D.	CBS-P-004	85
Carbonell, J.	CPS-P-009	90	Cheng, Y.D.	CBS-P-008	86
Carbonell, J.	CPS-P-020	92	Cheng, H.H.	CPS-P-054	101
Carbonell, J.	PI-P-010	152	Cheng, Y.D.	HPS-P-024	118
Carter, C.	HPS-P-033	121	Cheng, Y.D.	HPS-P-025	119
Castensson, S.B.	CPS-P-045	99	Cheng, T.S.	HPS-P-037	122
Castot, A.	CPS-P-073	106	Cheng, A.C.	HPS-P-041	123
Castro, L.L.C.	PI-P-024	155	Cheng, T.S.	HPS-P-060	127
Castro-Ramirez, V.R.	APS-O-002	83	Cheng, C.F.	HPS-P-072	130
Cater, C.N.	CPS-P-077	107	Cheng, Y.D.	HPS-P-077	132
Catizone, C.A.	B P1-004	4	Cheng, T.S.	NS-P-015	180
Chae, K.R.	QP-P-012	175	Chiang, S.C.	APS-P-012	81
Chae, K.R.	QP-P-013	176	Chiang, C.H.	HPS-P-041	123
Chaiyakunapruk, N.	CPS-P-013	91	Chiang, S.W.	HPS-P-041	123
Cham, T.M.	HPS-P-037	122	Chiang, J.	PI-P-026	156
Cham, T.M.	HPS-P-046	124	Chida, M.C.	HPS-P-050	125
Cham, T.M.	HPS-P-056	126	Chien, S.Y.	APS-P-009	81
Cham, T.M.	HPS-P-060	127	Chien, S.C.	APS-P-010	81
Chambuso, M.	LMCS-P-005	145	Chien, S.Y.	APS-P-010	81
Chan, Y.Y.	HPS-P-057	127	Chien, S.C.	HPS-P-014	116
Chan, Y.Y.	HPS-P-068	129	Chien, S.Y.	HPS-P-054	126
Chan, Y.Y.	HPS-P-079	132	Chin, F.S.	LMCS-P-010	146
Chan, Y.Y.	PP-P-002	171	Chou, Y.C.	HPS-P-041	123
Chang, H.J.	HPS-P-011	115	Chou, L.	HPS-P-068	129
Chang, C.Y.	HPS-P-041	123	Chuang, M.H.	HPS-P-022	118
Chang, M.H.	HPS-P-042	123	Clark, M.	CPS-P-058	102
Chang, H.C.	HPS-P-074	131	Clarke, L.	HPS-P-028	119
Chao, F.H.	HPS-P-041	123	Coelho, P.M.	B G02-004	35
Chen, Y.C.	AS-O-008	77	Cooper, J.	CPS-P-055	101
Chen, C.Y.	APS-P-004	79	Corona-Rojo, J.A.	CPS-P-004	88
Chen, K.C.S.	APS-P-007	80	Cornea-de-Araujo, R.	PI-O-002	158
Chen, C.H.	APS-P-009	81	Costa, S.	B G13-003	60
Chen, G.T.	APS-P-012	81	Costa, S.	G13-002	62
Chen, F.H.	CPS-P-012	90	Costa, F. A.	CPS-P-076	106
Chen, C.E.	CPS-P-031	95	Costa, F. A.	CPS-P-082	108
Chen, C.E.	CPS-P-033	96	Costa, F. A.	CPS-P-083	108
Chen, K.P.	CPS-P-033	96	Costa, F.	CPS-O-009	112
Chen, H.C.	CPS-P-052	100	Coucha, A.M.	IPS-P-031	141
Chen, Y.C.	CPS-P-052	100	Coucha, A.M.	IPS-P-032	141
Chen, C.Yu	CPS-P-054	101	Couto, S.	CPS-P-083	108
Chen, J.Y.	CPS-P-054	101	Crísóstomo, S.	CPS-P-082	108
Chen, W.J.	HPS-P-005	114	Crommelin, D.J.A.	B S2-005	20
Chen, Y.H.	HPS-P-005	114	Crommelin, D.J.A.	S2-003	21
Chen, C.H.	HPS-P-054	126	Crommelin, D.J.A.	S2-006	22
Chen, Y.S.	HPS-P-055	126	Cuddy, B.	B P4-002	11
Chen, H.M.	HPS-P-072	130	Cui, F.	IPS-P-024	139
Chen, J.S.	HPS-P-073	131	D' souza, A.A.	QP-P-004	173
Chen, J.Y.	HPS-P-078	132	D'Mello, P.M.	NS-P-006	178
Chen, L.W.	HPS-P-078	132	D'Souza, M.	CBS-P-009	87
Chen, H.Y.	HPS-P-079	132	Dahdal, W.Y.	AS-O-010	78
Chen, J.D.	HPS-P-082	133	Danagulyan, H.G.	CPS-P-056	101
Chen, C.Y.	LMCS-P-010	146	Danagulyan, H.G.	PI-P-019	154
Chen, N.	PI-P-026	156	Daners, M.	HPS-P-061	128

AUTHOR INDEX

Author	Code	Page	Author	Code	Page
Darwish, M.	HPS-P-026	119	Eghan, K.	CPS-P-061	103
Darwish, M.	HPS-P-062	126	Ekedahl, A.	CPS-P-045	99
Darwish, I.A.	IPS-P-038	143	El Gamal, S.S.	IPS-P-035	142
Darwish, I.A.	IPS-P-039	143	El Gamal, S.S.	IPS-P-036	142
Davey, A.K.	BB-P-005	161	EL Laithy, H.M.	IPS-P-017	136
Dawoud, D.M.	CPS-P-002	88	EL Laithy, H.M.	PB-P-012	169
Dawson, J.	G08-002	50	El Maghraby, G.M.M.	IPS-P-014	137
De Ancos, F.	CPS-P-020	92	El Maradny, H.	IPS-P-004	134
Delmas, J.L.	APS-P-016	82	El Massik, M.A.	IPS-P-001	134
Deng, S.T.	APS-P-012	81	El-Nabarawi, M.A.	IPS-P-029	141
Deng, S.T.	CBS-P-008	86	El Sawy, M.M.A.	CBS-P-007	86
Deng, S.T.	CPS-P-052	100	Elazazy, E.M.	B G12-003	58
Deng, S.T.	HPS-P-024	118	Elazazy, E.M.	G12-002	59
Deng, S.T.	HPS-P-025	119	Elbayomy, S.A.	LMCS-P-013	147
Deng, S.T.	HPS-P-042	123	Elfeky, G.S.F.	HPS-P-013	116
Deng, S.T.	HPS-P-044	123	El-Gazayerly, O.N.	IPS-P-011	136
Deng, S.T.	HPS-P-045	124	El-Gizawy, S.A.	BB-P-006	161
Deng, S.T.	HPS-P-052	125	El-Haggar, S.M.	BB-P-006	161
Deng, S.T.	HPS-P-071	130	Eihopishy, H.	CBS-P-005	86
Deng, S.T.	HPS-P-075	131	Elias, A.	LMCS-P-007	145
Deng, S.T.	QP-P-011	175	Elkhesen, S.A.	IPS-P-028	140
Deshmukh, R.	NS-P-003	177	Elkhesen, S.A.	BB-P-020	164
Deshpande, M.M.	APS-P-005	80	El-Khordagui, L.K.	IPS-P-008	135
Dhat, S.P.	AS-P-015	75	El-Khordagui, L.K.	IPS-P-009	136
Dhat, S.P.	CPS-P-006	89	El-Khordagui, L.K.	IPS-P-012	136
Dhat, S.P.	NS-P-018	161	El-Khordagui, L.K.	IPS-P-013	137
Diaz, W.	MEPS-P-004	148	El-Khordagui, L.K.	IPS-P-038	143
Digné, K.	CPS-P-039	97	El-Khordagui, L.K.	IPS-P-039	143
Djukic, L.	PI-P-030	157	El-Khordagui, L.K.	PB-P-008	168
Djukic, D.	NS-P-005	178	El-Khordagui, L.K.	PB-P-009	169
Djuric, T.	PI-P-015	153	El-Leithy, M.N.	LMCS-P-013	147
Djurovic, D.D.	PI-P-012	152	Ellis, J.J.	HPS-P-039	122
Dodoo, A.N.O.	B G09-001	51	Elmaraghy, S.A.	CBS-P-005	86
Dodoo, A.N.O.	G09-002	52	El-Nabarawi, M.A.	IPS-P-010	136
Dodoo, A.N.O.	G09-004	52	El-Samaligy, M.S.	BB-P-017	164
Dodoo, A.	CPS-P-061	103	El-Sayed, A.	IPS-P-008	135
Doolin, E.N.	HPS-P-070	130	El-Sayed, A.	IPS-P-009	136
Dorval, E.	PP-P-001	171	El-Sayed, M.A.	QP-P-005	174
Dowse, R.	B G07-002	45	Elshafeey, A.H.	BB-P-002	160
Dowse, R.	G07-002	47	Elshafeey, A.H.	BB-P-003	160
Dowse, R.	CPS-O-001	110	El-Wafa, A.A.A.	IPS-P-019	138
Dragojevic Curic, N.	CPS-P-057	102	Emerson, L.E.	B P3-003	9
Dreux, C.	CPS-P-036	96	Emerson, L.E.	P3-001	10
Dreux, C.	CPS-P-073	106	Enare, E.	CPS-P-039	97
Duggan, C.	CPS-P-078	106	Encinosa, W.	PI-O-002	158
Dukes, M.G.	B P5-002	13	Endou, C.	PI-P-027	156
Dukes, M.G.	P5-001	14	Enlund, H.	AS-O-002	76
Dyssegaard, A.D.	CPS-P-042	98	Eriksson, L.	CPS-P-079	107
Dzilnic, O.	LMCS-P-006	145	Etubiebi, W.O.	CPS-P-011	90
Dzilnic, O.	LMCS-P-006	145	Etubiebi, W.O.	CPS-P-011	90
Ebeid, Z.M.K.	BB-P-004	160	Everard, M.M.	B G10-004	53
Ecke, D.	CPS-P-005	89	Everard, M.M.	G10-003	55
Ed, B.S.	CPS-P-043	98	Ewen, M.A.	P2-001	8
Egan, E.E.	CPS-P-061	103	Fahey, M.	B G11-003	56
Eghan, E.	B P2-003	7	Fahey, M.	G11-002	57
Eghan, E.	P2-003	8	Fahim, A.T.	CBS-P-006	86

AUTHOR INDEX

Author	Code	Page	Author	Code	Page
Fahmy, R.H.	BB-P-011	162	Gaudiano, J.	NRP-P-002	166
Fahmy, R.H.	BB-P-012	162	Gauthier, C.	APS-O-008	84
Fahmy, R.H.	QP-P-003	173	Gayathri Devi, S.	IPS-P-003	134
Fahmy, O.T.	QP-P-007	174	Gayathri Devi, S.	IPS-P-006	135
Fahmy, O.	QP-P-008	174	Gazy, A.A.	QP-P-005	174
Fahmy, O.T.	QP-P-009	175	Gean, P.	IM-P-005	183
Farinha, A.	B S3-004	23	Gervais, A.	APS-O-008	84
Farinha, A.	S3-001	25	Gervais, A.	CPS-P-048	99
Fatahall, F.A.A.	B IPCD-001	69	Gervais, A.	MEPS-P-006	149
Fatahall, F.A.A.	IPCD-002	71	Ghorab, M.	IPS-P-026	140
Fatahalla, F.A.	PB-P-006	168	Ghorab, M.	BB-P-008	161
Fausto Ferreira, J.	AS-O-007	77	Ghous, Z.	APS-O-006	84
Favre, M.	CPS-P-081	108	Ghous, Z.	HPS-P-058	127
Fazly Bazzaz, B.S.	NS-P-017	181	Ghous, Z.	HPS-P-059	127
Fazly Bazzaz, B.S.	NS-P-017	181	Gibson, M.J.	CPS-P-065	104
Fedotova, I.F.	HPS-P-007	114	Gómez-Alejandro, R.	APS-O-002	83
Feng, C.H.	HPS-P-065	129	Gómez-Alejandro, R.	CPS-P-004	88
Fernandes, M.	PI-P-013	153	Goodyer, L.I.	CPS-P-002	88
Fernandez, D.	CPS-P-023	93	Goodyer, L.	HPS-P-016	116
Fernandez, D.	PP-P-006	172	Goodyer, L.	HPS-P-017	117
Ferreira, B.E.S.	CPS-P-063	103	Goud, R.S.	LMCS-P-014	147
Ferreira, G.	CPS-P-082	108	Gouda, N.M.Z.	QP-P-014	176
Ferreira, A.P.	CPS-P-083	108	Gouveia, V.	CPS-P-083	108
Figueiredo, H.F.	CPS-P-081	108	Gray, A.L.	B G04-002	39
Fonnesbæk, L.	CPS-P-037	97	Gray, A.L.	G04-002	40
Fonnesbæk Jensen, L.	CPS-P-042	98	Gray, A.L.	B G11-001	56
Forsén, A.M.	CPS-P-043	98	Grégoire, J-P	PP-P-001	171
Forsstrom, A.F.	B G10-001	53	Grigoryan, L.	PI-P-019	154
Fortuit, P.	CPS-P-075	106	Grønne, J.	CPS-P-040	97
Frempong, N.A.	B G09-004	51	Groves, S.V.	G08-002	50
Frempong, N.A.	G09-002	52	Groves, S.	NS-P-013	180
Friedel, H.D.	B S3-005	24	Grundler, A.	CPS-P-064	103
Friedel, H.D.	S3-002	25	Guénette, L.	PP-P-001	171
Frieslaar, D.F.	AS-P-013	75	Guerreiro, J.	PI-P-013	153
Frøkjær, B.	CPS-P-037	97	Guh, J.H.	PB-P-005	168
Fuentes, M.	CPS-P-008	89	Guignard Heftli, E.	CPS-P-070	105
Fuentes, M.	CPS-P-009	90	Gujar, K.N.	AS-P-015	75
Fuentes, M.	CPS-P-020	92	Gujar, K.N.	CPS-O-010	112
Fuentes, M.	PI-P-010	152	Gul, A.	APS-O-006	84
Fujii, M.	PB-P-004	167	Gungor, S.	BB-P-007	161
Gabhe, S.Y.	NS-P-003	177	Gunnarsson, C.	CPS-P-078	107
Gad, M.Z.	CBS-P-006	86	Gupta, G.D.	LMCS-P-014	147
Gad, M.Z.	CBS-P-006	86	Gustafsson, S.	CPS-P-078	107
Gallego, G.	B G05-002	41	Gustafsson, S.	CPS-P-080	107
Gallego, G.	G05	42	Gyansa-Lutterodt, M.	G09-002	52
Gallego, G.	B G11-004	56	Hadzidedic, S.	IPS-P-027	140
Gallego, G.	G11-003	57	Haigh, J.M.	BB-P-016	164
Gallego, G.	HPS-P-018	117	Haigh, J.M.	BB-P-021	165
Gallèli, J.	HPS-P-033	121	Haigh, J.M.	BB-P-023	165
Gariépy, Y.G.	B G15-003	64	Hajji, M.	LMCS-P-007	145
Gariépy, Y.G.	G15-001	66	Hakobyan, V.P.	HPS-P-006	114
Gau, C.S.	APS-P-013	82	Hall, F.	MEPS-P-003	148
Gau, C.S.	CPS-P-038	97	Hall, F.	MEPS-P-005	149
Gau, C.S.	CPS-P-052	100	Hamdy, MA	CBS-P-006	86
Gau, C.S.	PI-P-017	154	Hamdy, D.	HPS-P-026	119
Gau Mau-Shiung, M.S.	HPS-P-005	114	Hamdy, D.	HPS-P-062	128

AUTHOR INDEX

Author	Code	Page	Author	Code	Page
Hamdy, D.	QP-P-008	174	Horikawa, T.	HPS-P-012	115
Hammarlund-Udenaes, M.	CPS-P-021	93	Hosseinzadeh Ardakani, Y.	BB-P-015	163
Han, K.	PB-P-003	167	Houghton, P.J.	B S5-001	28
Hansen, R.D.	HPS-P-008	114	Hsiao, F.Y.	APS-O-005	84
Hansson, R.	B G01-001	32	Hsiao, D.J.	CPS-P-050	100
Hara, H.H.	AS-P-008	73	Hsiao, S.Y.	PI-P-017	154
Harashima, H.	B S2-007	20	Hsiao, F.Y.	PP-P-005	172
Harashima, H.	S2-005	22	Hsieh, M.C.	CBS-P-008	86
Harashima, H.	PB-P-010	169	Hsieh, Y.W.	CPS-P-052	100
Harish, C.G.	IPS-P-005	135	Hsieh, W.C.	HPS-P-031	120
Hartzema, A.G.	B G13-005	61	Hsieh, T.Y.	HPS-P-069	130
Hartzema, A.G.	G13-004	62	Hsieh, M.C.	HPS-P-077	132
Harutyunyan, H.CH.	CPS-P-056	101	Hsieh, Y.W.	HPS-P-077	132
Harutyunyan, H.CH.	PI-P-019	154	Hsing, Y.P.	HPS-P-047	124
Hashem, F.M.	BB-P-004	160	Hsiung, C.H.	NS-P-008	178
Hashimoto, A.H.	HPS-P-051	125	Hsiu, S.L.	PB-P-005	168
Hassan, E.	QP-P-008	174	Hsu, Y.M.	APS-P-004	79
Hassanin, S.	HPS-P-026	119	Hsu, J.	BB-P-016	163
Hassanin, S.	HPS-P-082	128	Hsu, K.Y.	BB-P-016	163
Hayakawa, T.	PB-P-004	167	Hsu, L.F.	NS-P-008	178
Hayase, Y.H.	CPS-P-003	88	Hu, O.	NS-P-008	178
Hedaya, M.A.	BB-P-006	161	Huang, W.F.	APS-O-005	84
Helbo, A.H.	CPS-P-029	95	Huang, L.	CPS-P-031	95
Hellebek, A.M.	CPS-P-047	99	Huang, L.	CPS-P-038	97
Helmy, M.	CBS-P-007	86	Huang, L.J.	CPS-P-052	100
Heltzer, N.	CPS-P-058	102	Huang, L.	CPS-O-006	111
Hemanth, P.J.	IPS-P-005	135	Huang, M.J.	HPS-P-036	121
Henell, U.M.	CPS-P-022	93	Huang, H.C.	HPS-P-067	129
Herborg, H.	B R2-002	1	Huang, C.L.	HPS-P-069	130
Herborg, H.	CPS-P-037	97	Huang, W.T.	HPS-P-072	130
Herborg, H.	CPS-P-047	99	Huang, C.M.	HPS-P-073	131
Herrida, J.C.	NRP-P-001	166	Huang, C.M.	HPS-P-074	131
Herradón, J.	CPS-P-008	89	Huang, L.J.	HPS-P-078	132
Herradón, J.	CPS-P-009	90	Huang, C.M.	HPS-P-083	133
Herradón, J.	CPS-P-020	92	Huang, W.F.	PP-P-005	172
Herradón, J.	PI-P-010	152	Huang, M.H.	NS-P-015	180
Hidalgo, T.	CPS-P-020	92	Hubbard, J.W.	S1-002	17
Hikal, A.	IPS-P-004	134	Hubbell, E.	PB-P-011	169
Hildgen, P.	QP-P-014	176	Hukkeri, V.I.	CBS-P-009	87
Hill, P.W.	CPS-O-001	110	Hukkeri, V.I.	NS-P-004	177
Hindi-Alexander, M.	PI-O-002	158	Hukkeri, V.I.	IM-P-004	182
Hirano, M.	AS-P-005	73	Hussein, G.	AS-O-011	78
Hisakazu, S.	IPS-P-020	138	Hussein, G.	PI-O-006	159
Ho, C.C.	HPS-P-041	123	Hussieni, F.	IM-P-001	182
Hogerzell, H.V.	B P1-003	4	Hwei, D.Z.	APS-P-008	80
Hogerzell, H.V.	P1-001	6	Ibrahim, M.Y.M.	B IPCD-004	69
Hogerzell, H.V.	B P2-001	7	Ichikawa, N.	G04-001	40
Holland, R.W.	B R2-001	1	Ichikawa, N.	HPS-P-021	118
Holland, R.W.	R2-001	3	Idun, J.	CPS-P-061	103
Hoime Christensen, K.	AS-O-006	77	In J., S.	HPS-P-066	129
Hong, J.R.	APS-P-010	81	Inagaki, S.	AS-P-005	73
Hong, L.L.	QP-P-011	175	Inagaki, S.	HPS-P-012	115
Honrao, M.S.	AS-P-015	75	Isawa, M.I.	CPS-P-018	92
Honrao, M.S.	CPS-P-006	89	Ismail, H.I.	AS-P-004	72
Honrao, M.S.	CPS-O-010	112	Ismail, H.I.	CBS-P-002	85
Honrao, M.S.	NS-P-018	181	Ismail, F. A.	IPS-P-008	135

AUTHOR INDEX

Author	Code	Page	Author	Code	Page
Ismail, F. A.	IPS-P-009	136	Karim, A.M.	B S2-003	19
Ismail, H.I.	PI-P-001	150	Karim, A.M.	S2-001	21
Itoh, I.H.	CPS-P-018	92	Kariyazono, H.	HPS-P-081	133
Iwamoto, K.	HPS-P-040	122	Kartasasmita, R.E.	QP-P-002	173
Iwamoto, K.	HPS-P-076	131	Kassam, R.	CPS-P-048	99
Iwase, H.	HPS-P-076	131	Kassem, M.A.	AS-P-004	72
Izumisawa, M.I.	PI-O-003	158	Kassem, M.A.	CBS-P-002	85
Jadhav, S.B.	CPS-P-006	89	Kassem, M.A.	PI-P-001	150
Jadhav, S.B.	NS-P-018	181	Kassem, M.A.	BB-P-011	162
Jaiprakash, B.	IM-P-004	182	Kassem, M.A.	BB-P-012	162
Jakimavicius, M.	LMCS-P-002	144	Kato, H.K.	HPS-P-051	125
Jakimavicius, M.J.	LMCS-P-002	144	Kause, J.	CPS-P-028	94
Jallow, A.J.	CPS-P-010	90	Kazaryan Ghazaryan, I.	AS-P-009	74
Jallow, A.J.	CPS-O-003	110	Kazaryan Ghazaryan, I.	APS-P-011	81
Jani, G.K.	LMCS-P-014	147	Kazaryan Ghazaryan, I.	PI-P-004	150
Jansen, H.S.	B IPCD-005	70	Kearney, M.	CPS-P-048	99
Jayakar, B.	CPS-P-060	102	Kearney, M.	MEPS-P-006	149
Jebbar, A.H.	PI-O-001	158	Kee, A.J.	HPS-P-008	114
Jiang, R.L.	HPS-P-024	118	Kehraus, S.K.	NS-P-001	177
Jiang, R.L.	HPS-P-025	119	Keitel, S.K.	B S3-001	23
Jimenez, E.	CPS-P-020	92	Kelani, K.M.	LMCS-P-009	146
Joda, A.E.	CPS-P-068	104	Kelani, K.M.	LMCS-P-013	147
Johansson, H.	CPS-P-045	99	Kennedy, J.	HPS-P-028	119
Johnson, K.W.	B P4-001	11	Keyer Uysal, M.	BB-P-007	161
Johnson, K.W.	B G06-002	43	Khachatryan, V.	APS-P-011	81
Johnson, K.W.	G06-001	44	Khairy, L.	IPS-P-031	141
Johnson, K.	PI-P-009	152	Khairy, L.	IPS-P-032	141
Johnson, K.	PI-P-011	152	Khalafallah, N.A.	IPS-P-012	136
Joshi, V.M.	IPS-P-037	143	Khalafallah, N.A.	IPS-P-013	137
Jukic, M.	CPS-P-032	95	Khalafallah, N.A.	PB-P-008	168
Jung, M.J.	QP-P-012	175	Khalafallah, N.A.	PB-P-009	169
Jung, M.J.	QP-P-013	176	Khalifa, M.M.	AS-P-004	72
Junginger, H.E.	B S1-006	16	Khalifa, A.E.	AS-P-011	74
Junginger, H.E.	S1-005	18	Khalifa, M.M.	CBS-P-002	85
Junginger, H.E.	IPS-P-002	134	Khalifa, M.M.	PI-P-001	150
Jurlina, S.	IPS-P-023	139	Khalil, S.A.	IPS-P-008	135
Juzenas, M.	LMCS-P-002	144	Khalil, S.A.	IPS-P-009	136
Kaaril, L.K.	CPS-P-042	98	Khalil, S.A.	IPS-P-012	136
Kabasakal, L.	BB-P-007	161	Khalil, S.A.	IPS-P-013	137
Kairu, S.M.	MEPS-P-001	148	Khalil, S.A.	PB-P-008	168
Kalala, W.	G06-003	44	Khalil, S.A.	PB-P-009	169
Källemark-Sporrong, S.	CPS-P-039	97	Khalil, I.A.	PB-P-010	169
Kamei, H.	AS-P-005	73	Khambhojja, K.M.	NS-P-006	178
Kamel, O.	IPS-P-004	134	Khamis, E.F.	QP-P-005	174
Kamel Mohamed, O.H.	CPS-O-005	111	Khan, T.A.	NS-P-003	177
Kamiya, H.	B S2-007	20	Khattab, I.	IPS-P-028	140
Kamiya, H.	S2-005	22	Khattab, I.	BB-P-020	164
Kanai, R.	HPS-P-076	131	Khayyal, M.T.	B S5-007	29
Kane, M.L.L.	CPS-O-004	110	Khayyal, M.T.	S5-005	31
Kane, R.N.	CPS-O-010	112	Khoza, S.	G06-003	44
Kang, Y.	CPS-P-021	93	Kim, J.S.	QP-P-012	175
Kania, R.	QP-P-002	173	Kim, M.J.	QP-P-012	175
Kansanaho, H.	G18-002	68	Kim, M.K.	QP-P-012	175
Kao Yang, Y.H.	HPS-P-011	115	Kim, J.S.	QP-P-013	176
Karadi, R.V.	NS-P-004	177	Kim, M.J.	QP-P-013	176
Karadi, R.V.	IM-P-004	182	Kim, M.K.	QP-P-013	176

AUTHOR INDEX

Author	Code	Page	Author	Code	Page
Kirby, B.	PI-P-021	155	Lai, H.C.	HPS-P-069	130
Kitkannakorn, N.	PI-P-029	157	Lai, S.H.	HPS-P-069	130
Kleppin, S.M.	B G10-002	53	Lai, M.C.	NS-P-015	180
Kleppin, S.M.	G10-001	55	Lakshmi, P.K.	IPS-P-003	134
Klinke, B.K.	CPS-P-074	106	Lakshmi, P.K.	IPS-P-005	135
Knapp, P.R.	CPS-P-065	104	Lakshmi, P.K.	IPS-P-006	135
Knapp, P.	PI-O-001	158	Lakshmi, P.K.	PI-P-005	151
Knudsen, M.S.	CPS-P-047	99	Lakshmi, P.K.	PI-P-006	151
Knudsen, P.	CPS-P-047	99	Lan, T.H.	HPS-P-037	122
Kocic Pesic, V.	CPS-P-015	91	Lan, T.H.	HPS-P-060	127
Kocova El-Arini, S.	IPS-P-027	140	Larsen, M.	CPS-P-040	97
Kofod, S.K.	CPS-P-053	101	Larsson, H.	CPS-P-079	107
Koga, N.K.	HPS-P-051	125	Lau, Y.J.	HPS-P-069	130
Kogure, K.	B S2-007	20	Laue, von, S.	B S5-004	28
Kogure, K.	S2-005	22	Laue, von, S.	S5-001	30
Kogure, K.	PB-P-010	169	Lauemoeller, C.L.	CPS-P-007	89
Koizumi, N.	PB-P-004	167	Layloff, T.	LMCS-P-004	144
Komokata, T.	HPS-P-081	133	Layloff, T.	LMCS-P-005	145
Kondo, N.K.	HPS-P-051	125	Layloff, T.	LMCS-P-007	145
Kondoh, M.	PB-P-004	167	Layloff, T.	LMCS-P-008	145
König, G.M.	NS-P-001	177	Lee, H.L.	CPS-P-031	95
Konishi, K.	IPS-P-021	139	Lee, H.L.	CPS-P-033	96
Korany, H.M.	QP-P-003	173	Lee, Y.H.	CPS-P-033	96
Korzth, I.V.	HPS-P-007	114	Lee, Y.S.	CPS-P-035	96
Kosaras, B.	PI-O-005	159	Lee, S.P.	CPS-P-046	99
Kose, N.	CPS-P-021	93	Lee, Ch.	HPS-P-022	118
Kothare, S.	NS-P-003	177	Lee, S.P.	HPS-P-037	122
Kowero, O.	LMCS-P-003	144	Lee, C.H.	HPS-P-041	123
Kowero, O.	LMCS-P-005	145	Lee, C.Y.	HPS-P-041	123
Kowero, O.	LMCS-P-007	145	Lee, L.S.	HPS-P-041	123
Kowero, O.	LMCS-P-008	145	Lee, P.Y.	HPS-P-047	124
Kozjek, F.	LMCS-P-011	146	Lee, D.K.	HPS-P-053	126
Kozjek, F.	LMCS-P-012	146	Lee, E.K.	HPS-P-053	126
Krähenbühl, J.M.	CPS-O-007	111	Lee, D.K.	HPS-P-055	126
Kraushaar, H.	PI-O-005	159	Lee, E.K.	HPS-P-055	126
Kravzov-Jlnich, J.	APS-P-002	79	Lee, D.K.	HPS-P-056	126
Kravzov-Jlnich, J.	APS-O-002	83	Lee, E.K.L.	HPS-P-056	126
Krick, A.K.	NS-P-001	177	Lee, S.P.	HPS-P-060	127
Krishna Murthy, G.	NS-P-004	177	Lee, C.H.	HPS-P-075	131
Krishna Murthy, G.	IM-P-004	182	Lee, D.K.	HPS-P-080	132
Kubota, A.K.	HPS-P-050	125	Lee, E.K.	HPS-P-080	132
Kubota, A.K.	HPS-P-051	125	Leelamanit, W.	IPS-P-002	134
Kume, A.	HPS-P-009	115	Leem, D.G.	QP-P-012	175
Kume, T.	HPS-P-009	115	Leem, D.G.	QP-P-013	176
Kuo, W.Y.	HPS-P-027	119	Lepage, H.	CPS-O-008	111
Kuo, C.W.	HPS-P-073	131	Leuenberger, H.	IPS-P-027	140
Kuo, P.C.	NS-P-008	178	Li, J.H.	AS-P-003	72
Kushida, K.	CPS-P-027	94	Lian, J.H.	HPS-P-074	131
Kyoung, P.	HPS-P-066	129	Liao, C.C.	HPS-P-077	132
Laboula, I.M.	HPS-P-001	113	Liao, C.H.	NS-P-010	179
Ladavac, M.	CPS-P-032	95	Liao, L.F.	NS-P-010	179
Lai, L.	APS-P-001	79	Lien, J.M.	CPS-P-012	90
Lai, Y.Y.	CBS-P-008	86	Lien, J.M.	HPS-P-005	114
Lai, M.C.	CPS-P-046	99	Lien, J.M.	HPS-P-074	131
Lai, H.S.	HPS-P-005	114	Lien, J.M.	HPS-P-083	133
Lai, M.C.	HPS-P-046	124	Lin, Y.S.	APS-P-006	80

AUTHOR INDEX

Author	Code	Page	Author	Code	Page
Lin, C.S.	APS-P-012	81	Mahgoub, H.A.	QP-P-005	174
Lin, T.H.	CBS-P-004	85	Mahmoud, A.	BB-P-008	161
Lin, L.J.	CPS-P-012	90	Mahmoud, A.A.	BB-P-008	161
Lin, S.R.	CPS-P-054	101	Mahmoud, E.A.	BB-P-017	164
Lin, F.Y.	HPS-P-005	114	Majstorovic, Lj.	CPS-P-032	95
Lin, L.J.	HPS-P-005	114	Malcom, K.	MEPS-P-001	148
Lin, M.T.	HPS-P-005	114	Malesic, I.	LMCS-P-011	146
Lin, C.Y.	HPS-P-011	115	Malesic, I.	LMCS-P-012	146
Lin, Y.Y.	HPS-P-014	116	Malmqvist, S.	CPS-P-059	102
Lin, L.I.	HPS-P-022	118	Manasse, H.R.	B P5-001	13
Lin, C.L.	HPS-P-025	119	Manavalan, R.	AS-P-012	74
Lin, C.C.	HPS-P-053	126	Manohara, K.P.	NS-P-004	177
Lin, C.C.	HPS-P-055	126	Manohara, K.P.	IM-P-004	182
Lin, C.C.	HPS-P-056	126	Mansour, A.	QP-P-001	173
Lin, H.Y.	HPS-P-067	129	Mao, C.T.	HPS-P-044	123
Lin, H.Y.	HPS-P-072	130	Mao, C.T.	HPS-P-045	124
Lin, C.C.	HPS-P-080	132	Mao, C.M.	HPS-P-053	126
Lin, C.C.	NS-P-010	179	Mao, C.M.	HPS-P-055	126
Linaza, I.	CPS-P-008	89	Mao, C.M.	HPS-P-056	126
Linaza, I.	CPS-P-009	90	Mao, C.M.	HPS-P-080	132
Linaza, I.	CPS-P-020	92	Mariko, T.	CPS-P-021	93
Linaza, I.	PI-P-010	152	Mariko, N.	IPS-P-020	138
Lindberg, M.	CPS-P-039	97	Markovic, V.	LMCS-P-015	147
Lindborg, K.	CPS-P-045	99	Marsden, A.	CPS-P-061	103
Liou, W.S.	APS-P-003	79	Martins, A.P.	CPS-P-082	108
Liou, W.S.	HPS-P-082	133	Masako Chiba, M.C.	CPS-P-003	88
Liu, H.Y.	CBS-P-004	85	Mashally, S.A.	HPS-P-026	119
Liu, T.Y.	HPS-P-031	120	Mashally, S.A.	HPS-P-082	128
Lo, Y.N.	AS-O-008	77	Matowe, L.K.	HPS-P-010	115
Lo, Y.N.	CPS-P-038	97	Matsuba, K.M.	AS-P-005	73
Lo, Y.C.	CPS-P-050	100	Matsumoto, K.	HPS-P-043	123
Lo, Y.N.	CPS-P-052	100	Mauga, E.	LMCS-P-005	145
Lo, Y.N.	CPS-O-006	111	Mbwasi, R.	CPS-P-058	102
Locca, J.F.	CPS-P-069	105	McCaw, B.	AS-P-014	75
Lopez, P.	CPS-P-020	92	McClure, L.	B G05-001	41
López, J.	NRP-P-002	166	McClure, L.	B G06-003	43
Lovrek, V.	CPS-P-019	92	McClure, L.	G06-002	44
Lu, M.I.	AS-P-003	72	McClure, L.	B G09-002	51
Lu, Y.M.	HPS-P-073	131	McElnay, J.	B R2-005	2
Lualon, W.	PB-P-007	168	McElnay, J.C.	AS-P-014	75
Lui, W.Y.	HPS-P-041	123	McFadyen, J.E.	PI-P-016	153
Lusina, M.	IPS-P-023	139	Mdhluli, M.	BB-P-014	163
Lyttingsmo, S.	PI-O-004	158	Medema, J.K.	G08-001	50
Lynge, M.	CPS-P-037	97	Medic-Saric, M.	CPS-P-019	92
Ma, J.	CPS-P-048	99	Meek, W.A.	CPS-P-024	93
Ma, J.	MEPS-P-002	148	Meek, W.A.	CPS-P-055	101
Ma, J.	MEPS-P-003	148	Melkonyan, K.V.	HPS-P-006	114
Ma, J.	MEPS-P-005	149	Melo, V.A.	PI-P-024	155
Ma, C.	MEPS-P-006	149	Mendes, Z.	CPS-P-082	108
Ma, J.	MEPS-P-008	149	Mensah, D.	CPS-P-061	103
Macheras, P.	B S3-003	23	Meštrović, A.	CPS-P-064	103
Mahajan, K.	NS-P-003	177	Metwa, F.H.	LMCS-P-013	147
Maher, M.	HPS-P-026	119	Mfuko, W.	LMCS-P-007	145
Maher, M.	HPS-P-062	128	Mfuko, W.	LMCS-P-008	145
Maher, H.M.	QP-P-003	173	Miah, M.A.	PB-P-003	167
Mahgoub, H.M.	QP-P-003	173	Michitaka, O.	CPS-P-021	93

AUTHOR INDEX

Author	Code	Page	Author	Code	Page
Midha, K.K.	B S1-001	15	Nakamura, T.	HPS-P-021	118
Midha, K.K.	S1-002	17	Nakamura, Y.	HPS-P-021	118
Mihajlovic, G.M.	PI-P-018	154	Nakamura, K.	HPS-P-081	133
Miho Murakami, M.M.	CPS-P-003	88	Nakamura, N.	HPS-P-081	133
Mihoci, M.	IPS-P-023	139	Nakanishi, T.	PB-P-004	167
Milosevic Kostadinovic, K.	APS-P-008	80	Nakashima, M.	G04-001	40
Milosevic Kostadinovic, K.	CPS-P-057	102	Nakashima, E.	CPS-P-018	92
Milosevic Kostadinovic, K.	NS-P-016	180	Nakashima, E.	CPS-P-021	93
Milovanovic, Lj.	LMCS-P-006	145	Nakashima, M.	HPS-P-021	118
Minae, M.I.	CPS-P-021	93	Nanaumi, Y.N.	CPS-P-041	98
Miyagoe, T.	HPS-P-043	123	Nanaumi, Y.N.	CPS-P-051	100
Miyauchi, K.	HPS-P-043	123	Nanaumi, Y.N.	PI-P-020	154
Mizuguchi, H.	PB-P-004	167	Naokata Shimizu, N.S.	PI-O-003	158
Mockute, R.	LMCS-P-002	144	Naora, K.	HPS-P-040	122
Mohamed Sherif Mokhta, M.S.M.	HPS-P-013	116	Naora, K.	HPS-P-076	131
Mohammed Safwat, N.A.S.	HPS-P-016	116	Nappinnai, M.	AS-P-012	74
Mohammed Safwat, N.A.S.	HPS-P-017	117	Nappinnai, M.	CPS-P-034	96
Mohanty, S.G.	NS-P-011	179	Narayana, T.V.	CBS-P-009	87
Moisan, J.	PP-P-001	171	Narayana, T.V.	NS-P-004	177
Mokheri, M.	BB-P-015	163	Narayana, T.V.	IM-P-004	182
Mokhtar, H.	QP-P-001	173	Närhi, M.T.	CPS-P-022	93
Molokhia, A.M.	B S2-002	19	Nasr, M.M.	B S4-002	26
Moneeb, M.S.	QP-P-007	174	Nasr, M.M.	S4-001	27
Moneeb, M.S.	QP-P-009	175	Nasra, M.A.	IPS-P-001	134
Moody, K.G.	B G07-004	45	Naves, J.O.S.	PI-P-024	155
Moody, K.G.	G07-004	47	Ndomondo-Sigonda, M.	B P4-004	11
Moraes, de, L.B.	PI-P-025	156	Ndomondo-Sigonda, M.	P4-001	12
Morgall Traulsen, J.	CPS-P-074	106	Ndomondo-Sigonda, M.	LMCS-P-003	144
Moriuchi, H.	MEPS-P-007	149	Ndomondo-Sigonda, M.	LMCS-P-003	144
Mortada, S.	IPS-P-004	134	Ndomondo-Sigonda, M.	LMCS-P-004	144
Mortada, N.D.	IPS-P-031	141	Ndomondo-Sigonda, M.	LMCS-P-004	144
Mortada, N.D.	IPS-P-032	141	Ndomondo-Sigonda, M.	LMCS-P-005	145
Mortada, N.D.	BB-P-022	165	Ndomondo-Sigonda, M.	LMCS-P-005	145
Mortensen, B.	CPS-P-037	97	Ndomondo-Sigonda, M.	LMCS-P-007	145
Mortensen, A.R.	CPS-P-047	99	Ndomondo-Sigonda, M.	LMCS-P-007	145
Mosha, E.	LMCS-P-003	144	Ndomondo-Sigonda, M.	LMCS-P-008	145
Mosha, E.	LMCS-P-005	145	Ndomondo-Sigonda, M.	LMCS-P-008	145
Mosha, E.	LMCS-P-007	145	Ndomondo-Sigonda, M.	PI-O-005	159
Mostafa, D.A.A.	CPS-P-016	91	Neamtu, J.	PP-P-003	171
Motero, M.	CPS-P-020	92	Neamtu, J.	NS-P-002	177
Mshana, L.	LMCS-P-007	145	Nemtsova, V.D.	HPS-P-007	114
Msuya, Z.	LMCS-P-003	144	Ngassapa, O.	LMCS-P-005	145
Msuya, Z.	LMCS-P-004	144	Ngo, S.N.T.	BB-P-005	161
Msuya, Z.	LMCS-P-005	145	Nguyen, Y.H.	B G18-001	67
Msuya, Z.	LMCS-P-007	145	Nicholl, E.	AS-O-005	77
Msuya, Z.	LMCS-P-008	145	Nicholson, M.J.	B G09-003	51
Muganga, R.	BB-P-014	163	Nicholson, M.J.	G09-001	52
Mursi, N.M.	IPS-P-019	138	Nicolcescu, P.	HPS-P-034	121
Muzzin, L.J.	AS-P-010	74	Nicolcescu, P.	NS-P-014	180
Nabil, N.	HPS-P-001	113	Nicolet, V.	CPS-O-007	111
Nafadi, M.M.	PB-P-006	168	Nimmo, C.M.	B R2-007	2
Naggar, V.F.	IPS-P-001	134	Nimpitakpong, P.	CPS-P-013	91
Naggar, V.F.	IPS-P-035	142	Niquille, A.	CPS-P-070	105
Naggar, V.F.	IPS-P-036	142	Nishida, K.	HPS-P-021	118
Nagy, H.A.	QP-P-003	173	Nishimura, N.	HPS-P-040	122
Nakamura, J.	HPS-P-021	118	Nishimura, N.	HPS-P-076	131

AUTHOR INDEX

Author	Code	Page	Author	Code	Page
Nogueira, A.	PI-P-013	153	Peterson, M.B.	IPS-P-002	134
Nogueira, A.M.	PI-P-013	153	Pettersson, S.G.	CPS-P-014	91
Nordqvist, M.	CPS-P-080	107	Petrova, G.I.	APS-P-008	80
Norelius, M.	CPS-P-066	104	Phadnis, A.	NS-P-012	179
Nørregård, S.	CPS-P-037	97	Phumtim, G.	PI-P-009	152
Norris, P.	AS-O-002	76	Phumtim, G.	PI-O-005	159
Norris, P.T.	CPS-P-005	89	Piange-Rhule, J.	HPS-P-010	115
Nounou, M.M.	IPS-P-012	136	Plant, E.A.	B G10-003	53
Nounou, M.M.	IPS-P-013	137	Plant, E.A.	G10-002	55
Nounou, M.M.	PB-P-008	168	Poeaknapo, C.	QP-P-006	174
Nounou, M.M.	PB-P-009	169	Polnok, A.	IPS-P-002	134
Nour, S.A.	IPS-P-028	140	Popescu, F.	AS-P-001	72
Nour, S.A.	BB-P-020	164	Popescu, F.	NS-P-002	177
Nummela, L.	CPS-P-028	94	Popescu, F.	IM-P-002	182
Nwogalanya, F.O.	CPS-P-011	90	Poston, J.	CPS-P-024	93
Nyeura, E.	LMCS-P-007	145	Pozalic Frketic, L.	IPS-P-023	139
Nylander, E.	CPS-P-039	97	Preeprame, S.	NS-P-007	178
Odin-Liljedahl, K.	CPS-P-059	102	Price, S.	PI-O-001	158
Ofori-Adjei, D.	CPS-P-061	103	Pundech, A.	NS-P-007	178
Ognjanovic, J.	LMCS-P-015	147	Purdon, C.H.	BB-P-023	165
Olso, S.	HPS-P-043	123	Putalun, W.	PB-P-013	170
Okafor, U.G.	CPS-P-001	88	Puumalainen, I.	G18-002	68
Okazaki, O.O.	HPS-P-051	125	Radonjic, V.	PI-P-003	150
Oliveira Filho, J.B.	PI-P-024	155	Raju, H.V.	CBS-P-009	87
Olmos, V.	HPS-P-061	128	Ramesh, C.	AS-O-003	76
Omar, A.G.	CBS-P-007	86	Ramesh, M.	PI-P-005	151
Ombaka, E.M.A.	B P1-005	5	Ramesh, M.	PI-P-006	151
Ombaka, E.M.A.	P1-002	6	Ramesh, R.	NS-P-004	177
On, A.W.F.	CPS-P-031	95	Ramesh, R.	IM-P-004	182
Orii, T.	HPS-P-066	129	Ramirez-Camacho, A.	CPS-P-004	88
Orii, T.	HPS-P-070	130	Ramos, F.	AS-O-007	77
Orozovic, A.	CPS-P-017	92	Ramtoola, Z.	PI-P-021	155
Orozovic, A.	HPS-P-035	121	Ramtoola, Z.	PI-P-022	155
Orozovic, A.	LMCS-P-015	147	Raposo, C.	CPS-P-020	92
Osada, K.	PI-P-027	156	Rathore, K.	LMCS-P-014	147
Oshima, T.O.	PI-P-014	153	Ray, C.Y.	HPS-P-071	130
Osman, H.	HPS-P-026	119	Raynor, D.K.	CPS-P-065	104
Osman, H.	HPS-P-062	128	Raynor, D.K.	PI-O-001	158
Otero, M.J.	CPS-P-020	92	Raza, S.S.	APS-O-006	84
Pai, S.Y.	CPS-P-052	100	Raza, S.S.	HPS-P-032	120
Pao, J.B.	HPS-P-082	133	Raza, S.S.	HPS-P-058	127
Paolino, A.	NRP-P-001	166	Raza, S.S.	HPS-P-059	127
Paolino, A.	NRP-P-002	166	Reddy, P.	G07-005	48
Park, J.Y.	QP-P-012	175	Retief, J.D.	PB-P-011	169
Parojcic, D.	AS-O-009	78	Rhee, J.D.	PB-P-003	167
Parojcic, D.	CPS-P-057	102	Ricca, M.	MEPS-P-004	148
Parthasarathi, G.	PI-P-005	151	Risha, P.	LMCS-P-004	144
Parthasarathi, G.	PI-P-006	151	Risha, P.	LMCS-P-005	145
Patnaik, R.	S1-002	17	Risha, P.	LMCS-P-007	145
Paulino, E.I.	CPS-O-009	112	Risha, P.	PI-O-005	159
Pavlovic, L.	CPS-P-077	107	Roberts, A.S.	B R2-003	1
Peña, C.	CPS-P-008	89	Rodrigues, V.	CPS-P-082	108
Peña, C.	CPS-P-009	90	Rosales-Romero, V.G.	APS-P-002	79
Peña, C.	CPS-P-020	92	Ross-Degnan, D.	CPS-P-049	100
Peña, C.	PI-P-010	152	Rostom, O.K.	B P3-002	9
Pertovaara, A.M.	CPS-P-044	98	Rosu, L.	HPS-P-034	121

AUTHOR INDEX

Author	Code	Page	Author	Code	Page
Rosu, L.	NS-P-014	180	Savadi, R.V.	NS-P-004	177
Rouini, M.R.	BB-P-015	163	Savadi, R.V.	IM-P-004	182
Rouini, M.	BB-P-019	164	Savio, E.O.	NRP-P-001	166
ROULEAU, A.	CPS-P-073	106	Savio, E.O.	NRP-P-002	166
Rouse, M.J.	B G03-001	37	Sävneby Berit, B.S.	CPS-O-003	110
Rowland, M.	B S1-003	15	Sawa, T.S.	HPS-P-050	125
Rowland, M.	S1-001	17	Sawant, S.D.	AS-P-015	75
Roy, M.	NS-P-013	180	Sawant, S.D.	CPS-O-010	112
Rubio Garcia, R.	BB-P-001	160	Schaafsma, E.	G18-002	68
Rubio-Poo, M.	APS-P-002	79	Schaefer, M.A.	B G13-001	60
Ruggli, M.	CPS-P-069	105	Schaffalitzky, H.U.	CPS-P-037	97
Ryan, K.M.	B G01-004	32	Schajquevich, P.S.	BB-P-001	160
Ryan, K.M.	G01-002	34	Schilling Hansen, T.S.	AS-O-006	77
Ryan, J.	G08-001	50	Schneider, P.J.	B P1-001	4
Saad, E.I.	CBS-P-007	86	Schneider, M.P.	CPS-P-070	105
Saad, H.	HPS-P-026	119	Schneider, M.P.	CPS-P-081	108
Saad, H.	HPS-P-062	128	Schulz, M.	B R2-004	1
Sabeti Noghabi, Z.	NS-P-017	181	Segal, R.	G13-004	62
Sabra, K.	B G10-005	54	Sehic, S.	IPS-P-027	140
Sabra, K.	G10-004	55	Seier, J.	BB-P-014	163
Sabra, K.	HPS-P-028	119	Seimersom, M.	CPS-P-039	97
Sabra, K.	HPS-P-033	121	Sensui, S.R.	HPS-P-050	125
Sabri, N.A.	CPS-P-018	91	Serdarevic, N.	LMCS-P-011	146
Sabri, N.A.	IPS-P-016	137	Serdarevic, N.	LMCS-P-012	146
Sabri, N.A.	IPS-P-030	141	Serracino-Inglott, A.	AS-O-005	77
Sabri, N.A.	BB-P-009	162	Serracino-Inglott, A.	CPS-P-071	105
Sabri, N.A.	BB-P-010	162	Serracino-Inglott, A.	CPS-P-072	105
Sabry, S.S.	QP-P-010	175	Serracino-Inglott, A.	PI-P-023	155
Sacchidananda, S.	IPS-P-006	135	Serracino-Inglott, A.	PP-P-006	172
Sadray, S.	BB-P-019	164	Serutoka, J.P.R.	B G07-003	45
Safari, S.	BB-P-019	164	Serutoka, J.P.R.	G07-003	47
Sahakyan, K.	APS-P-011	81	Sevette, A.	HPS-P-008	114
Said, S.A.	B G03-003	37	Sevilyan, A.	AS-P-009	74
Said, S.A.	G03-002	38	Seyoum, D.	PI-P-007	151
Sakaguchi, M.	HPS-P-009	115	Shafiq, Y.	APS-O-006	84
Sakakibara, K.	HPS-P-070	130	Shah, P.	B S1-002	15
Sakata, R.	HPS-P-081	133	Shah, N.S.	B S1-004	15
Sakr, A.A.	B S1-005	16	Shah, V.P.	S1-002	17
Sakr, A.A.	S1-004	17	Shah, N.S.	S1-003	17
Sakran, W.	BB-P-004	160	Shah, A. N.	APS-P-005	60
Salama, H.A.	BB-P-008	161	Shaheen, A.R.	B IPCD-002	69
Salem, M.Y.	LMCS-P-009	146	Shaheen, A.R.	IPCD-001	71
Salih, F.S.	CPS-P-010	90	Shaikh, K.A.	B S2-006	20
Salo, R.	CPS-P-028	94	Shaji, J.	IPS-P-037	143
Sam, A.P.	B S3-002	23	Shakaryan, Ch.	CPS-P-056	101
Sam, A.P.	B S4-001	26	Shakaryan, Ch.	PI-P-019	154
Sam, A.P.	S4-002	27	Shantha, A.	AS-P-012	74
Sampalis, J.	MEPS-P-002	148	Shantha, A.	CPS-P-034	96
Sampalis, J.	NS-P-013	180	Shantha, A.	NS-P-009	179
Sanaa Abdelshafie, S.S.A.	HPS-P-013	116	Sharaf, M.A.	IPS-P-028	140
Saraiya, T.	AS-O-007	77	Sharaf, M.A.	BB-P-020	164
Saraswathy,	NS-P-009	179	Sharaf el Din, M.A.	IPS-P-028	140
Sarisuta, N.	IPS-P-002	134	Sharaf el Din, M.A.	BB-P-020	164
Sasaki, H.	B G04-001	39	Sharpe, S.	B G15-001	64
Sasaki, H.	G04-001	40	Sharpe, S.E.	G15-002	66
Sasaki, H.	HPS-P-021	118	Shaw, J.P.	B G01-005	33

AUTHOR INDEX

Author	Code	Page	Author	Code	Page
Sheikh, A.Latif	APS-O-006	84	Srivilal, A.	HPS-P-063	128
Sheikh, A.L	HPS-P-032	120	Srivilal, A.	HPS-P-064	128
Sheikh, A.Latif	HPS-P-058	127	Staley, R.	CPS-P-061	103
Sheikh, A.Latif	HPS-P-059	127	Stålsby Lundborg, C.	G06-003	44
Shen, C.S.H	APS-P-007	80	Stanimirovic, V.S.	PI-P-030	157
Shen, C.S.H	CPS-P-054	101	Stenseke, L.I.M.	CPS-P-026	94
Shen, C.S.H	HPS-P-038	122	Stevenson, J.G.	HPS-P-039	122
Shen, A.Y.	NS-P-010	179	Stiblik-Stipesevic, S.	HPS-P-015	116
Shen, A.Y.	NS-P-015	180	Stiblik-Stipesevic, S.S-S.	HPS-P-019	117
Shiau, D.J.	CPS-P-038	97	Stiblik-Stipesevic, S.S-S.	HPS-P-020	117
Shiau, D.J.	CPS-P-052	100	Stojanovic, S.	CPS-P-015	91
Shiau, D.J.	CPS-O-006	111	Stupar, D.	AS-O-009	78
Shiau, D.J.	PI-P-017	154	Stupar, M.	CPS-P-057	102
Shibuya, F.	HPS-P-009	115	Sun, Y.C.	HPS-P-083	133
Shih, R.L.	LMCS-P-010	146	Sunada, H.	IPS-P-021	139
Shimada, H.	CPS-P-018	92	Sunada, H.	IPS-P-024	139
Shimada, Y.	IPS-P-033	142	Sunada, H.	IPS-P-025	140
Shimodozono, Y.	HPS-P-043	123	Sunada, H.	IPS-P-033	142
Shin, M.H.	QP-P-012	175	Sunderland, V.B.	CPS-P-067	104
Shin, M.H.	QP-P-013	176	Sung, L.S.	APS-P-015	82
Shirima, R.	CPS-P-058	102	Sung, S.C.	CPS-O-006	111
Shirotani, M.S.	HPS-P-051	125	Suttajit, S.	CPS-P-049	100
Shu, A.T.	AS-O-008	77	Suzuki, Y.S.	HPS-P-050	125
Shu, A.T.	CPS-P-052	100	Suzuki, Y.S.	HPS-P-051	125
Shue, L.	PI-P-017	154	Syce, J.A.	AS-P-013	75
Shyamala Bhaskaran, S.	IPS-P-003	134	Syce, J.A.	BB-P-014	163
Shyamala Bhaskaran, S.	IPS-P-006	135	Sylvestre, R.	MEPS-P-003	148
Shyamala Bhaskaran, S.	IPS-P-034	142	Sylvestre, R.	MEPS-P-005	149
Shyamala Bhaskaran, S.	PI-P-005	151	Szerman, D.	HPS-P-061	128
Shyamala Bhaskaran, S.	PI-P-006	151	T Hoen, E.	B P2-002	7
Siau, A.	B G08-003	49	T Hoen, E.	P2-002	8
Sigonda-Ndomondo, M.	CPS-P-058	102	Tadros, M.I.	IPS-P-017	138
Silva, I.	AS-O-007	77	Tagwireyi, D.	AS-O-002	76
Silva, da, E.V.	PI-P-024	155	Taha, A.M.	B P1-002	4
Simon, D.	LMCS-P-007	145	Tahami, S.M.H.	BB-P-019	164
Singh, K.K.	NS-P-012	179	Tai, H.Y.	APS-P-014	82
Sitthi-amorn, Ch.	CPS-P-049	100	Tai, H.Y.	APS-O-007	84
Sitthiworanan, C.	PI-P-029	157	Tai, S.H.	HPS-P-011	115
Sjölander, I.	CPS-P-080	107	Tai, C.L.	HPS-P-047	124
Skier, E.M.	PI-O-003	158	Tajerzadeh, H.	IM-P-003	182
Skromne, D.S.K.	APS-P-002	79	Takanaka, K.	PI-P-027	156
Smith, G.H.	B G07-001	45	Takeda, T.	HPS-P-012	115
Smith, G.H.	G07-001	47	Takeda, Y.	HPS-P-043	123
Smith, R.C.	HPS-P-008	114	Taketani, T.	HPS-P-076	131
Smolcic-Bubalo, A.	CPS-P-019	92	Tambouly, N.	B S5-005	29
Snedecor, S.	G13-004	62	Tambouly, N.	S5-003	30
Söderberg, J.	CPS-P-066	104	Tanaka, K.	PB-P-004	167
Soghoyan, A.	CPS-P-056	101	Tang, C.S.	CPS-P-046	99
Solarovic, T.S.	PI-P-030	157	Tang, C.S.	NS-P-015	180
Soletti, J.	CPS-P-036	96	Tanniru, V.N.	AS-O-003	76
Sonar, V.V.	APS-P-005	80	Tanniru, V.N.	CPS-P-060	102
Sorfleet, C.R.	G08-002	50	Tantipidoke, R.	CPS-P-049	100
Speed, A.C.	PI-P-009	152	Tanwar, Y.S.	LMCS-P-014	147
Speed, A.C.	PI-P-011	152	Tarn, Y.H.	CPS-P-035	96
Speed, A.C.	PI-P-016	153	Tasic, M.	IPS-P-015	137
Speed, A.C.	PI-O-005	159	Tasic, M.	IPS-P-015	137

AUTHOR INDEX

Author	Code	Page	Author	Code	Page
Tatke, P.A.	NS-P-003	177	Tsai, Y.C.	HPS-P-054	126
Tatke, P.A.	NS-P-011	179	Tsai, C.Y.	HPS-P-057	127
Tatke, P.A.	NS-P-012	179	Tsai, C.C.	HPS-P-065	129
Tawfik, S.A.	LMCS-P-016	147	Tsai, C.Y.	HPS-P-068	129
Tayel, S.A.	PB-P-012	169	Tsai, C.Y.	HPS-P-079	132
Taylor, S.	G11-003	57	Tsai, C.Y.	PP-P-002	171
Taylor, M.D.	G13-004	62	Tsai, Y.W.	PP-P-005	172
Taylor, S.	HPS-P-018	117	Tseng, A.C.	AS-O-008	77
Taylor, J.	MEPS-P-006	149	Tseng, C.H.	HPS-P-042	123
Teeling, M.	HPS-P-026	119	Tseng, P.L.	HPS-P-053	126
Teles, A.T.	CPS-P-062	103	Tseng, C.C.	BB-P-016	163
Teles, A.T.	CPS-P-063	103	Tseng, HM	PP-P-002	171
Terán, M.A.	NRP-P-001	166	Turcotte, M.	PP-P-001	171
Teräsalmi, E.K.	B P3-001	9	Turpaz, Y.	PB-P-011	169
Teräsalmi, E.K.	B G14-001	63	Turpin, P.	CPS-P-065	104
Terzic, B.T.	PI-P-030	157	Twahir, A.	MEPS-P-001	148
Tetty-Amlalo, R.N.O.	BB-P-018	164	Uang, Y.S.	BB-P-016	163
Tetty-Amlalo, R.N.O.	BB-P-021	165	Uemura, T.	HPS-P-040	122
Tetty-Amlalo, R.N.O.	BB-P-023	165	Uemura, N.U.	HPS-P-051	125
Thananithisak, C.	CPS-P-013	91	Ugresic, N.	PI-P-030	157
Thomas, D.	CPS-P-073	106	Uno, K.	PI-P-027	156
Thomsen, M.H.T.	CPS-P-007	89	Ures, C.	NRP-P-002	166
Thongnopnu, P.	QP-P-006	174	Urosev, U.D.	PI-P-012	152
Tien, J.H.	HPS-P-041	123	Uzunkaya, G.	BB-P-007	161
Tisocki, K.	APS-O-004	83	Vaillancourt, R.	B G08-002	49
Tjahjono, D.H.	QP-P-002	173	Vaillancourt, R.	G08-002	50
Todic, V.	PI-P-015	153	Vaillancourt, R.	APS-O-008	84
Tomic Radovanovic, L.	IPS-P-015	137	Vaillancourt, R.	CPS-P-048	99
Tomsen, D.	CPS-P-037	97	Vaillancourt, R.	MEPS-P-002	148
Tomson, G.	G06-003	44	Vaillancourt, R.	MEPS-P-003	148
Tong, Y.	BB-P-005	161	Vaillancourt, R.	MEPS-P-005	149
Toru Ebihara, T.E.	PI-O-003	158	Vaillancourt, R.	MEPS-P-006	149
Toscano, M.J.	CPS-P-062	103	Vaillancourt, R.	NS-P-013	180
Toscano, M.J.	CPS-P-063	103	Van Mil, J.W.F.	B R2-006	2
Toskic Radojicic, M.	HPS-P-029	120	Van Mil, J.W.F.	R2-002	3
Toskic Radojicic, M.	HPS-P-030	120	Vardanyan, L.	AS-P-009	74
Toskic-Radojicic, M.	CPS-P-017	92	Vassallo, J.A.	CPS-P-071	105
Toskic-Radojicic, M.	HPS-P-035	121	Veerareddy, V.	IPS-P-007	135
Trasca, D.	NS-P-014	180	Vellingkar, V.S.	QP-P-004	173
Traulsen, J.M.	CPS-P-084	108	Verhoef, J.C.	IPS-P-002	134
Tredree, R.L.	B S2-004	19	Viberg, N.	B G06-004	43
Tredree, R.L.	S2-002	21	Viberg, N.	G06-003	44
Trindade, V.	NRP-P-002	166	Vidotti, C.C.F.	PI-P-024	155
Triveni, M.	PI-P-005	151	Vidotti, C.C.F.	PI-P-025	156
Triveni, M.	PI-P-006	151	Vieira, C.A.L.	PI-P-024	155
Trobradovic, H.	IPS-P-027	140	Vihavainen, K.M.	CPS-P-022	93
Troelin, P.	B P3-004	9	Virovkc-Zunec, B.	HPS-P-015	116
Troelin, P.	P3-002	10	Virovkc-Zunec, B.V-Z.	HPS-P-019	117
Tromp, Th.F.J.	B P4-003	11	Virovkc-Zunec, B.V-Z.	HPS-P-020	117
Tromp, Th.F.J.	P4-002	12	Vishwanath, B.A.	IPS-P-034	142
Tsai, Y.W.	APS-O-005	84	Vivaldo, J.	PI-P-008	151
Tsai, J.C.	HPS-P-011	115	Vivek, V.B.	CBS-P-009	87
Tsai, M.J.	HPS-P-024	118	Vobalaboina, V.	IPS-P-007	135
Tsai, Y.C.	HPS-P-024	118	Wable, P.J.	APS-P-005	80
Tsai, T.C.	HPS-P-042	123	Wagner, J.W.	CPS-P-030	95
Tsai, P.L.	HPS-P-054	126	Wagner, A.	CPS-P-049	100

AUTHOR INDEX

Author	Code	Page	Author	Code	Page
Wahbi, A.	QP-P-007	174	Yamaguchi, S.	HPS-P-076	131
Wahbi, A.	QP-P-008	174	Yamamoto, A.	HPS-P-040	122
Wahbi, A.	QP-P-009	175	Yamamura, S.Y.	HPS-P-048	124
Wang, H.P.	APS-P-014	82	Yang, J.T.	CBS-P-004	85
Wang, H.P.	APS-O-007	84	Yang, R.C.	HPS-P-038	122
Wang, C.S.	CBS-P-008	86	Yang, Y.F.	HPS-P-052	125
Wang, C.M.	CPS-P-012	90	Yang Kao, Y.H.	HPS-P-073	131
Wang, W.F.	CPS-P-050	100	Yano, H.	AS-P-005	73
Wang, C.M.	CPS-P-052	100	Yasuhiro/Shimada, Y.S.	IPS-P-020	138
Wang, C.Y.	HPS-P-036	121	Yasui, S.	IPS-P-025	140
Wang, L.	IPS-P-024	139	Yasumizu, T.	HPS-P-070	130
Wang, L.H.	BB-P-016	163	Yehia, D.	HPS-P-026	119
Wang, F.	PB-P-001	167	Yehia, D.	HPS-P-062	128
Wang, F.	PB-P-002	167	Yen, T.C.	HPS-P-037	122
Wang, H.P.	PB-P-005	168	Yen, T.C.	HPS-P-046	124
Wang, M.T.	NS-P-008	178	Yen, T.C.	HPS-P-060	127
Wang, T.S.	NS-P-010	179	Yen chih ho, A.	HPS-P-049	125
Watanabe, Y.	PB-P-004	167	Yonezawa, Y.	IPS-P-020	138
Weir, K.	CPS-P-024	93	Yonezawa, Y.	IPS-P-021	139
Wen, Y.H.	CPS-P-046	99	Yonezawa, Y.	IPS-P-025	140
Wen, H.L.	HPS-P-047	124	Yonezawa, Y.	IPS-P-033	142
Wen, Y.H.	HPS-P-047	124	Yoo, B.K.	PB-P-003	167
Wen, C.C.	PB-P-005	168	Yoshimichi/Sai, Y.S.	CPS-P-021	93
Wen, K.C.	PB-P-005	168	Yoshino, N.Y.	HPS-P-050	125
Wertheimer, A.I.	B G15-002	64	Yoshino, N.Y.	HPS-P-051	125
Westerlund, T.	CPS-P-078	107	Yousef, W.M.Y.	CBS-P-001	85
Westerlund, T.	CPS-P-079	107	Yousef, W.M.Y.	IM-P-001	162
Westerlund, T.	CPS-P-080	107	Youssef, D.Y.	B S5-003	28
Winslade, N.	MEPS-P-003	148	Youssef, D.Y.	S5-002	30
Winslade, N.	MEPS-P-005	149	Youssef, R.M.	QP-P-005	174
Winstedt sandin, P.	CPS-P-025	94	Yu, C.T.	HPS-P-011	115
Winterstein, A.G.	B G13-004	60	Yu, P.Ch.	HPS-P-046	124
Winterstein, A.G.	G13-003	62	Yu, C.P.	HPS-P-073	131
Winterstein, A.G.	G13-004	62	Yu-Ju Chiao, Y.J.	HPS-P-082	133
Winterstein, A.G.	APS-O-003	83	Yurdun, T.	BB-P-007	161
Wisbech, P.	CPS-P-037	97	Zaheer, F.	HPS-P-059	127
Woodend, K.	CPS-P-024	93	Zaki, N.	BB-P-022	165
Worsley, A J	B G02-003	35	Zarb-Adami, M.	AS-O-005	77
Worsley, A J	G02-002	36	Zarb-Adami, M.	CPS-P-071	105
Wright, A.D.	NS-P-001	177	Zarb-Adami, M.	CPS-P-072	105
Wu, M.M.	AS-P-003	72	Zarb-Adami, M.	PI-P-023	155
Wu, J.B.	CBS-P-004	85	Zarb-Adami, M.	PP-P-006	172
Wu, S.	CPS-P-012	90	Zayed, N.	PI-P-021	155
Wu, S.S.	CPS-P-046	99	Zayed, N.	PI-P-022	155
Wu, C.J.	HPS-P-027	119	Zhang, R.	BB-P-005	161
Wu, S.S.	HPS-P-047	124	Zoellner, Y.F.	B G08-001	49
Wu, S.N.	NS-P-015	180	Zoellner, Y.F.	G08-001	50
Wulji, T.	B G01-002	32	Zorc, B.	CPS-P-019	92
Wynne Howells, C.M.	B G11-002	56	Zoric, T.	LMCS-P-006	145
Wynne Howells, C.M.	G11-001	57	Zunec, I.Z.	HPS-P-019	117
Yamada, K.	G04-001	40	Zunec, I.Z.	HPS-P-020	117
Yamada, K.	HPS-P-043	123	Zwicker, L.A.	B G01-003	32
Yamada, K.	HPS-P-081	133	Zwicker, L.A.	G01-001	34
Yamada, Y.	IPS-P-020	138	Zwicker, L.A.	B G06-001	43
Yamada, Y.Y.	IPS-P-020	138			
Yamada, R.	IPS-P-033	142			



FIP Congresses & Conferences
P.O. Box 84200
2508 AE The Hague
The Netherlands
Tel.: +31 (0)70 302 1982
Fax: +31 (0)70 302 1998
E-mail: congress@fip.org
Website: www.fip.org/cairo2005